nct_id,downcase_mesh_term,official_title,all_conditions,study_first_submitted_date,primary_completion_date,completion_date,study_type,overall_status,study_phases,funded_bys,sponsors_name,investigators,intervention_types,location,minimum_age_num,maximum_age_num,category_age,category,sub_category,URL
NCT00001159,graves disease,Evaluation of Patients With Thyroid Function Disorders,Grave's Disease|Hyperthyroidism|Hypothyroidism,1999-11-03,,,Observational,Recruiting,,National Institutes of Health Clinical Center (CC),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),"National Institutes of Health Clinical Center, 9000 Rockville Pike",,United States,6.0,120.0,[0-17]|[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT00001159
NCT00001159,goiter,Evaluation of Patients With Thyroid Function Disorders,Grave's Disease|Hyperthyroidism|Hypothyroidism,1999-11-03,,,Observational,Recruiting,,National Institutes of Health Clinical Center (CC),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),"National Institutes of Health Clinical Center, 9000 Rockville Pike",,United States,6.0,120.0,[0-17]|[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT00001159
NCT00209235,pseudopseudohypoparathyroidism,Natural History Study of Albright Hereditary Osteodystrophy: Includes Substudies on Effects of Growth Hormone in Patients With Pseudohypoparathyroidism Type 1a and Cognitive & Behavioral Studies in Albright Hereditary Osteodystrophy,Albright Hereditary Osteodystrophy|Pseudohypoparathyroidism Type 1A,2005-09-13,2026-10-31,2027-12-31,Interventional,Recruiting,Not Applicable,Connecticut Children's Medical Center,"Connecticut Children's Medical Center|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Hugo W. Moser Research Institute at Kennedy Krieger, Inc.|Johns Hopkins University|UConn Health",Connecticut Children's Medical Center,Behavioral,United States,2.0,89.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,pseudohypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00209235
NCT00381641,"thyroid cancer, papillary","Phase II Trial of Sunitinib (SU11248) in Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers and Medullary Thyroid Cancers",Differentiated Thyroid Gland Carcinoma|Recurrent Thyroid Gland Carcinoma|Refractory Thyroid Gland Carcinoma|Stage III Thyroid Gland Follicular Carcinoma AJCC v7|Stage III Thyroid Gland Medullary Carcinoma AJCC v7|Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVA Thyroid Gland Medullary Carcinoma AJCC v7|Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVB Thyroid Gland Medullary Carcinoma AJCC v7|Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVC Thyroid Gland Medullary Carcinoma AJCC v7|Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7|Stage IV Thyroid Gland Follicular Carcinoma AJCC v7|Stage IV Thyroid Gland Medullary Carcinoma AJCC v7|Stage IV Thyroid Gland Papillary Carcinoma AJCC v7|Thyroid Gland Hurthle Cell Carcinoma|Unresectable Thyroid Gland Carcinoma,2006-09-26,2016-12-31,,Interventional,"Active, not recruiting",Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),University of Chicago Comprehensive Cancer Center|Decatur Memorial Hospital|NorthShore University HealthSystem-Evanston Hospital|Ingalls Memorial Hospital|Duly Health and Care Joliet|Loyola University Medical Center|Illinois CancerCare-Peoria|Central Illinois Hematology Oncology Center|Southern Illinois University School of Medicine|Fort Wayne Medical Oncology and Hematology Inc-Parkview|Northern Indiana Cancer Research Consortium|University of Maryland/Greenebaum Cancer Center|University of Michigan Comprehensive Cancer Center|Oncology Care Associates PLLC|Mercy Hospital Saint Louis|M D Anderson Cancer Center|Medical College of Wisconsin,Other|Other|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT00381641
NCT00381641,"adenocarcinoma, follicular","Phase II Trial of Sunitinib (SU11248) in Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers and Medullary Thyroid Cancers",Differentiated Thyroid Gland Carcinoma|Recurrent Thyroid Gland Carcinoma|Refractory Thyroid Gland Carcinoma|Stage III Thyroid Gland Follicular Carcinoma AJCC v7|Stage III Thyroid Gland Medullary Carcinoma AJCC v7|Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVA Thyroid Gland Medullary Carcinoma AJCC v7|Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVB Thyroid Gland Medullary Carcinoma AJCC v7|Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVC Thyroid Gland Medullary Carcinoma AJCC v7|Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7|Stage IV Thyroid Gland Follicular Carcinoma AJCC v7|Stage IV Thyroid Gland Medullary Carcinoma AJCC v7|Stage IV Thyroid Gland Papillary Carcinoma AJCC v7|Thyroid Gland Hurthle Cell Carcinoma|Unresectable Thyroid Gland Carcinoma,2006-09-26,2016-12-31,,Interventional,"Active, not recruiting",Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),University of Chicago Comprehensive Cancer Center|Decatur Memorial Hospital|NorthShore University HealthSystem-Evanston Hospital|Ingalls Memorial Hospital|Duly Health and Care Joliet|Loyola University Medical Center|Illinois CancerCare-Peoria|Central Illinois Hematology Oncology Center|Southern Illinois University School of Medicine|Fort Wayne Medical Oncology and Hematology Inc-Parkview|Northern Indiana Cancer Research Consortium|University of Maryland/Greenebaum Cancer Center|University of Michigan Comprehensive Cancer Center|Oncology Care Associates PLLC|Mercy Hospital Saint Louis|M D Anderson Cancer Center|Medical College of Wisconsin,Other|Other|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, follicular",https://clinicaltrials.gov/ct2/show/NCT00381641
NCT00390325,thyroid neoplasms,Phase II Study of Sorafenib (BAY 43-9006) in Patients With Metastatic Medullary Thyroid Carcinoma,Hereditary Thyroid Gland Medullary Carcinoma|Locally Advanced Thyroid Gland Medullary Carcinoma|Multiple Endocrine Neoplasia Type 2A|Multiple Endocrine Neoplasia Type 2B|Recurrent Thyroid Gland Medullary Carcinoma|Sporadic Thyroid Gland Medullary Carcinoma|Stage III Thyroid Gland Medullary Carcinoma AJCC v7|Stage IVA Thyroid Gland Medullary Carcinoma AJCC v7|Stage IVB Thyroid Gland Medullary Carcinoma AJCC v7|Stage IVC Thyroid Gland Medullary Carcinoma AJCC v7|Stage IV Thyroid Gland Medullary Carcinoma AJCC v7,2006-10-18,2017-01-30,,Interventional,"Active, not recruiting",Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),Washington University School of Medicine|Duke University Medical Center|Ohio State University Comprehensive Cancer Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00390325
NCT00415233,thyroid neoplasms,"Multicentre Randomised Trial of High Dose Versus Low Dose Radioiodine, With or Without Recombinant Human Thyroid Stimulating Hormone, for Remnant Ablation Following Surgery for Differentiated Thyroid Cancer [HILO]",Head and Neck Cancer,2006-12-20,2011-06-30,2025-07-31,Interventional,"Active, not recruiting",Phase 3,"University College, London","University College, London",Sussex Cancer Centre at Royal Sussex County Hospital|Addenbrooke's Hospital|Kent and Canterbury Hospital|Castle Hill Hospital|Derbyshire Royal Infirmary|Royal Devon and Exeter Hospital|Gloucestershire Royal Hospital|St. Luke's Cancer Centre at Royal Surrey County Hospital|Ipswich Hospital|Leeds Cancer Centre at St. James's University Hospital|Leicester Royal Infirmary|Guy's Hospital|Royal Marsden - London|Maidstone Hospital|Christie Hospital|James Cook University Hospital|Newcastle Upon Tyne Hospitals NHS Trust|Northampton General Hospital|Mount Vernon Cancer Centre at Mount Vernon Hospital|Norfolk and Norwich University Hospital|Dorset Cancer Centre|Cancer Research Centre at Weston Park Hospital|University Hospital of North Staffordshire|Velindre Cancer Center at Velindre Hospital|Glan Clwyd Hospital,Biological|Radiation,United Kingdom,16.0,80.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00415233
NCT00556530,parathyroid diseases,Genetic Modifiers of 22q11.2 Deletion Syndrome,22q11.2 Deletion Syndrome|DiGeorge Syndrome,2007-11-08,2022-06-06,2025-07-31,Observational,Recruiting,,Albert Einstein College of Medicine,"Albert Einstein College of Medicine|National Heart, Lung, and Blood Institute (NHLBI)",Albert Einstein College of Medicine|Children's Hospital of Philadelphia,,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT00556530
NCT00768820,parathyroid diseases,"The Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome (VCFS), Williams Syndrome (WS)and Fragile X Syndrome Characterization, Treatment and Examining the Connection to Developmental and Molecular Factors",Fragile X Syndrome|Velocardiofacial Syndrome|Williams Syndrome,2008-10-07,2022-12-31,2022-12-31,Interventional,Recruiting,Phase 4,The Chaim Sheba Medical Center,The Chaim Sheba Medical Center,Schneider Children's Mediac Center of Israel,Drug,Israel,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT00768820
NCT01005654,parathyroid diseases,Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms,Adrenal Neoplasm|Endocrine Tumors|Neuroblastoma|Parathyroid Neoplasms|Thyroid Neoplasms,2009-10-30,,,Observational,Recruiting,,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),"National Institutes of Health Clinical Center, 9000 Rockville Pike",,United States,4.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT01005654
NCT01109420,"thyroid cancer, papillary",Clinical and Genetic Studies in Familial Non-Medullary Thyroid Cancer,Non-Medullary Thyroid Cancer,2010-04-22,,,Observational,Recruiting,,National Institutes of Health Clinical Center (CC),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),"National Institutes of Health Clinical Center, 9000 Rockville Pike",,United States,7.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT01109420
NCT01539486,parathyroid diseases,Relationship of Preoperative PTH and Ex-Vivo Gamma Counts in Minimally Invasive Parathyroidectomy,Parathyroid Disease,2012-02-21,2023-12-31,2023-12-31,Observational,"Active, not recruiting",,University of Arkansas,University of Arkansas,University of Arkansas for Medical Sciences,,United States,18.0,90.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT01539486
NCT01611896,hyperthyroidism,"GRAves Selenium Supplementation Trial (GRASS) - an Investigator-initiated Randomised, Blinded, Multicentre Clinical Trial of Selenium Supplementation Versus Placebo in Patients With Graves' Hyperthyroidism",Graves' Hyperthyroidism,2012-05-29,2021-08-31,2021-08-31,Interventional,"Active, not recruiting",Not Applicable,"Rigshospitalet, Denmark","Bispebjerg Hospital|Copenhagen Trial Unit, Center for Clinical Intervention Research|Danish Council for Independent Research|Herlev Hospital|Hillerod Hospital, Denmark|Hospital of South West Denmark|Hvidovre University Hospital|Odense University Hospital|Rigshospitalet, Denmark|The Danish Council for Strategic Research","Department of Endocrinology and Gastroenterology, Bispebjerg Hospital|Department of Medical Endocrinology, Rigshospitalet|Department of Endocrinology, Hospital of Southwest Denmark|Department of Medicine, Gentofte Hospital|Department of Internal Medicine O 106, Endocrine Unit, Herlev Hospital|Department of Cardiology and Endocrinology, Endocrine Unit, Hillerød Hospital|Department of Endocrinology, Section 541, Hvidovre Hospital|Department of Endocrinology and Metabolism, Odense University Hospital",Dietary Supplement|Other,Denmark,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01611896
NCT01638533,thyroid neoplasms,"A Phase 1 and Pharmacokinetic Single Agent Study of Romidepsin in Patients With, Lymphomas, Chronic Lymphocytic Leukemia, and Select Solid Tumors and Varying Degrees of Liver Dysfunction",Glioma|Hematopoietic and Lymphoid Cell Neoplasm|Lymphoma|Metastatic Malignant Solid Neoplasm|Neuroendocrine Neoplasm|Recurrent Adult Soft Tissue Sarcoma|Recurrent Bladder Carcinoma|Recurrent Breast Carcinoma|Recurrent Chronic Lymphocytic Leukemia|Recurrent Colorectal Carcinoma|Recurrent Head and Neck Carcinoma|Recurrent Lung Carcinoma|Recurrent Malignant Solid Neoplasm|Recurrent Melanoma|Recurrent Pancreatic Carcinoma|Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Recurrent Prostate Carcinoma|Recurrent Renal Cell Carcinoma|Recurrent Thyroid Gland Carcinoma|Refractory Chronic Lymphocytic Leukemia|Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma|Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Stage IIIA Breast Cancer AJCC v7|Stage IIIA Colorectal Cancer AJCC v7|Stage IIIA Cutaneous Melanoma AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage IIIB Colorectal Cancer AJCC v7|Stage IIIB Cutaneous Melanoma AJCC v7|Stage III Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7|Stage IIIC Colorectal Cancer AJCC v7|Stage IIIC Cutaneous Melanoma AJCC v7|Stage III Colorectal Cancer AJCC v7|Stage III Cutaneous Melanoma AJCC v7|Stage III Lung Cancer AJCC v7|Stage III Pancreatic Cancer AJCC v6 and v7|Stage III Prostate Cancer AJCC v7|Stage III Renal Cell Cancer AJCC v7|Stage III Soft Tissue Sarcoma AJCC v7|Stage IVA Colorectal Cancer AJCC v7|Stage IVB Colorectal Cancer AJCC v7|Stage IV Breast Cancer AJCC v6 and v7|Stage IV Colorectal Cancer AJCC v7|Stage IV Cutaneous Melanoma AJCC v6 and v7|Stage IV Lung Cancer AJCC v7|Stage IV Pancreatic Cancer AJCC v6 and v7|Stage IV Prostate Cancer AJCC v7|Stage IV Renal Cell Cancer AJCC v7|Stage IV Soft Tissue Sarcoma AJCC v7|Unresectable Solid Neoplasm,2012-07-09,2018-11-29,,Interventional,"Active, not recruiting",Phase 1,National Cancer Institute (NCI),Celgene Corporation|National Cancer Institute (NCI),City of Hope Comprehensive Cancer Center|University of California Davis Comprehensive Cancer Center|Emory University Hospital/Winship Cancer Institute|University of Chicago Comprehensive Cancer Center|Johns Hopkins University/Sidney Kimmel Cancer Center|National Cancer Institute Developmental Therapeutics Clinic|Wayne State University/Karmanos Cancer Institute|Mayo Clinic in Rochester|Case Western Reserve University|Penn State Milton S Hershey Medical Center|Thomas Jefferson University Hospital|University Health Network-Princess Margaret Hospital,Other|Drug,Canada|United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01638533
NCT01704586,thyroid neoplasms,Clinical Evaluation of a I-124 PET/CT Based Remnant Radioiodine Ablation Decision Concept in Differentiated Thyroid Cancer Using PROBE Design,Differentiated Thyroid Carcinoma,2012-10-04,2021-05-31,2025-11-30,Interventional,Recruiting,Not Applicable,University of Wuerzburg,"Deutsche Krebshilfe e.V., Bonn (Germany)|University of Wuerzburg","Clinic of Nuclear Medicine, University Clinic Essen|University Clinic Würzburg",Radiation|Radiation,Germany,18.0,80.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01704586
NCT01821781,parathyroid diseases,A Study of Hematopoietic Stem Cell Transplantation (HSCT) in Immune Function Disorders Using a Reduced Intensity Preparatory Regime,Autoimmune Lymphoproliferative Syndrome|Chediak-Higashi Syndrome|Chronic Granulomatous Disease|Common Variable Immune Deficiency|DiGeorge Syndrome|Hemophagocytic Lymphohistiocytosis|Hyper-IgM|Immune Deficiency Disorders|Immune Dysregulatory Disorders|IPEX|Severe Combined Immunodeficiency|Wiskott-Aldrich Syndrome|X-linked Agammaglobulinemia|X-linked Lymphoproliferative Syndrome,2013-03-19,2022-03-31,2024-03-31,Interventional,Recruiting,Phase 2,Washington University School of Medicine,Washington University School of Medicine,Washington University|Methodist Heathcare,Drug,United States,0.0,21.0,[0-17]|[18-65],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT01821781
NCT01837745,thyroid neoplasms,Differentiated Thyroid Cancer: is There a Need for Radioiodine Ablation in Low Risk Patients?,Low Risk Differentiated Thyroid Cancer,2013-04-16,2020-03-31,2022-05-12,Interventional,"Active, not recruiting",Phase 3,"Gustave Roussy, Cancer Campus, Grand Paris","Gustave Roussy, Cancer Campus, Grand Paris",Institut Gustave Roussy,Drug|Drug|Other,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01837745
NCT02041260,thyroid neoplasms,A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting,Differentiated Thyroid Cancer (DTC)|Poorly Differentiated Thyroid Cancer,2014-01-17,2022-05-31,2022-05-31,Interventional,"Active, not recruiting",Phase 2,Thomas Jefferson University,Thomas Jefferson University,Abramson Cancer Center of the University of Pennsylvania,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02041260
NCT02061111,hypothyroidism,NeoThyr - the Role of Mitochondria-dysfunction in Newborns of Mothers With Autoimmune Thyroid Disease,Alteration of Mitochondrial Membrane|Autoimmune Thyroid Disease|Subclinical Hypothyroidism,2014-01-22,2017-12-31,2022-11-30,Observational,"Active, not recruiting",,Naestved Hospital,Naestved Hospital|Region Zealand|University of Southern Denmark,Gynaecologic-Obstetrics Department Naestved Hospital,,Denmark,18.0,50.0,[18-65],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT02061111
NCT02143726,thyroid neoplasms,Randomized Phase II Study of Sorafenib With or Without Everolimus in Patients With Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer,Refractory Hurthle Cell Thyroid Cancer,2014-05-19,2021-01-28,2024-08-06,Interventional,"Active, not recruiting",Phase 2,Alliance for Clinical Trials in Oncology,Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|Novartis,Mayo Clinic in Florida|Northwestern University|Siouxland Regional Cancer Center|University of Michigan Comprehensive Cancer Center|Mayo Clinic|Nebraska Methodist Hospital|Memorial Sloan Kettering Basking Ridge|Memorial Sloan Kettering Monmouth|Memorial Sloan Kettering Bergen|Memorial Sloan Kettering Commack|Memorial Sloan Kettering Westchester|Memorial Sloan Kettering Cancer Center|Memorial Sloan Kettering Sleepy Hollow|Memorial Sloan Kettering Nassau|Southeastern Medical Oncology Center-Clinton|Southeastern Medical Oncology Center-Goldsboro|Wayne Memorial Hospital|Southeastern Medical Oncology Center-Jacksonville|Ohio State University Comprehensive Cancer Center|Fox Chase Cancer Center|Mercy Health System,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02143726
NCT02147782,parathyroid diseases,Continuous Clinical Observation on Bone Metabolism Induced by Chronic Renal Insufficiency in Different Stages,Chronic Renal Insufficiency|Renal Osteodystrophy,2014-05-13,2022-12-31,2022-12-31,Observational [Patient Registry],Recruiting,,Shanghai University of Traditional Chinese Medicine,Anhui Provincial Hospital|Huadong Hospital|Longhua Hospital|Shanghai University of Traditional Chinese Medicine,Anhui Province Hospital of TCM|Jiangsu Province Hospital of TCM|Longhua hospital affiliated to Shanghai University of TCM|Huadong Hospital Affiliated to Fudan University,,China,20.0,50.0,[18-65],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT02147782
NCT02152995,"thyroid cancer, papillary","A Phase 2 Study of Trametinib in Combination With Radioiodine (RAI) for RAS Mutant or RAS/RAF Wild-Type, RAI-Refractory Recurrent and/or Metastatic Thyroid Cancers",Metastatic Thyroid Gland Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Recurrent Thyroid Gland Carcinoma|Refractory Thyroid Gland Carcinoma|Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7|Stage IV Thyroid Gland Follicular Carcinoma AJCC v7|Stage IV Thyroid Gland Papillary Carcinoma AJCC v7,2014-05-29,2021-08-25,2023-01-12,Interventional,"Active, not recruiting",Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),Memorial Sloan Kettering Cancer Center,Procedure|Other|Radiation|Other|Other|Procedure|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT02152995
NCT02152995,"adenocarcinoma, follicular","A Phase 2 Study of Trametinib in Combination With Radioiodine (RAI) for RAS Mutant or RAS/RAF Wild-Type, RAI-Refractory Recurrent and/or Metastatic Thyroid Cancers",Metastatic Thyroid Gland Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Recurrent Thyroid Gland Carcinoma|Refractory Thyroid Gland Carcinoma|Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7|Stage IV Thyroid Gland Follicular Carcinoma AJCC v7|Stage IV Thyroid Gland Papillary Carcinoma AJCC v7,2014-05-29,2021-08-25,2023-01-12,Interventional,"Active, not recruiting",Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),Memorial Sloan Kettering Cancer Center,Procedure|Other|Radiation|Other|Other|Procedure|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, follicular",https://clinicaltrials.gov/ct2/show/NCT02152995
NCT02203682,goiter,The Effect of Subantimicrobial Dose Doxycycline in Mild Thyroid-Associated Ophthalmopathy,"Autoimmune Diseases|Endocrine System Diseases|Eye Diseases, Hereditary|Graves Disease|Graves Ophthalmopathy|Hyperthyroidism|Immune System Diseases|Thyroid-associated Ophthalmopathy|Thyroid Diseases",2014-07-28,2022-07-31,2022-07-31,Interventional,Recruiting,Phase 2,Sun Yat-sen University,Sun Yat-sen University,Zhongshan Ophthalmic Center,Drug|Drug,China,18.0,70.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT02203682
NCT02210741,goiter,Next-generation Sequencing (NGS) of Peripheral Blood Immune Repertoire in Graves' Disease,Graves Disease,2014-08-04,2024-02-29,2024-02-29,Observational,Not yet recruiting,,National Taiwan University Hospital,National Taiwan University Hospital,National Taiwan University Hospital,,Taiwan,20.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT02210741
NCT02210741,hyperthyroidism,Next-generation Sequencing (NGS) of Peripheral Blood Immune Repertoire in Graves' Disease,Graves Disease,2014-08-04,2024-02-29,2024-02-29,Observational,Not yet recruiting,,National Taiwan University Hospital,National Taiwan University Hospital,National Taiwan University Hospital,,Taiwan,20.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02210741
NCT02378298,graves ophthalmopathy,Rituximab (RTX) Therapy in Steroid Resistant Patients or Patients Relapsing After Intravenous Steroids With Active TAO,"Ophthalmopathy, Thyroid-Associated",2015-01-20,2020-02-01,2022-03-31,Interventional,"Active, not recruiting",Phase 4,Göteborg University,"Göteborg University|Sahlgrenska University Hospital, Sweden","Center for Endocrinology and Metabolism, Sahlgrenska University Hospital|MedTech West, Institute of Neuro Science and Physiology, Department for Clinical Neuro Science and Rehabilitation, Sahlgrenska Academy, University of Gothenburg|Department of Ophthalmology, Sahlgrenska University Hospital/Mölndal|Department of Rheumatology, Sahlgrenska University Hospital/Mölndal|Department of Radiology, Karolinska University Hospital",Drug|Drug|Drug,Sweden,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT02378298
NCT02378298,graves disease,Rituximab (RTX) Therapy in Steroid Resistant Patients or Patients Relapsing After Intravenous Steroids With Active TAO,"Ophthalmopathy, Thyroid-Associated",2015-01-20,2020-02-01,2022-03-31,Interventional,"Active, not recruiting",Phase 4,Göteborg University,"Göteborg University|Sahlgrenska University Hospital, Sweden","Center for Endocrinology and Metabolism, Sahlgrenska University Hospital|MedTech West, Institute of Neuro Science and Physiology, Department for Clinical Neuro Science and Rehabilitation, Sahlgrenska Academy, University of Gothenburg|Department of Ophthalmology, Sahlgrenska University Hospital/Mölndal|Department of Rheumatology, Sahlgrenska University Hospital/Mölndal|Department of Radiology, Karolinska University Hospital",Drug|Drug|Drug,Sweden,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT02378298
NCT02378298,goiter,Rituximab (RTX) Therapy in Steroid Resistant Patients or Patients Relapsing After Intravenous Steroids With Active TAO,"Ophthalmopathy, Thyroid-Associated",2015-01-20,2020-02-01,2022-03-31,Interventional,"Active, not recruiting",Phase 4,Göteborg University,"Göteborg University|Sahlgrenska University Hospital, Sweden","Center for Endocrinology and Metabolism, Sahlgrenska University Hospital|MedTech West, Institute of Neuro Science and Physiology, Department for Clinical Neuro Science and Rehabilitation, Sahlgrenska Academy, University of Gothenburg|Department of Ophthalmology, Sahlgrenska University Hospital/Mölndal|Department of Rheumatology, Sahlgrenska University Hospital/Mölndal|Department of Radiology, Karolinska University Hospital",Drug|Drug|Drug,Sweden,18.0,70.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT02378298
NCT02378298,hyperthyroidism,Rituximab (RTX) Therapy in Steroid Resistant Patients or Patients Relapsing After Intravenous Steroids With Active TAO,"Ophthalmopathy, Thyroid-Associated",2015-01-20,2020-02-01,2022-03-31,Interventional,"Active, not recruiting",Phase 4,Göteborg University,"Göteborg University|Sahlgrenska University Hospital, Sweden","Center for Endocrinology and Metabolism, Sahlgrenska University Hospital|MedTech West, Institute of Neuro Science and Physiology, Department for Clinical Neuro Science and Rehabilitation, Sahlgrenska Academy, University of Gothenburg|Department of Ophthalmology, Sahlgrenska University Hospital/Mölndal|Department of Rheumatology, Sahlgrenska University Hospital/Mölndal|Department of Radiology, Karolinska University Hospital",Drug|Drug|Drug,Sweden,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02378298
NCT02393690,"thyroid cancer, papillary",Randomized Double-Blind Phase II Study of Radioactive Iodine (RAI) in Combination With Placebo or Selumetinib for the Treatment of RAI-Avid Recurrent/Metastatic Thyroid Cancers,Metastatic Thyroid Gland Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Recurrent Thyroid Gland Carcinoma|Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7|Stage IV Thyroid Gland Follicular Carcinoma AJCC v7|Stage IV Thyroid Gland Papillary Carcinoma AJCC v7,2015-03-16,2020-07-17,2022-12-31,Interventional,"Active, not recruiting",Phase 2,Academic and Community Cancer Research United,Academic and Community Cancer Research United|National Cancer Institute (NCI),UC San Diego Moores Cancer Center|Hoag Memorial Hospital|University of Colorado Hospital|MedStar Georgetown University Hospital|Dana-Farber Cancer Institute|Mayo Clinic in Rochester|Memorial Sloan Kettering Cancer Center|Duke University Medical Center|Ohio State University Comprehensive Cancer Center|Vanderbilt University/Ingram Cancer Center|M D Anderson Cancer Center,Radiation|Other|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT02393690
NCT02393690,"adenocarcinoma, follicular",Randomized Double-Blind Phase II Study of Radioactive Iodine (RAI) in Combination With Placebo or Selumetinib for the Treatment of RAI-Avid Recurrent/Metastatic Thyroid Cancers,Metastatic Thyroid Gland Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Recurrent Thyroid Gland Carcinoma|Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7|Stage IV Thyroid Gland Follicular Carcinoma AJCC v7|Stage IV Thyroid Gland Papillary Carcinoma AJCC v7,2015-03-16,2020-07-17,2022-12-31,Interventional,"Active, not recruiting",Phase 2,Academic and Community Cancer Research United,Academic and Community Cancer Research United|National Cancer Institute (NCI),UC San Diego Moores Cancer Center|Hoag Memorial Hospital|University of Colorado Hospital|MedStar Georgetown University Hospital|Dana-Farber Cancer Institute|Mayo Clinic in Rochester|Memorial Sloan Kettering Cancer Center|Duke University Medical Center|Ohio State University Comprehensive Cancer Center|Vanderbilt University/Ingram Cancer Center|M D Anderson Cancer Center,Radiation|Other|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, follicular",https://clinicaltrials.gov/ct2/show/NCT02393690
NCT02430584,parathyroid diseases,Whole Blood Specimen Collection From Pregnant Subjects,DiGeorge Syndrome|Down Syndrome|Edwards Syndrome|Klinefelter Syndrome|Patau Syndrome|Perinatal Infections|Turner Syndrome,2015-04-27,2021-03-31,2021-05-31,Observational,"Active, not recruiting",,"Progenity, Inc.","Progenity, Inc.",Regional Obstetrical Consultants,Other,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT02430584
NCT02432274,thyroid neoplasms,Phase 1/2 Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma,Differentiated Thyroid Cancer (DTC)|Osteosarcoma|Solid Malignant Tumors|Tumors,2015-04-22,2019-07-18,2022-03-31,Interventional,"Active, not recruiting",Phase 1/Phase 2,Eisai Inc.,Eisai Limited|Merck Sharp & Dohme Corp.,Texas Children's Hospital|CHU Strasbourg - Hopital Hautepierre|Centre Oscar Lambret Lille|Centre Leon Berard|CHU Nantes - Hopital Mere-Enfant|Institut Curie - Centre de Lutte Contre le Cancer (CLCC) de Paris|Institut Gustave Roussy|CHU de Toulouse - Hopital des Enfants|Universitaetsklinikum Muenster|Kinderklinik des Olga hospitals|Istituto Ortopedico Rizzoli|Fondazione IRCCS Istituto Nazionale dei Tumori|Ospedale Pediatrico Bambino Gesu|Hospital Universitari Vall d'Hebron|Hospital Infantil Universitario Nino Jesus|Hospital Universitario y Politecnico La Fe Hospital La Fe Valencia|Birmingham Children's Hospital|University College London Hospital|Royal Victoria Infirmary,Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug,France|Germany|Italy|Spain|United Kingdom|United States,2.0,25.0,[0-17]|[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02432274
NCT02440581,parathyroid diseases,Renal Osteodystrophy: A Fresh Approach,"Kidney Failure, Chronic",2015-05-07,2023-06-30,2023-06-30,Interventional,"Active, not recruiting",Not Applicable,University of Kentucky,"Hartmut Malluche, MD|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Wright State University",University of Kentucky,Drug|Drug|Drug,United States,21.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT02440581
NCT02609685,thyroid neoplasms,Active Surveillance of Papillary Thyroid Microcarcinoma,Papillary Thyroid Microcarcinoma,2015-11-18,2030-12-31,2030-12-31,Interventional,Recruiting,Not Applicable,Cedars-Sinai Medical Center,Cedars-Sinai Medical Center,Cedars-Sinai Medical Center,Other,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02609685
NCT02681328,thyroid nodule,Randomized Trial Comparing Performance of Molecular Markers for Indeterminate Thyroid Nodules,Thyroid,2016-02-10,2022-08-01,2023-12-01,Observational,Recruiting,,Jonsson Comprehensive Cancer Center,Jonsson Comprehensive Cancer Center,Jonsson Comprehensive Cancer Center at UCLA,Other|Other|Other|Other,United States,18.0,100.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT02681328
NCT02681328,thyroid neoplasms,Randomized Trial Comparing Performance of Molecular Markers for Indeterminate Thyroid Nodules,Thyroid,2016-02-10,2022-08-01,2023-12-01,Observational,Recruiting,,Jonsson Comprehensive Cancer Center,Jonsson Comprehensive Cancer Center,Jonsson Comprehensive Cancer Center at UCLA,Other|Other|Other|Other,United States,18.0,100.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02681328
NCT02725879,"thyroiditis, autoimmune","Association of Serum Fibroblast Growth Factor 21 (FGF-21) Levels With Resting Metabolic Rate (RMR), in Children and Adolescents With Hashimoto's Thyroiditis.",Thyroiditis Hashimoto,2016-01-09,2020-09-30,2020-12-31,Observational,Recruiting,,Aristotle University Of Thessaloniki,Aristotle University Of Thessaloniki,"2nd Department of Paediatrics, School of Medicine Faculty of Health Sciences, Aristotle University of Thessaloniki, AHEPA Hospital Thessaloniki, Greece",Other,Greece,5.0,18.0,[0-17]|[18-65],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT02725879
NCT02839655,thyroid neoplasms,Prospective Study Assessing Thyroidectomy Using Robot,Patients With Thyroid Cancer,2016-07-12,2018-05-15,2022-08-31,Interventional,"Active, not recruiting",Phase 2,"Gustave Roussy, Cancer Campus, Grand Paris","Gustave Roussy, Cancer Campus, Grand Paris",Gustave Roussy,Device,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02839655
NCT02859896,parathyroid diseases,"An Open-Label, Randomized, Parallel Group Study to Assess the Safety and Efficacy of Hectorol® (Doxercalciferol Capsules) in Pediatric Patients With Chronic Kidney Disease Stages 3 and 4 With Secondary Hyperparathyroidism Not Yet on Dialysis",Secondary Hyperparathyroidism-Chronic Kidney Disease,2016-08-04,2025-11-12,2025-11-12,Interventional,Recruiting,Phase 3,Sanofi,Sanofi,Investigational Site Number :8400022|Investigational Site Number :8400023|Investigational Site Number :8400033|Investigational Site Number :8400005|Investigational Site Number :8400029|Investigational Site Number :8400006|Investigational Site Number :8400008|Investigational Site Number :8400020|Investigational Site Number :8400036|Investigational Site Number :8400014|Investigational Site Number :8400015|Investigational Site Number :8400010|Investigational Site Number :8400016|Investigational Site Number :8400017|Investigational Site Number :8400007|Investigational Site Number :8400021|Investigational Site Number :8400034|Investigational Site Number :8400025|Investigational Site Number :8400004|Investigational Site Number :8400035|Investigational Site Number :8400028|Investigational Site Number :8400027|Investigational Site Number :8400024|Investigational Site Number :8400013|Investigational Site Number :8400019|Investigational Site Number :8400026|Investigational Site Number :8400009|Investigational Site Number :8400001|Investigational Site Number :1520004|Investigational Site Number :1520003,Drug|Drug,Chile|United States,5.0,18.0,[0-17]|[18-65],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT02859896
NCT02973997,"adenocarcinoma, follicular","Combination Targeted Therapy With Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers: A Phase II Study",Columnar Cell Variant Thyroid Gland Papillary Carcinoma|Follicular Variant Thyroid Gland Papillary Carcinoma|Metastatic Thyroid Gland Follicular Carcinoma|Metastatic Thyroid Gland Papillary Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Recurrent Differentiated Thyroid Gland Carcinoma|Recurrent Thyroid Gland Follicular Carcinoma|Recurrent Thyroid Gland Papillary Carcinoma|Stage III Differentiated Thyroid Gland Carcinoma AJCC v7|Stage III Thyroid Gland Follicular Carcinoma AJCC v7|Stage III Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v7|Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v7|Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVC Differentiated Thyroid Gland Carcinoma AJCC v7|Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7|Stage IV Thyroid Gland Follicular Carcinoma AJCC v7|Stage IV Thyroid Gland Papillary Carcinoma AJCC v7|Tall Cell Variant Thyroid Gland Papillary Carcinoma|Thyroid Gland Hurthle Cell Carcinoma|Unresectable Differentiated Thyroid Gland Carcinoma|Unresectable Thyroid Gland Carcinoma,2016-11-23,2022-10-08,2024-09-30,Interventional,"Active, not recruiting",Phase 2,Academic and Community Cancer Research United,Academic and Community Cancer Research United|National Cancer Institute (NCI),Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center|University of Colorado Hospital|Massachusetts General Hospital Cancer Center|University of Michigan Comprehensive Cancer Center|Memorial Sloan Kettering Cancer Center|Ohio State University Comprehensive Cancer Center|M D Anderson Cancer Center,Other|Drug|Drug|Biological,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, follicular",https://clinicaltrials.gov/ct2/show/NCT02973997
NCT03012620,thyroid neoplasms,Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types,"Carcinoma, Neuroendocrine|Central Nervous System Neoplasm|Neoplasms, Germ Cell and Embryonal|NK/T-cell Lymphoma|Ovarian Neoplasm|Sarcoma|Thyroid Neoplasm",2017-01-02,2023-01-31,2023-12-31,Interventional,"Active, not recruiting",Phase 2,UNICANCER,"Ligue contre le cancer, France|Merck Sharp & Dohme Corp.|National Cancer Institute, France|UNICANCER",Gustave Roussy Cancer Campus,Drug,France,15.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03012620
NCT03013257,goiter,"A Randomized, Open-label, Parallel-group Study to Explore the Efficacy of High-intensity Focused Ultrasound (HIFU) Versus Fixed-dose Radioiodine-131 in the Treatment of Relapsed Graves' Disease",Graves Disease,2017-01-04,2022-04-30,2022-12-31,Interventional,Recruiting,Not Applicable,The University of Hong Kong,The University of Hong Kong,Queen Mary Hospital,Device,Hong Kong,18.0,70.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03013257
NCT03013257,hyperthyroidism,"A Randomized, Open-label, Parallel-group Study to Explore the Efficacy of High-intensity Focused Ultrasound (HIFU) Versus Fixed-dose Radioiodine-131 in the Treatment of Relapsed Graves' Disease",Graves Disease,2017-01-04,2022-04-30,2022-12-31,Interventional,Recruiting,Not Applicable,The University of Hong Kong,The University of Hong Kong,Queen Mary Hospital,Device,Hong Kong,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03013257
NCT03051126,parathyroid diseases,Establishment of a Parathyroid Tissue Bank,Parathyroid Disease,2017-02-02,2025-07-01,2025-07-01,Observational,Recruiting,,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center,University of Texas MD Anderson Cancer Center,Other,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT03051126
NCT03093909,thyroid neoplasms,Phase I Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases,Malignant Neoplasm of Bone and Articular Cartilage|Malignant Neoplasm of Male Genital Organs|Malignant Neoplasm of Respiratory and Intrathoracic Organ Carcinoma|Malignant Neoplasms of Female Genital Organs|Malignant Neoplasms of Independent (Primary) Multiple Sites|Malignant Neoplasms of Lip Oral Cavity and Pharynx|Malignant Neoplasms of Mesothelial and Soft Tissue|Malignant Neoplasms of Thyroid and Other Endocrine Glands|Malignant Neoplasms of Urinary Tract|Melanoma and Other Malignant Neoplasms of Skin,2017-03-21,2021-11-30,2022-11-30,Interventional,Recruiting,Phase 1,M.D. Anderson Cancer Center,Gateway for Cancer Research|James B. and Lois R. Archer Charitable Foundation|M.D. Anderson Cancer Center,The University of Texas MD Anderson Cancer Center,Drug,United States,12.0,50.0,[0-17]|[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03093909
NCT03098225,graves ophthalmopathy,"A Phase IV, Randomized, Multi-center Clinical Trial to Compare the Efficacy of Orbital Radiotherapy in Association With Intravenous Glucocorticoids vs Intravenous Glucocorticoids Alone for Moderately Severe and Active Graves' Orbitopathy",Thyroid Associated Ophthalmopathy,2017-03-21,2024-03-31,2024-03-31,Interventional,Not yet recruiting,Phase 4,University of Pisa,University of Pisa,,Radiation|Drug,,35.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT03098225
NCT03098225,graves disease,"A Phase IV, Randomized, Multi-center Clinical Trial to Compare the Efficacy of Orbital Radiotherapy in Association With Intravenous Glucocorticoids vs Intravenous Glucocorticoids Alone for Moderately Severe and Active Graves' Orbitopathy",Thyroid Associated Ophthalmopathy,2017-03-21,2024-03-31,2024-03-31,Interventional,Not yet recruiting,Phase 4,University of Pisa,University of Pisa,,Radiation|Drug,,35.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT03098225
NCT03098225,goiter,"A Phase IV, Randomized, Multi-center Clinical Trial to Compare the Efficacy of Orbital Radiotherapy in Association With Intravenous Glucocorticoids vs Intravenous Glucocorticoids Alone for Moderately Severe and Active Graves' Orbitopathy",Thyroid Associated Ophthalmopathy,2017-03-21,2024-03-31,2024-03-31,Interventional,Not yet recruiting,Phase 4,University of Pisa,University of Pisa,,Radiation|Drug,,35.0,75.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03098225
NCT03098225,hyperthyroidism,"A Phase IV, Randomized, Multi-center Clinical Trial to Compare the Efficacy of Orbital Radiotherapy in Association With Intravenous Glucocorticoids vs Intravenous Glucocorticoids Alone for Moderately Severe and Active Graves' Orbitopathy",Thyroid Associated Ophthalmopathy,2017-03-21,2024-03-31,2024-03-31,Interventional,Not yet recruiting,Phase 4,University of Pisa,University of Pisa,,Radiation|Drug,,35.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03098225
NCT03105648,thyroid neoplasms,Diagnostic and Prognostic Significance of Computerized Cytologic Morphometry of the Thyroid Neoplasm,Computerized Cytomorphometry,2017-04-04,2026-04-20,2026-04-20,Observational,Recruiting,,National Taiwan University Hospital,National Taiwan University Hospital,National Taiwan University Hospital,Other,Taiwan,20.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03105648
NCT03109847,thyroid neoplasms,Pilot Study of Metformin to Mitigate Sequelae of Radioactive Iodine Treatment for Well-Differentiated Thyroid Cancers,Thyroid,2017-03-06,2022-01-31,2022-01-31,Interventional,"Active, not recruiting",Phase 2,Thomas Jefferson University,Sidney Kimmel Cancer Center at Thomas Jefferson University,Sidney Kimmel Cancer Center at Thomas Jefferson University,Drug|Other|Other,United States,18.0,90.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03109847
NCT03122496,"thyroid carcinoma, anaplastic",A Pilot Study of Durvalumab (MEDI4736) With Tremelimumab in Combination With Image Guided Stereotactic Body Radiotherapy (SBRT) in the Treatment of Metastatic Anaplastic Thyroid Cancer,Metastatic Anaplastic Thyroid Cancer,2017-04-18,2023-04-30,2023-04-30,Interventional,"Active, not recruiting",Phase 1,Memorial Sloan Kettering Cancer Center,AstraZeneca|Memorial Sloan Kettering Cancer Center,Memoral Sloan Kettering Basking Ridge|Memoral Sloan Kettering Monmouth|Memorial Sloan Kettering Bergen|Memorial Sloan Kettering Commack|Memoral Sloan Kettering Westchester|Memorial Sloan Kettering Cancer Center|Memorial Sloan Kettering @ Rockville|Memorial Sloan Kettering Nassau,Drug|Drug|Radiation,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT03122496
NCT03122847,graves disease,The Effect of 4.5 Gram Methylprednisolone Administered Once Weekly for 12 Weeks on Bone Metabolism in Graves´ Ophthalmopathy,Graves Ophthalmopathy,2017-04-18,2022-07-31,2023-07-31,Observational,"Active, not recruiting",,Aarhus University Hospital,Odense University Hospital|Torben Harsløf,Aarhus University Hospital|Odense University Hospital,Drug,Denmark,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT03122847
NCT03122847,goiter,The Effect of 4.5 Gram Methylprednisolone Administered Once Weekly for 12 Weeks on Bone Metabolism in Graves´ Ophthalmopathy,Graves Ophthalmopathy,2017-04-18,2022-07-31,2023-07-31,Observational,"Active, not recruiting",,Aarhus University Hospital,Odense University Hospital|Torben Harsløf,Aarhus University Hospital|Odense University Hospital,Drug,Denmark,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03122847
NCT03122847,hyperthyroidism,The Effect of 4.5 Gram Methylprednisolone Administered Once Weekly for 12 Weeks on Bone Metabolism in Graves´ Ophthalmopathy,Graves Ophthalmopathy,2017-04-18,2022-07-31,2023-07-31,Observational,"Active, not recruiting",,Aarhus University Hospital,Odense University Hospital|Torben Harsløf,Aarhus University Hospital|Odense University Hospital,Drug,Denmark,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03122847
NCT03131726,graves disease,Treatment of Graves´Ophthalmopathy With Simvastatin (GO-DS),Graves Ophthalmopathy|Thyroid Associated Ophthalmopathy|Thyroid Associated Orbitopathy,2017-03-10,2024-01-26,2024-03-30,Interventional,Recruiting,Phase 3,Lund University,Lund University,"Dpt. of Endocrinology, SUS Malmö",Drug,Sweden,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT03131726
NCT03131726,goiter,Treatment of Graves´Ophthalmopathy With Simvastatin (GO-DS),Graves Ophthalmopathy|Thyroid Associated Ophthalmopathy|Thyroid Associated Orbitopathy,2017-03-10,2024-01-26,2024-03-30,Interventional,Recruiting,Phase 3,Lund University,Lund University,"Dpt. of Endocrinology, SUS Malmö",Drug,Sweden,18.0,70.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03131726
NCT03131726,hyperthyroidism,Treatment of Graves´Ophthalmopathy With Simvastatin (GO-DS),Graves Ophthalmopathy|Thyroid Associated Ophthalmopathy|Thyroid Associated Orbitopathy,2017-03-10,2024-01-26,2024-03-30,Interventional,Recruiting,Phase 3,Lund University,Lund University,"Dpt. of Endocrinology, SUS Malmö",Drug,Sweden,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03131726
NCT03162627,thyroid neoplasms,"Evaluation of the Combination of Selumetinib and Olaparib in Endometrial, Ovarian and Other Solid Tumors With Ras Pathway Alterations, and Ovarian Tumors With PARP Resistance",Malignant Neoplasm of Breast|Malignant Neoplasms of Digestive Organs|Malignant Neoplasms of Female Genital Organs|Malignant Neoplasms of Male Genital Organs|Malignant Neoplasms of Thyroid and Other Endocrine Glands,2017-05-18,2026-08-30,2026-08-30,Interventional,Recruiting,Phase 1,M.D. Anderson Cancer Center,AstraZeneca|M.D. Anderson Cancer Center,University of Texas MD Anderson Cancer Center,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03162627
NCT03244956,thyroid neoplasms,Efficacy of a Selective MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors Associated With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer With RAS or BRAFV600E Mutation,Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation,2017-08-07,2021-11-18,2022-12-31,Interventional,"Active, not recruiting",Phase 2,"Gustave Roussy, Cancer Campus, Grand Paris","Gustave Roussy, Cancer Campus, Grand Paris",Gustave Roussy,Drug|Drug|Radiation|Drug,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03244956
NCT03249012,parathyroid diseases,Comparing the Quality of Life Associated With Empiric Calcium Repletion and Parathormone (PTH) Based Calcium Repletion for Post Thyroidectomy Hypoparathyroidism,Hypoparathyroidism Postprocedural|Quality of Life,2017-08-09,2022-09-01,2022-09-01,Interventional,Recruiting,Not Applicable,CHU de Quebec-Universite Laval,CHU de Quebec-Universite Laval,CHU de Quebec,Other|Other,Canada,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT03249012
NCT03271892,"thyroid cancer, papillary",Deciding on Active Surveillance as an Alternative Option to Surgery in the Primary Management of Low Risk Papillary Thyroid Cancer,Thyroid Cancer Stage I,2017-08-28,2026-05-11,2026-12-31,Observational,Recruiting,,"University Health Network, Toronto","Canadian Cancer Society (CCS)|Ontario Ministry of Health and Long Term Care|University Health Network, Toronto",University Health Network|University Health Network,,Canada,18.0,100.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT03271892
NCT03274258,thyroid neoplasms,Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma,Kidney Medullary Carcinoma|Loss of INI 1 Protein Expression|Stage III Renal Cell Cancer AJCC v8|Stage IV Renal Cell Cancer AJCC v8,2017-09-05,2022-07-31,2023-07-31,Interventional,"Active, not recruiting",Phase 2,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center|National Cancer Institute (NCI),M D Anderson Cancer Center,Biological|Biological,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03274258
NCT03285854,parathyroid diseases,Assessing Calcium Balance in Children With Chronic Kidney Disease to Optimise Treatment Strategies,Chronic Kidney Disease Mineral and Bone Disorder,2017-09-12,2021-12-30,2022-12-30,Observational,"Active, not recruiting",,Great Ormond Street Hospital for Children NHS Foundation Trust,"Athens General Children's Hospital ""Pan. & Aglaia Kyriakou""|Cukurova University|Great Ormond Street Hospital for Children NHS Foundation Trust|University of Kiel",Great Ormond Street Hospital for Children NHS Foundation Trust,Diagnostic Test,United Kingdom,0.0,18.0,[0-17]|[18-65],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT03285854
NCT03300284,"thyroid cancer, papillary",Decision Making and Psychological Outcomes in Low-Risk Papillary Thyroid Cancer,Thyroid Cancer,2017-09-28,2022-08-31,2022-08-31,Observational,"Active, not recruiting",,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Hartford Healthcare (Data Collection)|Memoral Sloan Kettering Monmouth (Consent and Follow up)|MAIMONIDES MEDICAL CENTER (Data collection only)|NYU Langone Health|Memorial Sloan Kettering Cancer Center|Lehigh Valley Health Network,Behavioral,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT03300284
NCT03309384,parathyroid diseases,Intraoperative Monitoring (Parathormone Values and Continuous Neuromonitoring) to Predict Postoperative Complications After Total Thyroidectomy,Endocrine Procedural Complications|Laryngeal Injury|Parathyroid; Deficiency|Thyroid,2017-09-06,2026-03-20,2026-03-20,Observational [Patient Registry],Recruiting,,"Central Hospital, Nancy, France","Central Hospital, Nancy, France",CHU Nancy,,France,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT03309384
NCT03375359,parathyroid diseases,"First Trimester Screening for Trisomy 21, 18, 13 and 22q11.2 Deletion Syndrome - ReFaPo02",Pregnancy,2017-12-12,2022-08-31,2022-08-31,Observational,Recruiting,,University Hospital Tuebingen,University Hospital Tuebingen,"University Hospital Tuebingen, Department of Women's Health",Diagnostic Test,Germany,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT03375359
NCT03382158,goiter,"International Pleuropulmonary Blastoma Registry for PPB, DICER1 and Associated Conditions",Ciliary Body Medulloepithelioma|Cystic Nephroma|DICER1 Syndrome|Embryonal Rhabdomyosarcoma|Nasal Chondromesenchymal Hamartoma|Neuroblastoma|Nodular Hyperplasia of Thyroid|Pineoblastoma|Pituitary Cancer|Pleuropulmonary Blastoma|Renal Sarcoma|Sertoli-Leydig Cell Tumor|Wilms Tumor,2017-10-11,2023-12-06,2026-12-06,Observational,Recruiting,,Children's Hospitals and Clinics of Minnesota,"Beijing Children's Hospital|Children's Hospitals and Clinics of Minnesota|Children's National Research Institute|Dana-Farber Cancer Institute|Emory University|ResourcePath, LLC|University of Cambridge|Washington University School of Medicine",Children's Minnesota,,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03382158
NCT03395925,thyroid neoplasms,Evaluation of the Thyroid Volume After Radiofrequency Ablation of Thyroid Nodules and Recurrent Thyroid,Thyroid Nodule,2017-12-17,2021-10-30,2022-01-30,Interventional,"Active, not recruiting",Not Applicable,Olympus Surgical Technologies Europe,Olympus Surgical Technologies Europe,Johann-Wolfgang Goethe University,Device,Germany,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03395925
NCT03420963,thyroid neoplasms,Ex-Vivo Expanded Allogeneic NK Cells for the Treatment of Solid Tumors of Pediatric Origin in Children and Young Adults,Recurrent Cutaneous Melanoma|Recurrent Lip and Oral Cavity Carcinoma|Recurrent Malignant Endocrine Neoplasm|Recurrent Malignant Female Reproductive System Neoplasm|Recurrent Malignant Male Reproductive System Neoplasm|Recurrent Malignant Mesothelioma|Recurrent Malignant Neoplasm of Multiple Primary Sites|Recurrent Malignant Oral Neoplasm|Recurrent Malignant Pharyngeal Neoplasm|Recurrent Malignant Skin Neoplasm|Recurrent Malignant Soft Tissue Neoplasm|Recurrent Malignant Solid Neoplasm|Recurrent Malignant Thyroid Gland Neoplasm|Recurrent Malignant Urinary System Neoplasm|Refractory Cutaneous Melanoma|Refractory Malignant Bone Neoplasm|Refractory Malignant Endocrine Neoplasm|Refractory Malignant Female Reproductive System Neoplasm|Refractory Malignant Male Reproductive System Neoplasm|Refractory Malignant Mesothelioma|Refractory Malignant Neoplasm of Multiple Primary Sites|Refractory Malignant Oral Neoplasm|Refractory Malignant Pharyngeal Neoplasm|Refractory Malignant Skin Neoplasm|Refractory Malignant Soft Tissue Neoplasm|Refractory Malignant Solid Neoplasm|Refractory Malignant Thyroid Gland Neoplasm|Refractory Malignant Urinary System Neoplasm,2018-01-29,2022-12-01,2022-12-01,Interventional,Recruiting,Phase 1,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center|National Cancer Institute (NCI),M D Anderson Cancer Center,Biological|Drug|Drug,United States,12.0,40.0,[0-17]|[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03420963
NCT03435952,thyroid neoplasms,A Phase Ib Investigation of Pembrolizumab in Combination With Intratumoral Injection of Clostridium Novyi-NT in Patients With Treatment-Refractory Solid Tumors,Malignant Neoplasm of Breast|Malignant Neoplasms of Digestive Organs|Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System|Malignant Neoplasms of Female Genital Organs|Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites|Malignant Neoplasms of Independent (Primary) Multiple Sites|Malignant Neoplasms of Lip Oral Cavity and Pharynx|Malignant Neoplasms of Male Genital Organs|Malignant Neoplasms of Mesothelial and Soft Tissue|Malignant Neoplasms of Respiratory and Intrathoracic Organs|Malignant Neoplasms of Thyroid and Other Endocrine Glands|Malignant Neoplasms of Urinary Tract,2018-02-09,2021-10-31,2021-10-31,Interventional,Recruiting,Phase 1,M.D. Anderson Cancer Center,"BioMed Valley Discoveries, Inc|M.D. Anderson Cancer Center|Merck Sharp & Dohme Corp.",University of Texas MD Anderson Cancer Center,Drug|Biological|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03435952
NCT03440697,parathyroid diseases,Pathogenetic Basis of Aortopathy and Aortic Valve Disease,Aortic Valve Disease|Aortopathies|Arterial Tortuosity Syndrome|Ascending Aortic Aneurysm|Ascending Aortic Disease|Autosomal Recessive Cutis Laxa|Congenital Contractural Arachnodactyly|Descending Aortic Aneurysm|Descending Aortic Disease|Ehlers-Danlos Syndrome|Loeys-Dietz Syndrome|Marfan Syndrome|PHACE Syndrome|Shprintzen-Goldberg Syndrome|Thoracic Aortic Aneurysm|Thoracic Aortic Disease|Thoracic Aortic Dissection|Thoracic Aortic Rupture|Turner Syndrome,2017-10-06,2025-12-31,2028-12-31,Observational,Recruiting,,Indiana University,Indiana University,IU School of Medicine,,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT03440697
NCT03498183,thyroid nodule,Value of the Combination Ultrasonography With Ti-RADS Score / Dual Tracer Scintigraphy MIBI-Tc99m/Iodine-123 in the Detection of Malignancy of Thyroid Nodules (Sup or Egal to 15 mm) Classified Bethesda III or IV on Cytology,Malignancy of Thyroid Nodules,2018-03-29,2021-07-01,2021-07-01,Interventional,Recruiting,Phase 2/Phase 3,Nantes University Hospital,Nantes University Hospital,Centre Hospitalier et Universitaire (chu)|CHU|CHU|CHU|Hospices Civils|CHU|Assistance publique des Hôpitaux de Paris,Drug,France,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT03498183
NCT03498183,thyroid neoplasms,Value of the Combination Ultrasonography With Ti-RADS Score / Dual Tracer Scintigraphy MIBI-Tc99m/Iodine-123 in the Detection of Malignancy of Thyroid Nodules (Sup or Egal to 15 mm) Classified Bethesda III or IV on Cytology,Malignancy of Thyroid Nodules,2018-03-29,2021-07-01,2021-07-01,Interventional,Recruiting,Phase 2/Phase 3,Nantes University Hospital,Nantes University Hospital,Centre Hospitalier et Universitaire (chu)|CHU|CHU|CHU|Hospices Civils|CHU|Assistance publique des Hôpitaux de Paris,Drug,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03498183
NCT03515863,graves ophthalmopathy,Natural History and Genetic Risk Factors of Thyroid Associated Ophthalmopathy (TAO),Thyroid Associated Ophthalmopathy,2018-04-23,2021-05-09,2022-05-09,Observational,Recruiting,,Sun Yat-sen University,Sun Yat-sen University,"Zhognshan Ophthalmic Center, Sun Yat-sen University|the First People's Hospital of Zhaoqing",Genetic|Device|Other,China,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT03515863
NCT03515863,graves disease,Natural History and Genetic Risk Factors of Thyroid Associated Ophthalmopathy (TAO),Thyroid Associated Ophthalmopathy,2018-04-23,2021-05-09,2022-05-09,Observational,Recruiting,,Sun Yat-sen University,Sun Yat-sen University,"Zhognshan Ophthalmic Center, Sun Yat-sen University|the First People's Hospital of Zhaoqing",Genetic|Device|Other,China,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT03515863
NCT03515863,goiter,Natural History and Genetic Risk Factors of Thyroid Associated Ophthalmopathy (TAO),Thyroid Associated Ophthalmopathy,2018-04-23,2021-05-09,2022-05-09,Observational,Recruiting,,Sun Yat-sen University,Sun Yat-sen University,"Zhognshan Ophthalmic Center, Sun Yat-sen University|the First People's Hospital of Zhaoqing",Genetic|Device|Other,China,18.0,80.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03515863
NCT03515863,hyperthyroidism,Natural History and Genetic Risk Factors of Thyroid Associated Ophthalmopathy (TAO),Thyroid Associated Ophthalmopathy,2018-04-23,2021-05-09,2022-05-09,Observational,Recruiting,,Sun Yat-sen University,Sun Yat-sen University,"Zhognshan Ophthalmic Center, Sun Yat-sen University|the First People's Hospital of Zhaoqing",Genetic|Device|Other,China,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03515863
NCT03517579,goiter,Personalized Treatment Planning for Radio-iodine Therapy of Thyroid Disease,Graves Disease|Thyroid Cancer,2018-04-03,2024-10-15,2024-12-15,Interventional,Recruiting,Not Applicable,Johns Hopkins University,Johns Hopkins University,Johns Hopkins Hospital,Device,United States,21.0,65.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03517579
NCT03517579,hyperthyroidism,Personalized Treatment Planning for Radio-iodine Therapy of Thyroid Disease,Graves Disease|Thyroid Cancer,2018-04-03,2024-10-15,2024-12-15,Interventional,Recruiting,Not Applicable,Johns Hopkins University,Johns Hopkins University,Johns Hopkins Hospital,Device,United States,21.0,65.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03517579
NCT03574051,hypothyroidism,Distinct Shifts in the Microbiota Are Associated With Iodine-131 Therapy and Hypothyroidism,Microbiota,2018-06-19,2020-05-01,2022-05-01,Interventional,Recruiting,Early Phase 1,First Affiliated Hospital of Harbin Medical University,First Affiliated Hospital of Harbin Medical University,First affiliated hospital of Harbin medical university,Drug,China,18.0,65.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT03574051
NCT03602261,parathyroid diseases,"A Multi-Center, Randomized, Two-Cohort Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of CTAP101 (Calcifediol) Extended-Release Capsules to Treat Secondary Hyperparathyroidism in Subjects With Vitamin D Insufficiency and Chronic Kidney Disease Requiring Regular Hemodialysis.",Chronic Kidney Diseases|Secondary Hyperparathyroidism Due to Renal Causes|Stage 5 Chronic Kidney Disease|Vitamin D Deficiency,2018-07-13,2023-03-31,2023-03-31,Interventional,"Active, not recruiting",Phase 2,"OPKO Health, Inc.","OPKO Health, Inc.","AKDHC Medical Research Services|AKDHC Medical Research Services|AKDHC Medical Research Services|AKDHC Medical Research Services|WCCT Global, Inc.|Hacienda Dialysis Center|California Institute of Renal Research CKD/Dialysis & Transplant Division|Long Beach Quest Dialysis Center|Ontario Dialysis Center|North America Research Institute, Inc.|Laurel Canyon Dialysis, LLC|University of Colorado Denver Anschutz Medical Campus|Research by Design, LLC|Northshore University Health|Renal and Transplant Associates of New England|Southwest MS Nephrology|Southwest Houston Research LTD|Kidney & Hypertension Specialists",Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT03602261
NCT03643081,parathyroid diseases,"Evaluation of the Interest of the Medical Device Called ""Fluobeam"" in the Localization, Visualization of the Parathyroid Glands for Patients With Mild Primary Hyperparathyroidism. A Randomized Controled Prospective Open -Labeled Monocentric Study.",Mild Primary Hyperparathyroidism,2018-08-21,2024-06-30,2024-06-30,Interventional,Recruiting,Not Applicable,Nantes University Hospital,Nantes University Hospital,CHU de Nantes,Device,France,18.0,80.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT03643081
NCT03646383,thyroid nodule,Study of the Feasibility of Radiofrequency Ablation of Benign Thyroid Nodules by Percutaneous Radiological Approach,Benign Thyroid Nodules,2018-03-25,2021-12-31,2021-12-31,Interventional,Recruiting,Not Applicable,"University Hospital, Toulouse","University Hospital, Toulouse","CHU Toulouse, Hôpital Larrey",Procedure,France,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT03646383
NCT03646383,thyroid neoplasms,Study of the Feasibility of Radiofrequency Ablation of Benign Thyroid Nodules by Percutaneous Radiological Approach,Benign Thyroid Nodules,2018-03-25,2021-12-31,2021-12-31,Interventional,Recruiting,Not Applicable,"University Hospital, Toulouse","University Hospital, Toulouse","CHU Toulouse, Hôpital Larrey",Procedure,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03646383
NCT03676647,thyroid neoplasms,Retrospective-Prospective Collection of Thyroid Specimens After FNA,Thyroid Gland Nodule,2018-09-17,2023-12-31,2023-12-31,Observational,Recruiting,,City of Hope Medical Center,City of Hope Medical Center|National Cancer Institute (NCI),City of Hope Medical Center,Other,United States,19.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03676647
NCT03708627,graves disease,The Role of Bimatoprost in Graves' Periorbitopathy,Graves Ophthalmopathy,2018-10-13,2022-05-31,2022-06-30,Interventional,Recruiting,Early Phase 1,Johns Hopkins University,Johns Hopkins University,University of Washington,Drug,United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT03708627
NCT03708627,goiter,The Role of Bimatoprost in Graves' Periorbitopathy,Graves Ophthalmopathy,2018-10-13,2022-05-31,2022-06-30,Interventional,Recruiting,Early Phase 1,Johns Hopkins University,Johns Hopkins University,University of Washington,Drug,United States,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03708627
NCT03708627,hyperthyroidism,The Role of Bimatoprost in Graves' Periorbitopathy,Graves Ophthalmopathy,2018-10-13,2022-05-31,2022-06-30,Interventional,Recruiting,Early Phase 1,Johns Hopkins University,Johns Hopkins University,University of Washington,Drug,United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03708627
NCT03718403,pseudopseudohypoparathyroidism,Effect of Theophylline in Pseudohypoparathyroidism,Php1C|PHP Ia|PHP IB,2017-09-08,2030-04-10,2032-04-10,Interventional,Not yet recruiting,Phase 4,Massachusetts General Hospital,Massachusetts General Hospital,,Drug,,5.0,21.0,[0-17]|[18-65],Parathyroid diseases,pseudohypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03718403
NCT03724188,parathyroid diseases,Impact of Parathyroidectomy on Vascular Calcification and Clinical Outcome in Hemodialysis Patients,Hyperparathyroidism Tertiary,2018-10-24,2022-12-30,2022-12-30,Observational,Recruiting,,Mansoura General Hospital,Mansoura General Hospital,Faculty of medicine - Mansoura university,Procedure,Egypt,18.0,80.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT03724188
NCT03732495,thyroid neoplasms,"A Prospective, Multicentre Phase II Study of the Efficacy of Lenvatinib Combined With Denosumab in the Treatment of Patients With Predominant Bone Metastatic Radioiodine Refractory Differentiated Thyroid Carcinomas (LENVOS)",Thyroid Cancer Metastatic,2018-10-31,2022-12-15,2023-01-15,Interventional,Recruiting,Phase 2,Centre Leon Berard,Centre Leon Berard,CHU Angers|CHRU Besançon|CHU Bordeaux - Hôpital Saint-André|Institut Bergonie|Hospices Civils de Lyon - Groupement Hospitalier Est|Centre Geogres François Leclerc|Centre Léon Bérard|Centre Antoine Lacassagne|APHP Saint Louis|APHP La Pitié Salpétrière|Institut Jean Godinot|Institut du Cancer Strasbourg (ICANS)|Institut Universitaire du Cancer de Toulouse - Oncopole|Institut Gustave Roussy,Drug,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03732495
NCT03753919,"adenocarcinoma, follicular","A Phase II Study of Durvalumab (MEDI4736) Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma - The DUTHY Trial",Metastatic Thyroid Cancer|Metastatic Thyroid Follicular Carcinoma|Metastatic Thyroid Papillary Carcinoma,2018-11-20,2022-07-31,2022-12-31,Interventional,Recruiting,Phase 2,Grupo Espanol de Tumores Neuroendocrinos,Grupo Espanol de Tumores Neuroendocrinos|MFAR,Instituto Catalán de Oncología de Hospitalet|Hospital Provincial de Castellón|Hospital Clínic Barcelona|Hospital Universitari Vall d'Hebron|MD Anderson Cancer Center|Hospital Clínico San Carlos|Hospital Universitario 12 de Octubre|Hospital Universitario HM Sanchinarro|Hospital Universitario La Paz|Hospital Universitario Ramón y Cajal|Hospital General Universitario Morales Meseguer|Hospital Universitario Virgen de la Victoria|Clínica Universidad de Navarra|Instituto Valenciano de Oncología|Complejo Hospitalario Universitario de Vigo (CHUVI),Drug|Drug,Spain,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, follicular",https://clinicaltrials.gov/ct2/show/NCT03753919
NCT03753919,"thyroid cancer, papillary","A Phase II Study of Durvalumab (MEDI4736) Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma - The DUTHY Trial",Metastatic Thyroid Cancer|Metastatic Thyroid Follicular Carcinoma|Metastatic Thyroid Papillary Carcinoma,2018-11-20,2022-07-31,2022-12-31,Interventional,Recruiting,Phase 2,Grupo Espanol de Tumores Neuroendocrinos,Grupo Espanol de Tumores Neuroendocrinos|MFAR,Instituto Catalán de Oncología de Hospitalet|Hospital Provincial de Castellón|Hospital Clínic Barcelona|Hospital Universitari Vall d'Hebron|MD Anderson Cancer Center|Hospital Clínico San Carlos|Hospital Universitario 12 de Octubre|Hospital Universitario HM Sanchinarro|Hospital Universitario La Paz|Hospital Universitario Ramón y Cajal|Hospital General Universitario Morales Meseguer|Hospital Universitario Virgen de la Victoria|Clínica Universidad de Navarra|Instituto Valenciano de Oncología|Complejo Hospitalario Universitario de Vigo (CHUVI),Drug|Drug,Spain,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT03753919
NCT03808779,thyroid neoplasms,"A Multicenter, Randomized and Controlled Trial of Radiofrequency Ablation vs. Conventional Surgery as Treatment of Papillary Thyroid Microcarcinoma (PTMC)",Papillary Thyroid Microcarcinoma,2019-01-13,2024-02-01,2024-02-01,Interventional,Recruiting,Not Applicable,"Second Affiliated Hospital, School of Medicine, Zhejiang University","Second Affiliated Hospital, School of Medicine, Zhejiang University","General Surgery Department, Tianjin Medical University General Hospital|Department of Ultrasound, Second Affiliated Hospital, School of Medicine, Zhejiang University|Interventional Oncology Centre, State Institution ""Grigoriev Intstitute for Medical Radiology NAMS of Ukraine""",Procedure|Procedure,China|Ukraine,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03808779
NCT03813173,"thyroid cancer, papillary",Central Cervical Dissection for Clinical Node Negative Papillary Thyroid Carcinoma: a Prospective Study,Lymph Node Metastases,2019-01-16,2040-12-31,2040-12-31,Interventional,Not yet recruiting,Not Applicable,Zhejiang University,Zhejiang University,,Procedure,,18.0,80.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT03813173
NCT03813706,"thyroid cancer, papillary",Prospective Study for the Dissection of Lymph Node Posterior to Right Recurrent Laryngeal Nerve for Papillary Thyroid Carcinoma,Lymph Node Metastases,2019-01-16,2040-12-31,2040-12-31,Interventional,Not yet recruiting,Not Applicable,Zhejiang University,Zhejiang University,,Procedure,,18.0,80.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT03813706
NCT03830242,"thyroid cancer, papillary","Diagnostic Significance of Single Center, Open and Prospective Evaluation of <Sup>18<Sup>F-FDG PET/CT Dynamic Imaging in Detecting Metastatic Central Lymph Nodes in Patients With Papillary Thyroid Cancer",Lymph Node Metastases|Positron-Emission Tomography|Thyroid Cancer,2018-12-17,2022-12-31,2022-12-31,Interventional,Recruiting,Not Applicable,"Fifth Affiliated Hospital, Sun Yat-Sen University","Fifth Affiliated Hospital, Sun Yat-Sen University","Fifth Affiliated Hospital, Sun Yat-Sen University",Diagnostic Test|Diagnostic Test,China,18.0,65.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT03830242
NCT03866382,thyroid neoplasms,"A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)","Bladder Adenocarcinoma|Bladder Clear Cell Adenocarcinoma|Bladder Mixed Adenocarcinoma|Bladder Neuroendocrine Carcinoma|Bladder Small Cell Neuroendocrine Carcinoma|Bladder Squamous Cell Carcinoma|Bladder Urachal Adenocarcinoma|Chromophobe Renal Cell Carcinoma|Collecting Duct Carcinoma|Infiltrating Bladder Lymphoepithelioma-Like Carcinoma|Infiltrating Bladder Urothelial Carcinoma|Infiltrating Bladder Urothelial Carcinoma, Nested Variant|Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant|Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Variant|Infiltrating Bladder Urothelial Carcinoma With Giant Cells|Kidney Medullary Carcinoma|Large Cell Neuroendocrine Carcinoma|Metastatic Bladder Carcinoma|Metastatic Bladder Large Cell Neuroendocrine Carcinoma|Metastatic Bladder Small Cell Neuroendocrine Carcinoma|Metastatic Bladder Squamous Cell Carcinoma|Metastatic Infiltrating Bladder Urothelial Carcinoma, Clear Cell Variant|Metastatic Infiltrating Bladder Urothelial Carcinoma, Lipid-Rich Variant|Metastatic Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant|Metastatic Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant|Metastatic Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Variant|Metastatic Kidney Medullary Carcinoma|Metastatic Malignant Genitourinary System Neoplasm|Metastatic Penile Carcinoma|Metastatic Prostate Small Cell Neuroendocrine Carcinoma|Metastatic Sarcomatoid Renal Cell Carcinoma|Metastatic Urethral Carcinoma|Papillary Renal Cell Carcinoma|Sarcomatoid Renal Cell Carcinoma|Stage IVA Bladder Cancer AJCC v8|Stage IVA Prostate Cancer AJCC v8|Stage IVB Bladder Cancer AJCC v8|Stage IV Bladder Cancer AJCC v8|Stage IVB Prostate Cancer AJCC v8|Stage IV Penile Cancer AJCC v8|Stage IV Prostate Cancer AJCC v8|Stage IV Renal Cell Cancer AJCC v8|Stage IV Urethral Cancer AJCC v8|Testicular Leydig Cell Tumor|Testicular Sertoli Cell Tumor|Urethral Clear Cell Adenocarcinoma",2019-03-06,2023-02-28,2023-02-28,Interventional,Recruiting,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),University of Alabama at Birmingham Cancer Center|Anchorage Associates in Radiation Medicine|Anchorage Radiation Therapy Center|Alaska Breast Care and Surgery LLC|Alaska Oncology and Hematology LLC|Alaska Women's Cancer Care|Anchorage Oncology Centre|Katmai Oncology Group|Providence Alaska Medical Center|Kingman Regional Medical Center|Cancer Center at Saint Joseph's|Mayo Clinic Hospital in Arizona|Mayo Clinic in Arizona|University of Arizona Cancer Center-Orange Grove Campus|Banner University Medical Center - Tucson|University of Arizona Cancer Center-North Campus|Mercy Hospital Fort Smith|CHI Saint Vincent Cancer Center Hot Springs|Mission Hope Medical Oncology - Arroyo Grande|PCR Oncology|Providence Saint Joseph Medical Center/Disney Family Cancer Center|Community Cancer Institute|University Oncology Associates|Epic Care-Dublin|Bay Area Breast Surgeons Inc|Epic Care Partners in Cancer Care|Marin Cancer Care Inc|Los Angeles County-USC Medical Center|USC / Norris Comprehensive Cancer Center|UCLA / Jonsson Comprehensive Cancer Center|Contra Costa Regional Medical Center|USC Norris Oncology/Hematology-Newport Beach|Alta Bates Summit Medical Center - Summit Campus|Bay Area Tumor Institute|Pacific Central Coast Health Center-San Luis Obispo|Mission Hope Medical Oncology - Santa Maria|Epic Care Cyberknife Center|Penrose-Saint Francis Healthcare|Rocky Mountain Cancer Centers-Penrose|Porter Adventist Hospital|Mercy Medical Center|Southwest Oncology PC|Saint Anthony Hospital|Littleton Adventist Hospital|Longmont United Hospital|Rocky Mountain Cancer Centers-Longmont|Parker Adventist Hospital|Saint Mary Corwin Medical Center|MedStar Georgetown University Hospital|Mount Sinai Comprehensive Cancer Center at Aventura|Holy Cross Hospital|Mayo Clinic in Florida|Mount Sinai Medical Center|Orlando Health Cancer Institute|Emory University Hospital Midtown|Emory University Hospital/Winship Cancer Institute|Emory Saint Joseph's Hospital|Emory Johns Creek Hospital|Saint Alphonsus Cancer Care Center-Boise|Saint Luke's Cancer Institute - Boise|Saint Alphonsus Cancer Care Center-Caldwell|Kootenai Health - Coeur d'Alene|Walter Knox Memorial Hospital|Saint Luke's Cancer Institute - Fruitland|Idaho Urologic Institute-Meridian|Saint Luke's Cancer Institute - Meridian|Saint Alphonsus Medical Center-Nampa|Saint Luke's Cancer Institute - Nampa|Kootenai Clinic Cancer Services - Post Falls|Kootenai Cancer Clinic|Saint Luke's Cancer Institute - Twin Falls|Saint Anthony's Health|Rush - Copley Medical Center|Illinois CancerCare-Bloomington|Loyola Center for Health at Burr Ridge|Illinois CancerCare-Canton|Memorial Hospital of Carbondale|SIH Cancer Institute|Illinois CancerCare-Carthage|Northwestern University|Rush University Medical Center|University of Illinois|University of Chicago Comprehensive Cancer Center|Carle on Vermilion|Cancer Care Specialists of Illinois - Decatur|Decatur Memorial Hospital|Illinois CancerCare-Dixon|Carle Physician Group-Effingham|Crossroads Cancer Center|Illinois CancerCare-Eureka|Illinois CancerCare-Galesburg|Western Illinois Cancer Treatment Center|Loyola Medicine Homer Glen|Illinois CancerCare-Kewanee Clinic|Northwestern Medicine Lake Forest Hospital|Illinois CancerCare-Macomb|Carle Physician Group-Mattoon/Charleston|Loyola University Medical Center|Marjorie Weinberg Cancer Center at Loyola-Gottlieb|Good Samaritan Regional Health Center|UC Comprehensive Cancer Center at Silver Cross|Cancer Care Center of O'Fallon|University of Chicago Medicine-Orland Park|Illinois CancerCare-Ottawa Clinic|Illinois CancerCare-Pekin|Illinois CancerCare-Peoria|Methodist Medical Center of Illinois|Illinois CancerCare-Peru|Valley Radiation Oncology|Illinois CancerCare-Princeton|Southern Illinois University School of Medicine|Springfield Clinic|Memorial Medical Center|Southwest Illinois Health Services LLP|Carle Cancer Center|The Carle Foundation Hospital|Illinois CancerCare - Washington|Rush-Copley Healthcare Center|Reid Health|Mary Greeley Medical Center|McFarland Clinic PC - Ames|McFarland Clinic PC-Boone|Medical Oncology and Hematology Associates-West Des Moines|Mercy Cancer Center-West Lakes|Alegent Health Mercy Hospital|Greater Regional Medical Center|Medical Oncology and Hematology Associates-Laurel|Mercy Medical Center - Des Moines|McFarland Clinic PC-Trinity Cancer Center|McFarland Clinic PC-Jefferson|McFarland Clinic PC-Marshalltown|Mercy Medical Center-West Lakes|Cancer Center of Kansas - Chanute|Cancer Center of Kansas - Dodge City|Cancer Center of Kansas - El Dorado|University of Kansas Clinical Research Center|Central Care Cancer Center - Garden City|Central Care Cancer Center - Great Bend|HaysMed University of Kansas Health System|Cancer Center of Kansas-Independence|Cancer Center of Kansas-Kingman|Lawrence Memorial Hospital|Cancer Center of Kansas-Liberal|Cancer Center of Kansas-Manhattan|Cancer Center of Kansas - McPherson|Cancer Center of Kansas - Newton|Olathe Health Cancer Center|Cancer Center of Kansas - Parsons|Ascension Via Christi - Pittsburg|Cancer Center of Kansas - Pratt|Cancer Center of Kansas - Salina|Salina Regional Health Center|University of Kansas Health System Saint Francis Campus|Cancer Center of Kansas - Wellington|University of Kansas Hospital-Westwood Cancer Center|Cancer Center of Kansas-Wichita Medical Arts Tower|Ascension Via Christi Hospitals Wichita|Cancer Center of Kansas - Wichita|Cancer Center of Kansas - Winfield|Flaget Memorial Hospital|Commonwealth Cancer Center-Corbin|Saint Joseph Radiation Oncology Resource Center|Saint Joseph Hospital East|University of Kentucky/Markey Cancer Center|Saint Joseph London|Jewish Hospital|Saints Mary and Elizabeth Hospital|UofL Health Medical Center Northeast|Jewish Hospital Medical Center South|Hematology/Oncology Clinic PLLC|Ochsner High Grove|Ochsner Medical Center Kenner|East Jefferson General Hospital|LSU Healthcare Network / Metairie Multi-Specialty Clinic|Louisiana State University Health Science Center|Tulane University Health Sciences Center|Ochsner Medical Center Jefferson|Greater Baltimore Medical Center|National Institutes of Health Clinical Center|Lahey Hospital and Medical Center|Lahey Medical Center-Peabody|Mercy Medical Center|Winchester Hospital|Saint Joseph Mercy Hospital|IHA Hematology Oncology Consultants-Brighton|Saint Joseph Mercy Brighton|Henry Ford Cancer Institute-Downriver|IHA Hematology Oncology Consultants-Canton|Saint Joseph Mercy Canton|Caro Cancer Center|IHA Hematology Oncology Consultants-Chelsea|Saint Joseph Mercy Chelsea|Hematology Oncology Consultants-Clarkston|Newland Medical Associates-Clarkston|Henry Ford Macomb Hospital-Clinton Township|Henry Ford Medical Center-Fairlane|Henry Ford Hospital|Ascension Saint John Hospital|Great Lakes Cancer Management Specialists-Doctors Park|Genesee Cancer and Blood Disease Treatment Center|Genesee Hematology Oncology PC|Genesys Hurley Cancer Institute|Hurley Medical Center|Academic Hematology Oncology Specialists|Great Lakes Cancer Management Specialists-Van Elslander Cancer Center|Michigan Breast Specialists-Grosse Pointe Woods|Allegiance Health|Sparrow Hospital|Hope Cancer Clinic|Saint Mary Mercy Hospital|Great Lakes Cancer Management Specialists-Macomb Medical Campus|Michigan Breast Specialists-Macomb Township|Saint Mary's Oncology/Hematology Associates of Marlette|Henry Ford Medical Center-Columbus|21st Century Oncology-Pontiac|Hope Cancer Center|Newland Medical Associates-Pontiac|Saint Joseph Mercy Oakland|Huron Medical Center PC|Lake Huron Medical Center|Great Lakes Cancer Management Specialists-Rochester Hills|Ascension Saint Mary's Hospital|Oncology Hematology Associates of Saginaw Valley PC|Henry Ford Macomb Health Center - Shelby Township|Bhadresh Nayak MD PC-Sterling Heights|Ascension Saint Joseph Hospital|Advanced Breast Care Center PLLC|Great Lakes Cancer Management Specialists-Macomb Professional Building|Macomb Hematology Oncology PC|Michigan Breast Specialists-Warren|Saint John Macomb-Oakland Hospital|Henry Ford West Bloomfield Hospital|Saint Mary's Oncology/Hematology Associates of West Branch|Huron Gastroenterology PC|IHA Hematology Oncology Consultants-Ann Arbor|Riverwood Healthcare Center|Essentia Health Saint Joseph's Medical Center|Fairview Ridges Hospital|Minnesota Oncology - Burnsville|Cambridge Medical Center|Mercy Hospital|Essentia Health - Deer River Clinic|Essentia Health Saint Mary's - Detroit Lakes Clinic|Essentia Health Cancer Center|Essentia Health Saint Mary's Medical Center|Miller-Dwan Hospital|Fairview Southdale Hospital|Lake Region Healthcare Corporation-Cancer Care|Essentia Health - Fosston|Unity Hospital|Essentia Health Hibbing Clinic|Fairview Clinics and Surgery Center Maple Grove|Minnesota Oncology Hematology PA-Maplewood|Saint John's Hospital - Healtheast|Abbott-Northwestern Hospital|Hennepin County Medical Center|Health Partners Inc|Monticello Cancer Center|New Ulm Medical Center|Essentia Health - Park Rapids|Fairview Northland Medical Center|North Memorial Medical Health Center|Mayo Clinic in Rochester|Park Nicollet Clinic - Saint Louis Park|Regions Hospital|United Hospital|Essentia Health Sandstone|Saint Francis Regional Medical Center|Lakeview Hospital|Essentia Health Virginia Clinic|Ridgeview Medical Center|Rice Memorial Hospital|Minnesota Oncology Hematology PA-Woodbury|Fairview Lakes Medical Center|University of Mississippi Medical Center|Saint Louis Cancer and Breast Institute-Ballwin|Central Care Cancer Center - Bolivar|Parkland Health Center-Bonne Terre|Cox Cancer Center Branson|Saint Francis Medical Center|Southeast Cancer Center|Siteman Cancer Center at West County Hospital|Parkland Health Center - Farmington|Capital Region Southwest Campus|Freeman Health System|Mercy Hospital Joplin|Truman Medical Centers|University of Kansas Cancer Center - Lee's Summit|Delbert Day Cancer Institute at PCRMC|Mercy Clinic-Rolla-Cancer and Hematology|Heartland Regional Medical Center|Saint Louis Cancer and Breast Institute-South City|Washington University School of Medicine|Mercy Hospital South|Siteman Cancer Center-South County|Missouri Baptist Medical Center|Siteman Cancer Center at Christian Hospital|Mercy Hospital Saint Louis|Siteman Cancer Center at Saint Peters Hospital|Sainte Genevieve County Memorial Hospital|Mercy Hospital Springfield|CoxHealth South Hospital|Missouri Baptist Sullivan Hospital|Missouri Baptist Outpatient Center-Sunset Hills|Mercy Hospital Washington|Community Hospital of Anaconda|Billings Clinic Cancer Center|Bozeman Deaconess Hospital|Benefis Healthcare- Sletten Cancer Institute|Great Falls Clinic|Saint Peter's Community Hospital|Kalispell Regional Medical Center|Saint Patrick Hospital - Community Hospital|Community Medical Hospital|Nebraska Medicine-Bellevue|CHI Health Saint Francis|CHI Health Good Samaritan|Saint Elizabeth Regional Medical Center|Nebraska Methodist Hospital|Nebraska Medicine-Village Pointe|Alegent Health Immanuel Medical Center|Alegent Health Bergan Mercy Medical Center|Alegent Health Lakeside Hospital|Creighton University Medical Center|University of Nebraska Medical Center|Midlands Community Hospital|Carson Tahoe Regional Medical Center|Cancer and Blood Specialists-Henderson|Comprehensive Cancer Centers of Nevada - Henderson|Comprehensive Cancer Centers of Nevada-Horizon Ridge|Las Vegas Cancer Center-Henderson|OptumCare Cancer Care at Seven Hills|Comprehensive Cancer Centers of Nevada-Southeast Henderson|GenesisCare USA - Henderson|Las Vegas Urology - Green Valley|Las Vegas Urology - Pebble|Urology Specialists of Nevada - Green Valley|Las Vegas Urology - Pecos|Desert West Surgery|OptumCare Cancer Care at Charleston|University Medical Center of Southern Nevada|Hope Cancer Care of Nevada|Cancer and Blood Specialists-Shadow|Radiation Oncology Centers of Nevada Central|Urology Specialists of Nevada - Central|GenesisCare USA - Las Vegas|HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway|Sunrise Hospital and Medical Center|HealthCare Partners Medical Group Oncology/Hematology-San Martin|Las Vegas Prostate Cancer Center|Las Vegas Urology - Sunset|Urology Specialists of Nevada - Southwest|Radiation Oncology Centers of Nevada Southeast|Ann M Wierman MD LTD|Cancer and Blood Specialists-Tenaya|Comprehensive Cancer Centers of Nevada - Northwest|GenesisCare USA - Vegas Tenaya|HealthCare Partners Medical Group Oncology/Hematology-Tenaya|Las Vegas Urology - Cathedral Rock|Las Vegas Urology - Smoke Ranch|OptumCare Cancer Care at MountainView|Urology Specialists of Nevada - Northwest|Alliance for Childhood Diseases/Cure 4 the Kids Foundation|Comprehensive Cancer Centers of Nevada - Town Center|Comprehensive Cancer Centers of Nevada-Summerlin|Summerlin Hospital Medical Center|Las Vegas Cancer Center-Medical Center|Comprehensive Cancer Centers of Nevada|GenesisCare USA - Fort Apache|OptumCare Cancer Care at Fort Apache|HealthCare Partners Medical Group Oncology/Hematology-Centennial Hills|Comprehensive Cancer Centers of Nevada - Central Valley|University Cancer Center|Hope Cancer Care of Nevada-Pahrump|Renown Regional Medical Center|Saint Mary's Regional Medical Center|Radiation Oncology Associates|Memorial Sloan Kettering Basking Ridge|Memorial Sloan Kettering Monmouth|Memorial Sloan Kettering Bergen|New York-Presbyterian/Brooklyn Methodist Hospital|Maimonides Medical Center|Roswell Park Cancer Institute|Memorial Sloan Kettering Commack|Memorial Sloan Kettering Westchester|Northwell Health/Center for Advanced Medicine|NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center|Memorial Sloan Kettering Cancer Center|NYP/Weill Cornell Medical Center|University of Rochester|State University of New York Upstate Medical University|Memorial Sloan Kettering Nassau|UNC Lineberger Comprehensive Cancer Center|Margaret R Pardee Memorial Hospital|Essentia Health Cancer Center-South University Clinic|Essentia Health - Jamestown Clinic|Indu and Raj Soin Medical Center|Strecker Cancer Center-Belpre|Saint Elizabeth Boardman Hospital|Dayton Physicians LLC-Miami Valley South|Miami Valley Hospital South|Adena Regional Medical Center|University of Cincinnati Cancer Center-UC Medical Center|Good Samaritan Hospital - Cincinnati|Oncology Hematology Care Inc-Kenwood|Bethesda North Hospital|TriHealth Cancer Institute-Westside|TriHealth Cancer Institute-Anderson|Ohio State University Comprehensive Cancer Center|Mount Carmel East Hospital|Columbus Oncology and Hematology Associates Inc|Riverside Methodist Hospital|Grant Medical Center|The Mark H Zangmeister Center|Mount Carmel Health Center West|Doctors Hospital|Good Samaritan Hospital - Dayton|Miami Valley Hospital|Dayton Physician LLC-Miami Valley Hospital North|Miami Valley Hospital North|Delaware Health Center-Grady Cancer Center|Grady Memorial Hospital|Dublin Methodist Hospital|Armes Family Cancer Center|Blanchard Valley Hospital|Orion Cancer Care|Atrium Medical Center-Middletown Regional Hospital|Dayton Physicians LLC-Atrium|Central Ohio Breast and Endocrine Surgery|Dayton Physicians LLC-Wayne|Wayne Hospital|Mount Carmel Grove City Hospital|Greater Dayton Cancer Center|First Dayton Cancer Care|Kettering Medical Center|Fairfield Medical Center|Saint Rita's Medical Center|OhioHealth Mansfield Hospital|Marietta Memorial Hospital|OhioHealth Marion General Hospital|Knox Community Hospital|Licking Memorial Hospital|Newark Radiation Oncology|Mercy Health Perrysburg Cancer Center|Southern Ohio Medical Center|Springfield Regional Cancer Center|Springfield Regional Medical Center|Saint Vincent Mercy Medical Center|Mercy Health - Saint Anne Hospital|Dayton Physicians LLC-Upper Valley|Upper Valley Medical Center|Saint Joseph Warren Hospital|University of Cincinnati Cancer Center-West Chester|Saint Ann's Hospital|Saint Elizabeth Youngstown Hospital|Genesis Healthcare System Cancer Care Center|Cancer Centers of Southwest Oklahoma Research|University of Oklahoma Health Sciences Center|Mercy Hospital Oklahoma City|Oklahoma Cancer Specialists and Research Institute-Tulsa|Saint Alphonsus Medical Center-Baker City|Saint Charles Health System|Clackamas Radiation Oncology Center|Providence Cancer Institute Clackamas Clinic|Bay Area Hospital|Providence Newberg Medical Center|Saint Alphonsus Medical Center-Ontario|Providence Portland Medical Center|Providence Saint Vincent Medical Center|Oregon Health and Science University|Saint Charles Health System-Redmond|Lehigh Valley Hospital-Cedar Crest|Lehigh Valley Hospital - Muhlenberg|Pocono Medical Center|Saint Vincent Hospital|UPMC Cancer Centers - Arnold Palmer Pavilion|Lehigh Valley Hospital-Hazleton|Jefferson Hospital|Forbes Hospital|UPMC Cancer Center - Monroeville|Allegheny Valley Hospital|Allegheny General Hospital|West Penn Hospital|University of Pittsburgh Cancer Institute (UPCI)|UPMC-Shadyside Hospital|UPMC-Passavant Hospital|Wexford Health and Wellness Pavilion|Medical University of South Carolina|Vanderbilt-Ingram Cancer Center Cool Springs|Vanderbilt Breast Center at One Hundred Oaks|Vanderbilt University/Ingram Cancer Center|Saint Joseph Regional Cancer Center|UT Southwestern/Simmons Cancer Center-Dallas|UT Southwestern/Simmons Cancer Center-Fort Worth|UT Southwestern Clinical Center at Richardson/Plano|Providence Regional Cancer System-Aberdeen|Overlake Medical Center|PeaceHealth Saint Joseph Medical Center|Harrison HealthPartners Hematology and Oncology-Bremerton|Harrison Medical Center|Highline Medical Center-Main Campus|Providence Regional Cancer System-Centralia|Swedish Cancer Institute-Edmonds|Saint Elizabeth Hospital|Providence Regional Cancer Partnership|Saint Francis Hospital|Swedish Cancer Institute-Issaquah|Kadlec Clinic Hematology and Oncology|Providence Regional Cancer System-Lacey|Saint Clare Hospital|PeaceHealth Saint John Medical Center|Harrison HealthPartners Hematology and Oncology-Poulsbo|Valley Medical Center|Pacific Gynecology Specialists|Swedish Medical Center-Ballard Campus|Swedish Medical Center-First Hill|Swedish Medical Center-Cherry Hill|PeaceHealth United General Medical Center|Providence Regional Cancer System-Shelton|Franciscan Research Center-Northwest Medical Plaza|Northwest Medical Specialties PLLC|PeaceHealth Southwest Medical Center|Providence Saint Mary Regional Cancer Center|North Star Lodge Cancer Center at Yakima Valley Memorial Hospital|Providence Regional Cancer System-Yelm|Duluth Clinic Ashland|Northwest Wisconsin Cancer Center|Aurora Cancer Care-Southern Lakes VLCC|Aurora Saint Luke's South Shore|Marshfield Medical Center-EC Cancer Center|Mayo Clinic Health System-Eau Claire Clinic|Aurora Health Care Germantown Health Center|Aurora Cancer Care-Grafton|Aurora BayCare Medical Center|Aurora Cancer Care-Kenosha South|Aurora Bay Area Medical Group-Marinette|Marshfield Medical Center-Marshfield|Aurora Cancer Care-Milwaukee|Aurora Saint Luke's Medical Center|Aurora Sinai Medical Center|Marshfield Clinic-Minocqua Center|ProHealth D N Greenwald Center|Cancer Center of Western Wisconsin|ProHealth Oconomowoc Memorial Hospital|Vince Lombardi Cancer Clinic - Oshkosh|Aurora Cancer Care-Racine|Marshfield Medical Center-Rice Lake|Vince Lombardi Cancer Clinic-Sheboygan|Marshfield Clinic Stevens Point Center|Aurora Medical Center in Summit|Vince Lombardi Cancer Clinic-Two Rivers|ProHealth Waukesha Memorial Hospital|UW Cancer Center at ProHealth Care|Aurora Cancer Care-Milwaukee West|Aurora West Allis Medical Center|Marshfield Medical Center - Weston|Billings Clinic-Cody|Welch Cancer Center|Pan American Center for Oncology Trials LLC,Drug|Biological|Biological,Puerto Rico|United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03866382
NCT03872284,thyroiditis,Study of Neuro-ophthalmology Disorders in Autoimmune Encephalitis (NODE),Autoimmune Encephalitis,2019-03-11,2027-01-24,2027-01-24,Observational,Recruiting,,Hospices Civils de Lyon,Hospices Civils de Lyon,Hospices Civils de Lyon,Other,France,18.0,70.0,[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT03872284
NCT03878953,parathyroid diseases,"A Phase 3, Open-label Clinical Study of rhPTH(1-84) Treatment in Japanese Subjects With Chronic Hypoparathyroidism",Chronic Hypoparathyroidism,2019-03-15,2023-05-31,2023-05-31,Interventional,Not yet recruiting,Phase 3,Takeda,Shire,Fujita Health University Hospital|University of Occupational and Environmental Health Japan|Osaka City University Hospital|Shimane University Hospital|Tokushima University Hospital|University of Tokyo Hospital|The Cancer Institute Hospital of JFCR|Toranomon Hospital|Keio University Hospital|Tokyo Women's Medical University Hospital,Drug,Japan,20.0,85.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT03878953
NCT03884140,thyroid neoplasms,Clinical Diagnostic Evaluation of Thyroid Nodules,Thyroid Nodule,2019-03-19,2022-06-01,2022-09-01,Observational [Patient Registry],Not yet recruiting,,Assiut University,Assiut University,,,,18.0,75.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03884140
NCT03896958,"thyroid carcinoma, anaplastic",The PIONEER Initiative: Precision Insights On N-of-1 Effectiveness Research. Tissue Ownership by the Individual With the Return of Actionable Information to the Individual Patient and Physician (Precision Oncology),"Adenocarcinoma Lung|Adrenal Cancer|Breast Cancer|Bronchoalveolar Cell Lung Cancer|Cancer, Advanced|Cancer, All Types|Cancer, Anal|Cancer, Anaplastic Thyroid|Cancer, Bile Duct|Cancer, Bladder|Cancer Cords Vocal|Cancer Differentiated Poorly|Cancer, Metastatic|Cancer of Brain and Nervous System|Cancer of Cervix|Cancer of Colon|Cancer of Esophagus|Cancer of Head and Neck|Cancer of Kidney|Cancer of Larynx|Cancer of Liver|Cancer of Lung|Cancer of Neck|Cancer of Pancreas|Cancer of Prostate|Cancer of Rectum|Cancer of Stomach|Cancer of Vulva, Disseminated|Cancer, Other|Cancers Cell Neuroendocrine|Cancer Skin|Cancer Unknown Primary|Cholangiocarcinoma|GIST|Glioblastoma Multiforme|Hepatocellular Carcinoma|Melanoma|Oligodendroglioma|Renal Cell Carcinoma|Sarcoma|Small-cell Lung Cancer|Squamous Cell Carcinoma|Testicular Cancer|Transitional Cell Carcinoma|Uterine Cancer",2019-03-26,2024-03-12,2024-03-12,Observational,Recruiting,,SpeciCare,Georgia Institute of Technology|Netnoids|Northeast Georgia Hospital System|Predictive Oncology|SpeciCare|University of Washington,Specicare,,United States,1.0,99.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT03896958
NCT03924804,thyroid nodule,Effect of Different Infusion Volume on Perioperative Bladder and Blood Volume in Patients Undergoing Daytime Surgery.,Cholecystolithiasis and Thyroid Nodule,2019-04-18,2022-08-30,2022-09-30,Interventional,Recruiting,Not Applicable,"China Medical University, China","China Medical University, China",the First Hospital of China Medical University,Drug|Drug|Drug,China,18.0,65.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT03924804
NCT03924804,thyroid neoplasms,Effect of Different Infusion Volume on Perioperative Bladder and Blood Volume in Patients Undergoing Daytime Surgery.,Cholecystolithiasis and Thyroid Nodule,2019-04-18,2022-08-30,2022-09-30,Interventional,Recruiting,Not Applicable,"China Medical University, China","China Medical University, China",the First Hospital of China Medical University,Drug|Drug|Drug,China,18.0,65.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03924804
NCT03960437,parathyroid diseases,The Effect of Etelcalcetide on Bone-tissue Properties and Calcification Propensity in End Stage Kidney Disease,"Chronic Kidney Disease Mineral and Bone Disorder|Hyperparathyroidism; Secondary, Renal|Renal Osteodystrophy|Vascular Calcification",2019-05-21,2021-12-31,2021-12-31,Interventional,Recruiting,Phase 2,Columbia University,"Thomas Nickolas, MD MS",Columbia University Medical Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT03960437
NCT03960554,parathyroid diseases,"The Effects of 12-months of Denosumab on Bone Density, Quality and Strength in Prevalent Kidney Transplant Recipients",Kidney Transplant; Complications|Osteoporosis|Renal Osteodystrophy,2019-05-21,2022-06-30,2022-06-30,Interventional,Recruiting,Phase 2,Columbia University,"Thomas Nickolas, MD MS","Northwestern University, Feinburg School of Medicine|NorthShore University HealthSystem|Columbia University Medical Center",Drug|Other,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT03960554
NCT03980132,graves disease,"Randomized Clinical Trial, Blinded for the Researcher and Multicenter, to Evaluate the Efficacy and Safety of Preoperative Preparation With Lugol Solution in Euthyroid Patients With Graves-Basedow Disease.","Hyperthyroidism, Autoimmune",2019-05-30,2023-01-31,2023-09-30,Interventional,Recruiting,Phase 4,Fundación de Investigación Biomédica - Hospital Universitario de La Princesa,Jesús María Villar del Moral,Hospital Universitario de Bellvitge|Hospital Universitario Donostia|Hospital Clínico Universitario|Hospital Universitario Insular de Gran Canaria|Hospital Universitario Puerta de Hierro|Hospital Clínico Universitario Virgen de la Arrixaca|Hospital Universitario de Cruces|Hospital Universitario de Basurto|Hospital Universitario del Mar|Hospital Clinic|Hospital Universitario Virgen de las Nieves|Hospital Universitario de La princesa|Hospital General Universitario Gregorio Marañón|Hospital Universitario Ramón y Cajal|Hospital Universitario Fundación Jiménez Díaz|Hospital Universitario 12 de Octubre|Complejo Asistencial Universitario de Salamanca|Hospital Universitario Virgen Macarena|Hospital Universitario Virgen del Rocío|Hospital Clínico Universitario|Hospital Clínico Universitario Lozano Blesa,Drug,Spain,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT03980132
NCT03980132,hyperthyroidism,"Randomized Clinical Trial, Blinded for the Researcher and Multicenter, to Evaluate the Efficacy and Safety of Preoperative Preparation With Lugol Solution in Euthyroid Patients With Graves-Basedow Disease.","Hyperthyroidism, Autoimmune",2019-05-30,2023-01-31,2023-09-30,Interventional,Recruiting,Phase 4,Fundación de Investigación Biomédica - Hospital Universitario de La Princesa,Jesús María Villar del Moral,Hospital Universitario de Bellvitge|Hospital Universitario Donostia|Hospital Clínico Universitario|Hospital Universitario Insular de Gran Canaria|Hospital Universitario Puerta de Hierro|Hospital Clínico Universitario Virgen de la Arrixaca|Hospital Universitario de Cruces|Hospital Universitario de Basurto|Hospital Universitario del Mar|Hospital Clinic|Hospital Universitario Virgen de las Nieves|Hospital Universitario de La princesa|Hospital General Universitario Gregorio Marañón|Hospital Universitario Ramón y Cajal|Hospital Universitario Fundación Jiménez Díaz|Hospital Universitario 12 de Octubre|Complejo Asistencial Universitario de Salamanca|Hospital Universitario Virgen Macarena|Hospital Universitario Virgen del Rocío|Hospital Clínico Universitario|Hospital Clínico Universitario Lozano Blesa,Drug,Spain,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03980132
NCT03980132,goiter,"Randomized Clinical Trial, Blinded for the Researcher and Multicenter, to Evaluate the Efficacy and Safety of Preoperative Preparation With Lugol Solution in Euthyroid Patients With Graves-Basedow Disease.","Hyperthyroidism, Autoimmune",2019-05-30,2023-01-31,2023-09-30,Interventional,Recruiting,Phase 4,Fundación de Investigación Biomédica - Hospital Universitario de La Princesa,Jesús María Villar del Moral,Hospital Universitario de Bellvitge|Hospital Universitario Donostia|Hospital Clínico Universitario|Hospital Universitario Insular de Gran Canaria|Hospital Universitario Puerta de Hierro|Hospital Clínico Universitario Virgen de la Arrixaca|Hospital Universitario de Cruces|Hospital Universitario de Basurto|Hospital Universitario del Mar|Hospital Clinic|Hospital Universitario Virgen de las Nieves|Hospital Universitario de La princesa|Hospital General Universitario Gregorio Marañón|Hospital Universitario Ramón y Cajal|Hospital Universitario Fundación Jiménez Díaz|Hospital Universitario 12 de Octubre|Complejo Asistencial Universitario de Salamanca|Hospital Universitario Virgen Macarena|Hospital Universitario Virgen del Rocío|Hospital Clínico Universitario|Hospital Clínico Universitario Lozano Blesa,Drug,Spain,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03980132
NCT03986593,thyroid neoplasms,Cone-beam Computed Tomography Guided Percutaneous Cryoablation of Bone Metastases From Endocrine Tumors,Adrenal Neoplasm|Bone Metastases|Neoplasm Metastasis|Neuroendocrine Tumors|Pheochromocytoma|Thyroid Neoplasm,2019-05-22,2021-06-15,2023-06-15,Interventional,Recruiting,Not Applicable,Instituto do Cancer do Estado de São Paulo,Instituto do Cancer do Estado de São Paulo|University of Sao Paulo General Hospital,Instituto do Cancer do Estado de São Paulo,Device,Brazil,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03986593
NCT04009863,goiter,"A Randomized, Open-label, Parallel-group Study to Determine the Efficacy of Sequential High-intensity Focused Ultrasound (HIFU) Ablation Versus Fixed-dose Radioiodine-131 Therapy in Moderate-sized Non-toxic Multinodular Goiter",High Intensity Focused Ultrasound|Non Toxic Multinodular Goiter|RAI,2019-06-26,2023-04-30,2023-09-30,Interventional,Not yet recruiting,Not Applicable,The University of Hong Kong,The University of Hong Kong,Queen Mary Hospital,Device|Radiation,Hong Kong,18.0,70.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04009863
NCT04013100,parathyroid neoplasms,Cohort Trial on Perioperative Localization Techniques of Parathyroid Adenomas,Primary Hyperparathyroidism,2019-07-05,2029-12-31,2029-12-31,Observational [Patient Registry],Not yet recruiting,,IHU Strasbourg,IHU Strasbourg,,Diagnostic Test,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04013100
NCT04019379,parathyroid diseases,Calcium and Phosphorus Whole-Body Balance and Kinetics in Patients With Moderate Chronic Kidney Disease,Chronic Kidney Disease Mineral and Bone Disorder|Chronic Kidney Diseases|Phosphorus and Calcium Disorders,2019-07-09,2020-10-28,2022-12-01,Interventional,"Active, not recruiting",Not Applicable,University of Minnesota,Indiana University|University of Minnesota,Indiana CTSI CRC,Other|Other,United States,30.0,75.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT04019379
NCT04028479,parathyroid diseases,The Registry of Oncology Outcomes Associated With Testing and Treatment (ROOT),"Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Adenocarcinoma|Adenocystic Carcinoma|Adrenal Cancer|Anal Cancer|Appendix Cancer|Astrocytoma|Bile Duct Cancer|Bladder Cancer|Bone Cancer|Brain Stem Neoplasms|Brain Tumor|Breast Cancer|Cancer, Advanced|Cancer of Colon|Cancer of Pancreas|Carcinoid Tumor|Cervical Cancer|Cholangiocarcinoma|Chondrosarcoma|Chronic Myeloid Leukemia|CNS Cancer|Colon Cancer|Colorectal Cancer|Esophageal Cancer|Esophagus Cancer|Fallopian Tube Cancer|Gestational Trophoblastic Tumor|Glioblastoma|Head and Neck Neoplasms|Hepatic Cancer|Kidney Cancer|Larynx Cancer|Liposarcoma|Liver Cancer|Lung Cancer|Melanoma|Mesothelioma|Multiple Endocrine Neoplasia|Multiple Myeloma|Nasopharyngeal Carcinoma|Neuroendocrine Tumors|Non Hodgkin Lymphoma|Osteosarcoma|Ovarian Cancer|Pancreatic Cancer|Parathyroid Neoplasms|Parotid Tumor|Penile Cancer|Pharynx Cancer|Pheochromocytoma|Prostate Cancer|Pulmonary Carcinoma|Rectal Cancer|Renal Cell Carcinoma|Salivary Gland Cancer|Sarcoma|Sarcoma, Kaposi|Sarcoma,Soft Tissue|Skin Cancer|Small Bowel Cancer|Small Cell Carcinoma|Stomach Cancer|Synovial Sarcoma|Testicular Cancer|Testis Cancer|Thymus Cancer|Thyroid Cancer|Tongue Cancer|Unknown Primary Tumors|Ureter Cancer|Uterine Cancer|Vaginal Cancer|Vulvar Cancer|Waldenstrom Macroglobulinemia",2019-07-17,2029-10-01,2031-10-01,Observational [Patient Registry],Recruiting,,Taproot Health,Taproot Health,Teton Cancer Institute,Diagnostic Test|Drug|Other,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT04028479
NCT04031638,thyroid neoplasms,Prospective and Retrospective Thyroid Cancer Database,Patients With a Thyroid Tumor Who Received Radioactive Iodine Treatment,2019-07-01,2025-01-01,2025-01-01,Observational,Recruiting,,Centre Georges Francois Leclerc,Centre Georges Francois Leclerc,"Methodology, Biostatistics and Data Management",Other,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04031638
NCT04040946,parathyroid neoplasms,Phase III Trial Comparing 2 Diagnostic Strategies for Preoperative Localization of Parathyroid Adenoma in Primary Hyperparathyroidism:TEMP / CT With Tc99m-sestaMIBI or PET / CT With F18-choline in First Intention,F18-choline|Hyperparathyroidism|Parathyroid Adenoma,2019-07-29,2022-09-30,2023-03-31,Interventional,Recruiting,Phase 3,Centre Francois Baclesse,Centre Francois Baclesse|Fondation de l'Avenir,CHU Brest|Centre François Baclesse|Centre Eugène Marquis|CHU,Diagnostic Test|Diagnostic Test,France,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04040946
NCT04046354,thyroid nodule,Clinical Trial of Microwave Ablation System,Ablation|Benign Thyroid Nodules,2019-08-05,2020-11-19,2021-12-31,Interventional,"Active, not recruiting",Not Applicable,Chinese PLA General Hospital,Chinese PLA General Hospital,Chinese PLA General Hospital,Device|Device,China,18.0,75.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT04046354
NCT04046354,thyroid neoplasms,Clinical Trial of Microwave Ablation System,Ablation|Benign Thyroid Nodules,2019-08-05,2020-11-19,2021-12-31,Interventional,"Active, not recruiting",Not Applicable,Chinese PLA General Hospital,Chinese PLA General Hospital,Chinese PLA General Hospital,Device|Device,China,18.0,75.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04046354
NCT04064827,parathyroid diseases,"A Phase 3, Prospective, Open-Label, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Paricalcitol Oral Solution for the Treatment of Secondary Hyperparathyroidism in Pediatric Subjects Ages 0 to 9 Years With Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or Hemodialysis",Chronic Kidney Disease (CKD)|Secondary Hyperparathyroidism (SHPT),2019-08-20,2024-03-09,2026-04-30,Interventional,Recruiting,Phase 3,AbbVie,AbbVie,"Arkansas Children's Hospital /ID# 225417|University of California, Los Angeles /ID# 140668|Children's National Medical Center /ID# 225991|Holtz Childrens Hospital, University of Miami /ID# 225636|Nicklaus Children's Hospital /ID# 210517|Emory Midtown Infectious Disease Clinic /ID# 140665|Boston Children's Hospital /ID# 162863|Levine Children's Specialty Center- Charlotte /ID# 216057|Children's Hospital of Philadelphia - Main /ID# 213802|University of Texas Southwestern Medical Center /ID# 210495|University of Utah /ID# 140669|Seattle Children's Hospital /ID# 162861|School of Medicine University of Puerto Rico-Medical Science Campus /ID# 140663",Drug,Puerto Rico|United States,0.0,9.0,[0-17],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT04064827
NCT04075851,thyroiditis,The Prevalence of Serum Thyroid Hormone Autoantibodies in Autoimmune Thyroid Diseases,Autoimmune Thyroid Disease,2019-08-29,2022-08-01,2022-08-01,Observational,Recruiting,,Shandong Provincial Hospital,Shandong Provincial Hospital,Shandong Province Hospital,,China,18.0,65.0,[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT04075851
NCT04080505,goiter,Does the Use of Pre-operative SSKI Actually Reduce Vascularity and Improve Surgical Outcomes for Total Thyroidectomy in Graves' Disease?,Graves Disease,2019-09-04,2021-12-31,2022-12-31,Interventional,Recruiting,Phase 3,Columbia University,Columbia University,Columbia University Medical Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04080505
NCT04080505,hyperthyroidism,Does the Use of Pre-operative SSKI Actually Reduce Vascularity and Improve Surgical Outcomes for Total Thyroidectomy in Graves' Disease?,Graves Disease,2019-09-04,2021-12-31,2022-12-31,Interventional,Recruiting,Phase 3,Columbia University,Columbia University,Columbia University Medical Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04080505
NCT04129281,thyroid neoplasms,Prospective Active Surveillance Versus Surgery in Thyroid Papillary Microcarcinoma,Papillary Microcarcinoma of the Thyroid,2019-10-15,2022-01-23,2023-02-23,Interventional,Recruiting,Not Applicable,"National Cancer Institute, Naples","National Cancer Institute, Naples",Istitute Nazionale Tumori - Fondazione G. Pascale,Procedure,Italy,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04129281
NCT04135573,goiter,Mechanism of NK Cell Disfunction in Graves' Disease,Graves Disease,2019-01-03,2022-06-30,2022-06-30,Observational [Patient Registry],"Active, not recruiting",,Shandong Provincial Hospital,Shandong Provincial Hospital,Shandong Provincial Hospital,,China,18.0,75.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04135573
NCT04135573,hyperthyroidism,Mechanism of NK Cell Disfunction in Graves' Disease,Graves Disease,2019-01-03,2022-06-30,2022-06-30,Observational [Patient Registry],"Active, not recruiting",,Shandong Provincial Hospital,Shandong Provincial Hospital,Shandong Provincial Hospital,,China,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04135573
NCT04171622,"thyroid carcinoma, anaplastic",Lenvatinib in Combination With Pembrolizumab for Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer,Metastatic Thyroid Gland Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8|Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8|Thyroid Gland Squamous Cell Carcinoma|Unresectable Thyroid Gland Carcinoma,2019-11-19,2022-08-31,2022-08-31,Interventional,Not yet recruiting,Phase 2,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center|National Cancer Institute (NCI),M D Anderson Cancer Center,Drug|Biological,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT04171622
NCT04193332,parathyroid diseases,Near Infrared (NIR) Autofluorescence Image-guided Thyroid Surgery Can Prevent Post-thyroidectomy Hypoparathyroidism,Hypocalcemia|Hypoparathyroidism Postprocedural|Surgery--Complications,2019-12-06,2023-10-01,2023-12-01,Interventional,Recruiting,Not Applicable,"Rigshospitalet, Denmark","Cluster for molecular imaging, Denmark|Dept of Otorhinolaryngology and Maxillofacial Surgery, Zealand University Hospital, Denmark|Rigshospitalet, Denmark","Rigshospitalet|Dept of Otorhinolaryngology and Maxillofacial Surgery, Zealand University Hospital, Denmark",Device,Denmark,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT04193332
NCT04216732,thyroid neoplasms,Utilization of the Natural History of Medullary Thyroid Carcinoma to Inform Advanced Disease Management,Advanced Thyroid Gland Medullary Carcinoma|Stage III Thyroid Gland Medullary Carcinoma AJCC v8|Stage IVA Thyroid Gland Medullary Carcinoma AJCC v8|Stage IVB Thyroid Gland Medullary Carcinoma AJCC v8|Stage IVC Thyroid Gland Medullary Carcinoma AJCC v8|Stage IV Thyroid Gland Medullary Carcinoma AJCC v8,2019-11-14,2023-09-01,2023-09-01,Observational,Recruiting,,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center|National Cancer Institute (NCI),University of California San Francisco|M D Anderson Cancer Center,Other|Other,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04216732
NCT04233398,thyroid nodule,"A Multi-center, Randomized, Controlled Trial of High Intensity Focused Ultrasound (HIFU) Treatment of Benign Thyroid Nodules",Thyroid Nodule (Benign),2020-01-15,2023-11-30,2023-11-30,Interventional,Not yet recruiting,Not Applicable,Theraclion,Theraclion,,Device,,18.0,70.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT04233398
NCT04233398,thyroid neoplasms,"A Multi-center, Randomized, Controlled Trial of High Intensity Focused Ultrasound (HIFU) Treatment of Benign Thyroid Nodules",Thyroid Nodule (Benign),2020-01-15,2023-11-30,2023-11-30,Interventional,Not yet recruiting,Not Applicable,Theraclion,Theraclion,,Device,,18.0,70.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04233398
NCT04239521,goiter,"The Epidemiology, Management, and the Associated Burden of Mental Health, Atopic and Autoimmune Conditions, and Common Infections in Alopecia Areata",Acute Bronchitis|Allergic Rhinitis|Alopecia Areata|Ankylosing Spondylitis|Anxiety Disorders|Asthma|Atopic Dermatitis|Celiac Disease|Crohn Disease|Depressive Episode|Gastrointestinal Infection|Genital Infection|Graves Disease|Hashimoto Thyroiditis|Herpes Simplex|Herpes Zoster|Infection|Infection Viral|Influenza|Lower Resp Tract Infection|Multiple Sclerosis|Pernicious Anemia|Pneumonia|Polymyalgia Rheumatica|Psoriasis|Psoriatic Arthritis|Recurrent Depressive Disorder|Rheumatoid Arthritis|Sjogren's Syndrome|Skin Infection|Systemic Lupus Erythematosus|Type 1 Diabetes|Ulcerative Colitis|Upper Respiratory Tract Infection|Urinary Tract Infections|Vitiligo,2020-01-09,2021-10-31,2021-12-31,Observational,"Active, not recruiting",,Momentum Data,Momentum Data|Pfizer|University of Oxford|University of Surrey,Momentum Data Ltd,Other,United Kingdom,0.0,120.0,[0-17]|[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04239521
NCT04239521,hyperthyroidism,"The Epidemiology, Management, and the Associated Burden of Mental Health, Atopic and Autoimmune Conditions, and Common Infections in Alopecia Areata",Acute Bronchitis|Allergic Rhinitis|Alopecia Areata|Ankylosing Spondylitis|Anxiety Disorders|Asthma|Atopic Dermatitis|Celiac Disease|Crohn Disease|Depressive Episode|Gastrointestinal Infection|Genital Infection|Graves Disease|Hashimoto Thyroiditis|Herpes Simplex|Herpes Zoster|Infection|Infection Viral|Influenza|Lower Resp Tract Infection|Multiple Sclerosis|Pernicious Anemia|Pneumonia|Polymyalgia Rheumatica|Psoriasis|Psoriatic Arthritis|Recurrent Depressive Disorder|Rheumatoid Arthritis|Sjogren's Syndrome|Skin Infection|Systemic Lupus Erythematosus|Type 1 Diabetes|Ulcerative Colitis|Upper Respiratory Tract Infection|Urinary Tract Infections|Vitiligo,2020-01-09,2021-10-31,2021-12-31,Observational,"Active, not recruiting",,Momentum Data,Momentum Data|Pfizer|University of Oxford|University of Surrey,Momentum Data Ltd,Other,United Kingdom,0.0,120.0,[0-17]|[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04239521
NCT04239521,"thyroiditis, autoimmune","The Epidemiology, Management, and the Associated Burden of Mental Health, Atopic and Autoimmune Conditions, and Common Infections in Alopecia Areata",Acute Bronchitis|Allergic Rhinitis|Alopecia Areata|Ankylosing Spondylitis|Anxiety Disorders|Asthma|Atopic Dermatitis|Celiac Disease|Crohn Disease|Depressive Episode|Gastrointestinal Infection|Genital Infection|Graves Disease|Hashimoto Thyroiditis|Herpes Simplex|Herpes Zoster|Infection|Infection Viral|Influenza|Lower Resp Tract Infection|Multiple Sclerosis|Pernicious Anemia|Pneumonia|Polymyalgia Rheumatica|Psoriasis|Psoriatic Arthritis|Recurrent Depressive Disorder|Rheumatoid Arthritis|Sjogren's Syndrome|Skin Infection|Systemic Lupus Erythematosus|Type 1 Diabetes|Ulcerative Colitis|Upper Respiratory Tract Infection|Urinary Tract Infections|Vitiligo,2020-01-09,2021-10-31,2021-12-31,Observational,"Active, not recruiting",,Momentum Data,Momentum Data|Pfizer|University of Oxford|University of Surrey,Momentum Data Ltd,Other,United Kingdom,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT04239521
NCT04281875,parathyroid diseases,Assessing Benefits of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Total Thyroidectomy.,Postoperative Hypoparathyroidism|Thyroid Cancer|Thyroid Neoplasms,2020-02-19,2022-03-31,2023-02-28,Interventional,Recruiting,Not Applicable,Vanderbilt-Ingram Cancer Center,National Cancer Institute (NCI)|Vanderbilt-Ingram Cancer Center,Vanderbilt University Medical Center,Device,United States,18.0,99.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT04281875
NCT04284774,thyroid neoplasms,NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Tipifarnib in Patients With Tumors Harboring HRAS Genomic Alterations,Malignant Solid Neoplasm|Recurrent Adrenal Gland Pheochromocytoma|Recurrent Ectomesenchymoma|Recurrent Ependymoma|Recurrent Ewing Sarcoma|Recurrent Hepatoblastoma|Recurrent Kidney Wilms Tumor|Recurrent Langerhans Cell Histiocytosis|Recurrent Malignant Germ Cell Tumor|Recurrent Malignant Glioma|Recurrent Medulloblastoma|Recurrent Melanoma|Recurrent Neuroblastoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Osteosarcoma|Recurrent Peripheral Primitive Neuroectodermal Tumor|Recurrent Rhabdoid Tumor|Recurrent Rhabdoid Tumor of the Kidney|Recurrent Rhabdomyosarcoma|Recurrent Soft Tissue Sarcoma|Recurrent Thyroid Gland Carcinoma|Recurrent WHO Grade 2 Glioma|Refractory Adrenal Gland Pheochromocytoma|Refractory Ependymoma|Refractory Ewing Sarcoma|Refractory Hepatoblastoma|Refractory Langerhans Cell Histiocytosis|Refractory Malignant Germ Cell Tumor|Refractory Malignant Glioma|Refractory Medulloblastoma|Refractory Melanoma|Refractory Neuroblastoma|Refractory Non-Hodgkin Lymphoma|Refractory Osteosarcoma|Refractory Peripheral Primitive Neuroectodermal Tumor|Refractory Rhabdoid Tumor|Refractory Rhabdoid Tumor of the Kidney|Refractory Rhabdomyosarcoma|Refractory Soft Tissue Sarcoma|Refractory Thyroid Gland Carcinoma|Refractory WHO Grade 2 Glioma,2020-02-25,2027-09-30,2027-09-30,Interventional,Recruiting,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),Children's Hospital of Alabama|Providence Alaska Medical Center|Banner Children's at Desert|Phoenix Childrens Hospital|Banner University Medical Center - Tucson|Arkansas Children's Hospital|Kaiser Permanente Downey Medical Center|City of Hope Comprehensive Cancer Center|Loma Linda University Medical Center|Miller Children's and Women's Hospital Long Beach|Children's Hospital Los Angeles|Cedars Sinai Medical Center|Mattel Children's Hospital UCLA|Valley Children's Hospital|UCSF Benioff Children's Hospital Oakland|Kaiser Permanente-Oakland|Children's Hospital of Orange County|Lucile Packard Children's Hospital Stanford University|University of California Davis Comprehensive Cancer Center|Rady Children's Hospital - San Diego|Naval Medical Center -San Diego|UCSF Medical Center-Mission Bay|Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center|Children's Hospital Colorado|Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center|Connecticut Children's Medical Center|Yale University|Alfred I duPont Hospital for Children|MedStar Georgetown University Hospital|Children's National Medical Center|Broward Health Medical Center|Golisano Children's Hospital of Southwest Florida|University of Florida Health Science Center - Gainesville|Memorial Regional Hospital/Joe DiMaggio Children's Hospital|Nemours Children's Clinic-Jacksonville|University of Miami Miller School of Medicine-Sylvester Cancer Center|Nicklaus Children's Hospital|Miami Cancer Institute|AdventHealth Orlando|Arnold Palmer Hospital for Children|Nemours Children's Hospital|Sacred Heart Hospital|Johns Hopkins All Children's Hospital|Tampa General Hospital|Saint Joseph's Hospital/Children's Hospital-Tampa|Saint Mary's Hospital|Children's Healthcare of Atlanta - Egleston|Memorial Health University Medical Center|Kapiolani Medical Center for Women and Children|Saint Luke's Cancer Institute - Boise|Lurie Children's Hospital-Chicago|University of Illinois|University of Chicago Comprehensive Cancer Center|Loyola University Medical Center|Saint Jude Midwest Affiliate|Southern Illinois University School of Medicine|Riley Hospital for Children|Saint Vincent Hospital and Health Care Center|Blank Children's Hospital|University of Iowa/Holden Comprehensive Cancer Center|University of Kentucky/Markey Cancer Center|Norton Children's Hospital|Children's Hospital New Orleans|Ochsner Medical Center Jefferson|Eastern Maine Medical Center|Maine Children's Cancer Program|University of Maryland/Greenebaum Cancer Center|Sinai Hospital of Baltimore|Johns Hopkins University/Sidney Kimmel Cancer Center|National Institutes of Health Clinical Center|Massachusetts General Hospital Cancer Center|Dana-Farber Cancer Institute|UMass Memorial Medical Center - University Campus|C S Mott Children's Hospital|Wayne State University/Karmanos Cancer Institute|Helen DeVos Children's Hospital at Spectrum Health|Bronson Methodist Hospital|Beaumont Children's Hospital-Royal Oak|Children's Hospitals and Clinics of Minnesota - Minneapolis|University of Minnesota/Masonic Cancer Center|Mayo Clinic in Rochester|University of Mississippi Medical Center|Children's Mercy Hospitals and Clinics|Cardinal Glennon Children's Medical Center|Washington University School of Medicine|Mercy Hospital Saint Louis|Children's Hospital and Medical Center of Omaha|University of Nebraska Medical Center|University Medical Center of Southern Nevada|Sunrise Hospital and Medical Center|Alliance for Childhood Diseases/Cure 4 the Kids Foundation|Summerlin Hospital Medical Center|Renown Regional Medical Center|Dartmouth Hitchcock Medical Center|Hackensack University Medical Center|Morristown Medical Center|Saint Peter's University Hospital|Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital|Albany Medical Center|Roswell Park Cancer Institute|NYU Winthrop Hospital|The Steven and Alexandra Cohen Children's Medical Center of New York|Laura and Isaac Perlmutter Cancer Center at NYU Langone|NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center|Memorial Sloan Kettering Cancer Center|NYP/Weill Cornell Medical Center|University of Rochester|Stony Brook University Medical Center|State University of New York Upstate Medical University|New York Medical College|Mission Hospital|UNC Lineberger Comprehensive Cancer Center|Carolinas Medical Center/Levine Cancer Institute|Novant Health Presbyterian Medical Center|Duke University Medical Center|East Carolina University|Wake Forest University Health Sciences|Sanford Broadway Medical Center|Children's Hospital Medical Center of Akron|Cincinnati Children's Hospital Medical Center|Rainbow Babies and Childrens Hospital|Cleveland Clinic Foundation|Nationwide Children's Hospital|Dayton Children's Hospital|ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital|University of Oklahoma Health Sciences Center|Legacy Emanuel Children's Hospital|Oregon Health and Science University|Lehigh Valley Hospital-Cedar Crest|Geisinger Medical Center|Children's Hospital of Philadelphia|Saint Christopher's Hospital for Children|Children's Hospital of Pittsburgh of UPMC|Rhode Island Hospital|Prisma Health Richland Hospital|BI-LO Charities Children's Cancer Center|Sanford USD Medical Center - Sioux Falls|T C Thompson Children's Hospital|East Tennessee Childrens Hospital|Saint Jude Children's Research Hospital|The Children's Hospital at TriStar Centennial|Vanderbilt University/Ingram Cancer Center|Dell Children's Medical Center of Central Texas|Driscoll Children's Hospital|Medical City Dallas Hospital|UT Southwestern/Simmons Cancer Center-Dallas|El Paso Children's Hospital|Cook Children's Medical Center|Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center|M D Anderson Cancer Center|Covenant Children's Hospital|UMC Cancer Center / UMC Health System|Children's Hospital of San Antonio|Methodist Children's Hospital of South Texas|University of Texas Health Science Center at San Antonio|Scott and White Memorial Hospital|Primary Children's Hospital|University of Vermont and State Agricultural College|Children's Hospital of The King's Daughters|Naval Medical Center - Portsmouth|Virginia Commonwealth University/Massey Cancer Center|Seattle Children's Hospital|Providence Sacred Heart Medical Center and Children's Hospital|Mary Bridge Children's Hospital and Health Center|Madigan Army Medical Center|West Virginia University Healthcare|University of Wisconsin Hospital and Clinics|Marshfield Medical Center-Marshfield|Children's Hospital of Wisconsin|University Pediatric Hospital,Drug,Puerto Rico|United States,12.0,21.0,[0-17]|[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04284774
NCT04288115,hypothyroidism,"Discontinuation of Levothyroxine Therapy for Patients With Subclinical Hypothyroidism: a Pilot Randomized, Double-blinded, Placebo-controlled Study",Subclinical Hypothyroidism,2020-02-14,2022-05-31,2022-12-31,Interventional,Recruiting,Phase 4,VA Office of Research and Development,Central Arkansas Veterans Healthcare System|VA Office of Research and Development,"Central Arkansas Veterans Healthcare System Eugene J. Towbin Healthcare Center, Little Rock, AR",Drug|Other,United States,18.0,89.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT04288115
NCT04288531,hypothyroidism,"Observational Study on the Impact of Iodine Supplementation on Maternal and Child's Thyroid Hormone Homeostasis and on the Child's Psychomotor Development, in the Portuguese Minho Region (IodineMinho)",Hypothyroidism in Pregnancy|Iodine Deficiency|Nutrient Deficiency|Pregnancy Related|Psychomotor Impairment|Thyroid,2020-02-25,2024-01-10,2025-01-10,Observational,Recruiting,,University of Minho,"Administração Regional de Saúde do Norte, Portugal|Clinical Academic Center (2CA-Braga)|Hospital de Braga|Instituto Nacional de Saúde Dr Ricardo Jorge, Portugal|University of Minho",Usf Maxisaude|Usf Braga Norte|Usf Ruães|Usf S. Lourenço|Usf Gualtar|Usf + Carandá|Usf Manuel Rocha Peixoto|Usf Bracara Augusta|Usf Do Minho|Usf S. João de Braga,Dietary Supplement,Portugal,18.0,50.0,[18-65],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT04288531
NCT04298684,thyroid nodule,Efficacy of Metformin Versus Sitagliptin on Benign Thyroid Nodules Size in Type 2 Diabetes: a 2-years Prospective Multicentric Study,"Diabetes Mellitus, Type 2|Thyroid Nodule (Benign)",2020-02-05,2022-02-01,2024-07-01,Interventional,Not yet recruiting,Phase 4,Centre Hospitalier Universitaire de Pointe-a-Pitre,Centre Hospitalier Universitaire de Pointe-a-Pitre,CHU Bordeaux|CHU Limoges|University Hospital Center of Guadeloupe|CHU de la Réunion,Drug|Drug,France|Guadeloupe|Réunion,18.0,65.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT04298684
NCT04298684,thyroid neoplasms,Efficacy of Metformin Versus Sitagliptin on Benign Thyroid Nodules Size in Type 2 Diabetes: a 2-years Prospective Multicentric Study,"Diabetes Mellitus, Type 2|Thyroid Nodule (Benign)",2020-02-05,2022-02-01,2024-07-01,Interventional,Not yet recruiting,Phase 4,Centre Hospitalier Universitaire de Pointe-a-Pitre,Centre Hospitalier Universitaire de Pointe-a-Pitre,CHU Bordeaux|CHU Limoges|University Hospital Center of Guadeloupe|CHU de la Réunion,Drug|Drug,France|Guadeloupe|Réunion,18.0,65.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04298684
NCT04311606,graves disease,Anti-VEGF Therapy for Acute Thyroid Eye Disease (AcTED Study),Thyroid Eye Disease,2020-03-12,2025-09-30,2027-01-01,Interventional,Recruiting,Phase 2,Massachusetts Eye and Ear Infirmary,Massachusetts Eye and Ear Infirmary|Regeneron Pharmaceuticals,Mass Eye and Ear,Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04311606
NCT04311606,goiter,Anti-VEGF Therapy for Acute Thyroid Eye Disease (AcTED Study),Thyroid Eye Disease,2020-03-12,2025-09-30,2027-01-01,Interventional,Recruiting,Phase 2,Massachusetts Eye and Ear Infirmary,Massachusetts Eye and Ear Infirmary|Regeneron Pharmaceuticals,Mass Eye and Ear,Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04311606
NCT04311606,hyperthyroidism,Anti-VEGF Therapy for Acute Thyroid Eye Disease (AcTED Study),Thyroid Eye Disease,2020-03-12,2025-09-30,2027-01-01,Interventional,Recruiting,Phase 2,Massachusetts Eye and Ear Infirmary,Massachusetts Eye and Ear Infirmary|Regeneron Pharmaceuticals,Mass Eye and Ear,Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04311606
NCT04329455,thyroid nodule,Evaluation of Endoscopic Thyroidectomy Via Axillo-breast Approach in Thyroid Nodules,Safety and Cosmetic Issues in Endoscopic Thyroidectomy,2020-03-30,2022-04-01,2023-04-01,Observational,Recruiting,,Assiut University,Assiut University,Ahmed Gamal,Procedure,Egypt,18.0,55.0,[18-65],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT04329455
NCT04329455,thyroid neoplasms,Evaluation of Endoscopic Thyroidectomy Via Axillo-breast Approach in Thyroid Nodules,Safety and Cosmetic Issues in Endoscopic Thyroidectomy,2020-03-30,2022-04-01,2023-04-01,Observational,Recruiting,,Assiut University,Assiut University,Ahmed Gamal,Procedure,Egypt,18.0,55.0,[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04329455
NCT04333342,graves disease,Clinical Usefulness of Monitoring Heart Rate Using Wearable Devices in the Patients of Graves' Disease Who Discontinue Anti-thyroid Drugs,Graves' Disease in Remission (Disorder),2020-03-11,2021-09-30,2021-12-31,Interventional,Recruiting,Not Applicable,Seoul National University Bundang Hospital,Seoul National University Bundang Hospital,Chungbuk National University Hospital|Chung-Ang University Hospital|Eulji University Nowon Eulji Medical Center|Korea University Guro Hospital|Seoul National University Hospital|The Catholic University of Korea Eunpyeong St. Mary's Hospital,Device,"Korea, Republic of",20.0,60.0,[18-65],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04333342
NCT04333342,goiter,Clinical Usefulness of Monitoring Heart Rate Using Wearable Devices in the Patients of Graves' Disease Who Discontinue Anti-thyroid Drugs,Graves' Disease in Remission (Disorder),2020-03-11,2021-09-30,2021-12-31,Interventional,Recruiting,Not Applicable,Seoul National University Bundang Hospital,Seoul National University Bundang Hospital,Chungbuk National University Hospital|Chung-Ang University Hospital|Eulji University Nowon Eulji Medical Center|Korea University Guro Hospital|Seoul National University Hospital|The Catholic University of Korea Eunpyeong St. Mary's Hospital,Device,"Korea, Republic of",20.0,60.0,[18-65],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04333342
NCT04333342,hyperthyroidism,Clinical Usefulness of Monitoring Heart Rate Using Wearable Devices in the Patients of Graves' Disease Who Discontinue Anti-thyroid Drugs,Graves' Disease in Remission (Disorder),2020-03-11,2021-09-30,2021-12-31,Interventional,Recruiting,Not Applicable,Seoul National University Bundang Hospital,Seoul National University Bundang Hospital,Chungbuk National University Hospital|Chung-Ang University Hospital|Eulji University Nowon Eulji Medical Center|Korea University Guro Hospital|Seoul National University Hospital|The Catholic University of Korea Eunpyeong St. Mary's Hospital,Device,"Korea, Republic of",20.0,60.0,[18-65],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04333342
NCT04339205,thyroiditis,Diffusion Imaging in Acute Auto-immune Encephalitis : a Cohort of 80 Patients,Auto-immune Encephalitis,2020-04-06,2020-03-01,2020-07-01,Observational,Recruiting,,Hospices Civils de Lyon,Hospices Civils de Lyon,Hospices Civils de Lyon,Other,France,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT04339205
NCT04359979,graves disease,Treatment With Tamsulosin for Upper Eyelid Retraction Related to Thyroid Eye Disease.,Eyelid Diseases|Thyroid Eye Disease,2020-04-21,2021-05-31,2021-12-31,Interventional,Recruiting,Not Applicable,Sheba Medical Center,Sheba Medical Center,Sheba Medical Center,Drug,Israel,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04359979
NCT04359979,goiter,Treatment With Tamsulosin for Upper Eyelid Retraction Related to Thyroid Eye Disease.,Eyelid Diseases|Thyroid Eye Disease,2020-04-21,2021-05-31,2021-12-31,Interventional,Recruiting,Not Applicable,Sheba Medical Center,Sheba Medical Center,Sheba Medical Center,Drug,Israel,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04359979
NCT04359979,hyperthyroidism,Treatment With Tamsulosin for Upper Eyelid Retraction Related to Thyroid Eye Disease.,Eyelid Diseases|Thyroid Eye Disease,2020-04-21,2021-05-31,2021-12-31,Interventional,Recruiting,Not Applicable,Sheba Medical Center,Sheba Medical Center,Sheba Medical Center,Drug,Israel,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04359979
NCT04373226,parathyroid diseases,Study of Arithmetic Abilities of Children With 22q11.2 Deletion Syndrome Aged From 4 to 11 Years Old,22q11.2 Deletion Syndrome,2020-04-30,2023-07-20,2023-10-20,Interventional,Recruiting,Not Applicable,Hôpital le Vinatier,Hôpital le Vinatier,Hopital Vinatier,Behavioral,France,4.0,11.0,[0-17],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT04373226
NCT04376203,thyroid neoplasms,What is the Relation of Microbiome to Papillary Thyroid Microcarcinoma Development?,Microbiome|Papillary Thyroid Microcarcinoma,2020-05-02,2022-05-30,2023-05-30,Observational,Not yet recruiting,,University of Ioannina,University of Ioannina,,Procedure,,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04376203
NCT04383795,graves disease,A Prospective Study Analyzing the Change of Gut Microbiome With Antithyroid Drug Treatment of Graves' Disease,Graves' Disease,2020-05-07,2021-05-04,2023-05-04,Observational,Recruiting,,Seoul St. Mary's Hospital,Seoul St. Mary's Hospital,Seoul St. Mary hospital,Drug,"Korea, Republic of",19.0,69.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04383795
NCT04383795,goiter,A Prospective Study Analyzing the Change of Gut Microbiome With Antithyroid Drug Treatment of Graves' Disease,Graves' Disease,2020-05-07,2021-05-04,2023-05-04,Observational,Recruiting,,Seoul St. Mary's Hospital,Seoul St. Mary's Hospital,Seoul St. Mary hospital,Drug,"Korea, Republic of",19.0,69.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04383795
NCT04383795,hyperthyroidism,A Prospective Study Analyzing the Change of Gut Microbiome With Antithyroid Drug Treatment of Graves' Disease,Graves' Disease,2020-05-07,2021-05-04,2023-05-04,Observational,Recruiting,,Seoul St. Mary's Hospital,Seoul St. Mary's Hospital,Seoul St. Mary hospital,Drug,"Korea, Republic of",19.0,69.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04383795
NCT04396158,thyroid neoplasms,Effect of Radioiodine Therapy on Ovarian Reserve in Female Patients With Differentiated Thyroid Cancer,Ovarian Insufficiency|Radiation Exposure,2020-05-16,2021-06-15,2021-12-15,Interventional,Not yet recruiting,Not Applicable,Assiut University,Assiut University,,Radiation,,15.0,45.0,[0-17]|[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04396158
NCT04396912,parathyroid diseases,"Post-thyroidectomy Vocal Cord Paralysis Along With Hypocalcemia: Prospective, Matched-randomized Observational Cohort Compatible With STROBE Guidelines","Calcium Deficiency|Iatrogenic Hypocalcemia|Iatrogenic Hypoparathyroidism|Multinodular Goiter|PTH|Thyroid Cancer|Thyroid Cancer, Papillary|Thyroid Neoplasms|Thyroid Nodule|Vocal Cord; Injury, Superficial|Vocal Cord Paralysis|Vocal Cord Paresis",2020-05-15,2021-06-01,2021-06-01,Observational,Recruiting,,Umraniye Education and Research Hospital,Umraniye Education and Research Hospital,"Umraniye Education and Research Hospital, Health Sciences University",Procedure,Turkey,17.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT04396912
NCT04410601,thyroid nodule,Pre-and Post-operative Risk Factors Affecting the Incidence and Severity of Dysphagia Following Total Thyroidectomy: An International Multi-centric Prospective Randomized Controlled Clinical Trial (RCT),"Dysphagia Comes and Goes|Dysphagia, Esophageal|Dysphagia, Oral Phase|Thyroid Cancer|Thyroid Goiter|Thyroiditis|Thyroid Neoplasms|Thyroid Nodule (Benign)",2020-05-15,2021-06-30,2021-06-30,Interventional,Recruiting,Not Applicable,Umraniye Education and Research Hospital,Umraniye Education and Research Hospital,"Umraniye Education and Research Hospital, Health Sciences University",Procedure,Turkey,17.0,120.0,[0-17]|[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT04410601
NCT04410601,goiter,Pre-and Post-operative Risk Factors Affecting the Incidence and Severity of Dysphagia Following Total Thyroidectomy: An International Multi-centric Prospective Randomized Controlled Clinical Trial (RCT),"Dysphagia Comes and Goes|Dysphagia, Esophageal|Dysphagia, Oral Phase|Thyroid Cancer|Thyroid Goiter|Thyroiditis|Thyroid Neoplasms|Thyroid Nodule (Benign)",2020-05-15,2021-06-30,2021-06-30,Interventional,Recruiting,Not Applicable,Umraniye Education and Research Hospital,Umraniye Education and Research Hospital,"Umraniye Education and Research Hospital, Health Sciences University",Procedure,Turkey,17.0,120.0,[0-17]|[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04410601
NCT04412694,parathyroid diseases,The Impact of Preoperative Oral Dexamethasone Supplementation on the Biochemical Parameters and Results of Surgical Treatment in Patients With Nontoxic Multinodular Goiter Undergoing Total Thyroidectomy.,Hypocalcemia|Hypoparathyroidism Postprocedural|Postoperative Complications|Postoperative Nausea|Postoperative Pain|Vitamin D Deficiency|Voice Hoarseness,2020-05-23,2022-09-30,2022-12-31,Interventional,Recruiting,Phase 4,Medical University of Lodz,Medical University of Lodz,"Department of General and Oncological Surgery, Medical University of Lodz",Drug|Drug|Diagnostic Test|Diagnostic Test|Diagnostic Test|Diagnostic Test|Procedure|Other|Other|Other|Other|Other|Other|Other|Other,Poland,18.0,100.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT04412694
NCT04424485,"thyroid cancer, papillary",Near-infrared (NIR) Fluorescence Imaging With Indocyanine Green (ICG) for Identification of Sentinel Lymph Nodes and Parathyroid Glands During Total Thyroidectomy: Prospective Randomized Clinical Trial,"Lymph Node Metastases|Sentinel Lymph Node|Thyroid Cancer|Thyroid Carcinoma, Papillary|Thyroid Metastases|Thyroid Neoplasms",2020-06-02,2021-06-01,2021-06-01,Interventional,Recruiting,Not Applicable,Umraniye Education and Research Hospital,Umraniye Education and Research Hospital,"Umraniye Education and Research Hospital, Department of General Surgery",Procedure|Procedure|Diagnostic Test|Diagnostic Test,Turkey,17.0,80.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT04424485
NCT04458233,thyroid neoplasms,FNA Guided Ultrasonography Needle Technique Axial Vs Lateral Approach Study,Thyroid Nodule,2020-06-30,2021-06-01,2021-07-01,Interventional,Recruiting,Not Applicable,Ziv Hospital,Ziv Hospital,Ziv Medical Center,Procedure,Israel,18.0,85.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04458233
NCT04463316,parathyroid diseases,GROWing Up With Rare GENEtic Syndromes ….When Children With Complex Genetic Syndromes Reach Adult Age,"17p- Deletiesyndrome|1q25-32 Deletie|22q11 Deletion Syndrome|46, XY DSD|Albright Hereditaire Osteodystrofie|Allan-Herndon-Dudley Syndrome|Bardet Biedl Syndrome|CHARGE Syndrome|Congenital Adrenal Hyperplasia|Congenital Hypopituitarism|Cornelia de Lange Syndrome|Disorders of Sex Development|Jacobsen Syndrome / 11 q Syndrome|Kallmann Syndrome|Klinefelter (XXY-)Syndrome|Myrhe Syndrome|Neurofibromatosis|Noonan Syndrome|Ohdo Syndrome|POLR3A Mutatie|Prader-Willi Syndrome|PWS-like Syndrome|Rare Bone Disorders|Rett Syndrome|Saethre-Chotzen Syndrome|Silver Russel Syndrome|Tuberous Sclerosis|Turner Syndrome|VCF Syndrome|Williams-Beuren Syndrome|XXXX Syndrome (Tetra-X Syndrome)|XXXXY Syndrome|XXYY Syndrome",2020-07-02,2030-01-01,2030-01-01,Observational,Recruiting,,Erasmus Medical Center,dr. Laura C. G. de Graaff-Herder,Erasmus Medical Center,Diagnostic Test,Netherlands,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT04463316
NCT04463719,thyroid nodule,Adequate Selection of Patients for Thyroid Biopsy: Evaluation of a Shared Decision Making Conversation Aid,Thyroid Cancer|Thyroid Nodules,2020-07-06,2022-06-30,2025-06-30,Interventional,Not yet recruiting,Not Applicable,University of Florida,National Cancer Institute (NCI)|University of Florida,University of Florida|Mayo Clinic,Behavioral|Behavioral,United States,18.0,99.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT04463719
NCT04467021,thyroid neoplasms,Cancer Therapy Risk-Reduction With Intensive Systolic BP Management (CARISMA) - a Phase II Study,Cardiovascular Disorder|Chronic Kidney Disease|Metastatic Renal Cell Carcinoma|Metastatic Thyroid Gland Medullary Carcinoma|Stage IVA Thyroid Gland Medullary Carcinoma AJCC v8|Stage IVB Thyroid Gland Medullary Carcinoma AJCC v8|Stage IVC Thyroid Gland Medullary Carcinoma AJCC v8|Stage IV Renal Cell Cancer AJCC v8|Stage IV Thyroid Gland Medullary Carcinoma AJCC v8,2020-07-07,2023-02-01,2023-02-01,Interventional,Recruiting,Not Applicable,Eastern Cooperative Oncology Group,ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI),Siteman Cancer Center at West County Hospital|Washington University School of Medicine|Montefiore Medical Center-Einstein Campus|Montefiore Medical Center-Weiler Hospital|Montefiore Medical Center - Moses Campus|University of Pennsylvania/Abramson Cancer Center|University of Pittsburgh Cancer Institute (UPCI)|UT Southwestern/Simmons Cancer Center-Dallas|Aurora Cancer Care-Southern Lakes VLCC|Aurora Saint Luke's South Shore|Aurora Health Care Germantown Health Center|Aurora Cancer Care-Grafton|Aurora BayCare Medical Center|Aurora Cancer Care-Kenosha South|Aurora Bay Area Medical Group-Marinette|Aurora Cancer Care-Milwaukee|Aurora Saint Luke's Medical Center|Aurora Sinai Medical Center|Vince Lombardi Cancer Clinic - Oshkosh|Aurora Cancer Care-Racine|Vince Lombardi Cancer Clinic-Sheboygan|Aurora Medical Center in Summit|Vince Lombardi Cancer Clinic-Two Rivers|Aurora Cancer Care-Milwaukee West|Aurora West Allis Medical Center,Other|Other|Other|Other|Other,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04467021
NCT04472026,thyroid nodule,Adequate Selection of Patients for Thyroid Biopsy: Evaluation of a Shared Decision Making Conversation Aid,Thyroid Cancer|Thyroid Nodules,2020-07-10,2022-06-30,2025-06-30,Interventional,Recruiting,Not Applicable,University of Florida,National Cancer Institute (NCI)|University of Florida,University of Florida|Mayo Clinic,Behavioral,United States,18.0,99.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT04472026
NCT04477798,thyroid neoplasms,Protein Classifier for Thyroid Indeterminate Nodules： a Multi-center Prospective Clinical Study,Thyroid Nodule,2020-07-10,2021-07-01,2021-12-31,Interventional,Recruiting,Not Applicable,Zhejiang University,Luo Dingcun,Hangzhou First People's Hospital Affiliated to Zhejiang University Medical College,Diagnostic Test,China,18.0,70.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04477798
NCT04509011,parathyroid diseases,Randomized Controlled Trial of Fluobeam® LX Compared With Clinical Assessment of Parathyroid Glands to Counteract Postoperatively Failing Parathyroid Function With Low Blood Calcium After Thyroid Surgery,Hypoparathyroidism Postprocedural,2020-08-04,2022-12-31,2023-07-31,Interventional,Recruiting,Not Applicable,Region Skane,"Haukeland University Hospital|Hospital Rudolfstiftung|Jagiellonian University|Region Skane|Sahlgrenska University Hospital, Sweden","Rudolfstiftung|Haukeland University Hospital|Jagiellonian University Medical College|Sahlgrenska University Hospital|Skåne University Hospital, Department of Surgery, Lund",Device,Austria|Norway|Poland|Sweden,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT04509011
NCT04514484,thyroid neoplasms,Pilot Trial of Nivolumab Plus Cabozantinib for Advanced Solid Tumors in Patients With HIV Infection,Advanced Differentiated Thyroid Gland Carcinoma|Advanced Head and Neck Carcinoma|Advanced Hepatocellular Carcinoma|Advanced Kaposi Sarcoma|Advanced Lung Non-Small Cell Carcinoma|Advanced Lung Small Cell Carcinoma|Advanced Malignant Solid Neoplasm|Advanced Melanoma|Advanced Ovarian Carcinoma|Advanced Prostate Carcinoma|Advanced Renal Cell Carcinoma|Advanced Thyroid Gland Medullary Carcinoma|Advanced Urothelial Carcinoma|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Castration-Resistant Prostate Carcinoma|Clinical Stage III Cutaneous Melanoma AJCC v8|Clinical Stage IV Cutaneous Melanoma AJCC v8|HIV Infection|Metastatic Differentiated Thyroid Gland Carcinoma|Metastatic Head and Neck Carcinoma|Metastatic Hepatocellular Carcinoma|Metastatic Kaposi Sarcoma|Metastatic Lung Non-Small Cell Carcinoma|Metastatic Lung Small Cell Carcinoma|Metastatic Malignant Solid Neoplasm|Metastatic Melanoma|Metastatic Ovarian Carcinoma|Metastatic Prostate Carcinoma|Metastatic Renal Cell Carcinoma|Metastatic Thyroid Gland Medullary Carcinoma|Metastatic Triple-Negative Breast Carcinoma|Metastatic Urothelial Carcinoma|Pathologic Stage IIIA Cutaneous Melanoma AJCC v8|Pathologic Stage IIIB Cutaneous Melanoma AJCC v8|Pathologic Stage IIIC Cutaneous Melanoma AJCC v8|Pathologic Stage III Cutaneous Melanoma AJCC v8|Pathologic Stage IIID Cutaneous Melanoma AJCC v8|Pathologic Stage IV Cutaneous Melanoma AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage IV Breast Cancer AJCC v8|Recurrent Differentiated Thyroid Gland Carcinoma|Recurrent Head and Neck Carcinoma|Recurrent Hepatocellular Carcinoma|Recurrent Kaposi Sarcoma|Recurrent Lung Non-Small Cell Carcinoma|Recurrent Lung Small Cell Carcinoma|Recurrent Malignant Solid Neoplasm|Recurrent Melanoma|Recurrent Ovarian Carcinoma|Recurrent Prostate Carcinoma|Recurrent Renal Cell Carcinoma|Recurrent Thyroid Gland Medullary Carcinoma|Recurrent Triple-Negative Breast Carcinoma|Recurrent Urothelial Carcinoma|Refractory Differentiated Thyroid Gland Carcinoma|Stage IIIA1 Ovarian Cancer AJCC v8|Stage IIIA2 Ovarian Cancer AJCC v8|Stage IIIA Hepatocellular Carcinoma AJCC v8|Stage IIIA Lung Cancer AJCC v8|Stage IIIA Ovarian Cancer AJCC v8|Stage IIIA Prostate Cancer AJCC v8|Stage IIIB Hepatocellular Carcinoma AJCC v8|Stage IIIB Lung Cancer AJCC v8|Stage IIIB Ovarian Cancer AJCC v8|Stage IIIB Prostate Cancer AJCC v8|Stage IIIC Lung Cancer AJCC v8|Stage IIIC Ovarian Cancer AJCC v8|Stage IIIC Prostate Cancer AJCC v8|Stage III Differentiated Thyroid Gland Carcinoma AJCC v8|Stage III Hepatocellular Carcinoma AJCC v8|Stage III Lung Cancer AJCC v8|Stage III Ovarian Cancer AJCC v8|Stage III Prostate Cancer AJCC v8|Stage III Renal Cell Cancer AJCC v8|Stage III Thyroid Gland Medullary Carcinoma AJCC v8|Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v8|Stage IVA Hepatocellular Carcinoma AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVA Ovarian Cancer AJCC v8|Stage IVA Prostate Cancer AJCC v8|Stage IVA Thyroid Gland Medullary Carcinoma AJCC v8|Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v8|Stage IVB Hepatocellular Carcinoma AJCC v8|Stage IVB Lung Cancer AJCC v8|Stage IVB Ovarian Cancer AJCC v8|Stage IVB Prostate Cancer AJCC v8|Stage IVB Thyroid Gland Medullary Carcinoma AJCC v8|Stage IVC Thyroid Gland Medullary Carcinoma AJCC v8|Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8|Stage IV Hepatocellular Carcinoma AJCC v8|Stage IV Lung Cancer AJCC v8|Stage IV Ovarian Cancer AJCC v8|Stage IV Prostate Cancer AJCC v8|Stage IV Renal Cell Cancer AJCC v8|Stage IV Thyroid Gland Medullary Carcinoma AJCC v8|Triple-Negative Breast Carcinoma,2020-08-14,2025-11-02,2025-11-02,Interventional,Recruiting,Phase 1,National Cancer Institute (NCI),National Cancer Institute (NCI),Northwestern University|Montefiore Medical Center-Einstein Campus|University of Pittsburgh Cancer Institute (UPCI),Drug|Biological,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04514484
NCT04522622,parathyroid diseases,Treatment of Adynamic Bone Disorder With Parathyroid Hormone in Patients With Chronic Kidney Disease,Adynamic Bone Disease|Cardiac Disease|Chronic Kidney Disease-Mineral and Bone Disorder|Chronic Kidney Diseases,2020-08-13,2024-02-01,2025-02-01,Interventional,Recruiting,Phase 4,Herlev Hospital,"Ditte Hansen|Odense University Hospital|Rigshospitalet, Denmark|Steno Diabetes Center Copenhagen|Universiteit Antwerpen","Steno Diabetes Center Copenhagen|Herlev and Gentofte Hospital, Herlev Hospital|Odense University Hospital",Drug|Diagnostic Test|Procedure|Diagnostic Test|Other|Other,Denmark,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT04522622
NCT04523974,parathyroid diseases,Preemptive Surgical Intervention and Precise Efficacy Evaluation for Hyperparathyroidism Secondary to Chronic Kidney Disease,"Hyperparathyroidism; Secondary, Renal",2020-08-17,2022-09-30,2022-12-31,Observational,Not yet recruiting,,Shanghai Zhongshan Hospital,Shanghai Zhongshan Hospital,,Procedure,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT04523974
NCT04548284,graves ophthalmopathy,Periorbitally Injected Glucocorticoids for Mild TAO: A Randomized Controlled Study,Thyroid Associated Ophthalmopathy,2020-09-07,2023-06-30,2023-12-31,Interventional,Recruiting,Phase 3,Sun Yat-sen University,Sun Yat-sen University,"Zhongshan Ophthalmic Center, Sun Yat-sen University",Drug,China,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT04548284
NCT04548284,graves disease,Periorbitally Injected Glucocorticoids for Mild TAO: A Randomized Controlled Study,Thyroid Associated Ophthalmopathy,2020-09-07,2023-06-30,2023-12-31,Interventional,Recruiting,Phase 3,Sun Yat-sen University,Sun Yat-sen University,"Zhongshan Ophthalmic Center, Sun Yat-sen University",Drug,China,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04548284
NCT04548284,goiter,Periorbitally Injected Glucocorticoids for Mild TAO: A Randomized Controlled Study,Thyroid Associated Ophthalmopathy,2020-09-07,2023-06-30,2023-12-31,Interventional,Recruiting,Phase 3,Sun Yat-sen University,Sun Yat-sen University,"Zhongshan Ophthalmic Center, Sun Yat-sen University",Drug,China,18.0,80.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04548284
NCT04548284,hyperthyroidism,Periorbitally Injected Glucocorticoids for Mild TAO: A Randomized Controlled Study,Thyroid Associated Ophthalmopathy,2020-09-07,2023-06-30,2023-12-31,Interventional,Recruiting,Phase 3,Sun Yat-sen University,Sun Yat-sen University,"Zhongshan Ophthalmic Center, Sun Yat-sen University",Drug,China,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04548284
NCT04560127,thyroid neoplasms,"A Single-arm, Non-randomized, Single-center Study to Evaluate Camrelizumab in Combination With Apatinib in Patients With Radioactive Iodine-refractory Differentiated Thyroid Cancer",Radioactive Iodine-refractory Differentiated Thyroid Cancer,2020-09-17,2022-12-31,2023-06-30,Interventional,Recruiting,Phase 2,Peking Union Medical College Hospital,Peking Union Medical College Hospital,Peking Union Medical College Hospital,Drug,China,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04560127
NCT04564924,parathyroid diseases,To Investigate the Bone and Muscle Abnormalities in Patients With Chronic Kidney Disease Compared to Healthy Volunteers With MRI,Chronic Kidney Disease-Mineral and Bone Disorder,2020-09-14,2021-09-30,2022-01-30,Observational,Recruiting,,Tongji Hospital,Tongji Hospital,Tongji Hospital,Radiation,China,18.0,70.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT04564924
NCT04574947,thyroid neoplasms,Intravenous Or Topical Lidocaine And Neuromonitoring in Thyroid Surgery (IOLANT Study),Anesthesia|Parathyroid Neoplasms|Thyroid Neoplasm,2020-09-24,2021-11-15,2021-12-01,Interventional,Recruiting,Phase 4,"Saint Petersburg State University, Russia","Saint Petersburg State University, Russia",St. Petersburg State University Hospital,Drug|Drug|Procedure|Procedure,Russian Federation,45.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04574947
NCT04574947,parathyroid diseases,Intravenous Or Topical Lidocaine And Neuromonitoring in Thyroid Surgery (IOLANT Study),Anesthesia|Parathyroid Neoplasms|Thyroid Neoplasm,2020-09-24,2021-11-15,2021-12-01,Interventional,Recruiting,Phase 4,"Saint Petersburg State University, Russia","Saint Petersburg State University, Russia",St. Petersburg State University Hospital,Drug|Drug|Procedure|Procedure,Russian Federation,45.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT04574947
NCT04577664,graves disease,Total Versus Subtotal Thyroidectomy in Graves' Disease : A Randomized Controlled Trial,Thyroid Goiter,2020-07-28,2021-11-30,2021-12-31,Interventional,Not yet recruiting,Not Applicable,Assiut University,Assiut University,,Procedure|Procedure,,18.0,65.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04577664
NCT04577664,goiter,Total Versus Subtotal Thyroidectomy in Graves' Disease : A Randomized Controlled Trial,Thyroid Goiter,2020-07-28,2021-11-30,2021-12-31,Interventional,Not yet recruiting,Not Applicable,Assiut University,Assiut University,,Procedure|Procedure,,18.0,65.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04577664
NCT04577664,hyperthyroidism,Total Versus Subtotal Thyroidectomy in Graves' Disease : A Randomized Controlled Trial,Thyroid Goiter,2020-07-28,2021-11-30,2021-12-31,Interventional,Not yet recruiting,Not Applicable,Assiut University,Assiut University,,Procedure|Procedure,,18.0,65.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04577664
NCT04580199,thyroid neoplasms,"Surgical (Total or Hemithyroidectomy)Versus Non Surgical (Ethanol Ablation ,RF Ablation ,Laser Ablation) Management of Thyroid Nodule",Thyroid Nodule,2020-10-02,2021-12-01,2022-12-01,Interventional,Not yet recruiting,Not Applicable,Assiut University,Mahmoud Fahd,,Procedure,,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04580199
NCT04583735,graves disease,"A Phase 4, Randomized, Double-masked, Placebo-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of TEPEZZA® in Treating Patients With Chronic (Inactive) Thyroid Eye Disease",Chronic (Inactive) Thyroid Eye Disease|Thyroid Eye Disease,2020-10-06,2022-09-30,2023-04-30,Interventional,Recruiting,Phase 4,"Horizon Pharma USA, Inc.","Horizon Therapeutics USA, Inc.",Perlman Medical Offices / UCSD|MACRO Trials|Univ of Colorado Dept of Opthalmology|Bascom Palmer Eye Institute / Univ of Miami|Mayo Clinic|Washington University|Hamilton Eye Institute / U Tennessee|Medical College of Wisconsin,Biological|Drug,United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04583735
NCT04583735,goiter,"A Phase 4, Randomized, Double-masked, Placebo-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of TEPEZZA® in Treating Patients With Chronic (Inactive) Thyroid Eye Disease",Chronic (Inactive) Thyroid Eye Disease|Thyroid Eye Disease,2020-10-06,2022-09-30,2023-04-30,Interventional,Recruiting,Phase 4,"Horizon Pharma USA, Inc.","Horizon Therapeutics USA, Inc.",Perlman Medical Offices / UCSD|MACRO Trials|Univ of Colorado Dept of Opthalmology|Bascom Palmer Eye Institute / Univ of Miami|Mayo Clinic|Washington University|Hamilton Eye Institute / U Tennessee|Medical College of Wisconsin,Biological|Drug,United States,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04583735
NCT04583735,hyperthyroidism,"A Phase 4, Randomized, Double-masked, Placebo-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of TEPEZZA® in Treating Patients With Chronic (Inactive) Thyroid Eye Disease",Chronic (Inactive) Thyroid Eye Disease|Thyroid Eye Disease,2020-10-06,2022-09-30,2023-04-30,Interventional,Recruiting,Phase 4,"Horizon Pharma USA, Inc.","Horizon Therapeutics USA, Inc.",Perlman Medical Offices / UCSD|MACRO Trials|Univ of Colorado Dept of Opthalmology|Bascom Palmer Eye Institute / Univ of Miami|Mayo Clinic|Washington University|Hamilton Eye Institute / U Tennessee|Medical College of Wisconsin,Biological|Drug,United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04583735
NCT04598815,graves disease,"A Phase II, Randomized, Superiority, Adaptive, Open-label, Single-center, Clinical Trial to Evaluate the Efficacy of Sirolimus (Rapamycin) in Patients With Graves' Disease and Moderate-to-severe and Active Graves' Orbitopathy (GO)",Graves Ophthalmopathy,2020-10-16,2025-01-01,2025-01-01,Interventional,Not yet recruiting,Phase 2,University of Pisa,University of Pisa,Ospedale Cisanello-Endocrinology II,Drug,Italy,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04598815
NCT04598815,goiter,"A Phase II, Randomized, Superiority, Adaptive, Open-label, Single-center, Clinical Trial to Evaluate the Efficacy of Sirolimus (Rapamycin) in Patients With Graves' Disease and Moderate-to-severe and Active Graves' Orbitopathy (GO)",Graves Ophthalmopathy,2020-10-16,2025-01-01,2025-01-01,Interventional,Not yet recruiting,Phase 2,University of Pisa,University of Pisa,Ospedale Cisanello-Endocrinology II,Drug,Italy,18.0,75.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04598815
NCT04598815,hyperthyroidism,"A Phase II, Randomized, Superiority, Adaptive, Open-label, Single-center, Clinical Trial to Evaluate the Efficacy of Sirolimus (Rapamycin) in Patients With Graves' Disease and Moderate-to-severe and Active Graves' Orbitopathy (GO)",Graves Ophthalmopathy,2020-10-16,2025-01-01,2025-01-01,Interventional,Not yet recruiting,Phase 2,University of Pisa,University of Pisa,Ospedale Cisanello-Endocrinology II,Drug,Italy,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04598815
NCT04614389,thyroid neoplasms,Utility of Contrast-Enhanced Sonography and Shear Wave Elastography in Conjunction With ACR TI-RADS for the Evaluation of Thyroid Nodules,Thyroid Nodule,2019-09-25,2021-04-30,2021-07-01,Interventional,Recruiting,Not Applicable,University of Southern California,Siemens Medical Solutions USA - CSG|University of Southern California,USC Department of Radiology,Other|Other|Device,United States,18.0,70.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04614389
NCT04632524,goiter,Evaluation of the Role of Low Dose Magnesium Sulfate in Anesthesia for Toxic Goiter Resection: A Randomized Controlled Trial,Haemodynamic Stability,2020-08-30,2021-12-20,2022-01-30,Interventional,Recruiting,Phase 4,Fayoum University Hospital,Fayoum University Hospital,Atef,Drug,Egypt,20.0,70.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04632524
NCT04639388,parathyroid diseases,Characterize the Behavioral Prodromes of Psychotic Disorders in Children With 22q11.2DS Aged From 4 to 13 Years Old,22q11.2 Deletion Syndrome,2020-10-01,2024-10-31,2025-01-31,Interventional,Recruiting,Not Applicable,Hôpital le Vinatier,Hôpital le Vinatier,Hopital Vinatier,Behavioral,France,4.0,13.0,[0-17],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT04639388
NCT04639960,parathyroid diseases,Effects of Modulation of the Dopaminergic System Using Risperidone on Memory and Executive Processes in Individuals With 22q11.2 Deletion Syndrome,22q11.2 Deletion Syndrome,2020-11-03,2022-09-30,2022-09-30,Interventional,Recruiting,Not Applicable,"University of Geneva, Switzerland","University of Geneva, Switzerland",Developmental imaging and psychopathology lab,Drug|Drug,Switzerland,11.0,25.0,[0-17]|[18-65],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT04639960
NCT04647500,parathyroid diseases,Effects of Modulation of the Dopaminergic System Using Methylphenidate on Memory and Executive Processes in Individuals With 22q11.2 Deletion Syndrome,22q11.2 Deletion Syndrome,2020-11-03,2022-09-30,2022-09-30,Interventional,Recruiting,Not Applicable,"University of Geneva, Switzerland","University of Geneva, Switzerland",Developmental imaging and psychopathology lab,Drug,Switzerland,8.0,25.0,[0-17]|[18-65],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT04647500
NCT04662190,graves ophthalmopathy,Eficàcia i Seguretat de la descompressió orbitària en Orbitopatia distiroïdal Utilitzant Models Individualitzats d'impressió 3D Per la planificació i simulació de la Cirurgia.,"Surgical Procedure, Unspecified|Thyroid Associated Ophthalmopathy",2020-12-06,2022-07-31,2022-11-30,Interventional,Recruiting,Not Applicable,Althaia Xarxa Assistencial Universitària de Manresa,Althaia Xarxa Assistencial Universitària de Manresa|Societat Catalana d'Oftalmologia,Eduard Pedemonte Sarrias,Device|Procedure,Spain,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT04662190
NCT04662190,graves disease,Eficàcia i Seguretat de la descompressió orbitària en Orbitopatia distiroïdal Utilitzant Models Individualitzats d'impressió 3D Per la planificació i simulació de la Cirurgia.,"Surgical Procedure, Unspecified|Thyroid Associated Ophthalmopathy",2020-12-06,2022-07-31,2022-11-30,Interventional,Recruiting,Not Applicable,Althaia Xarxa Assistencial Universitària de Manresa,Althaia Xarxa Assistencial Universitària de Manresa|Societat Catalana d'Oftalmologia,Eduard Pedemonte Sarrias,Device|Procedure,Spain,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04662190
NCT04662190,goiter,Eficàcia i Seguretat de la descompressió orbitària en Orbitopatia distiroïdal Utilitzant Models Individualitzats d'impressió 3D Per la planificació i simulació de la Cirurgia.,"Surgical Procedure, Unspecified|Thyroid Associated Ophthalmopathy",2020-12-06,2022-07-31,2022-11-30,Interventional,Recruiting,Not Applicable,Althaia Xarxa Assistencial Universitària de Manresa,Althaia Xarxa Assistencial Universitària de Manresa|Societat Catalana d'Oftalmologia,Eduard Pedemonte Sarrias,Device|Procedure,Spain,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04662190
NCT04662190,hyperthyroidism,Eficàcia i Seguretat de la descompressió orbitària en Orbitopatia distiroïdal Utilitzant Models Individualitzats d'impressió 3D Per la planificació i simulació de la Cirurgia.,"Surgical Procedure, Unspecified|Thyroid Associated Ophthalmopathy",2020-12-06,2022-07-31,2022-11-30,Interventional,Recruiting,Not Applicable,Althaia Xarxa Assistencial Universitària de Manresa,Althaia Xarxa Assistencial Universitària de Manresa|Societat Catalana d'Oftalmologia,Eduard Pedemonte Sarrias,Device|Procedure,Spain,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04662190
NCT04663451,hypothyroidism,"An Assessment of the Occurrence of Hypothyroidism in Patients Treated With RAI For Hyperthyroidism, And it's Prognostic Factors.",Nodule Solitary Thyroid|Radioactive Iodine-Induced Hypothyroidism|Toxic Multinodular Goiter,2020-11-26,2020-11-24,2021-05-31,Observational,"Active, not recruiting",,Universitair Ziekenhuis Brussel,Universitair Ziekenhuis Brussel,Universitair Ziekenhuis Brussel,Radiation,Belgium,18.0,120.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT04663451
NCT04663451,hyperthyroidism,"An Assessment of the Occurrence of Hypothyroidism in Patients Treated With RAI For Hyperthyroidism, And it's Prognostic Factors.",Nodule Solitary Thyroid|Radioactive Iodine-Induced Hypothyroidism|Toxic Multinodular Goiter,2020-11-26,2020-11-24,2021-05-31,Observational,"Active, not recruiting",,Universitair Ziekenhuis Brussel,Universitair Ziekenhuis Brussel,Universitair Ziekenhuis Brussel,Radiation,Belgium,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04663451
NCT04666103,thyroid nodule,Preserving Function Integrity of Neck Anatomy in Thyroid Surgery: A Randomized Clinical Trial,Ablation; Retina|Thyroid Carcinoma|Thyroid Nodule (Benign),2020-12-07,2021-12-31,2026-12-12,Interventional,Recruiting,Not Applicable,Wuhan University,Wuhan University,Zhongnan Hospital of Wuhan University,Procedure,China,18.0,75.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT04666103
NCT04671719,pseudopseudohypoparathyroidism,Autotaxin in Patients With GNAS/PTH Abnormalities,Adult Children|Albright Syndrome|Fibrous Dysplasia|Hyperparathyroidism|Hypoparathyroidism|Pseudo Hypoparathyroidism,2020-12-11,2024-03-10,2024-03-10,Observational,Recruiting,,Hospices Civils de Lyon,Hospices Civils de Lyon,"Centre de compétence des maladies rares de l'insulino-sécrétion et de l'insulino-sensibilité|Centre de référence Dysplasie Fibreuse des os Service rhumatologie et pathologie osseuse Hôpital Edouard Herriot, Lyon|Centre de Référence des Maladies Rares du Métabolisme du Calcium et du Phosphate Service d'Endocrinologie et Diabète de l'Enfant Hôpital Bicêtre Paris Saclay",Biological,France,10.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,pseudohypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04671719
NCT04680650,thyroid neoplasms,Comparison of Anesthesia Effects of Sevoflurane and Propofol Combined With Dexmedetomidine in Intraoperative Neuromonitoring During Thyroidectomy,Thyroid Nodule,2020-12-11,2021-03-31,2021-03-31,Interventional,"Active, not recruiting",Not Applicable,Affiliated Cancer Hospital & Institute of Guangzhou Medical University,Affiliated Cancer Hospital & Institute of Guangzhou Medical University,Cancer Center of Guangzhou Medical University,Drug|Drug,China,18.0,65.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04680650
NCT04683575,thyroid neoplasms,Distribution of Selenium in Patients With Differentiated Thyroid Carcinoma and Effect of Selenium Supplement on Prognosis of Patients With Differentiated Thyroid Carcinoma.,Metastasis|Recurrence|Selenium Deficiency|Thyroid Cancer TNM Staging,2020-11-26,2025-12-31,2025-12-31,Interventional,Not yet recruiting,Phase 4,Qianfoshan Hospital,Qianfoshan Hospital,The First affiliated hospital of Shandong First Medical University,Drug|Drug,China,18.0,75.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04683575
NCT04704414,graves disease,Exophthalmometry With 3D Face Scanners,Exophthalmos|Graves Ophthalmopathy|Orbital Fractures|Orbital Tumor,2021-01-06,2021-12-31,2022-12-31,Interventional,Recruiting,Not Applicable,University of Zurich,University of Zurich,"Ophthalmology Department, University Hospital Zurich",Device,Switzerland,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04704414
NCT04704414,goiter,Exophthalmometry With 3D Face Scanners,Exophthalmos|Graves Ophthalmopathy|Orbital Fractures|Orbital Tumor,2021-01-06,2021-12-31,2022-12-31,Interventional,Recruiting,Not Applicable,University of Zurich,University of Zurich,"Ophthalmology Department, University Hospital Zurich",Device,Switzerland,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04704414
NCT04704414,hyperthyroidism,Exophthalmometry With 3D Face Scanners,Exophthalmos|Graves Ophthalmopathy|Orbital Fractures|Orbital Tumor,2021-01-06,2021-12-31,2022-12-31,Interventional,Recruiting,Not Applicable,University of Zurich,University of Zurich,"Ophthalmology Department, University Hospital Zurich",Device,Switzerland,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04704414
NCT04708626,thyroiditis,Epidemiology of Autoimmune Encephalitides and Paraneoplastic Neurological Syndromes in Sweden,Autoimmune Encephalitis|Paraneoplastic Neurological Syndrome,2021-01-11,2022-02-28,2022-04-30,Observational,"Active, not recruiting",,Uppsala University,Uppsala University,Uppsala University,Other|Other,Sweden,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT04708626
NCT04714918,parathyroid diseases,Chinese Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Prevalence Survey,Chronic Kidney Disease-Mineral and Bone Disorder|Chronic Kidney Diseases,2021-01-14,2021-11-28,2021-11-28,Observational,Recruiting,,Peking Union Medical College Hospital,Limeng Chen,"Peking Union Medical College Hospital|The First Affiliated Hospital, Chongqing Medical University|Fujian Provincial Hospital|The Seventh Affiliated Hospital, Sun Yat-sen University|Xiangya Hospital of Central South University|The First Hospital of China Medical University|People's Hospital of Ningxia Hui Autonomous Region|People's Hospital of Xinjiang Uygur Autonomous Region|The Second Affiliated Hospital Zhejiang University School of Medicine",,China,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT04714918
NCT04730726,thyroid neoplasms,In Vivo Multispectral Optoacoustic Imaging of Thyroid Nodules,Thyroid Nodule,2021-01-26,2021-12-01,2022-04-01,Interventional,Recruiting,Not Applicable,University Medical Center Groningen,University Medical Center Groningen,University Medical Center Groningen,Device,Netherlands,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04730726
NCT04737330,graves disease,"A Two-year Multi-center Phase 3 Study to Investigate the Efficacy and Safety of Secukinumab in Adult Patients With Active, Moderate to Severe Thyroid Eye Disease (ORBIT), With a Randomized, Parallel-group, Double-blind, Placebo-controlled, 16-week Treatment Period, and a Follow-up/Retreatment Period",Graves Orbitopathy|Thyroid Eye Disease,2020-11-20,2023-04-27,2025-02-05,Interventional,Recruiting,Phase 3,Novartis,Novartis Pharmaceuticals,Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site,Drug|Drug,Germany,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04737330
NCT04737330,goiter,"A Two-year Multi-center Phase 3 Study to Investigate the Efficacy and Safety of Secukinumab in Adult Patients With Active, Moderate to Severe Thyroid Eye Disease (ORBIT), With a Randomized, Parallel-group, Double-blind, Placebo-controlled, 16-week Treatment Period, and a Follow-up/Retreatment Period",Graves Orbitopathy|Thyroid Eye Disease,2020-11-20,2023-04-27,2025-02-05,Interventional,Recruiting,Phase 3,Novartis,Novartis Pharmaceuticals,Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site,Drug|Drug,Germany,18.0,80.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04737330
NCT04737330,hyperthyroidism,"A Two-year Multi-center Phase 3 Study to Investigate the Efficacy and Safety of Secukinumab in Adult Patients With Active, Moderate to Severe Thyroid Eye Disease (ORBIT), With a Randomized, Parallel-group, Double-blind, Placebo-controlled, 16-week Treatment Period, and a Follow-up/Retreatment Period",Graves Orbitopathy|Thyroid Eye Disease,2020-11-20,2023-04-27,2025-02-05,Interventional,Recruiting,Phase 3,Novartis,Novartis Pharmaceuticals,Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site,Drug|Drug,Germany,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04737330
NCT04776993,graves ophthalmopathy,"A Phase III, Randomized, Controlled, Open Label, no Profit, Single-center Intervention Study to Compare the Effect of a Conservative (Antithyroid Drugs) and an Ablative Approach (Radioiodine or Total Thyroidectomy) for the Treatment of Hyperthyroidism in Patients With Graves' Disease and Moderate-to-severe and Active Graves' Orbitopathy (GO) Treated With Intravenous Glucocorticoids (ABLAGO Study)",Graves' Orbitopathy,2021-02-25,2022-10-30,2024-10-30,Interventional,Not yet recruiting,Phase 3,University of Pisa,University of Pisa,Endocrinology Unit II,Drug|Procedure,Italy,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT04776993
NCT04776993,hyperthyroidism,"A Phase III, Randomized, Controlled, Open Label, no Profit, Single-center Intervention Study to Compare the Effect of a Conservative (Antithyroid Drugs) and an Ablative Approach (Radioiodine or Total Thyroidectomy) for the Treatment of Hyperthyroidism in Patients With Graves' Disease and Moderate-to-severe and Active Graves' Orbitopathy (GO) Treated With Intravenous Glucocorticoids (ABLAGO Study)",Graves' Orbitopathy,2021-02-25,2022-10-30,2024-10-30,Interventional,Not yet recruiting,Phase 3,University of Pisa,University of Pisa,Endocrinology Unit II,Drug|Procedure,Italy,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04776993
NCT04776993,graves disease,"A Phase III, Randomized, Controlled, Open Label, no Profit, Single-center Intervention Study to Compare the Effect of a Conservative (Antithyroid Drugs) and an Ablative Approach (Radioiodine or Total Thyroidectomy) for the Treatment of Hyperthyroidism in Patients With Graves' Disease and Moderate-to-severe and Active Graves' Orbitopathy (GO) Treated With Intravenous Glucocorticoids (ABLAGO Study)",Graves' Orbitopathy,2021-02-25,2022-10-30,2024-10-30,Interventional,Not yet recruiting,Phase 3,University of Pisa,University of Pisa,Endocrinology Unit II,Drug|Procedure,Italy,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04776993
NCT04776993,goiter,"A Phase III, Randomized, Controlled, Open Label, no Profit, Single-center Intervention Study to Compare the Effect of a Conservative (Antithyroid Drugs) and an Ablative Approach (Radioiodine or Total Thyroidectomy) for the Treatment of Hyperthyroidism in Patients With Graves' Disease and Moderate-to-severe and Active Graves' Orbitopathy (GO) Treated With Intravenous Glucocorticoids (ABLAGO Study)",Graves' Orbitopathy,2021-02-25,2022-10-30,2024-10-30,Interventional,Not yet recruiting,Phase 3,University of Pisa,University of Pisa,Endocrinology Unit II,Drug|Procedure,Italy,18.0,75.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04776993
NCT04782856,goiter,Energy Metabolism in Thyroidectomized Patients,Hypothyroidism|Thyroid Cancer|Thyroid Goiter,2021-03-01,2022-05-31,2022-05-31,Interventional,Recruiting,Phase 2,Virginia Commonwealth University,Virginia Commonwealth University,Virginia Commonwealth University,Drug|Drug|Drug,United States,18.0,89.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04782856
NCT04785443,parathyroid diseases,Contribution of Indocyanine Green Angiography in the Detection of Parathyroids and the Prevention of Hypoparathyroidism Post Total Thyroidectomy,Thyroid Diseases,2021-02-25,2024-06-30,2025-03-31,Interventional,Recruiting,Phase 3,"University Hospital, Brest","University Hospital, Brest",CHRU de Brest,Drug|Procedure,France,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT04785443
NCT04806672,euthyroid sick syndromes,Euthyroid Sick Syndrome (ESS)….. Can it Influence Morbidity and Mortality in Moderate to Severe Traumatic Brain Injury Patients or Correlate With Glial Fibrillary Acidic Protein (GFAP) Level.,Euthyroid Sick Syndromes in Traumatic Brain Injury Patient and GFAP Level,2021-03-14,2021-12-31,2022-04-30,Observational,Not yet recruiting,,Minia University,Minia University,,,,18.0,60.0,[18-65],Euthyroid Sick Syndromes,Euthyroid Sick Syndromes,https://clinicaltrials.gov/ct2/show/NCT04806672
NCT04809454,hyperthyroidism,Frequency of Florid Hyperthyroidism In Patients Taking Iodinated Salt: A Cross Sectional Study,Thyroid Dysfunction,2021-03-16,2022-03-31,2022-03-31,Observational,Not yet recruiting,,"Services Institute of Medical Sciences, Pakistan","Services Institute of Medical Sciences, Pakistan",Mehwish Iftikhar,,Pakistan,18.0,60.0,[18-65],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04809454
NCT04823728,thyroiditis,Immunogenetic Characteristics in Autoimmune Encephalitis and Related Disorders: HLA Analysis: Part II,Autoimmune Encephalitis|Paraneoplastic Neurological Syndrome,2021-03-26,2024-12-31,2025-12-31,Observational,Recruiting,,Hospices Civils de Lyon,Hospices Civils de Lyon,Hôpital Neurologique,Genetic,France,18.0,120.0,[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT04823728
NCT04842994,thyroid neoplasms,"Phase III, Assessor Blinded, Randomised Controlled Trial of Use of Intraoperative Neuromonitoring (IONM) in Thyroid Cancer Surgery(ACTION)",Malignant Neoplasm of Thyroid Gland,2020-10-06,2024-08-31,2024-08-31,Interventional,Recruiting,Not Applicable,Tata Memorial Hospital,Tata Memorial Hospital,Tata Memorial Hospital,Device,India,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04842994
NCT04846010,hypothyroidism,Treating Sequalae Caused by Post-acute Sequelae of SARS (Severe Acute Respiratory Syndrome)-CoV-2 Infection,"Anxiety Disorders|Depression|Depression, Anxiety|Depression, Bipolar|Gastro Esophageal Reflux|GERD|Glomerulonephritis|Hepatitis|Insomnia|Post Infection Glomerulonephritis|Post-Infectious Arthritis|Post-Infectious Disorder (Disorder)|Post-Infectious Hypothyroidism|Post Infectious Osteoarthritis|Post-Infectious Parkinsonism|Post-Infectious Peripheral Neuralgia|Post-Infectious Polyneuritis|Sequelae of; Infection",2021-03-31,2022-05-01,2022-10-01,Interventional,Recruiting,Phase 1/Phase 2,"All Natural Medicine Clinic, LLC","All Natural Medicine Clinic, LLC","All Natural Medicine Clinic, LLC",Combination Product|Combination Product|Combination Product|Combination Product|Combination Product|Combination Product|Combination Product,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT04846010
NCT04856488,graves disease,Preoperative Lugol's Solution in Graves' Disease and Toxic Nodular Goiter,Hyperthyroidism,2021-04-06,2023-08-31,2024-02-29,Interventional,Recruiting,Phase 3,Karolinska University Hospital,Jan Calissendorff,"Department of Endocrinology, Karolinska University Hospital",Drug,Sweden,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04856488
NCT04856488,goiter,Preoperative Lugol's Solution in Graves' Disease and Toxic Nodular Goiter,Hyperthyroidism,2021-04-06,2023-08-31,2024-02-29,Interventional,Recruiting,Phase 3,Karolinska University Hospital,Jan Calissendorff,"Department of Endocrinology, Karolinska University Hospital",Drug,Sweden,18.0,75.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04856488
NCT04876534,graves disease,"Multicenter, Randomized, Observer-blind, Controlled Study of the Anti-IL-6 Receptor Antibody Tocilizumab (TCZ) or Methylprednisolone (MP) Treatment in Patients With Active Moderate-severe Graves' Orbitopathy",Graves Ophthalmopathy,2021-05-03,2022-12-18,2023-12-18,Interventional,Recruiting,Phase 2,"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","Azienda Ospedaliera ""Sant'Andrea""|Azienda Ospedaliero, Universitaria Pisana|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|Istituto Auxologico Italiano|Mauriziano Umberto I Hospital","Istituto Auxologico Italiano|Azienda Ospedaliero, Universitaria Pisana|Azienda Ospedaliera ""Sant'Andrea""|Mauriziano Umberto I Hospital",Drug|Drug,Italy,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04876534
NCT04876534,goiter,"Multicenter, Randomized, Observer-blind, Controlled Study of the Anti-IL-6 Receptor Antibody Tocilizumab (TCZ) or Methylprednisolone (MP) Treatment in Patients With Active Moderate-severe Graves' Orbitopathy",Graves Ophthalmopathy,2021-05-03,2022-12-18,2023-12-18,Interventional,Recruiting,Phase 2,"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","Azienda Ospedaliera ""Sant'Andrea""|Azienda Ospedaliero, Universitaria Pisana|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|Istituto Auxologico Italiano|Mauriziano Umberto I Hospital","Istituto Auxologico Italiano|Azienda Ospedaliero, Universitaria Pisana|Azienda Ospedaliera ""Sant'Andrea""|Mauriziano Umberto I Hospital",Drug|Drug,Italy,18.0,75.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04876534
NCT04876534,hyperthyroidism,"Multicenter, Randomized, Observer-blind, Controlled Study of the Anti-IL-6 Receptor Antibody Tocilizumab (TCZ) or Methylprednisolone (MP) Treatment in Patients With Active Moderate-severe Graves' Orbitopathy",Graves Ophthalmopathy,2021-05-03,2022-12-18,2023-12-18,Interventional,Recruiting,Phase 2,"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","Azienda Ospedaliera ""Sant'Andrea""|Azienda Ospedaliero, Universitaria Pisana|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|Istituto Auxologico Italiano|Mauriziano Umberto I Hospital","Istituto Auxologico Italiano|Azienda Ospedaliero, Universitaria Pisana|Azienda Ospedaliera ""Sant'Andrea""|Mauriziano Umberto I Hospital",Drug|Drug,Italy,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04876534
NCT04877613,thyroid neoplasms,Phase I Trial of GFRα4 CAR T Cells in Adult Patients With Recurrent or Metastatic Medullary Thyroid Cancer,Metastatic Medullary Thyroid Cancer,2021-05-03,2039-06-01,2039-06-01,Interventional,Recruiting,Phase 1,University of Pennsylvania,University of Pennsylvania,University of Pennsylvania,Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04877613
NCT04879173,thyrotoxicosis,The Clinical Value of Microvascular Ultrasonography in Real-time Differential Diagnosis of Thyrotoxic Patients Between Hyperthyroidism and Thyroiditis,Hyperthyroidism/Thyrotoxicosis,2021-05-04,2021-10-31,2022-10-31,Observational,Recruiting,,Seoul St. Mary's Hospital,Dong Jun Lim,Seoul St. Mary hospital,Device,"Korea, Republic of",0.0,120.0,[0-17]|[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04879173
NCT04879355,thyroid neoplasms,The Use of Spinal Needles for Ultrasound-guided Fine Needle Aspiration From Thyroid Nodules - a Protocol for a Multicentre Randomised Controlled Trial,Thyroid Nodule,2021-03-07,2022-11-01,2023-12-01,Interventional,Not yet recruiting,Not Applicable,Zealand University Hospital,"Herlev Hospital|Preben Homøe|Rigshospitalet, Denmark",,Device|Device,,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04879355
NCT04883294,thyroid neoplasms,Validation of the Diagnostic Accuracy of the Electronic Nose in the Detection of Thyroid Cancer,Thyroid Neoplasm,2021-05-11,2024-01-01,2025-01-01,Observational,Not yet recruiting,,Maastricht University Medical Center,Maastricht University Medical Center,,Diagnostic Test,,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04883294
NCT04895631,parathyroid neoplasms,18F-Fluorocholine Positron Emission Tomography (PET) for the Detection of Parathyroid Adenomas,"Hyperparathyroidism, Primary",2021-05-13,2026-06-30,2027-06-30,Interventional,Recruiting,Phase 3,"University of California, San Francisco",Thomas Hope,"University of California, San Francisco",Drug|Procedure,United States,13.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04895631
NCT04916262,thyroid neoplasms,Correlation Between TCM Syndrome Factors and TSH Changes of Thyroid Hormone Withdrawal Before Iodine Therapy in Postoperative Patients With Thyroid Cancer,Differentiated Thyroid Carcinoma|TCM Syndrome Type,2021-05-24,2021-12-01,2022-01-01,Observational,Not yet recruiting,,Qianfoshan Hospital,Qianfoshan Hospital,,,,18.0,75.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04916262
NCT04919694,graves ophthalmopathy,The Therapeutic Effect of Combination of Orbital Compression Surgery and Strabismus Surgery in Patients With Moderate to Severe Thyroid Associated Ophthalmopathy,Thyroid Associated Ophthalmopathy,2021-01-19,2023-12-31,2023-12-31,Interventional,Not yet recruiting,Not Applicable,Sun Yat-sen University,Sun Yat-sen University,"Zhongshan Ophthalmic Center, Sun Yat-sen University",Procedure|Procedure,China,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT04919694
NCT04919694,graves disease,The Therapeutic Effect of Combination of Orbital Compression Surgery and Strabismus Surgery in Patients With Moderate to Severe Thyroid Associated Ophthalmopathy,Thyroid Associated Ophthalmopathy,2021-01-19,2023-12-31,2023-12-31,Interventional,Not yet recruiting,Not Applicable,Sun Yat-sen University,Sun Yat-sen University,"Zhongshan Ophthalmic Center, Sun Yat-sen University",Procedure|Procedure,China,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04919694
NCT04919694,goiter,The Therapeutic Effect of Combination of Orbital Compression Surgery and Strabismus Surgery in Patients With Moderate to Severe Thyroid Associated Ophthalmopathy,Thyroid Associated Ophthalmopathy,2021-01-19,2023-12-31,2023-12-31,Interventional,Not yet recruiting,Not Applicable,Sun Yat-sen University,Sun Yat-sen University,"Zhongshan Ophthalmic Center, Sun Yat-sen University",Procedure|Procedure,China,18.0,80.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04919694
NCT04919694,hyperthyroidism,The Therapeutic Effect of Combination of Orbital Compression Surgery and Strabismus Surgery in Patients With Moderate to Severe Thyroid Associated Ophthalmopathy,Thyroid Associated Ophthalmopathy,2021-01-19,2023-12-31,2023-12-31,Interventional,Not yet recruiting,Not Applicable,Sun Yat-sen University,Sun Yat-sen University,"Zhongshan Ophthalmic Center, Sun Yat-sen University",Procedure|Procedure,China,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04919694
NCT04922892,parathyroid diseases,Total Parathyroidectomy With Autotransplantation Versus Total Parathyroidectomy Alone for Secondary Hyperparathyroidism,Secondary Hyperparathyroidism;Parathyroidectomy,2021-06-07,2023-05-31,2028-05-31,Interventional,Recruiting,Not Applicable,The Second Hospital of Nanjing Medical University,The Second Hospital of Nanjing Medical University,NanjingMU,Procedure,China,18.0,70.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT04922892
NCT04927416,thyroid neoplasms,The Role of 68-Gallium-DOTATATE-PET/CT in the Imaging of Metastatic Thyroid Cancer,Metastic Thyroid Cancer,2021-06-15,2030-11-30,2030-11-30,Interventional,Recruiting,Phase 2,National Institutes of Health Clinical Center (CC),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),National Institutes of Health Clinical Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04927416
NCT04927468,graves disease,The Management of Large-angle Strabismus in Grave's Ophthalmopathy With Supramaximal Rectus Recession,"Graves Ophthalmopathy|Strabismus, Mechanical",2021-06-08,2023-07-01,2023-07-01,Interventional,Not yet recruiting,Not Applicable,Sun Yat-sen University,Sun Yat-sen University,,Procedure|Procedure,,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04927468
NCT04927468,goiter,The Management of Large-angle Strabismus in Grave's Ophthalmopathy With Supramaximal Rectus Recession,"Graves Ophthalmopathy|Strabismus, Mechanical",2021-06-08,2023-07-01,2023-07-01,Interventional,Not yet recruiting,Not Applicable,Sun Yat-sen University,Sun Yat-sen University,,Procedure|Procedure,,18.0,80.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04927468
NCT04927468,hyperthyroidism,The Management of Large-angle Strabismus in Grave's Ophthalmopathy With Supramaximal Rectus Recession,"Graves Ophthalmopathy|Strabismus, Mechanical",2021-06-08,2023-07-01,2023-07-01,Interventional,Not yet recruiting,Not Applicable,Sun Yat-sen University,Sun Yat-sen University,,Procedure|Procedure,,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04927468
NCT04932135,goiter,Resting Heart Rate Monitoring for Optimized Treatment and Surveillance of Hyperthyroidism,Graves Disease|Hyperthyroidism,2021-06-14,2022-12-31,2023-03-31,Observational,Recruiting,,"University Hospital, Basel, Switzerland","University Hospital, Basel, Switzerland",University Hospital Basel,Diagnostic Test,Switzerland,18.0,80.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04932135
NCT04936854,graves ophthalmopathy,Prospective Comparison of Sirolimus Against Corticosteroids in Treatment of Patients With Active Thyroid Eye Disease,Thyroid-Associated Ophthalmopathy,2021-06-15,2026-01-31,2026-05-31,Interventional,Not yet recruiting,Phase 2,Haukeland University Hospital,Haukeland University Hospital,,Drug|Drug,,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT04936854
NCT04936854,graves disease,Prospective Comparison of Sirolimus Against Corticosteroids in Treatment of Patients With Active Thyroid Eye Disease,Thyroid-Associated Ophthalmopathy,2021-06-15,2026-01-31,2026-05-31,Interventional,Not yet recruiting,Phase 2,Haukeland University Hospital,Haukeland University Hospital,,Drug|Drug,,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04936854
NCT04936854,goiter,Prospective Comparison of Sirolimus Against Corticosteroids in Treatment of Patients With Active Thyroid Eye Disease,Thyroid-Associated Ophthalmopathy,2021-06-15,2026-01-31,2026-05-31,Interventional,Not yet recruiting,Phase 2,Haukeland University Hospital,Haukeland University Hospital,,Drug|Drug,,18.0,80.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04936854
NCT04936854,hyperthyroidism,Prospective Comparison of Sirolimus Against Corticosteroids in Treatment of Patients With Active Thyroid Eye Disease,Thyroid-Associated Ophthalmopathy,2021-06-15,2026-01-31,2026-05-31,Interventional,Not yet recruiting,Phase 2,Haukeland University Hospital,Haukeland University Hospital,,Drug|Drug,,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04936854
NCT04942769,hashimoto disease,Study on the Effect of Selenium Supplementation on the Structure and Function of Autoimmune Thyroiditis,Selenium,2021-06-24,2021-07-30,2021-10-30,Interventional,Recruiting,Not Applicable,Beijing Chao Yang Hospital,Beijing Chao Yang Hospital,"Beijing Chao-Yang Hospital, Capital Medical University",Drug,China,18.0,75.0,[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT04942769
NCT04953195,hypothyroidism,Effect of Thyroid Replacement Therapy on Thyroid Structure in Patients With Subclinical Hypothyroidism,Subclinical Hypothyroidisms,2021-06-25,2021-09-15,2021-10-30,Interventional,Recruiting,Phase 4,Beijing Chao Yang Hospital,Beijing Chao Yang Hospital,"Beijing Chao-Yang Hospital, Capital Medical University",Drug,China,18.0,75.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT04953195
NCT04969926,parathyroid neoplasms,Natural History Study of Parathyroid Disorders,"Inheritable Bone Diseases|Multiple Endocrine Neoplasia, Type 1|Parathyroid Cancer|Primary Hyperparathyroidism|Pseudohypoparathyroidism",2021-07-20,2031-01-22,2031-01-22,Observational,Recruiting,,National Institutes of Health Clinical Center (CC),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),National Institutes of Health Clinical Center,,United States,6.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04969926
NCT04976816,graves disease,Local Betamethasone Versus Triamcinolone Injection in Management of Thyroid-Related Upper Lid Retraction With and Without Proptosis,Thyroid Eye Disease,2021-07-13,2022-12-31,2023-01-31,Interventional,Not yet recruiting,Phase 4,Assiut University,Assiut University,,Procedure|Procedure|Procedure|Procedure,,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04976816
NCT04976816,goiter,Local Betamethasone Versus Triamcinolone Injection in Management of Thyroid-Related Upper Lid Retraction With and Without Proptosis,Thyroid Eye Disease,2021-07-13,2022-12-31,2023-01-31,Interventional,Not yet recruiting,Phase 4,Assiut University,Assiut University,,Procedure|Procedure|Procedure|Procedure,,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04976816
NCT04976816,hyperthyroidism,Local Betamethasone Versus Triamcinolone Injection in Management of Thyroid-Related Upper Lid Retraction With and Without Proptosis,Thyroid Eye Disease,2021-07-13,2022-12-31,2023-01-31,Interventional,Not yet recruiting,Phase 4,Assiut University,Assiut University,,Procedure|Procedure|Procedure|Procedure,,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04976816
NCT04988802,hypothyroidism,The Effect of Dietary Supplements for Pregnant Women on Levothyroxine Absorption,Hypothyroidism Primary,2021-07-25,2022-07-30,2022-09-30,Interventional,Recruiting,Not Applicable,University Hospital Dubrava,University Hospital Dubrava,Dubrava University Hospital,Dietary Supplement|Other,Croatia,18.0,120.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT04988802
NCT05002998,graves disease,"A Phase 3b/4, Double-masked, Randomized, International, Parallel-assignment, Multicenter Trial in Patients With Thyroid Eye Disease to Evaluate the Safety and Tolerability of Different Dosing Durations of Teprotumumab",Thyroid Eye Disease,2021-07-19,2025-08-31,2025-08-31,Interventional,Recruiting,Phase 4,"Horizon Pharma USA, Inc.","Horizon Therapeutics USA, Inc.",University of Colorado - Eye Center|Bascom Palmer Eye Institute,Drug|Drug,United States,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT05002998
NCT05002998,goiter,"A Phase 3b/4, Double-masked, Randomized, International, Parallel-assignment, Multicenter Trial in Patients With Thyroid Eye Disease to Evaluate the Safety and Tolerability of Different Dosing Durations of Teprotumumab",Thyroid Eye Disease,2021-07-19,2025-08-31,2025-08-31,Interventional,Recruiting,Phase 4,"Horizon Pharma USA, Inc.","Horizon Therapeutics USA, Inc.",University of Colorado - Eye Center|Bascom Palmer Eye Institute,Drug|Drug,United States,18.0,80.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT05002998
NCT05002998,hyperthyroidism,"A Phase 3b/4, Double-masked, Randomized, International, Parallel-assignment, Multicenter Trial in Patients With Thyroid Eye Disease to Evaluate the Safety and Tolerability of Different Dosing Durations of Teprotumumab",Thyroid Eye Disease,2021-07-19,2025-08-31,2025-08-31,Interventional,Recruiting,Phase 4,"Horizon Pharma USA, Inc.","Horizon Therapeutics USA, Inc.",University of Colorado - Eye Center|Bascom Palmer Eye Institute,Drug|Drug,United States,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT05002998
NCT05007093,thyroid neoplasms,An Exploratory Study on Efficacy of Anlotinib Hydrochloride in the Treatment of Locally Advanced or Metastatic Differentiated Thyroid Cancer,DTC - Differentiated Thyroid Cancer,2021-08-09,2023-12-07,2023-12-07,Interventional,Recruiting,Phase 2,Peking Union Medical College Hospital,Yansong Lin,Peking Union Medical College Hospital,Drug,China,18.0,70.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05007093
NCT05012033,graves disease,Evaluation of High Dose Prednisolone Pharmacokinetics in the Acute and Chronic Setting,Asthma|COPD Exacerbation Acute|Inflammatory Disease|Thyroid Eye Disease|Vasculitis,2021-07-30,2026-03-26,2026-03-26,Observational,Not yet recruiting,,Imperial College London,Imperial College London,Imperial College Healthcare NHS Trust,Other,United Kingdom,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT05012033
NCT05012033,goiter,Evaluation of High Dose Prednisolone Pharmacokinetics in the Acute and Chronic Setting,Asthma|COPD Exacerbation Acute|Inflammatory Disease|Thyroid Eye Disease|Vasculitis,2021-07-30,2026-03-26,2026-03-26,Observational,Not yet recruiting,,Imperial College London,Imperial College London,Imperial College Healthcare NHS Trust,Other,United Kingdom,18.0,75.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT05012033
NCT05012033,hyperthyroidism,Evaluation of High Dose Prednisolone Pharmacokinetics in the Acute and Chronic Setting,Asthma|COPD Exacerbation Acute|Inflammatory Disease|Thyroid Eye Disease|Vasculitis,2021-07-30,2026-03-26,2026-03-26,Observational,Not yet recruiting,,Imperial College London,Imperial College London,Imperial College Healthcare NHS Trust,Other,United Kingdom,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT05012033
NCT05015127,graves disease,"A Randomized, Double-blind, Placebo-controlled, Phase 2/3 Operational Seamless Design Clinical Study to Evaluate the Efficacy and Safety of HBM9161 Subcutaneous Injection in Chinese Patients With Active, Moderate to Severe Thyroid Eye Disease (TED)",Thyroid Ophthalmopathy,2021-08-03,2022-10-31,2022-12-31,Interventional,Recruiting,Phase 2/Phase 3,Harbour BioMed (Guangzhou) Co. Ltd.,Harbour BioMed (Guangzhou) Co. Ltd.,"Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine",Drug|Drug|Drug|Drug,China,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT05015127
NCT05015127,goiter,"A Randomized, Double-blind, Placebo-controlled, Phase 2/3 Operational Seamless Design Clinical Study to Evaluate the Efficacy and Safety of HBM9161 Subcutaneous Injection in Chinese Patients With Active, Moderate to Severe Thyroid Eye Disease (TED)",Thyroid Ophthalmopathy,2021-08-03,2022-10-31,2022-12-31,Interventional,Recruiting,Phase 2/Phase 3,Harbour BioMed (Guangzhou) Co. Ltd.,Harbour BioMed (Guangzhou) Co. Ltd.,"Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine",Drug|Drug|Drug|Drug,China,18.0,70.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT05015127
NCT05015127,hyperthyroidism,"A Randomized, Double-blind, Placebo-controlled, Phase 2/3 Operational Seamless Design Clinical Study to Evaluate the Efficacy and Safety of HBM9161 Subcutaneous Injection in Chinese Patients With Active, Moderate to Severe Thyroid Eye Disease (TED)",Thyroid Ophthalmopathy,2021-08-03,2022-10-31,2022-12-31,Interventional,Recruiting,Phase 2/Phase 3,Harbour BioMed (Guangzhou) Co. Ltd.,Harbour BioMed (Guangzhou) Co. Ltd.,"Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine",Drug|Drug|Drug|Drug,China,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT05015127
NCT05017142,thyroiditis,Swiss Pediatric Inflammatory Bain Disease Cohort Study,"Acute Disseminated Encephalomyelitis|Anti-AMPAR-1/2 Associated Autoimmune Encephalitis|Anti-CASPR-2 Associated Autoimmune Encephalitis|Anti-GABAR-1/2 Associated Autoimmune Encephalitis|Anti-GAD65 Associated Autoimmune Encephalitis|Anti-Lgi-1 Associated Autoimmune Encephalitis|Anti-NMDAR Encephalitis|CNS Lupus|CNS Sarcoidosis|CNS Vasculitis|Hashimoto Encephalitis|Multiple Sclerosis|Neuromyelitis Optica Spectrum Disorder|Onconeuronal Antibody (Hu, Ri, Yo, Amphiphysin, CRMP-5, Ma-1, Ma-2, SOX-1) Associated Autoimmune Encephalitis|Optic Neuritis|Rasmussen Encephalitis|Transverse Myelitis",2021-08-04,2071-01-01,2071-01-01,Observational [Patient Registry],Recruiting,,University of Bern,"Novartis|Roche Pharma (Switzerland) Ltd|Schweizerische Multiple Sklerose Gesellschaft|University Hospital Inselspital, Berne|University of Bern","Kantonsspital Aarau|Kantonsspital Graubünden|Children's Hospital of Eastern Switzerland|Pediatric Institute of Southern Switzerland, Ospedale San Giovanni|University Children's Hospital Lausanne (CHUV)|Kinderspital Winterthur|University Children's Hospital Basel, UKBB|University Children's Hospital, Inselspital Bern|Institute of Social and Preventive Medicine, University of Bern|University Hospitals of Geneva (HUG)|Luzerner Kantonsspital|University Children's Hospital Zurich",,Switzerland,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT05017142
NCT05019118,hypothyroidism,"Dietary Intervention With Únicla Dairy Products, Naturally Enriched With Selenium and Omega-3 Fatty Acids, May Improve Thyroid-stimulating Hormone (TSH) Levels in Women With Subclinical Hypothyroidism",Subclinical Hypothyroidism,2021-08-13,2021-12-30,2022-05-30,Interventional,Not yet recruiting,Not Applicable,Cooperativas Lacteas Unidas,Cooperativas Lacteas Unidas|Galician South Health Research Institute,Nursing University School of Ourense,Other|Other|Other|Other|Other|Other,Spain,40.0,65.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT05019118
NCT05043233,graves disease,The Observation Study of Graves' Disease Cohort,Patient Acceptance of Health Care,2021-08-30,2024-10-01,2025-10-01,Observational [Patient Registry],Recruiting,,Shanghai Jiao Tong University School of Medicine,Shanghai Jiao Tong University School of Medicine,"Ruijin hospital, Shanghai Jiaotong University School of Medicine",Drug,China,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT05043233
NCT05043233,goiter,The Observation Study of Graves' Disease Cohort,Patient Acceptance of Health Care,2021-08-30,2024-10-01,2025-10-01,Observational [Patient Registry],Recruiting,,Shanghai Jiao Tong University School of Medicine,Shanghai Jiao Tong University School of Medicine,"Ruijin hospital, Shanghai Jiaotong University School of Medicine",Drug,China,18.0,70.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT05043233
NCT05043233,hyperthyroidism,The Observation Study of Graves' Disease Cohort,Patient Acceptance of Health Care,2021-08-30,2024-10-01,2025-10-01,Observational [Patient Registry],Recruiting,,Shanghai Jiao Tong University School of Medicine,Shanghai Jiao Tong University School of Medicine,"Ruijin hospital, Shanghai Jiaotong University School of Medicine",Drug,China,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT05043233
NCT05049603,graves ophthalmopathy,"Phase III, Double-blinded, Multicenter, Randomized Clinical Trial to Evaluate the Effects of Atorvastatin on Moderate-to-severe and Active Graves' Orbitopathy (GO) Treated With Intravenous Glucocorticoids: the STAGO-2 Study",Graves' Orbitopathy,2021-09-02,2023-12-31,2024-12-31,Interventional,Not yet recruiting,Phase 3,University of Pisa,Università degli Studi dell'Insubria|University of Catania|University of Messina|University of Pisa,Ospedale Cisanello-Endocrinology II,Drug|Other,Italy,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT05049603
NCT05049603,graves disease,"Phase III, Double-blinded, Multicenter, Randomized Clinical Trial to Evaluate the Effects of Atorvastatin on Moderate-to-severe and Active Graves' Orbitopathy (GO) Treated With Intravenous Glucocorticoids: the STAGO-2 Study",Graves' Orbitopathy,2021-09-02,2023-12-31,2024-12-31,Interventional,Not yet recruiting,Phase 3,University of Pisa,Università degli Studi dell'Insubria|University of Catania|University of Messina|University of Pisa,Ospedale Cisanello-Endocrinology II,Drug|Other,Italy,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT05049603
NCT05049603,goiter,"Phase III, Double-blinded, Multicenter, Randomized Clinical Trial to Evaluate the Effects of Atorvastatin on Moderate-to-severe and Active Graves' Orbitopathy (GO) Treated With Intravenous Glucocorticoids: the STAGO-2 Study",Graves' Orbitopathy,2021-09-02,2023-12-31,2024-12-31,Interventional,Not yet recruiting,Phase 3,University of Pisa,Università degli Studi dell'Insubria|University of Catania|University of Messina|University of Pisa,Ospedale Cisanello-Endocrinology II,Drug|Other,Italy,18.0,75.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT05049603
NCT05049603,hyperthyroidism,"Phase III, Double-blinded, Multicenter, Randomized Clinical Trial to Evaluate the Effects of Atorvastatin on Moderate-to-severe and Active Graves' Orbitopathy (GO) Treated With Intravenous Glucocorticoids: the STAGO-2 Study",Graves' Orbitopathy,2021-09-02,2023-12-31,2024-12-31,Interventional,Not yet recruiting,Phase 3,University of Pisa,Università degli Studi dell'Insubria|University of Catania|University of Messina|University of Pisa,Ospedale Cisanello-Endocrinology II,Drug|Other,Italy,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT05049603
NCT05059470,thyroid neoplasms,IMRT Followed by Pembrolizumab in the Adjuvant Setting in Anaplastic Cancer of the Thyroid (IMPAACT): Phase II Trial Adjuvant Pembrolizumab After IMRT in ATC,Thyroid,2021-09-15,2023-10-01,2023-10-01,Interventional,"Active, not recruiting",Phase 2,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center,M D Anderson Cancer Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05059470
NCT05068687,thyroid neoplasms,"Peroperative Assessment of Tumour Resection Margins Using High-resolution 18F-FDG-PET/CT in Malignancies of the Head and Neck, a Pilot Study",Head and Neck Neoplasms|Skin Neoplasm|Thyroid Neoplasm,2021-09-24,2022-09-30,2022-09-30,Interventional,Recruiting,Not Applicable,"University Hospital, Ghent","University Hospital, Ghent|XEOS Medical",Ghent University Hospital,Diagnostic Test,Belgium,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05068687
NCT05096195,parathyroid diseases,"Denosumab for the Prevention of Fragility Fractures in Hemodialysis: a Pilot Study for an Innovative, Randomized-controlled Trial, Embedded in Routine Care",Chronic Kidney Disease-Mineral and Bone Disorder|Dialysis; Complications|Fragility Fracture|Kidney Diseases,2021-09-21,2023-04-30,2023-09-30,Interventional,Not yet recruiting,Phase 4,"Western University, Canada","Academic Medical Organization of Southwestern Ontario|ICES|The Kidney Foundation of Canada|Western University|Western University, Canada",,Drug|Other|Diagnostic Test,,40.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT05096195
NCT05098600,hypothyroidism,"The Epidemiology, Management and Associated Conditions in Alopecia Areata in Czech Republic: A University-clinic-based Retrospective Cohort Study","Alopecia Areata|Alopecia Areata (& Ophiasis)|Alopecia Barbae|Alopecia Diffuse|Alopecia Totalis|Alopecia Universalis|Anemia, Pernicious|Ankylosing Spondylitis|Atopic Asthma|Atopic Dermatitis|Atopic Rhinitis|Autoimmune Diseases|Autoimmune Hyperthyroidism|Autoimmune Hypothyroidism|COVID-19 Pandemic|Crohn Disease|Diabetes Mellitus, Type 1|Down Syndrome|Infections|Inflammatory Bowel Diseases|Lupus Erythematosus|Multiple Sclerosis|Psoriasis|Rheumatoid Arthritis|Ulcerative Colitis|Vaccine Reaction|Vitiligo",2021-10-16,2021-12-31,2022-01-10,Observational,"Active, not recruiting",,Faculty Hospital Kralovske Vinohrady,Faculty Hospital Kralovske Vinohrady,Teaching Hospital of Royal Vineguards,Other,Czechia,0.0,120.0,[0-17]|[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT05098600
NCT05098600,hyperthyroidism,"The Epidemiology, Management and Associated Conditions in Alopecia Areata in Czech Republic: A University-clinic-based Retrospective Cohort Study","Alopecia Areata|Alopecia Areata (& Ophiasis)|Alopecia Barbae|Alopecia Diffuse|Alopecia Totalis|Alopecia Universalis|Anemia, Pernicious|Ankylosing Spondylitis|Atopic Asthma|Atopic Dermatitis|Atopic Rhinitis|Autoimmune Diseases|Autoimmune Hyperthyroidism|Autoimmune Hypothyroidism|COVID-19 Pandemic|Crohn Disease|Diabetes Mellitus, Type 1|Down Syndrome|Infections|Inflammatory Bowel Diseases|Lupus Erythematosus|Multiple Sclerosis|Psoriasis|Rheumatoid Arthritis|Ulcerative Colitis|Vaccine Reaction|Vitiligo",2021-10-16,2021-12-31,2022-01-10,Observational,"Active, not recruiting",,Faculty Hospital Kralovske Vinohrady,Faculty Hospital Kralovske Vinohrady,Teaching Hospital of Royal Vineguards,Other,Czechia,0.0,120.0,[0-17]|[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT05098600
NCT05098600,goiter,"The Epidemiology, Management and Associated Conditions in Alopecia Areata in Czech Republic: A University-clinic-based Retrospective Cohort Study","Alopecia Areata|Alopecia Areata (& Ophiasis)|Alopecia Barbae|Alopecia Diffuse|Alopecia Totalis|Alopecia Universalis|Anemia, Pernicious|Ankylosing Spondylitis|Atopic Asthma|Atopic Dermatitis|Atopic Rhinitis|Autoimmune Diseases|Autoimmune Hyperthyroidism|Autoimmune Hypothyroidism|COVID-19 Pandemic|Crohn Disease|Diabetes Mellitus, Type 1|Down Syndrome|Infections|Inflammatory Bowel Diseases|Lupus Erythematosus|Multiple Sclerosis|Psoriasis|Rheumatoid Arthritis|Ulcerative Colitis|Vaccine Reaction|Vitiligo",2021-10-16,2021-12-31,2022-01-10,Observational,"Active, not recruiting",,Faculty Hospital Kralovske Vinohrady,Faculty Hospital Kralovske Vinohrady,Teaching Hospital of Royal Vineguards,Other,Czechia,0.0,120.0,[0-17]|[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT05098600
NCT05108298,thyroid neoplasms,Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials,"Bone Cancer, NOS|Breast Cancer, NOS|Cervical Cancer, NOS|CNS Primary Tumor, NOS|Colorectal Cancer, NOS|Leukemia, NOS|Lymphoma, NOS|Melanoma|Miscellaneous Neoplasm, NOS|Non-Rhabdomyosarcoma Soft Tissue Sarcoma, NOS|Testicular Nonseminomatous Germ Cell Tumor, NOS|Thyroid Cancer, NOS",2021-10-05,2023-03-31,2024-10-31,Observational,Recruiting,,Eastern Cooperative Oncology Group,Eastern Cooperative Oncology Group,Wake Forest School of Medicine,Other,United States,18.0,39.0,[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05108298
NCT05110040,graves ophthalmopathy,A Multi-model Image of Immunosuppressive Agents in Thyroid Associated Ophthalmopathy.,Thyroid Associated Ophthalmopathy,2021-10-27,2024-12-01,2025-12-01,Interventional,Recruiting,Not Applicable,Sun Yat-sen University,Sun Yat-sen University,Zhongshan Ophthalmic Center,Drug,China,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT05110040
NCT05110040,graves disease,A Multi-model Image of Immunosuppressive Agents in Thyroid Associated Ophthalmopathy.,Thyroid Associated Ophthalmopathy,2021-10-27,2024-12-01,2025-12-01,Interventional,Recruiting,Not Applicable,Sun Yat-sen University,Sun Yat-sen University,Zhongshan Ophthalmic Center,Drug,China,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT05110040
NCT05110040,goiter,A Multi-model Image of Immunosuppressive Agents in Thyroid Associated Ophthalmopathy.,Thyroid Associated Ophthalmopathy,2021-10-27,2024-12-01,2025-12-01,Interventional,Recruiting,Not Applicable,Sun Yat-sen University,Sun Yat-sen University,Zhongshan Ophthalmic Center,Drug,China,18.0,70.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT05110040
NCT05110040,hyperthyroidism,A Multi-model Image of Immunosuppressive Agents in Thyroid Associated Ophthalmopathy.,Thyroid Associated Ophthalmopathy,2021-10-27,2024-12-01,2025-12-01,Interventional,Recruiting,Not Applicable,Sun Yat-sen University,Sun Yat-sen University,Zhongshan Ophthalmic Center,Drug,China,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT05110040
NCT05112211,graves ophthalmopathy,A Multi-model Image to Evaluate the Efficacy of Doxycycline in Thyroid Associated Ophthalmopathy,Thyroid Associated Ophthalmopathy,2021-10-27,2023-12-01,2024-12-01,Interventional,Recruiting,Not Applicable,Sun Yat-sen University,Sun Yat-sen University,Zhongshan Ophthalmic Center,Drug,China,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT05112211
NCT05112211,graves disease,A Multi-model Image to Evaluate the Efficacy of Doxycycline in Thyroid Associated Ophthalmopathy,Thyroid Associated Ophthalmopathy,2021-10-27,2023-12-01,2024-12-01,Interventional,Recruiting,Not Applicable,Sun Yat-sen University,Sun Yat-sen University,Zhongshan Ophthalmic Center,Drug,China,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT05112211
NCT05112211,goiter,A Multi-model Image to Evaluate the Efficacy of Doxycycline in Thyroid Associated Ophthalmopathy,Thyroid Associated Ophthalmopathy,2021-10-27,2023-12-01,2024-12-01,Interventional,Recruiting,Not Applicable,Sun Yat-sen University,Sun Yat-sen University,Zhongshan Ophthalmic Center,Drug,China,18.0,70.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT05112211
NCT05112211,hyperthyroidism,A Multi-model Image to Evaluate the Efficacy of Doxycycline in Thyroid Associated Ophthalmopathy,Thyroid Associated Ophthalmopathy,2021-10-27,2023-12-01,2024-12-01,Interventional,Recruiting,Not Applicable,Sun Yat-sen University,Sun Yat-sen University,Zhongshan Ophthalmic Center,Drug,China,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT05112211
NCT05117853,parathyroid diseases,The Use of Autofluorescence and Indocyanine Green to Avoid Hypocalcemia After Total Thyroidectomy: A Randomized Clinical Trial,Hypoparathyroidism Postprocedural|Thyroid Disease,2021-10-21,2024-10-31,2025-05-31,Interventional,Not yet recruiting,Phase 3,Onze Lieve Vrouw Hospital,Onze Lieve Vrouw Hospital,Onze Lieve Vrouw Hospital,Drug|Procedure,Belgium,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT05117853
NCT05119296,"thyroid carcinoma, anaplastic",Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer,Thyroid Cancer,2021-10-29,2024-11-30,2026-11-30,Interventional,Recruiting,Phase 2,Stanford University,Merck Sharp & Dohme Corp.|Stanford University,Stanford University,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT05119296
NCT05126147,graves disease,A Randomized Controlled Trial on the Effect of Hydroxychloroquine in Graves' Orbitopathy,Graves Ophthalmopathy,2021-10-05,2023-12-01,2024-12-01,Interventional,Not yet recruiting,Phase 4,National Taiwan University Hospital,National Taiwan University Hospital,National Taiwan University Hospital,Drug,Taiwan,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT05126147
NCT05126147,goiter,A Randomized Controlled Trial on the Effect of Hydroxychloroquine in Graves' Orbitopathy,Graves Ophthalmopathy,2021-10-05,2023-12-01,2024-12-01,Interventional,Not yet recruiting,Phase 4,National Taiwan University Hospital,National Taiwan University Hospital,National Taiwan University Hospital,Drug,Taiwan,18.0,75.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT05126147
NCT05126147,hyperthyroidism,A Randomized Controlled Trial on the Effect of Hydroxychloroquine in Graves' Orbitopathy,Graves Ophthalmopathy,2021-10-05,2023-12-01,2024-12-01,Interventional,Not yet recruiting,Phase 4,National Taiwan University Hospital,National Taiwan University Hospital,National Taiwan University Hospital,Drug,Taiwan,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT05126147
NCT05126706,thyroid neoplasms,Validating Efficacy for Digital Lifestyle Management for Weight Loss Control After Thyroidectomy in Thyroid Cancer Patients,"Weight Change, Body",2021-09-26,2024-08-30,2024-08-30,Interventional,Recruiting,Not Applicable,Seoul National University Hospital,Seoul National University Hospital,Seoul National University Hospital,Behavioral,"Korea, Republic of",19.0,70.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05126706
NCT05130476,parathyroid diseases,Intraoperative Near-infrared Imaging Techniques for Identifying and Preserving Viable Parathyroid Glands During Total and Completion Thyroidectomy: a Matched Cohort Study,Hypoparathyroidism Postprocedural,2021-11-08,2023-09-30,2025-03-31,Interventional,Recruiting,Not Applicable,Odense University Hospital,Odense University Hospital,Odense University Hospital,Procedure,Denmark,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT05130476
NCT05142904,thyroid nodule,Ultrasound-guided Radiofrequency Ablation Versus Radioactive Iodine as Treatment for Hyperthyroidism Caused by Solitary Autonomous Thyroid Nodules,"Autonomous Thyroid Function|Iodine Adverse Reaction|Iodine Hyperthyroidism|Radiofrequency Ablation|Thyroid Nodule; Hyperthyroidism|Thyroid Nodule, Toxic or With Hyperthyroidism",2021-11-05,2023-12-31,2028-12-31,Interventional,Recruiting,Phase 3,Rijnstate Hospital,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Rijnstate Hospital|University of Twente|ZonMw: The Netherlands Organisation for Health Research and Development,"Rijnstate Hospital|Amsterdam UMC, location VUMC",Device|Drug|Drug,Netherlands,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT05142904
NCT05142904,hyperthyroidism,Ultrasound-guided Radiofrequency Ablation Versus Radioactive Iodine as Treatment for Hyperthyroidism Caused by Solitary Autonomous Thyroid Nodules,"Autonomous Thyroid Function|Iodine Adverse Reaction|Iodine Hyperthyroidism|Radiofrequency Ablation|Thyroid Nodule; Hyperthyroidism|Thyroid Nodule, Toxic or With Hyperthyroidism",2021-11-05,2023-12-31,2028-12-31,Interventional,Recruiting,Phase 3,Rijnstate Hospital,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Rijnstate Hospital|University of Twente|ZonMw: The Netherlands Organisation for Health Research and Development,"Rijnstate Hospital|Amsterdam UMC, location VUMC",Device|Drug|Drug,Netherlands,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT05142904
NCT05142904,thyroid neoplasms,Ultrasound-guided Radiofrequency Ablation Versus Radioactive Iodine as Treatment for Hyperthyroidism Caused by Solitary Autonomous Thyroid Nodules,"Autonomous Thyroid Function|Iodine Adverse Reaction|Iodine Hyperthyroidism|Radiofrequency Ablation|Thyroid Nodule; Hyperthyroidism|Thyroid Nodule, Toxic or With Hyperthyroidism",2021-11-05,2023-12-31,2028-12-31,Interventional,Recruiting,Phase 3,Rijnstate Hospital,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Rijnstate Hospital|University of Twente|ZonMw: The Netherlands Organisation for Health Research and Development,"Rijnstate Hospital|Amsterdam UMC, location VUMC",Device|Drug|Drug,Netherlands,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05142904
NCT05149898,parathyroid diseases,"Open-Label, Tolerability and Efficacy Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents With 22q11.2 Deletion Syndrome",22Q Deletion Syndrome,2021-10-05,2022-11-30,2022-12-31,Interventional,Recruiting,Phase 1/Phase 2,"Zynerba Pharmaceuticals, Inc.","Zynerba Pharmaceuticals, Inc.",Greenwood Genetic Center|Lady Cilento Children's Hospital - South Brisbane|Genetics Clinics Australia,Drug,Australia|United States,4.0,17.0,[0-17],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT05149898
NCT05176639,graves disease,"A Multiple Ascending Dose (MAD) Safety, Tolerability and Efficacy Study of VRDN 001, a Humanized Monoclonal Antibody Directed Against the IGF-1 Receptor, in Normal Healthy Volunteers (NHVs) and Subjects With Thyroid Eye Disease (TED)",Thyroid Eye Disease,2021-12-15,2023-06-30,2023-12-31,Interventional,Recruiting,Phase 1/Phase 2,"Viridian Therapeutics, Inc.","Viridian Therapeutics, Inc.","Sarasota Retina Institute|TKL Research, Inc.|Neuro-Eye Clinical Trials",Drug|Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT05176639
NCT05176639,goiter,"A Multiple Ascending Dose (MAD) Safety, Tolerability and Efficacy Study of VRDN 001, a Humanized Monoclonal Antibody Directed Against the IGF-1 Receptor, in Normal Healthy Volunteers (NHVs) and Subjects With Thyroid Eye Disease (TED)",Thyroid Eye Disease,2021-12-15,2023-06-30,2023-12-31,Interventional,Recruiting,Phase 1/Phase 2,"Viridian Therapeutics, Inc.","Viridian Therapeutics, Inc.","Sarasota Retina Institute|TKL Research, Inc.|Neuro-Eye Clinical Trials",Drug|Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT05176639
NCT05176639,hyperthyroidism,"A Multiple Ascending Dose (MAD) Safety, Tolerability and Efficacy Study of VRDN 001, a Humanized Monoclonal Antibody Directed Against the IGF-1 Receptor, in Normal Healthy Volunteers (NHVs) and Subjects With Thyroid Eye Disease (TED)",Thyroid Eye Disease,2021-12-15,2023-06-30,2023-12-31,Interventional,Recruiting,Phase 1/Phase 2,"Viridian Therapeutics, Inc.","Viridian Therapeutics, Inc.","Sarasota Retina Institute|TKL Research, Inc.|Neuro-Eye Clinical Trials",Drug|Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT05176639
NCT05177939,thyroiditis,Phase III Study to Evaluate the Efficacy and Safety of NPB-01 in Patients With Autoimmune Encephalitis Refractory to Steroid Pulse Therapy,Autoimmune Encephalitis,2021-12-03,2024-05-31,2024-10-31,Interventional,Not yet recruiting,Phase 3,"Nihon Pharmaceutical Co., Ltd","Nihon Pharmaceutical Co., Ltd",,Drug|Drug,,15.0,120.0,[0-17]|[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT05177939
NCT05186883,parathyroid diseases,Treatment of Postoperative Hypoparathyroidism Using Cultured Allogenic Parathyroid Cells,Postoperative Hypoparathyroidism,2021-12-01,2023-12-31,2023-12-31,Interventional,Not yet recruiting,Phase 1/Phase 2,Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus,Belarusian State Medical University|Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus,,Biological|Other,,18.0,70.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT05186883
NCT05189314,thyroid nodule,Clinical Outcomes and Quality of Life Measures After Surgical Resection and Radiofrequency Ablation of Benign Thyroid Nodules,Thyroid Nodules,2021-12-28,2023-08-30,2024-08-30,Observational,Recruiting,,Columbia University,Columbia University,Columbia University,Procedure|Procedure,United States,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT05189314
NCT05189314,thyroid neoplasms,Clinical Outcomes and Quality of Life Measures After Surgical Resection and Radiofrequency Ablation of Benign Thyroid Nodules,Thyroid Nodules,2021-12-28,2023-08-30,2024-08-30,Observational,Recruiting,,Columbia University,Columbia University,Columbia University,Procedure|Procedure,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05189314
NCT05189808,thyroid nodule,Radiofrequency Ablation for Indeterminate Bethesda III Thyroid Nodules,Indeterminate Bethesda III Thyroid Nodules,2021-12-28,2023-08-31,2024-08-31,Observational,Recruiting,,Columbia University,Columbia University,Columbia University,Procedure,United States,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT05189808
NCT05189808,thyroid neoplasms,Radiofrequency Ablation for Indeterminate Bethesda III Thyroid Nodules,Indeterminate Bethesda III Thyroid Nodules,2021-12-28,2023-08-31,2024-08-31,Observational,Recruiting,,Columbia University,Columbia University,Columbia University,Procedure,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05189808
NCT05189821,thyroid neoplasms,RFA Treatment for Papillary Thyroid Microcarcinoma Cohort,Papillary Thyroid Microcarcinoma,2021-12-28,2025-11-30,2026-11-30,Observational,Recruiting,,Columbia University,Columbia University,Columbia University,Procedure,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05189821
NCT05199103,graves ophthalmopathy,"Single-centre, Safety and Efficacy, Open-label Study Evaluating Antithymocyte Globulin Treatment in Subjects With Graves Orbitopathy",Graves Orbitopathy,2021-12-27,2023-12-31,2023-12-31,Interventional,Recruiting,Not Applicable,Medical University of Silesia,Medical University of Silesia,"Department of Internal Medicine and Oncological Chemotherapy, Medical Faculty in Katowice, Medical University of Silesia",Drug,Poland,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT05199103
NCT05199103,graves disease,"Single-centre, Safety and Efficacy, Open-label Study Evaluating Antithymocyte Globulin Treatment in Subjects With Graves Orbitopathy",Graves Orbitopathy,2021-12-27,2023-12-31,2023-12-31,Interventional,Recruiting,Not Applicable,Medical University of Silesia,Medical University of Silesia,"Department of Internal Medicine and Oncological Chemotherapy, Medical Faculty in Katowice, Medical University of Silesia",Drug,Poland,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT05199103
NCT05199103,goiter,"Single-centre, Safety and Efficacy, Open-label Study Evaluating Antithymocyte Globulin Treatment in Subjects With Graves Orbitopathy",Graves Orbitopathy,2021-12-27,2023-12-31,2023-12-31,Interventional,Recruiting,Not Applicable,Medical University of Silesia,Medical University of Silesia,"Department of Internal Medicine and Oncological Chemotherapy, Medical Faculty in Katowice, Medical University of Silesia",Drug,Poland,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT05199103
NCT05199103,hyperthyroidism,"Single-centre, Safety and Efficacy, Open-label Study Evaluating Antithymocyte Globulin Treatment in Subjects With Graves Orbitopathy",Graves Orbitopathy,2021-12-27,2023-12-31,2023-12-31,Interventional,Recruiting,Not Applicable,Medical University of Silesia,Medical University of Silesia,"Department of Internal Medicine and Oncological Chemotherapy, Medical Faculty in Katowice, Medical University of Silesia",Drug,Poland,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT05199103
NCT05214274,parathyroid diseases,The Status of Diagnosis and Treatment of Chronic Hypoparathyroidism in Chinese Adults: a Multicenter Registry Study,Chronic Hypoparathyroidism,2021-12-24,2022-12-31,2022-12-31,Observational,Recruiting,,Peking University,"Central South University|First Affiliated Hospital of Xinjiang Medical University|First Affiliated Hospital, Sun Yat-Sen University|First Hospital of China Medical University|Peking Union Medical College Hospital|Peking University|Shanghai 6th People's Hospital|West China Hospital","Peking Union Medical College Hospital|The First Hospital of China Medical University|The First Affiliated Hospital , Sun Yat-sen University|The Second Xiangya Hospital of Central South University|Shanghai Sixth People's Hospital|West China Hospital of Sichuan University|The First Affiliated Hospital of Xinjiang Medical University",Other,China,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT05214274
NCT05216718,thyroid neoplasms,Prospective Randomized Controlled Study on Mini-flap Bilateral Axillo-breast Approach Robotic Thyroidectomy : Effect on Postoperative Pain and Sensation,Thyroid Nodule,2021-12-30,2022-12-31,2023-12-01,Interventional,Not yet recruiting,Not Applicable,Inje University,Inje University,Dong sik Bae,Procedure|Procedure,"Korea, Republic of",19.0,69.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05216718
NCT05225883,thyroiditis,GEnome-wide Association Study in N-methyl-D-Aspartate Receptor and Other autoiMmune Encephalitis.,Autoimmune Encephalitis,2022-01-25,2023-12-31,2025-12-31,Observational,Recruiting,,Hospices Civils de Lyon,Hospices Civils de Lyon,Centre de référence des syndromes neurologiques paranéoplasiques et encéphalites auto-immunes,Genetic,France,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT05225883
NCT05229341,thyroid nodule,Evaluation of DNA Methylation Signatures in Diagnosis and Management of Thyroid Nodules,Thyroid Gland Carcinoma,2022-02-04,2026-10-22,2026-10-22,Interventional,Recruiting,Not Applicable,City of Hope Medical Center,City of Hope Medical Center|National Cancer Institute (NCI),City of Hope Medical Center,Procedure|Other|Procedure,United States,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT05229341
NCT05239221,parathyroid diseases,"A Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZP-3601, a Synthetic Parathyroid Hormone Analog, in Healthy Subjects and in Subjects With Hypoparathyroidism",Chronic Hypoparathyroidism,2022-01-07,2022-12-31,2023-01-31,Interventional,Recruiting,Phase 1,Amolyt Pharma,Amolyt Pharma,Amolyt Pharma Investigational Site Hungary|PRA-EDS,Drug|Drug,Hungary|Netherlands,18.0,75.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT05239221
NCT05242055,parathyroid diseases,"A Prospective, Cohort, and Observational Study of the Effect of Integrated Diagnosis and Treatment of Chronic Kidney Disease (CKD) on Clinical Outcomes in Real World Clinical Practice",Anemia|Chronic Kidney Disease-Mineral and Bone Disorder|Chronic Kidney Diseases|Hyperglycemia|Hyperlipidemias|Hypertension|Malnutrition,2022-01-29,2026-12-31,2026-12-31,Observational [Patient Registry],Not yet recruiting,,Capital Medical University,Capital Medical University,,Other,,18.0,100.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT05242055
NCT05264857,thyroid neoplasms,Decision Aid for Management of Thyroid Nodules and Early Thyroid Cancer,Thyroid Nodule,2022-02-17,2026-09-30,2026-09-30,Interventional,Recruiting,Not Applicable,Stony Brook University,Stony Brook University,Stony Brook University Cancer Center,Behavioral,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05264857
NCT05276063,graves disease,"A Phase 2b, Randomized, Double-Mask, Placebo-Controlled, Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)",Endocrine System Diseases|Exophthalmos|Eye Diseases|Graves Ophthalmopathy|Graves Orbitopathy|Hashimoto|IGF1R|Orbital Diseases|Proptosis|Thyroid Associated Ophthalmopathy|Thyroid Diseases|Thyroid Eye Disease,2022-03-02,2023-05-15,2025-06-13,Interventional,Not yet recruiting,Phase 2/Phase 3,"VasaraGen, Inc.","VasaraGen, Inc.",,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT05276063
NCT05276063,goiter,"A Phase 2b, Randomized, Double-Mask, Placebo-Controlled, Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)",Endocrine System Diseases|Exophthalmos|Eye Diseases|Graves Ophthalmopathy|Graves Orbitopathy|Hashimoto|IGF1R|Orbital Diseases|Proptosis|Thyroid Associated Ophthalmopathy|Thyroid Diseases|Thyroid Eye Disease,2022-03-02,2023-05-15,2025-06-13,Interventional,Not yet recruiting,Phase 2/Phase 3,"VasaraGen, Inc.","VasaraGen, Inc.",,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT05276063
NCT05276063,hyperthyroidism,"A Phase 2b, Randomized, Double-Mask, Placebo-Controlled, Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)",Endocrine System Diseases|Exophthalmos|Eye Diseases|Graves Ophthalmopathy|Graves Orbitopathy|Hashimoto|IGF1R|Orbital Diseases|Proptosis|Thyroid Associated Ophthalmopathy|Thyroid Diseases|Thyroid Eye Disease,2022-03-02,2023-05-15,2025-06-13,Interventional,Not yet recruiting,Phase 2/Phase 3,"VasaraGen, Inc.","VasaraGen, Inc.",,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT05276063
NCT05276856,hypothyroidism,Rate of Recovery of Secondary Hypothyroidism in Patients With Pituitary Disorders.,Secondary Hypothyroidism,2022-02-28,2022-11-01,2022-12-15,Observational,Not yet recruiting,,Nova Scotia Health Authority,Nova Scotia Health Authority,,Drug,,18.0,120.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT05276856
NCT05280379,thyroid neoplasms,Trained Immunity of Myeloid Cells and Their Progenitors in Patients With Non-medullary Thyroid Carcinoma and Colon Carcinoma,"Colon Carcinoma|Thyroid Cancer, Nonmedullary",2022-02-24,2024-04-07,2025-04-07,Observational,Not yet recruiting,,Radboud University Medical Center,Radboud University Medical Center,,Other,,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05280379
NCT05280600,thyroiditis,Developing Advanced Neuroimaging for Clinical Evaluation of Autoimmune Encephalitis,Anti-N-Methyl-D-Aspartate Receptor Encephalitis|Autoimmune Encephalitis,2022-02-10,2024-02-28,2026-02-28,Observational,Not yet recruiting,,King's College London,Action Medical Research|Guy's and St Thomas' NHS Foundation Trust|King's College London,Guy's and St Thomas' NHS Foundation Trust,Other,United Kingdom,8.0,24.0,[0-17]|[18-65],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT05280600
NCT05286801,thyroid neoplasms,A Phase 2 Study of Tiragolumab (NSC# 827799) and Atezolizumab (NSC# 783608) in Patients With Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors,Atypical Teratoid/Rhabdoid Tumor|Epithelioid Sarcoma|Kidney Medullary Carcinoma|Malignant Solid Neoplasm|Poorly Differentiated Chordoma|Recurrent Atypical Teratoid/Rhabdoid Tumor|Recurrent Chordoma|Recurrent Epithelioid Sarcoma|Recurrent Kidney Medullary Carcinoma|Recurrent Rhabdoid Tumor|Refractory Atypical Teratoid/Rhabdoid Tumor|Refractory Chordoma|Refractory Epithelioid Sarcoma|Refractory Kidney Medullary Carcinoma|Refractory Rhabdoid Tumor|Rhabdoid Tumor,2022-03-15,2025-07-31,2025-07-31,Interventional,Not yet recruiting,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),,Biological|Biological,,12.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05286801
NCT05290493,parathyroid diseases,"A Randomized, Placebo-Controlled Crossover Trial to Assess the Safety and Efficacy of NB-001 in Children and Adolescents With 22q11 Deletion Syndrome",22q11 Deletion Syndrome,2022-01-26,2022-12-31,2023-01-30,Interventional,Recruiting,Phase 2,"Nobias Therapeutics, Inc.","Nobias Therapeutics, Inc.",Children's Hospital of Philadelphia (CHOP)|Seattle Children's Hospital|The Hospital for Sick Children (SickKids),Drug|Other,Canada|United States,6.0,17.0,[0-17],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT05290493
NCT05299437,thyroid neoplasms,Personalized Therapy of Metastatic Thyroid Cancer: Biological Characterization and Optimization With 124I PET Dosimetry,Metastatic Differentiated Thyroid Cancer,2022-03-07,2024-03-30,2024-09-30,Interventional,Recruiting,Phase 2,"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano",Associazione Italiana per la Ricerca sul Cancro|Carlo Chiesa,"Nuclear Medicine, Ospedale Sacro Cuore - Don Calabria|Nuclear Medicine, Fondazione IRCCS Istituto Nazionale Tumori",Drug,Italy,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05299437
NCT05299632,parathyroid neoplasms,Pre-operative Localization of Parathyroid Adenomas Using F-18 PSMA PET/CT: A Pilot Study,Hyperparathyroidism,2022-03-09,2023-03-31,2023-12-31,Observational,Recruiting,,Emory University,Emory University,Emory Saint Joseph's Hospital|Emory University Hospital (EUH)|Emory Johns Creek Hospital,Diagnostic Test|Diagnostic Test,United States,18.0,99.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05299632
NCT02378233,thyroid diseases,A Double-blinded Randomised Study of Iodine Supplementation to Lactating Women in an Iodine-sufficient Area in Sweden and Evaluation of Maternal and Neonatal Iodine Levels and Thyroid Function,Lactation|Thyroid Gland; Node,2015-01-19,2017-12-31,2023-12-31,Interventional,"Active, not recruiting",Not Applicable,Göteborg University,"Göteborg University|Sahlgrenska University Hospital, Sweden",Health Care center,Dietary Supplement|Dietary Supplement,Sweden,18.0,40.0,[18-65],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT02378233
NCT02742597,thyroid diseases,Patient-Centred Innovations for Persons With Multimorbidity - Ontario,Alzheimer's Disease|Anxiety|Arthritis|Asthma|Cancer|Cardiovascular Disease|Chronic Bronchitis|Chronic Hepatitis|Chronic Obstructive Pulmonary Disease (COPD)|Crohn's Disease|Dementia|Depression|Diabetes|Diverticulosis|Gastroesophageal Reflux|Heart Failure|HIV|Hyperlipidemia|Hypertension|Irritable Bowel|Kidney Disease|Multimorbidity|Musculoskeletal Pain|Osteoporosis|Rheumatoid Arthritis|Stroke|Thyroid Disorder|Transient Ischemic Attacks|Ulcer|Ulcerative Colitis|Urinary Tract Problem,2016-03-21,2019-04-07,2022-03-30,Interventional,"Active, not recruiting",Not Applicable,Lawson Health Research Institute,"Canadian Institutes of Health Research (CIHR)|Lawson Health Research Institute|Michael Garron Hospital|Mount Sinai Hospital, Canada|Providence Healthcare|Sunnybrook Health Sciences Centre|Toronto Central Community Care Access Centre|Unity Health Toronto|Université de Sherbrooke|University Health Network, Toronto|Western University, Canada|Women's College Hospital",Western University|Mount Sinai Hospital|Providence Healthcare|St. Michael's Hospital|Sunnybrook Health Sciences Centre|Toronto Central Community Care Access Centre|Toronto East General Hospital|University Hospital Network|Women's College Hospital,Behavioral,Canada,18.0,80.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT02742597
NCT02789800,thyroid diseases,Patient-Centred Innovations for Persons With Multimorbidity - Quebec,Alzheimer's Disease|Anxiety|Arthritis|Asthma|Cancer|Cardiovascular Disease|Chronic Bronchitis|Chronic Hepatitis|Chronic Obstructive Pulmonary Disease (COPD)|Crohn's Disease|Dementia|Depression|Diabetes|Diverticulosis|Gastroesophageal Reflux|Heart Failure|HIV|Hyperlipidemia|Hypertension|Irritable Bowel|Kidney Disease|Musculoskeletal Pain|Osteoporosis|Rheumatoid Arthritis|Stroke|Thyroid Disorder|Transient Ischemic Attacks|Ulcer|Ulcerative Colitis|Urinary Tract Problem,2016-03-16,2022-04-01,2022-04-02,Interventional,"Active, not recruiting",Not Applicable,Université de Sherbrooke,"Agence de la Sante et des Services Sociaux du Saguenay-Lac-Saint-Jean|Canadian Institutes of Health Research (CIHR)|Université de Sherbrooke|Western University, Canada",Université de Sherbrooke|CIUSSS du Sageunay-Lac-Saint-Jean,Behavioral,Canada,18.0,80.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT02789800
NCT02966405,thyroid diseases,The Establish of Trimester-specific Reference Ranges for Thyroid Tests in Pregnant Women and the Influence of Thyroid Disorders on Pregnancy and Its Outcomes.,Diseases Pregnancy Thyroid,2016-10-24,2020-12-31,2020-12-31,Observational [Patient Registry],Recruiting,,Peking University International Hospital,Xiaomei Zhang,Peking University International Hospital|Peking University International Hospital,,China,19.0,45.0,[18-65],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT02966405
NCT03149354,thyroid diseases,Prevalence of Thyroid Function Abnormalities in HIV-infected Patients: State of Play in 2012,HIV Infections|Thyroid,2017-05-04,2022-12-19,2022-12-19,Interventional,Recruiting,Not Applicable,"Centre Hospitalier Universitaire, Amiens","Centre Hospitalier Universitaire, Amiens",CHU Amiens Picardie,Other,France,18.0,120.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT03149354
NCT03922087,thyroid diseases,Huizhou Mother-infant Cohort,"Allergic Disorder|Anemia in Pregnancy|Asthma|Complications, Pregnancy|Depression|Gestational Diabetes Mellitus in Pregnancy|Gestational Hypertension|Immune System Diseases|Neurodevelopmental Disorders|Obesity|Obstetric Labor Complications|Reproductive Disorder|Thyroid Disease Pregnancy",2019-04-13,2021-12-31,2025-12-31,Observational,Recruiting,,Sun Yat-sen University,Huizhou No.1 Maternal and Child Care Service Cencer|Sun Yat-sen University,School of Public Health of Sun Yat-sen University (North Campus),Other,China,18.0,49.0,[18-65],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT03922087
NCT03932487,thyroid diseases,"The Relationship Between Urine Iodine, Urine Bisphenol A and Autoimmune Thyroid Disease in Reproductive Women",The Effect of Iodine and BPA on AITD in Reproduction Women,2019-04-24,2022-10-01,2022-10-01,Observational,Recruiting,,Peking University International Hospital,Xiaomei Zhang,Peking University international hospital,Other,China,20.0,45.0,[18-65],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT03932487
NCT04019509,thyroid diseases,The Influence of Different Thyroid Autoantibodies on Thyroid Function and Pregnancy Outcome After Assisted Reproductive Technology,Fertility Disorders|Thyroid Dysfunction,2019-07-10,2022-01-01,2022-09-01,Interventional,Recruiting,Not Applicable,Universitair Ziekenhuis Brussel,Universitair Ziekenhuis Brussel,UZ Brussel,Diagnostic Test|Other,Belgium,18.0,36.0,[18-65],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT04019509
NCT04208503,thyroid diseases,Ultrasound and Functional Thyroid Evaluation in Preterm Infants Born Between 24 and 32 Weeks of Gestation,Gland; Functional Disturbance|Thyroid,2019-12-13,2021-12-30,2021-12-31,Observational [Patient Registry],Recruiting,,"Princess Anna Mazowiecka Hospital, Warsaw, Poland","Princess Anna Mazowiecka Hospital, Warsaw, Poland",Department of Neonatology and Neonatal Intensive Care Warsaw Medical University|Department of Neonatology and Neonatal Intensive Care Warsaw Medical University,Diagnostic Test,Poland,0.0,12.0,[0-17],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT04208503
NCT04323007,thyroid diseases,Thyroid Dysfunction in Patients With Nephrotic Syndrome,Thyroid Dysfunction,2020-01-12,2021-10-01,2022-10-01,Interventional,Not yet recruiting,Not Applicable,Assiut University,Assiut University|Merna Makram,,Diagnostic Test,,18.0,80.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT04323007
NCT04388956,thyroid diseases,Diagnosis of Thyroid Tumors by Multiple Ultrasonic Factors.,Diagnoses Disease|Nodule|Thyroid,2020-05-12,2022-12-31,2022-12-31,Observational [Patient Registry],Recruiting,,National Taiwan University Hospital,National Taiwan University Hospital,National Taiwan University Hospital,,Taiwan,0.0,120.0,[0-17]|[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT04388956
NCT04571736,thyroid diseases,Interest of Improving Preoperative Medical Information by Video Support and Personalized and Secure Web Platform: Pilot Study in Thyroid Surgery (AMEDOP),Thyroid,2020-07-27,2022-11-30,2022-11-30,Interventional,Recruiting,Not Applicable,"University Hospital, Montpellier","EDOP|University Hospital, Montpellier",CHU Gui de Chauliac,Other,France,18.0,75.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT04571736
NCT04585126,thyroid diseases,Effect of Ultrasound-guided Intermediate Cervical Block on Recurrent Laryngeal Nerve Monitoring During Thyroid Surgery : a Randomised Non-inferiority Study,Thyroid Surgery,2020-10-02,2021-11-30,2021-11-30,Interventional,Recruiting,Not Applicable,"University Hospital, Caen","Centre Francois Baclesse|University Hospital, Caen",Caen University Hospital,Drug,France,18.0,120.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT04585126
NCT04615988,thyroid diseases,Correlation of Serum Vitamin D Level With the Development of Endocrine Autoimmune Complications During Treatment With Immune Checkpoint Inhibitors,Cancer|PD-1|Thyroid,2020-10-29,2022-12-31,2024-06-30,Observational,Recruiting,,Icahn School of Medicine at Mount Sinai,Icahn School of Medicine at Mount Sinai,Mount Sinai Hospital /Tisch Cancer Cancer/Ruttenberg Treatment Center,,United States,18.0,120.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT04615988
NCT04658524,thyroid diseases,Evaluation of Thyroid Function in Patients With Chronic Kidney Disease,Chronic Kidney Disease|Thyroid Dysfunction,2020-11-20,2019-11-30,2025-12-30,Observational,"Active, not recruiting",,Rio de Janeiro State University,Rio de Janeiro State University,Ana Beatriz Winter Tavares,Diagnostic Test,Brazil,18.0,100.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT04658524
NCT04684953,thyroid diseases,Implantation of Thyroid Gland After Total Thyroidectomy in Quadriceps Femoris Muscle,Thyroid,2020-12-22,2022-10-31,2022-12-31,Interventional,Not yet recruiting,Not Applicable,Assiut University,Assiut University,,Procedure|Drug,,15.0,40.0,[0-17]|[18-65],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT04684953
NCT04708704,thyroid diseases,Investigation of Photodegraded Edible Food Dyes in Drinking Water on Thyroid Function,Thyroid; Functional Disturbance,2020-12-21,2023-12-31,2024-12-31,Interventional,Not yet recruiting,Not Applicable,Yale University,Yale University,Yale University,Dietary Supplement|Dietary Supplement|Dietary Supplement,United States,18.0,120.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT04708704
NCT04845867,thyroid diseases,Thyroid HEmorrhage DetectOr Study,Thyroid,2021-04-13,2022-06-30,2022-08-31,Observational [Patient Registry],Not yet recruiting,,ISAR-M GmbH,CRI-The Clinical Research Institute GmbH|ISAR-M GmbH,,Device,,18.0,120.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT04845867
NCT04936698,thyroid diseases,The Prevalence and Risk Factors for Thyroid Dysfunction in Pregnant Women in Taiwan,Thyroid Disease Pregnancy,2021-06-17,2022-03-31,2022-03-31,Observational,Recruiting,,Chang Gung Memorial Hospital,Chang Gung Memorial Hospital,Chang Gung Memorial hospital,Drug|Drug,Taiwan,18.0,50.0,[18-65],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT04936698
NCT04991493,thyroid diseases,Effect of Tramadol on Postoperative Sore Throat in Thyroid Surgery Under General Anesthesia With Endotracheal Intubation: A Randomized Controlled Trial,Intubation Intratracheal|Post-operative Sore Throat|Thyroid Surgery,2021-07-27,2023-07-31,2023-12-31,Interventional,Recruiting,Phase 4,Affiliated Cancer Hospital of Shantou University Medical College,Affiliated Cancer Hospital of Shantou University Medical College,Affiliated Cancer Hospital of Shantou University Medical College Medical,Drug|Other,China,18.0,60.0,[18-65],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT04991493
NCT05016518,thyroid diseases,Comparison of Quality of Recovery (QoR)-15 Scores According to the Use of Anesthetics During Total Intravenous Anesthesia in Female Patients Undergoing Thyroid Surgery,Patients Undergoing Thyroid Surgery for Neoplasm,2021-08-10,2022-06-30,2022-07-04,Interventional,Recruiting,Not Applicable,Gangnam Severance Hospital,Gangnam Severance Hospital,Gangnam Severance Hospital,Drug|Drug,"Korea, Republic of",20.0,65.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT05016518
NCT05103774,thyroid diseases,Thyroid Functions in Children With Congenital Heart Diseases,Value of Thyroid Functions in Children With Congenital Heart Diseases,2021-10-18,2022-11-01,2022-11-15,Observational,Not yet recruiting,,Sohag University,Sohag University,Hospital of Sohag University,Diagnostic Test,Egypt,1.0,12.0,[0-17],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT05103774
NCT05126108,thyroid diseases,Evaluation of the Decurarisation Kinetics of Rocuronium in Cervical Surgery,Equiring General Anesthesia With Intubation With a Nerve Integrity Monitor (NIM) Tube|Non-morbidly Obese Patients (BMI<35)|Thyroid and Parathyroid Surgery,2021-11-08,2022-05-31,2022-05-31,Observational,Not yet recruiting,,Assistance Publique - Hôpitaux de Paris,Assistance Publique - Hôpitaux de Paris,Surgical anesthesia service - Cochin Hospital,Procedure|Other,France,18.0,120.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT05126108
NCT05151120,thyroid diseases,Harmonization of Thyroid-stimulating Hormone Immunoassays Reagents - Blood Collection From Patients With Thyroid Disorders,"Thyroid Disorders|Thyroid Stimulating; Hormone, C",2021-10-21,2023-09-01,2023-09-01,Observational,Not yet recruiting,,Hospices Civils de Lyon,Hospices Civils de Lyon,Service D'endocrinologie - Hôpital Louis Pradel - Hospices Civils de Lyon|Service de Médecine Nucléaire - Hôpital Louis Pradel - Hospices Civils de Lyon,Biological,France,18.0,120.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT05151120
NCT05251194,thyroid diseases,The Effect of McGrath Video Laryngoscope on the Glottic View at Thyroid Surgery Position in Tracheal Intubation,Thyroid Surgery,2022-02-11,2022-06-30,2022-08-31,Interventional,Not yet recruiting,Not Applicable,Seoul National University Hospital,Seoul National University Hospital|SMG-SNU Boramae Medical Center,Seoul Metropolitan Government Seoul National University Boramae Medical Center,Device,"Korea, Republic of",19.0,120.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT05251194
NCT00001159,hyperthyroidism,Evaluation of Patients With Thyroid Function Disorders,Grave's Disease|Hyperthyroidism|Hypothyroidism,1999-11-03,,,Observational,Recruiting,,National Institutes of Health Clinical Center (CC),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),"National Institutes of Health Clinical Center, 9000 Rockville Pike",,United States,6.0,120.0,[0-17]|[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT00001159
NCT00001159,hypothyroidism,Evaluation of Patients With Thyroid Function Disorders,Grave's Disease|Hyperthyroidism|Hypothyroidism,1999-11-03,,,Observational,Recruiting,,National Institutes of Health Clinical Center (CC),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),"National Institutes of Health Clinical Center, 9000 Rockville Pike",,United States,6.0,120.0,[0-17]|[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT00001159
NCT00001160,tall cell variant thyroid cancer,Studies on Thyroid Nodules and Thyroid Cancer,Follicular Thyroid Cancer|Hurthle Cell Thyroid Cancer|Papillary Thyroid Cancer|Tall Cell Variant Thyroid Cancer|Thyroid Cancer,1999-11-03,,,Observational,Recruiting,,National Institutes of Health Clinical Center (CC),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),National Institutes of Health Clinical Center,,United States,6.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT00001160
NCT00001160,follicular thyroid cancer,Studies on Thyroid Nodules and Thyroid Cancer,Follicular Thyroid Cancer|Hurthle Cell Thyroid Cancer|Papillary Thyroid Cancer|Tall Cell Variant Thyroid Cancer|Thyroid Cancer,1999-11-03,,,Observational,Recruiting,,National Institutes of Health Clinical Center (CC),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),National Institutes of Health Clinical Center,,United States,6.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, follicular",https://clinicaltrials.gov/ct2/show/NCT00001160
NCT00001160,hurthle cell thyroid cancer,Studies on Thyroid Nodules and Thyroid Cancer,Follicular Thyroid Cancer|Hurthle Cell Thyroid Cancer|Papillary Thyroid Cancer|Tall Cell Variant Thyroid Cancer|Thyroid Cancer,1999-11-03,,,Observational,Recruiting,,National Institutes of Health Clinical Center (CC),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),National Institutes of Health Clinical Center,,United States,6.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Hurthle cell thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00001160
NCT00001242,pseudohypoparathyroidism,Studies of States With Resistance to Vitamin D and Parathyroid Hormone,Hypocalcemia|Osteomalacia|Pseudohypoparathyroidism|Pseudopseudohpoparathyroidism|Rickets,1999-11-03,,,Observational,Recruiting,,National Institutes of Health Clinical Center (CC),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),"National Institutes of Health Clinical Center, 9000 Rockville Pike",,United States,2.0,100.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,pseudohypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00001242
NCT00169806,hyperparathyroidism,Randall's Plaques: Pathogenesis and Relationship to Nephrolithiasis,Cystinuria|Hypercalciuria|Hyperparathyroidism|Nephrocalcinosis|Renal Calculi,2005-09-12,2025-12-31,2025-12-31,Interventional,Recruiting,Not Applicable,Indiana Kidney Stone Institute,Indiana Kidney Stone Institute|Indiana University School of Medicine|University of Chicago,IU Health Methodist Hospital,Other,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT00169806
NCT00342446,thyroid cancer,Follow-Up Study of Women Evaluated and Treated for Infertility,"Breast Cancer|Colorectal Cancer, Melanoma|Endometrial Cancer|Ovarian Cancer|Thyroid Cancer",2006-06-19,,,Observational,"Active, not recruiting",,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),Columbia University,,United States,44.0,88.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00342446
NCT00381641,thyroid gland hurthle cell carcinoma,"Phase II Trial of Sunitinib (SU11248) in Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers and Medullary Thyroid Cancers",Differentiated Thyroid Gland Carcinoma|Recurrent Thyroid Gland Carcinoma|Refractory Thyroid Gland Carcinoma|Stage III Thyroid Gland Follicular Carcinoma AJCC v7|Stage III Thyroid Gland Medullary Carcinoma AJCC v7|Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVA Thyroid Gland Medullary Carcinoma AJCC v7|Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVB Thyroid Gland Medullary Carcinoma AJCC v7|Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVC Thyroid Gland Medullary Carcinoma AJCC v7|Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7|Stage IV Thyroid Gland Follicular Carcinoma AJCC v7|Stage IV Thyroid Gland Medullary Carcinoma AJCC v7|Stage IV Thyroid Gland Papillary Carcinoma AJCC v7|Thyroid Gland Hurthle Cell Carcinoma|Unresectable Thyroid Gland Carcinoma,2006-09-26,2016-12-31,,Interventional,"Active, not recruiting",Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),University of Chicago Comprehensive Cancer Center|Decatur Memorial Hospital|NorthShore University HealthSystem-Evanston Hospital|Ingalls Memorial Hospital|Duly Health and Care Joliet|Loyola University Medical Center|Illinois CancerCare-Peoria|Central Illinois Hematology Oncology Center|Southern Illinois University School of Medicine|Fort Wayne Medical Oncology and Hematology Inc-Parkview|Northern Indiana Cancer Research Consortium|University of Maryland/Greenebaum Cancer Center|University of Michigan Comprehensive Cancer Center|Oncology Care Associates PLLC|Mercy Hospital Saint Louis|M D Anderson Cancer Center|Medical College of Wisconsin,Other|Other|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Hurthle cell thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00381641
NCT00410761,thyroid cancer,"An International, Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMATM) Versus Placebo in Subjects With Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer",Thyroid Cancer,2006-12-06,2009-07-31,2022-12-31,Interventional,"Active, not recruiting",Phase 3,Sanofi,"Genzyme, a Sanofi Company",Investigational Site Number 3|Investigational Site Number 8|Investigational Site Number 9|Investigational Site Number 11|Investigational Site Number 15|Investigational Site Number 18|Investigational Site Number 17|Investigational Site Number 2|Investigational Site Number 7|Investigational Site Number 14|Investigational Site Number 10|Investigational Site Number 6|Investigational Site Number 22|Investigational Site Number 19|Investigational Site Number 13|Investigational Site Number 21|Investigational Site Number 1001|Investigational Site Number 1901|Investigational Site Number 1101|Investigational Site Number 1102|Investigational Site Number 2301|Investigational Site Number 2302|Investigational Site Number 1203|Investigational Site Number 1202|Investigational Site Number 1201|Investigational Site Number 1204|Investigational Site Number 1205|Investigational Site Number 3601|Investigational Site Number 2701|Investigational Site Number 2802|Investigational Site Number 2803|Investigational Site Number 2801|Investigational Site Number 2002|Investigational Site Number 2001|Investigational Site Number 2005|Investigational Site Number 1601|Investigational Site Number 1401|Investigational Site Number 1402|Investigational Site Number 2506|Investigational Site Number 2502|Investigational Site Number 2503|Investigational Site Number 2501|Investigational Site Number 2505|Investigational Site Number 2504|Investigational Site Number 1501|Investigational Site Number 2403|Investigational Site Number 2402|Investigational Site Number 2404|Investigational Site Number 2902|Investigational Site Number 2901|Investigational Site Number 1701|Investigational Site Number 1702|Investigational Site Number 1703|Investigational Site Number 2602|Investigational Site Number 2601|Investigational Site Number 1801|Investigational Site Number 3301|Investigational Site Number 3402|Investigational Site Number 3401|Investigational Site Number 3003|Investigational Site Number 3001|Investigational Site Number 3002|Investigational Site Number 3102|Investigational Site Number 3101|Investigational Site Number 2101|Investigational Site Number 2102,Drug,"Australia|Austria|Belgium|Brazil|Canada|Czechia|Denmark|France|Germany|Hungary|India|Italy|Korea, Republic of|Mexico|Netherlands|Poland|Portugal|Romania|Russian Federation|Serbia|Spain|Sweden|Switzerland|United States",18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00410761
NCT00537095,thyroid neoplasms,"A Randomized, Double Blind, Placebo-controlled Phase II, Multi-Centre Study to Assess the Efficacy and Safety of Vandetanib (ZD6474) in Patients With Locally Advanced or Metastatic Papillary or Follicular Thyroid Carcinoma Failing or Unsuitable for Radioiodine Therapy",Thyroid Neoplasms,2007-09-27,2009-12-31,2022-12-31,Interventional,"Active, not recruiting",Phase 2,Sanofi,"Genzyme, a Sanofi Company",Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site,Drug|Other,Belgium|Denmark|France|Norway|Spain|Sweden|Switzerland,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00537095
NCT00591032,low t3 syndrome,Development of Rational and Standardized Diagnostics and Staging for a Differentiated Risk Stratification of Non-thyroidal Illness Syndrome,Euthyroid Sick Syndromes|Low T3 Syndrome|Non-thyroidal Illness Syndrome|TACITUS,2007-12-26,2017-11-30,2020-12-31,Observational,"Active, not recruiting",,Ruhr University of Bochum,Private Sponsor (Chantal C. Guilhemotonia-Urban)|Ruhr University of Bochum|Wissenschaftskommission des Universitaetsklinikums Bergmannsheil,"Department for medical informatics, biometry and epidemiology, Ruhr-University of Bochum|Institute of Clinical Chemistry, Transfusion and Laboratory Medicine, Universitätsklinikum Bergmannsheil, Ruhr-Universität Bochum|Medical Hospital II, Bergmannsheil University Hospitals, Ruhr University of Bochum|Medizinische Klinik I, Universitätsklinikum Bergmannsheil, Ruhr-Universität Bochum|Diabetes-Zentrum, Mathias-Spital|Abteilung für Laboratoriums- und Transfusionsmedizin, Westpfalz-Klinikum Kaiserslautern",,Germany,0.0,120.0,[0-17]|[18-65]|[65 and more],Euthyroid Sick Syndromes,Euthyroid Sick Syndromes,https://clinicaltrials.gov/ct2/show/NCT00591032
NCT00673010,thyroid cancer,Lesion Dosimetry With 124-Iodine in Metastatic Thyroid Carcinoma,Thyroid Cancer,2008-05-06,2023-03-31,2023-03-31,Interventional,"Active, not recruiting",Phase 1,Memorial Sloan Kettering Cancer Center,"Gustave Roussy, Cancer Campus, Grand Paris|Memorial Sloan Kettering Cancer Center",Memorial Sloan Kettering Cancer Center,Radiation,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00673010
NCT01005654,thyroid neoplasms,Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms,Adrenal Neoplasm|Endocrine Tumors|Neuroblastoma|Parathyroid Neoplasms|Thyroid Neoplasms,2009-10-30,,,Observational,Recruiting,,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),"National Institutes of Health Clinical Center, 9000 Rockville Pike",,United States,4.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01005654
NCT01005654,parathyroid neoplasms,Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms,Adrenal Neoplasm|Endocrine Tumors|Neuroblastoma|Parathyroid Neoplasms|Thyroid Neoplasms,2009-10-30,,,Observational,Recruiting,,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),"National Institutes of Health Clinical Center, 9000 Rockville Pike",,United States,4.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01005654
NCT01074684,thyroid cancer,"Defining Predictive Factors of Clinical, Laboratory and Imaging Criteria Routinely Used in the Diagnosis of Thyroid Cancer: Observational, Prospective Multicentered Study",Thyroid Cancer,2010-02-23,2021-12-31,2022-12-31,Observational,"Active, not recruiting",,"National Cancer Institute, Naples","National Cancer Institute, Naples",Università di Cagliari|Azienda Ospedaliera Unviersitaria Careggi - Firenze|ASL TO/4 Ospedale di Ivrea|Istituto Nazionale dei Tumori|Azienda Ospedaliera Universitaria di Padova|Università Cattolica del Sacro Cuore di Roma Policlinico Gemelli|Ospedale di Taormina|Università degli studi di Perugia - Sede di Terni,,Italy,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01074684
NCT01087619,primary hyperparathyroidism,Primary Hyperparathyroidism in Patients Older Than 65 Years: A Prospective Randomized Trial of Surgical Treatment Compared With Follow-up,Primary Hyperparathyroidism,2010-03-15,2023-12-31,2025-12-31,Interventional,Recruiting,Not Applicable,Region Skane,Region Skane,"Skåne University Hospital, Department of Surgery, Lund",Procedure,Sweden,66.0,120.0,[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT01087619
NCT01141309,thyroid cancer,Phase II Study Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer,Thyroid Cancer,2010-06-09,2022-06-30,2022-06-30,Interventional,"Active, not recruiting",Phase 2,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Memoral Sloan Kettering Cancer Center|Memorial Sloan Kettering Cancer Center @ Suffolk|Memorial Sloan Kettering Westchester|Memorial Sloan Kettering Cancer Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01141309
NCT01145040,hyperthyroidism,NOMOTHETICOS: Nonlinear Modelling of Thyroid Hormones' Effect on Thyrotropin Incretion in Confirmed Open-loop Situation. A Correlation Study,Hyperthyroidism|Hypothyroidism,2010-06-14,2018-07-31,2021-01-31,Observational,"Active, not recruiting",,Ruhr University of Bochum,Ruhr University of Bochum,"Klinikum Ludwigsburg-Bietigheim|Institute for diagnostical radiology, interventional radiology and nuclear medicine, Bergmannsheil University Hospitals, Ruhr University of Bochum|Medical Hospital I, Bergmannsheil University Hospitals, Ruhr University of Bochum",,Germany,14.0,120.0,[0-17]|[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01145040
NCT01145040,hypothyroidism,NOMOTHETICOS: Nonlinear Modelling of Thyroid Hormones' Effect on Thyrotropin Incretion in Confirmed Open-loop Situation. A Correlation Study,Hyperthyroidism|Hypothyroidism,2010-06-14,2018-07-31,2021-01-31,Observational,"Active, not recruiting",,Ruhr University of Bochum,Ruhr University of Bochum,"Klinikum Ludwigsburg-Bietigheim|Institute for diagnostical radiology, interventional radiology and nuclear medicine, Bergmannsheil University Hospitals, Ruhr University of Bochum|Medical Hospital I, Bergmannsheil University Hospitals, Ruhr University of Bochum",,Germany,14.0,120.0,[0-17]|[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT01145040
NCT01236547,thyroid gland anaplastic carcinoma,"A Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib (NSC 737754)/Placebo, for the Treatment of Anaplastic Thyroid Cancer",Thyroid Gland Anaplastic Carcinoma,2010-11-05,2020-03-09,,Interventional,"Active, not recruiting",Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI)|NRG Oncology,University of Alabama at Birmingham Cancer Center|The Kirklin Clinic at Acton Road|Cancer Center at Saint Joseph's|Saint Joseph's Hospital and Medical Center|Arizona Oncology-Deer Valley Center|Arizona Oncology Services Foundation|Sutter Cancer Centers Radiation Oncology Services-Auburn|Alta Bates Summit Medical Center-Herrick Campus|Mills-Peninsula Medical Center|Sutter Cancer Centers Radiation Oncology Services-Cameron Park|Eden Hospital Medical Center|Sutter Cancer Centers Radiation Oncology Services-Roseville|Sutter Medical Center Sacramento|California Pacific Medical Center-Pacific Campus|UCSF Medical Center-Mount Zion|UCSF Medical Center-Parnassus|Sutter Cancer Centers Radiation Oncology Services-Vacaville|Sutter Solano Medical Center/Cancer Center|Christiana Gynecologic Oncology LLC|Delaware Clinical and Laboratory Physicians PA|Helen F Graham Cancer Center|Medical Oncology Hematology Consultants PA|Christiana Care Health System-Christiana Hospital|Beebe Health Campus|Christiana Care Health System-Wilmington Hospital|Mayo Clinic in Florida|Moffitt Cancer Center|Emory University Hospital Midtown|Emory University Hospital/Winship Cancer Institute|Radiation Oncology Associates PC|Parkview Hospital Randallia|University of Kansas Cancer Center|The James Graham Brown Cancer Center at University of Louisville|Mary Bird Perkins Cancer Center|Touro Infirmary|Greater Baltimore Medical Center|Sinai Hospital of Baltimore|Boston Medical Center|Henry Ford Cancer Institute-Downriver|Henry Ford Macomb Hospital-Clinton Township|Henry Ford Medical Center-Fairlane|Henry Ford Hospital|West Michigan Cancer Center|Henry Ford Medical Center-Columbus|Henry Ford West Bloomfield Hospital|Fairview Ridges Hospital|Mercy Hospital|Fairview Southdale Hospital|Unity Hospital|Minnesota Oncology Hematology PA-Maplewood|Abbott-Northwestern Hospital|Hennepin County Medical Center|North Memorial Medical Health Center|Mayo Clinic in Rochester|Metro Minnesota Community Oncology Research Consortium|Park Nicollet Clinic - Saint Louis Park|Regions Hospital|United Hospital|Ridgeview Medical Center|Rice Memorial Hospital|University of Mississippi Medical Center|Billings Clinic Cancer Center|Memorial Sloan Kettering Basking Ridge|New York-Presbyterian/Brooklyn Methodist Hospital|Memorial Sloan Kettering Commack|Memorial Sloan Kettering Westchester|Memorial Sloan Kettering Cancer Center|Memorial Sloan Kettering Sleepy Hollow|Memorial Sloan Kettering Nassau|UNC Lineberger Comprehensive Cancer Center|Summa Health System - Akron Campus|Summa Health System - Barberton Campus|University of Cincinnati Cancer Center-UC Medical Center|Case Western Reserve University|Cleveland Clinic Foundation|Ohio State University Comprehensive Cancer Center|Mercy Cancer Center-Elyria|Summa Health Medina Medical Center|UH Seidman Cancer Center at Lake Health Mentor Campus|UH Seidman Cancer Center at Southwest General Hospital|University Hospitals Parma Medical Center|UH Seidman Cancer Center at Firelands Regional Medical Center|University of Cincinnati Cancer Center-West Chester|University of Oklahoma Health Sciences Center|UPMC-Heritage Valley Health System Beaver|UPMC Cancer Centers - Arnold Palmer Pavilion|Penn State Milton S Hershey Medical Center|UPMC-Johnstown/John P. Murtha Regional Cancer Center|UPMC Cancer Center at UPMC McKeesport|UPMC-Coraopolis/Heritage Valley Radiation Oncology|UPMC Cancer Center-Natrona Heights|UPMC Jameson|Thomas Jefferson University Hospital|UPMC-Presbyterian Hospital|UPMC-Saint Margaret|UPMC-Shadyside Hospital|UPMC Jefferson Regional Radiation Oncology|UPMC-Passavant Hospital|UPMC-Saint Clair Hospital Cancer Center|UPMC Cancer Center at UPMC Northwest|UPMC Uniontown Hospital Radiation Oncology|UPMC Washington Hospital Radiation Oncology|Prisma Health Cancer Institute - Spartanburg|Prisma Health Cancer Institute - Faris|Prisma Health Cancer Institute - Eastside|Prisma Health Cancer Institute - Greer|Prisma Health Cancer Institute - Seneca|Parkland Memorial Hospital|UT Southwestern/Simmons Cancer Center-Dallas|M D Anderson Cancer Center|American Fork Hospital / Huntsman Intermountain Cancer Center|Sandra L Maxwell Cancer Center|Logan Regional Hospital|Intermountain Medical Center|McKay-Dee Hospital Center|Utah Valley Regional Medical Center|Dixie Medical Center Regional Cancer Center|Utah Cancer Specialists-Salt Lake City|LDS Hospital|Sentara Cancer Institute at Sentara CarePlex Hospital|Sentara Norfolk General Hospital|Sentara Virginia Beach General Hospital|Green Bay Oncology at Saint Vincent Hospital|Saint Vincent Hospital Cancer Center Green Bay|Green Bay Oncology Limited at Saint Mary's Hospital|Saint Vincent Hospital Cancer Center at Saint Mary's|University of Wisconsin Hospital and Clinics|Holy Family Memorial Hospital|Bay Area Medical Center|Medical College of Wisconsin,Radiation|Drug|Drug|Other,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT01236547
NCT01263951,differentiated thyroid cancer,A Phase II Study of Everolimus and Sorafenib in Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Sorafenib Alone,Differentiated Thyroid Cancer,2010-11-29,2021-02-01,2022-05-31,Interventional,"Active, not recruiting",Phase 2,Thomas Jefferson University,Bayer|Novartis Pharmaceuticals|Thomas Jefferson University,Hospital of the University of Pennsylvania,Drug|Drug,United States,18.0,89.0,[18-65]|[65 and more],Thyroid neoplasms,"Differentiated thyroid cancer, all",https://clinicaltrials.gov/ct2/show/NCT01263951
NCT01298323,medullary thyroid cancer,"A Randomized,Int.,Open-Label Phase III Study to Assess the Effect of a Patient Outreach Program on the Percentage of Time Patients With Locally Advanced or Metastatic MTC Experience Grade 2 or Higher AEs in the First 12 Months of Treatment With Vandetanib",Locally Advanced or Metastatic Medullary Thyroid Cancer|Medullary Thyroid Cancer,2011-02-16,2013-04-30,2022-12-31,Interventional,"Active, not recruiting",Phase 3,Sanofi,"Genzyme, a Sanofi Company",Investigational Site Number 301|Investigational Site Number 401|Investigational Site Number 501|Investigational Site Number 701|Investigational Site Number 702|Investigational Site Number 901|Investigational Site Number 1001|Investigational Site Number 1002|Investigational Site Number 1003|Investigational Site Number 1301|Investigational Site Number 1302|Investigational Site Number 1901|Investigational Site Number 2001|Investigational Site Number 2201|Investigational Site Number 2602|Investigational Site Number 2603|Investigational Site Number 2601|Investigational Site Number 3001|Investigational Site Number 3501|Investigational Site Number 3502|Investigational Site Number 4001|Investigational Site Number 4104|Investigational Site Number 4101|Investigational Site Number 4102|Investigational Site Number 6001|Investigational Site Number 5702|Investigational Site Number 5703|Investigational Site Number 6201|Investigational Site Number 6204|Investigational Site Number 6202|Investigational Site Number 6203|Investigational Site Number 7201|Investigational Site Number 2802|Investigational Site Number 2801,Behavioral|Drug,"Australia|Austria|Belgium|Brazil|Bulgaria|Canada|China|Czechia|Denmark|Finland|Germany|Greece|India|Israel|Italy|Korea, Republic of|Poland|Russian Federation|Sweden|United Kingdom",18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, medullary",https://clinicaltrials.gov/ct2/show/NCT01298323
NCT01398085,thyroid cancer,Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients,Thyroid Cancer,2011-07-06,2023-03-31,2031-03-31,Interventional,"Active, not recruiting",Phase 2/Phase 3,"University College, London","Cancer Research UK|University College, London",University Hospitals Birmingham NHS Foundation Trust|Brighton and Sussex University Hospitals NHS Trust|University Hospital Bristol NHS Foundation Trust|Cambridge University Hospitals NHS Foundation Trust|East Kent Hospitals University NHS Foundation Trust|Mid Essex Hospitals Services NHS Trust|Gloucestershire Hospitals NHS Trust|Royal Derby hospital NHS foundation trust|NHS Lothian|Royal Devon and Exeter NHS Trust|Glasgow and Clyde NHS Trust|The Royal Surrey County Hospital NHS Foundation Trust|Ipswich Hospital NHS Trust|Leeds Teaching Hospitals NHS Trust|University Hospitals of Leicester NHS Trust|Royal Marsden NHS Foundation Trust|Imperial College Healthcare NHS Trust|Barts Health NHS Trust|Guys and St Thomas' NHS Foundation Trust|University College London Hospitals NHS Foundation Trust|Maidstone and Tunbridge Wells NHS Trust|The Christie NHS Foundation Trust|South Tees Hospitals NHS Trust|Velindre NHS Trust|Newcastle upon Tyne Hospitals NHS Foundation Trust|Norfolk and Norwich University Hospitals NHS Trust|Nottingham University Hospitals NHS Trust|Portsmouth Hospitals NHS Trust|Sheffield Teaching Hospitals NHS Foundation Trust|Southend University Hospitals NHS Trust|East and North Herts|Royal Wolverhampton NHS Trust,Radiation,United Kingdom,16.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01398085
NCT01412762,thyroid cancer,Measuring Patient Expectations for Thyroid Surgery: Development of a Patient-Reported Outcomes Instrument,Thyroid Cancer,2011-08-03,2022-07-31,2022-07-31,Observational,"Active, not recruiting",,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Behavioral|Behavioral,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01412762
NCT01496313,thyroid cancer,"An International, Randomised, Double-Blind, Two-Arm Study To Evaluate The Safety And Efficacy Of Vandetanib 150 And 300mg/Day In Patients With Unresectable Locally Advanced Or Metastatic Medullary Thyroid Carcinoma With Progressive Or Symptomatic Disease",Thyroid Cancer,2011-12-02,2014-04-30,2022-12-31,Interventional,"Active, not recruiting",Phase 4,Sanofi,"Genzyme, a Sanofi Company",Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site,Drug|Drug,Czechia|India|Israel|Italy|Netherlands|Poland|Russian Federation|United Kingdom|United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01496313
NCT01552434,thyroid gland neoplasm,"A Phase I Trial of Bevacizumab, Temsirolimus Alone and in Combination With Valproic Acid, or Cetuximab in Patients With Advanced Malignancy and Other Indications",Advanced Malignant Neoplasm|Castleman Disease|Digestive System Carcinoma|Erdheim-Chester Disease|Lip and Oral Cavity Carcinoma|Lymphangioleiomyomatosis|Malignant Endocrine Neoplasm|Malignant Female Reproductive System Neoplasm|Malignant Male Reproductive System Neoplasm|Malignant Neoplasm|Malignant Respiratory Tract Neoplasm|Malignant Thoracic Neoplasm|Malignant Urinary System Neoplasm|Mesothelial Neoplasm|Metastatic Malignant Neoplasm|Metastatic Urothelial Carcinoma|Neurofibromatosis Type 2|Recurrent Adult Soft Tissue Sarcoma|Recurrent Breast Carcinoma|Recurrent Childhood Soft Tissue Sarcoma|Recurrent Digestive System Carcinoma|Recurrent Female Reproductive System Carcinoma|Recurrent Male Reproductive System Carcinoma|Recurrent Malignant Neoplasm|Recurrent Pharyngeal Carcinoma|Recurrent Thyroid Gland Carcinoma|Refractory Malignant Neoplasm|Soft Tissue Neoplasm|Stage IIIA Breast Cancer AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage III Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7|Stage III Pharyngeal Cancer|Stage IVA Pharyngeal Cancer|Stage IVB Pharyngeal Cancer|Stage IV Breast Cancer AJCC v6 and v7|Stage IVC Pharyngeal Cancer|Stage IV Pharyngeal Cancer|Thyroid Gland Neoplasm,2012-03-07,2022-03-31,2022-03-31,Interventional,"Active, not recruiting",Phase 1,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center|National Cancer Institute (NCI),M D Anderson Cancer Center,Biological|Biological|Other|Other|Drug|Drug,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01552434
NCT01660984,medullary thyroid cancer,Longitudinal Assessment and Natural History Study of Children and Adults With MEN2A or MEN2B With or Without Medullary Thyroid Carcinoma,Medullary Thyroid Cancer,2012-08-07,,,Observational,Recruiting,,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),"National Institutes of Health Clinical Center, 9000 Rockville Pike",,United States,4.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, medullary",https://clinicaltrials.gov/ct2/show/NCT01660984
NCT01709292,thyroid cancer,Pharmacodynamic Study of Vemurafenib in the Neoadjuvant Setting in Patients With Locally Advanced Thyroid Cancer,Thyroid Cancer,2012-07-25,2022-09-30,2023-09-30,Interventional,"Active, not recruiting",Phase 2,M.D. Anderson Cancer Center,"Genentech, Inc.|M.D. Anderson Cancer Center",University of Texas MD Anderson Cancer Center,Drug|Drug|Other,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01709292
NCT01723202,papillary thyroid cancer,A Randomized Phase 2 Study of Single Agent Dabrafenib (BRAFi) vs. Combination Regimen Dabrafenib (BRAFi) and Trametinib (MEKi) in Patients With BRAF Mutated Thyroid Carcinoma,Follicular Thyroid Cancer|Insular Thyroid Cancer|Papillary Thyroid Cancer|Recurrent Thyroid Cancer,2012-10-22,2022-12-31,2022-12-31,Interventional,"Active, not recruiting",Phase 2,Ohio State University Comprehensive Cancer Center,Manisha Shah|National Comprehensive Cancer Network,"University of California, San Diego|University of Chicago Medical Center|Massachusetts General Hospital, Harvard Medical School|Ohio State University Medical Center|The University of Texas-MD Anderson Cancer Center",Drug|Drug|Other,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT01723202
NCT01723202,follicular thyroid cancer,A Randomized Phase 2 Study of Single Agent Dabrafenib (BRAFi) vs. Combination Regimen Dabrafenib (BRAFi) and Trametinib (MEKi) in Patients With BRAF Mutated Thyroid Carcinoma,Follicular Thyroid Cancer|Insular Thyroid Cancer|Papillary Thyroid Cancer|Recurrent Thyroid Cancer,2012-10-22,2022-12-31,2022-12-31,Interventional,"Active, not recruiting",Phase 2,Ohio State University Comprehensive Cancer Center,Manisha Shah|National Comprehensive Cancer Network,"University of California, San Diego|University of Chicago Medical Center|Massachusetts General Hospital, Harvard Medical School|Ohio State University Medical Center|The University of Texas-MD Anderson Cancer Center",Drug|Drug|Other,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, follicular",https://clinicaltrials.gov/ct2/show/NCT01723202
NCT01723202,insular thyroid cancer,A Randomized Phase 2 Study of Single Agent Dabrafenib (BRAFi) vs. Combination Regimen Dabrafenib (BRAFi) and Trametinib (MEKi) in Patients With BRAF Mutated Thyroid Carcinoma,Follicular Thyroid Cancer|Insular Thyroid Cancer|Papillary Thyroid Cancer|Recurrent Thyroid Cancer,2012-10-22,2022-12-31,2022-12-31,Interventional,"Active, not recruiting",Phase 2,Ohio State University Comprehensive Cancer Center,Manisha Shah|National Comprehensive Cancer Network,"University of California, San Diego|University of Chicago Medical Center|Massachusetts General Hospital, Harvard Medical School|Ohio State University Medical Center|The University of Texas-MD Anderson Cancer Center",Drug|Drug|Other,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Poorly differentiated thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01723202
NCT01723202,recurrent thyroid cancer,A Randomized Phase 2 Study of Single Agent Dabrafenib (BRAFi) vs. Combination Regimen Dabrafenib (BRAFi) and Trametinib (MEKi) in Patients With BRAF Mutated Thyroid Carcinoma,Follicular Thyroid Cancer|Insular Thyroid Cancer|Papillary Thyroid Cancer|Recurrent Thyroid Cancer,2012-10-22,2022-12-31,2022-12-31,Interventional,"Active, not recruiting",Phase 2,Ohio State University Comprehensive Cancer Center,Manisha Shah|National Comprehensive Cancer Network,"University of California, San Diego|University of Chicago Medical Center|Massachusetts General Hospital, Harvard Medical School|Ohio State University Medical Center|The University of Texas-MD Anderson Cancer Center",Drug|Drug|Other,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Recurrent Thyroid Cancer,https://clinicaltrials.gov/ct2/show/NCT01723202
NCT01774279,anaplastic thyroid cancer,interNational Anaplastic Thyroid Cancer Tissue Bank and Database (iNATT).,Anaplastic Thyroid Cancer,2013-01-18,2025-02-28,2025-03-31,Observational [Patient Registry],Recruiting,,Velindre NHS Trust,Velindre NHS Trust,"Beaumont Hospital|St Vincent's Hospital|Galway University Hospital|Addenbrookes Hospital|Velindre Hospital|University Hospitals of Coventry and Warwickshire|Castle Hill Hospital|St James' Institute|Royal Marsden Hospital|Norfolk and Norwich University Hospital NHS Foundation Trust|Nottingham University NHS Trust|Barking, Havering and Redbridge University Hospitals NHS Trust|Weston Park Hospital|Royal Shrewsbury Hospital|New Cross Hospital",Other,Ireland|United Kingdom,18.0,100.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT01774279
NCT01831869,hypothyroidism,The Beneficial Effect of L-Thyroxine Long -Term Replacement on Lipid Profiles and Atherosclerosis in Subclinical Hypothyroidism: A Prospective Study,Endocrine System Diseases|Hypothyroidism|Thyroid Diseases,2013-04-07,2022-04-30,2022-04-30,Interventional,"Active, not recruiting",Phase 4,Shandong Provincial Hospital,Shandong Provincial Hospital,Shandong Provincial Hospital,Drug,China,18.0,60.0,[18-65],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT01831869
NCT01831869,thyroid diseases,The Beneficial Effect of L-Thyroxine Long -Term Replacement on Lipid Profiles and Atherosclerosis in Subclinical Hypothyroidism: A Prospective Study,Endocrine System Diseases|Hypothyroidism|Thyroid Diseases,2013-04-07,2022-04-30,2022-04-30,Interventional,"Active, not recruiting",Phase 4,Shandong Provincial Hospital,Shandong Provincial Hospital,Shandong Provincial Hospital,Drug,China,18.0,60.0,[18-65],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT01831869
NCT01848171,hypothyroidism,Effects of Long-term L-thyroxine Replacement on Serum Lipid and Atherosclerosis in Patients With Hypothyroidism,Endocrine System Diseases|Hypothyroidism|Thyroid Diseases,2013-05-02,2023-07-31,2023-07-31,Interventional,"Active, not recruiting",Phase 4,Shandong Provincial Hospital,Shandong Provincial Hospital,Shandong Provincial Hospital,Drug,China,40.0,75.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT01848171
NCT01848171,thyroid diseases,Effects of Long-term L-thyroxine Replacement on Serum Lipid and Atherosclerosis in Patients With Hypothyroidism,Endocrine System Diseases|Hypothyroidism|Thyroid Diseases,2013-05-02,2023-07-31,2023-07-31,Interventional,"Active, not recruiting",Phase 4,Shandong Provincial Hospital,Shandong Provincial Hospital,Shandong Provincial Hospital,Drug,China,40.0,75.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT01848171
NCT01876784,differentiated thyroid cancer,"A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA™; SAR390530 (Formerly AstraZeneca ZD6474)) 300 mg in Patients With Differentiated Thyroid Cancer That Is Either Locally Advanced or Metastatic Who Are Refractory or Unsuitable for Radioiodine (RAI) Therapy.",Differentiated Thyroid Cancer,2013-06-11,2015-08-30,2022-12-31,Interventional,"Active, not recruiting",Phase 3,Sanofi,"Genzyme, a Sanofi Company",Research Site|Research Site|Research Site|Research Site|Research Site|Washington University|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site,Drug|Drug,Brazil|China|Czechia|Denmark|France|Italy|Japan|Poland|Russian Federation|Spain|Sweden|United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Differentiated thyroid cancer, all",https://clinicaltrials.gov/ct2/show/NCT01876784
NCT01896479,medullary thyroid cancer,"A Randomized, Double-blind Study To Evaluate the Efficacy and Safety of Cabozantinib (XL184) at 60 mg/Day Compared to a 140 mg/Day in Progressive, Metastatic Medullary Thyroid Cancer Patients",Medullary Thyroid Cancer,2013-07-08,2020-07-31,2022-12-31,Interventional,"Active, not recruiting",Phase 4,Exelixis,Exelixis,,Drug|Drug|Drug|Drug,"Australia|Canada|Croatia|France|Hungary|Israel|Italy|Korea, Republic of|Netherlands|Poland|Romania|Russian Federation|Spain|Sweden",18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, medullary",https://clinicaltrials.gov/ct2/show/NCT01896479
NCT01922440,hypoparathyroidism,PARADIGHM (Physicians Advancing Disease Knowledge in Hypoparathyroidism): A Registry for Patients With Chronic Hypoparathyroidism,Hypoparathyroidism,2013-08-01,2034-11-30,2034-11-30,Observational [Patient Registry],Recruiting,,Takeda,"Takeda|Takeda Development Center Americas, Inc.","University of Alabama at Birmingham|University of Arizona Medical Center|Children's Hospital Los Angeles|Cedars-Sinai Medical Center|Dr. Joselito Cabaccan|University of Colorado Hospital|Yale University|Hanson Clinical Research Center|Thyroid & Endocrine Center of Florida|East-West Medical Research Institute|Suburban Endocrinology & Diabetes|University of Chicago Medical Center|Northshore University Health System|Loyola University Medical Center|Indiana University Hospital|Tilak Mallik, MD F.A.C.E., LCC|Model Clinical Research|Medstar Union Memorial Hospital|Massachusetts General Hospital|Brigham and Women's Hospital|Harvard Medical School|Boston Medical Center|University of Minnesota|Mayo Clinic - Rochester|University of Missouri|Diabetes & Endocrine Associates, Methodist Physicians Clinic Diabetes and Endocrine Specialists|Palm Research Center, Inc.|Northern Nevada Endocrinology|Rutgers Robert Wood Johnson Medical School|Rutgers-Robert Wood Johnson Medical School|Albany Med Endocrine Specialists|Brokhin Medical PC|Gerald Friedman Diabetes Institute|Columbia University Medical Center|Endocrine Associates of Long Island, P.C.|University Physicians Group Research Division|State University Of New York Upstate Medical University|Mecklenburg Medical Group|Physicians East, PA|Cleveland Clinic|Ohio State University Wexner Medical Center|Ohio Health Research Institute|Endocrinology Associates of Armstrong|The Children's Hospital of Philadelphia|Thomas Jefferson University|Alleghany General Hospital|Hallett Center for Diabetes and Endocrinology|University of South Carolina|Texas Diabetes and Endocrinology, P.A.|Thyroid Endocrinology and Diabetes|Academy of Diabetes Thyroid and Endocrine|Diabetes and Thyroid Center of Fort Worth, PLLC|University of Vermont|University of Wisconsin|Medizinische Universitaetsklinik Graz, Universitätsklinik Für Innere Medizin Graz|AKH Wien, Universitaetsklinik fuer Innere Medizin III|Nova Scotia Health Authority|McMaster University|Aallborg University Hospital|Aarhus Universitetshospital|Nordsjaellands Hospital - Hillerod|Regions Hospitalet Viborg|Diakonie-Klinikum Stuttgart|Medizinische Hochschule Hannover|University Hospital Duesseldorf|University of Leipzig|Universitaetsklinik Aachen|Charite-Universitiitsmedizin Berlin (CCM)|Praxis an der Kaiserreiche|Medizinische Fakultaet Carl Gustav Carus Technische Universitaet Dresden|Endokrinologikum Frankfurt|MVZ endokrinologikum Göttingen|Universitaet Zur Luebeck|Medicover Neuroendokrinologie MVZ|Medicover Neu-Ulm Mvz|Medicover Oldenburg MVZ|Medicover Saarbuecken Mvz|Endokrinologie Zentrum Ulm|Universitaetsklinikum Wuerzburg|General Hospital Of Athens - Korgialenio-Benakio E.E.S.|General Hospital of Athens Georgios Gennimatas|General Hospital of Athens Alexandra|AHEPA University General Hospital of Thessaloniki|Hippokrateion General Hospital of Thessaloniki|Azienda Ospedaliero-Universitaria Careggi|Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico|Azienda Ospedaliera San Giovanni Addolorata|Azienda Ospedaliero-Universitaria Citta della Salute e della Scienza - Ospedale Molinette|Haukeland University Hospital|Spesialistsentret Pilestredet Park|Hospital Del Mar|Hospital Universitario San Cecilio|Hospital Universitario 12 de Octubre|Universitetssjukhuset I Linkoping|Universitetssjukhuset I Orebro|Karolinska Universitetssjukhuset Solna|Akademiska Sjukhuset - Uppsala University Hospital|Queen Elizabeth Hospital-Mindelsohn Way|University of Hospitals of Leicester|Norfolk And Norwich University Hospital - Norwich Medical School",Other,Austria|Canada|Denmark|Germany|Greece|Italy|Norway|Spain|Sweden|United Kingdom|United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT01922440
NCT01947023,metastatic thyroid gland carcinoma,A Phase 1 Study of Dabrafenib in Combination With Lapatinib in BRAF Mutant Thyroid Cancer,Metastatic Thyroid Gland Carcinoma|Unresectable Thyroid Gland Carcinoma,2013-09-16,2022-07-01,,Interventional,"Active, not recruiting",Phase 1,National Cancer Institute (NCI),National Cancer Institute (NCI),Memorial Sloan Kettering Cancer Center,Drug|Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Metastatic Thyroid Cancer,https://clinicaltrials.gov/ct2/show/NCT01947023
NCT02012699,thyroid cancer,Integrated Cancer Repository for Cancer Research,Anal Cancer|Bile Duct Cancer|Bladder Cancer|Breast Cancer|CNS Cancer|CNS Tumor|Colon Cancer|Duodenal Cancer|Endometrial Cancer|Esophageal Cancer|Familial Adenomatous Polyposis|Gallbladder Cancer|Gastric Cancer|GIST|Healthy Control|Hypopharyngeal Cancer|Kidney Cancer|Laryngeal Cancer|Leukemia|Lip Cancer|Liver Cancer|Lung Cancer|Lynch Syndrome|Melanoma|Mesothelioma|Multiple Myeloma|Nasal Cavity Cancer|Nasopharyngeal Cancer|Neuroendocrine Tumors|Oral Cavity Cancer|Oropharyngeal Cancer|Ovarian Cancer|Pancreatic Cancer|Paranasal Sinus Cancer|Penile Cancer|Peritoneal Surface Malignancies|Plasma Cell Dyscrasia|Prostate Cancer|Rectal Cancer|Salivary Gland Cancer|Sarcoma|Skin Cancer|Small Intestine Cancer|Testicular Cancer|Thymus Cancer|Thyroid Cancer|Unknown Primary Tumor|Ureter Cancer|Urethral Cancer|Vaginal Cancer,2013-12-02,2099-12-31,2099-12-31,Observational [Patient Registry],Recruiting,,University of Nebraska,University of Nebraska,"Penrose Cancer Center|Porter Adventist Hospital|Mercy Regional Medical Center|St. Anthony Hospital|Littleton Cancer Center|Longmont Cancer Center|Avista Cancer Center|Parker Adventist Hospital|St. Mary Corwin Medical Center|St. Anthony North Cancer Center|Florida Hospital Memorial Medical Center|Florida Hospital DeLand|Florida Hospital FISH|Florida Hospital Flagler|Rush-Copley Cancer Care Center|Trinity Medical Center|Rush-Copley Healthcare Center|Parkview Research Center|Community Health Network|Community Cancer Center South|Community Cancer Center North|Community Howard Regional Hospital|Methodist Jennie Edmundson Hospital|Genesis Medical Center|Abben Cancer Center|Covenant Medical Center, Inc|Saint Luke's Cancer Instititue - South|Tulane University|Breast Care Specialists of Maine|Northwest Hospital|William E Kahlert Regional Cancer Center|Holyoke Medical Center|University of Michigan Health System|Riverwood Healthcare Center|Essentia Health-St. Joseph's Medical Center|Essentia Health - Duluth Clinic|St. Luke's Hospital of Duluth|Lake Region Healthcare|Avera Cancer Institute- Marshall|Mercy Hospital - Joplin|Saint Luke's Cancer Institute - East|Saint Luke's Cancer Institute|Saint Luke's Cancer Institute - Kansas City North|Saint Luke's Cancer Institute - Liberty|Heartland Regional Medical Center dba Mosaic Life Care|Bozeman Health Deaconess Hospital|Logan Health|Providence St. Patrick Hospital Montana Cancer Center|Mary Lanning Healthcare/Morrison Cancer Center|Faith Regional Health Services, Carson Cancer Center|Great Plains Regional Medical Center|Avera St. Anthony's Hospital|Methodist Estabrook Cancer Center|Nebraska Methodist Health System|University of Nebraska Medical Center|Regional West Health Services|C.R. Wood Cancer Center, Glens Falls Hospital|Faxton St. Luke's Healthcare/Mohawk Valley|Cape Fear Valley Health System|Essentia Health|Trinity Hospital Cancer Care Center|Aultman Alliance Community Hospital|Aultman Hospital|University of Pittsburgh|Avera Medical Group Oncology and Hematology Aberdeen|Avera Cancer Institute|Avera Cancer Institute|Sanford Health|Avera Cancer Center Yankton|Avera Sacred Heart Hospital|Yankton Medical Clinic|Rutland Regional Medical Center|Mary Washington Hospital|Ascension St. Elizabeth Hospital|Wheaton Franciscan Healthcare - Elmbrook Memorial Hospital|Wheaton Franciscan Healthcare - Reiman Cancer Care|Columbia St. Mary's|Columbia St. Mary's|Ascension Mercy Hospital|Wheaton Franciscan Healthcare - All Saints|Wheaton Franciscan Healthcare - Wauwatosa Cancer Care",,United States,19.0,110.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02012699
NCT02013479,autoimmune thyroiditis,The Chronic Autoimmune Thyroiditis Quality Of Life Selenium Trial,Autoimmune Thyroiditis,2013-12-03,2022-08-31,2022-12-31,Interventional,"Active, not recruiting",Not Applicable,Odense University Hospital,"Bispebjerg Hospital|Hospital of South West Denmark|Pharma Nord|Region of Southern Denmark|Rigshospitalet, Denmark|Steen Bonnema|The Danish Medical Research Council|University of Southern Denmark","Clinic of Medical Endocrinology, Copenhagen University Hospital, Rigshospitalet|Department of Endocrinology and Gastroenterology, Bispebjerg Hospital|Department of Internal Medicine, Hospital of South West Denmark|Department of Endorcrinology and Metabolism, Odense University Hospital",Dietary Supplement|Dietary Supplement,Denmark,18.0,120.0,[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT02013479
NCT02088645,"thyroid cancer, medullary",177Lu-PP-F11N for Receptor Targeted Therapy and Imaging (Theranostics) of Metastatic Medullary Thyroid Cancer - a Pilot and a Phase I Study.,"Neuroendocrine Tumor GEP Grade 1-3|Neuroendocrine Tumor of the Lung Grade 1 and 2|Neuroendocrine Tumor of the Thymus Grade 1 and 2|Thyroid Cancer, Medullary",2014-02-19,2021-12-31,2022-03-31,Interventional,Recruiting,Phase 1,"University Hospital, Basel, Switzerland","Center for Proton Therapy, Paul Scherrer Institute, Villigen,Switzerland|Krebsforschung Schweiz, Bern, Switzerland|University Hospital, Basel, Switzerland|University Hospital Freiburg|University Hospital, Zürich","University Hospital Basel, Clinic for radiology and nuclear medicine",Drug,Switzerland,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, medullary",https://clinicaltrials.gov/ct2/show/NCT02088645
NCT02145143,thyroid carcinoma,"Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study",Thyroid Carcinoma,2014-05-20,2023-05-31,2023-05-31,Interventional,"Active, not recruiting",Not Applicable,Memorial Sloan Kettering Cancer Center,"Genentech, Inc.|Memorial Sloan Kettering Cancer Center",Memorial Sloan Kettering Cancer Center,Drug|Device|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02145143
NCT02152137,anaplastic thyroid cancer,"A Phase 2 Study of Efatutazone, an Oral PPAR Agonist, In Combination With Paclitaxel in Patients With Advanced Anaplastic Thyroid Cancer",Anaplastic Thyroid Cancer|Recurrent Thyroid Cancer,2014-05-29,2019-02-27,,Interventional,"Active, not recruiting",Phase 2,Alliance for Clinical Trials in Oncology,"Alliance for Clinical Trials in Oncology|Daiichi Sankyo, Inc.|National Cancer Institute (NCI)",Anchorage Associates in Radiation Medicine|Anchorage Radiation Therapy Center|Alaska Breast Care and Surgery LLC|Alaska Oncology and Hematology LLC|Alaska Regional Hospital|Alaska Women's Cancer Care|Anchorage Oncology Centre|Katmai Oncology Group|Providence Alaska Medical Center|Mayo Clinic Hospital|Mayo Clinic in Arizona|Providence Saint Joseph Medical Center/Disney Family Cancer Center|University of Colorado Hospital|Smilow Cancer Hospital Care Center at Saint Francis|Smilow Cancer Center/Yale-New Haven Hospital|Yale University|Beebe Medical Center|Christiana Gynecologic Oncology LLC|Delaware Clinical and Laboratory Physicians PA|Helen F Graham Cancer Center|Medical Oncology Hematology Consultants PA|Regional Hematology and Oncology PA|Christiana Care Health System-Christiana Hospital|Beebe Health Campus|Nanticoke Memorial Hospital|Christiana Care Health System-Wilmington Hospital|Mayo Clinic in Florida|Hawaii Oncology Inc-Pali Momi|Pali Momi Medical Center|The Cancer Center of Hawaii-Pali Momi|Hawaii Cancer Care Inc-POB II|Queen's Medical Center|Straub Clinic and Hospital|University of Hawaii Cancer Center|Hawaii Cancer Care Inc-Liliha|Hawaii Oncology Inc-Kuakini|Kuakini Medical Center|The Cancer Center of Hawaii-Liliha|Kapiolani Medical Center for Women and Children|Wilcox Memorial Hospital and Kauai Medical Clinic|Saint Alphonsus Cancer Care Center-Boise|Saint Luke's Mountain States Tumor Institute|Saint Alphonsus Cancer Care Center-Caldwell|Kootenai Medical Center|Walter Knox Memorial Hospital|Saint Luke's Mountain States Tumor Institute - Fruitland|Idaho Urologic Institute-Meridian|Saint Luke's Mountain States Tumor Institute - Meridian|Saint Alphonsus Medical Center-Nampa|Saint Luke's Mountain States Tumor Institute - Nampa|Kootenai Cancer Center|Kootenai Cancer Clinic|Saint Luke's Mountain States Tumor Institute-Twin Falls|Northwestern University|Cancer Center of Kansas - Chanute|Cancer Center of Kansas - Dodge City|Cancer Center of Kansas - El Dorado|Cancer Center of Kansas - Fort Scott|Central Care Cancer Center - Garden City|Central Care Cancer Center - Great Bend|Cancer Center of Kansas-Independence|Cancer Center of Kansas-Kingman|Lawrence Memorial Hospital|Kansas Institute of Medicine Cancer and Blood Center|Minimally Invasive Surgery Hospital|Cancer Center of Kansas-Liberal|Cancer Center of Kansas-Manhattan|Cancer Center of Kansas - McPherson|Cancer Center of Kansas - Newton|Menorah Medical Center|Saint Luke's South Hospital|Cancer Center of Kansas - Parsons|Cancer Center of Kansas - Pratt|Cancer Center of Kansas - Salina|Cancer Center of Kansas - Wellington|Associates In Womens Health|Cancer Center of Kansas-Wichita Medical Arts Tower|Cancer Center of Kansas - Wichita|Via Christi Regional Medical Center|Cancer Center of Kansas - Winfield|Mercy Medical Center|Saint Joseph Mercy Hospital|University of Michigan Comprehensive Cancer Center|IHA Hematology Oncology Consultants-Brighton|Saint Joseph Mercy Brighton|IHA Hematology Oncology Consultants-Canton|Saint Joseph Mercy Canton|Caro Cancer Center|IHA Hematology Oncology Consultants-Chelsea|Saint Joseph Mercy Chelsea|Hematology Oncology Consultants-Clarkston|Newland Medical Associates-Clarkston|Beaumont Hospital-Dearborn|Henry Ford Hospital|Ascension Saint John Hospital|Great Lakes Cancer Management Specialists-Doctors Park|Genesee Cancer and Blood Disease Treatment Center|Genesee Hematology Oncology PC|Genesys Hurley Cancer Institute|Hurley Medical Center|Great Lakes Cancer Management Specialists-Van Elslander Cancer Center|Lymphoma Clinic of Michigan|Michigan Breast Specialists-Grosse Pointe Woods|Allegiance Health|Sparrow Hospital|Hope Cancer Clinic|Saint Mary Mercy Hospital|Great Lakes Cancer Management Specialists-Macomb Medical Campus|Michigan Breast Specialists-Macomb Township|Saint Mary's Oncology/Hematology Associates of Marlette|21st Century Oncology-Pontiac|Hope Cancer Center|Newland Medical Associates-Pontiac|Saint Joseph Mercy Oakland|Lake Huron Medical Center|Great Lakes Cancer Management Specialists-Rochester Hills|Saint Mary's of Michigan|Oncology Hematology Associates of Saginaw Valley PC|Bhadresh Nayak MD PC-Sterling Heights|Saint Joseph Health System-Tawas City|Advanced Breast Care Center PLLC|Bhadresh Nayak MD PC-Warren|Great Lakes Cancer Management Specialists-Macomb Professional Building|Macomb Hematology Oncology PC|Michigan Breast Specialists-Warren|Saint John Macomb-Oakland Hospital|Saint Mary's Oncology/Hematology Associates of West Branch|Huron Gastroenterology PC|IHA Hematology Oncology Consultants-Ann Arbor|Sanford Joe Lueken Cancer Center|Fairview Ridges Hospital|Mercy Hospital|Fairview-Southdale Hospital|Unity Hospital|Fairview Maple Grove Medical Center|Minnesota Oncology Hematology PA-Maplewood|Saint John's Hospital - Healtheast|Abbott-Northwestern Hospital|Hennepin County Medical Center|Health Partners Inc|New Ulm Medical Center|North Memorial Medical Health Center|Mayo Clinic|Park Nicollet Clinic - Saint Louis Park|Regions Hospital|United Hospital|Saint Francis Regional Medical Center|Lakeview Hospital|Ridgeview Medical Center|Rice Memorial Hospital|Minnesota Oncology Hematology PA-Woodbury|Fairview Lakes Medical Center|Central Care Cancer Center - Bolivar|Centerpoint Medical Center LLC|Freeman Health System|Saint Luke's Hospital of Kansas City|Heartland Hematology and Oncology Associates Incorporated|Research Medical Center|Saint Luke's East - Lee's Summit|Liberty Radiation Oncology Center|Delbert Day Cancer Institute at PCRMC|Heartland Regional Medical Center|Saint Louis Cancer and Breast Institute-South City|Washington University School of Medicine|Mercy Hospital Saint Louis|Mercy Hospital Springfield|CoxHealth South Hospital|Community Hospital of Anaconda|Billings Clinic Cancer Center|Bozeman Deaconess Hospital|Benefis Healthcare- Sletten Cancer Institute|Great Falls Clinic|Saint Peter's Community Hospital|Kalispell Regional Medical Center|Saint Patrick Hospital - Community Hospital|Community Medical Hospital|Sanford Bismarck Medical Center|Roger Maris Cancer Center|Sanford Broadway Medical Center|University of Cincinnati/Barrett Cancer Center|Ohio State University Comprehensive Cancer Center|University Pointe|University of Oklahoma Health Sciences Center|Oklahoma Cancer Specialists and Research Institute-Tulsa|Saint Alphonsus Medical Center-Baker City|Saint Charles Health System|Clackamas Radiation Oncology Center|Providence Oncology and Hematology Care Southeast|Bay Area Hospital|Providence Newberg Medical Center|Saint Alphonsus Medical Center-Ontario|Providence Willamette Falls Medical Center|Providence Portland Medical Center|Providence Saint Vincent Medical Center|Saint Charles Health System-Redmond|Lehigh Valley Hospital-Cedar Crest|Lehigh Valley Hospital - Muhlenberg|Geisinger Medical Center|Pocono Medical Center|Geisinger Medical Center-Cancer Center Hazleton|Lehigh Valley Hospital-Hazleton|Geisinger Medical Oncology-Lewisburg|Lewistown Hospital|Geisinger Cancer Services-Pottsville|Community Medical Center|Geisinger Medical Oncology-Selinsgrove|Geisinger Medical Group|Geisinger Wyoming Valley/Henry Cancer Center|Greenville Health System Cancer Institute-Easley|Greenville Health System Cancer Institute-Andrews|Greenville Health System Cancer Institute-Butternut|Greenville Health System Cancer Institute-Faris|Greenville Memorial Hospital|Greenville Health System Cancer Institute-Eastside|Greenville Health System Cancer Institute-Greer|Greenville Health System Cancer Institute-Seneca|Greenville Health System Cancer Institute-Spartanburg|Sanford Cancer Center Oncology Clinic|Sanford USD Medical Center - Sioux Falls|Providence Regional Cancer System-Aberdeen|Cancer Care Center at Island Hospital|Swedish Cancer Institute-Eastside Oncology Hematology|PeaceHealth Saint Joseph Medical Center|Harrison HealthPartners Hematology and Oncology-Bremerton|Providence Regional Cancer System-Centralia|Swedish Medical Center-Edmonds|Providence Regional Cancer Partnership|Swedish Cancer Institute-Issaquah|Kadlec Clinic Hematology and Oncology|Providence Regional Cancer System-Lacey|PeaceHealth Saint John Medical Center|Jefferson Healthcare|Harrison HealthPartners Hematology and Oncology-Poulsbo|Minor and James Medical PLLC|Pacific Gynecology Specialists|Swedish Medical Center-Ballard Campus|Kaiser Permanente Washington|Swedish Medical Center-First Hill|Swedish Medical Center-Cherry Hill|PeaceHealth United General Medical Center|Providence Regional Cancer System-Shelton|Rockwood Clinic Cancer Treatment Center-Valley|Rockwood Cancer Treatment Center-DHEC-Downtown|Evergreen Hematology and Oncology PS|Rockwood North Cancer Treatment Center|PeaceHealth Southwest Medical Center|Providence Saint Mary Regional Cancer Center|North Star Lodge Cancer Center at Yakima Valley Memorial Hospital|Providence Regional Cancer System-Yelm|Froedtert and the Medical College of Wisconsin|Cancer Center of Western Wisconsin|Billings Clinic-Cody|Welch Cancer Center,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT02152137
NCT02152137,recurrent thyroid cancer,"A Phase 2 Study of Efatutazone, an Oral PPAR Agonist, In Combination With Paclitaxel in Patients With Advanced Anaplastic Thyroid Cancer",Anaplastic Thyroid Cancer|Recurrent Thyroid Cancer,2014-05-29,2019-02-27,,Interventional,"Active, not recruiting",Phase 2,Alliance for Clinical Trials in Oncology,"Alliance for Clinical Trials in Oncology|Daiichi Sankyo, Inc.|National Cancer Institute (NCI)",Anchorage Associates in Radiation Medicine|Anchorage Radiation Therapy Center|Alaska Breast Care and Surgery LLC|Alaska Oncology and Hematology LLC|Alaska Regional Hospital|Alaska Women's Cancer Care|Anchorage Oncology Centre|Katmai Oncology Group|Providence Alaska Medical Center|Mayo Clinic Hospital|Mayo Clinic in Arizona|Providence Saint Joseph Medical Center/Disney Family Cancer Center|University of Colorado Hospital|Smilow Cancer Hospital Care Center at Saint Francis|Smilow Cancer Center/Yale-New Haven Hospital|Yale University|Beebe Medical Center|Christiana Gynecologic Oncology LLC|Delaware Clinical and Laboratory Physicians PA|Helen F Graham Cancer Center|Medical Oncology Hematology Consultants PA|Regional Hematology and Oncology PA|Christiana Care Health System-Christiana Hospital|Beebe Health Campus|Nanticoke Memorial Hospital|Christiana Care Health System-Wilmington Hospital|Mayo Clinic in Florida|Hawaii Oncology Inc-Pali Momi|Pali Momi Medical Center|The Cancer Center of Hawaii-Pali Momi|Hawaii Cancer Care Inc-POB II|Queen's Medical Center|Straub Clinic and Hospital|University of Hawaii Cancer Center|Hawaii Cancer Care Inc-Liliha|Hawaii Oncology Inc-Kuakini|Kuakini Medical Center|The Cancer Center of Hawaii-Liliha|Kapiolani Medical Center for Women and Children|Wilcox Memorial Hospital and Kauai Medical Clinic|Saint Alphonsus Cancer Care Center-Boise|Saint Luke's Mountain States Tumor Institute|Saint Alphonsus Cancer Care Center-Caldwell|Kootenai Medical Center|Walter Knox Memorial Hospital|Saint Luke's Mountain States Tumor Institute - Fruitland|Idaho Urologic Institute-Meridian|Saint Luke's Mountain States Tumor Institute - Meridian|Saint Alphonsus Medical Center-Nampa|Saint Luke's Mountain States Tumor Institute - Nampa|Kootenai Cancer Center|Kootenai Cancer Clinic|Saint Luke's Mountain States Tumor Institute-Twin Falls|Northwestern University|Cancer Center of Kansas - Chanute|Cancer Center of Kansas - Dodge City|Cancer Center of Kansas - El Dorado|Cancer Center of Kansas - Fort Scott|Central Care Cancer Center - Garden City|Central Care Cancer Center - Great Bend|Cancer Center of Kansas-Independence|Cancer Center of Kansas-Kingman|Lawrence Memorial Hospital|Kansas Institute of Medicine Cancer and Blood Center|Minimally Invasive Surgery Hospital|Cancer Center of Kansas-Liberal|Cancer Center of Kansas-Manhattan|Cancer Center of Kansas - McPherson|Cancer Center of Kansas - Newton|Menorah Medical Center|Saint Luke's South Hospital|Cancer Center of Kansas - Parsons|Cancer Center of Kansas - Pratt|Cancer Center of Kansas - Salina|Cancer Center of Kansas - Wellington|Associates In Womens Health|Cancer Center of Kansas-Wichita Medical Arts Tower|Cancer Center of Kansas - Wichita|Via Christi Regional Medical Center|Cancer Center of Kansas - Winfield|Mercy Medical Center|Saint Joseph Mercy Hospital|University of Michigan Comprehensive Cancer Center|IHA Hematology Oncology Consultants-Brighton|Saint Joseph Mercy Brighton|IHA Hematology Oncology Consultants-Canton|Saint Joseph Mercy Canton|Caro Cancer Center|IHA Hematology Oncology Consultants-Chelsea|Saint Joseph Mercy Chelsea|Hematology Oncology Consultants-Clarkston|Newland Medical Associates-Clarkston|Beaumont Hospital-Dearborn|Henry Ford Hospital|Ascension Saint John Hospital|Great Lakes Cancer Management Specialists-Doctors Park|Genesee Cancer and Blood Disease Treatment Center|Genesee Hematology Oncology PC|Genesys Hurley Cancer Institute|Hurley Medical Center|Great Lakes Cancer Management Specialists-Van Elslander Cancer Center|Lymphoma Clinic of Michigan|Michigan Breast Specialists-Grosse Pointe Woods|Allegiance Health|Sparrow Hospital|Hope Cancer Clinic|Saint Mary Mercy Hospital|Great Lakes Cancer Management Specialists-Macomb Medical Campus|Michigan Breast Specialists-Macomb Township|Saint Mary's Oncology/Hematology Associates of Marlette|21st Century Oncology-Pontiac|Hope Cancer Center|Newland Medical Associates-Pontiac|Saint Joseph Mercy Oakland|Lake Huron Medical Center|Great Lakes Cancer Management Specialists-Rochester Hills|Saint Mary's of Michigan|Oncology Hematology Associates of Saginaw Valley PC|Bhadresh Nayak MD PC-Sterling Heights|Saint Joseph Health System-Tawas City|Advanced Breast Care Center PLLC|Bhadresh Nayak MD PC-Warren|Great Lakes Cancer Management Specialists-Macomb Professional Building|Macomb Hematology Oncology PC|Michigan Breast Specialists-Warren|Saint John Macomb-Oakland Hospital|Saint Mary's Oncology/Hematology Associates of West Branch|Huron Gastroenterology PC|IHA Hematology Oncology Consultants-Ann Arbor|Sanford Joe Lueken Cancer Center|Fairview Ridges Hospital|Mercy Hospital|Fairview-Southdale Hospital|Unity Hospital|Fairview Maple Grove Medical Center|Minnesota Oncology Hematology PA-Maplewood|Saint John's Hospital - Healtheast|Abbott-Northwestern Hospital|Hennepin County Medical Center|Health Partners Inc|New Ulm Medical Center|North Memorial Medical Health Center|Mayo Clinic|Park Nicollet Clinic - Saint Louis Park|Regions Hospital|United Hospital|Saint Francis Regional Medical Center|Lakeview Hospital|Ridgeview Medical Center|Rice Memorial Hospital|Minnesota Oncology Hematology PA-Woodbury|Fairview Lakes Medical Center|Central Care Cancer Center - Bolivar|Centerpoint Medical Center LLC|Freeman Health System|Saint Luke's Hospital of Kansas City|Heartland Hematology and Oncology Associates Incorporated|Research Medical Center|Saint Luke's East - Lee's Summit|Liberty Radiation Oncology Center|Delbert Day Cancer Institute at PCRMC|Heartland Regional Medical Center|Saint Louis Cancer and Breast Institute-South City|Washington University School of Medicine|Mercy Hospital Saint Louis|Mercy Hospital Springfield|CoxHealth South Hospital|Community Hospital of Anaconda|Billings Clinic Cancer Center|Bozeman Deaconess Hospital|Benefis Healthcare- Sletten Cancer Institute|Great Falls Clinic|Saint Peter's Community Hospital|Kalispell Regional Medical Center|Saint Patrick Hospital - Community Hospital|Community Medical Hospital|Sanford Bismarck Medical Center|Roger Maris Cancer Center|Sanford Broadway Medical Center|University of Cincinnati/Barrett Cancer Center|Ohio State University Comprehensive Cancer Center|University Pointe|University of Oklahoma Health Sciences Center|Oklahoma Cancer Specialists and Research Institute-Tulsa|Saint Alphonsus Medical Center-Baker City|Saint Charles Health System|Clackamas Radiation Oncology Center|Providence Oncology and Hematology Care Southeast|Bay Area Hospital|Providence Newberg Medical Center|Saint Alphonsus Medical Center-Ontario|Providence Willamette Falls Medical Center|Providence Portland Medical Center|Providence Saint Vincent Medical Center|Saint Charles Health System-Redmond|Lehigh Valley Hospital-Cedar Crest|Lehigh Valley Hospital - Muhlenberg|Geisinger Medical Center|Pocono Medical Center|Geisinger Medical Center-Cancer Center Hazleton|Lehigh Valley Hospital-Hazleton|Geisinger Medical Oncology-Lewisburg|Lewistown Hospital|Geisinger Cancer Services-Pottsville|Community Medical Center|Geisinger Medical Oncology-Selinsgrove|Geisinger Medical Group|Geisinger Wyoming Valley/Henry Cancer Center|Greenville Health System Cancer Institute-Easley|Greenville Health System Cancer Institute-Andrews|Greenville Health System Cancer Institute-Butternut|Greenville Health System Cancer Institute-Faris|Greenville Memorial Hospital|Greenville Health System Cancer Institute-Eastside|Greenville Health System Cancer Institute-Greer|Greenville Health System Cancer Institute-Seneca|Greenville Health System Cancer Institute-Spartanburg|Sanford Cancer Center Oncology Clinic|Sanford USD Medical Center - Sioux Falls|Providence Regional Cancer System-Aberdeen|Cancer Care Center at Island Hospital|Swedish Cancer Institute-Eastside Oncology Hematology|PeaceHealth Saint Joseph Medical Center|Harrison HealthPartners Hematology and Oncology-Bremerton|Providence Regional Cancer System-Centralia|Swedish Medical Center-Edmonds|Providence Regional Cancer Partnership|Swedish Cancer Institute-Issaquah|Kadlec Clinic Hematology and Oncology|Providence Regional Cancer System-Lacey|PeaceHealth Saint John Medical Center|Jefferson Healthcare|Harrison HealthPartners Hematology and Oncology-Poulsbo|Minor and James Medical PLLC|Pacific Gynecology Specialists|Swedish Medical Center-Ballard Campus|Kaiser Permanente Washington|Swedish Medical Center-First Hill|Swedish Medical Center-Cherry Hill|PeaceHealth United General Medical Center|Providence Regional Cancer System-Shelton|Rockwood Clinic Cancer Treatment Center-Valley|Rockwood Cancer Treatment Center-DHEC-Downtown|Evergreen Hematology and Oncology PS|Rockwood North Cancer Treatment Center|PeaceHealth Southwest Medical Center|Providence Saint Mary Regional Cancer Center|North Star Lodge Cancer Center at Yakima Valley Memorial Hospital|Providence Regional Cancer System-Yelm|Froedtert and the Medical College of Wisconsin|Cancer Center of Western Wisconsin|Billings Clinic-Cody|Welch Cancer Center,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Recurrent Thyroid Cancer,https://clinicaltrials.gov/ct2/show/NCT02152137
NCT02152995,poorly differentiated thyroid gland carcinoma,"A Phase 2 Study of Trametinib in Combination With Radioiodine (RAI) for RAS Mutant or RAS/RAF Wild-Type, RAI-Refractory Recurrent and/or Metastatic Thyroid Cancers",Metastatic Thyroid Gland Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Recurrent Thyroid Gland Carcinoma|Refractory Thyroid Gland Carcinoma|Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7|Stage IV Thyroid Gland Follicular Carcinoma AJCC v7|Stage IV Thyroid Gland Papillary Carcinoma AJCC v7,2014-05-29,2021-08-25,2023-01-12,Interventional,"Active, not recruiting",Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),Memorial Sloan Kettering Cancer Center,Procedure|Other|Radiation|Other|Other|Procedure|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Poorly differentiated thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02152995
NCT02152995,metastatic thyroid gland carcinoma,"A Phase 2 Study of Trametinib in Combination With Radioiodine (RAI) for RAS Mutant or RAS/RAF Wild-Type, RAI-Refractory Recurrent and/or Metastatic Thyroid Cancers",Metastatic Thyroid Gland Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Recurrent Thyroid Gland Carcinoma|Refractory Thyroid Gland Carcinoma|Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7|Stage IV Thyroid Gland Follicular Carcinoma AJCC v7|Stage IV Thyroid Gland Papillary Carcinoma AJCC v7,2014-05-29,2021-08-25,2023-01-12,Interventional,"Active, not recruiting",Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),Memorial Sloan Kettering Cancer Center,Procedure|Other|Radiation|Other|Other|Procedure|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Metastatic Thyroid Cancer,https://clinicaltrials.gov/ct2/show/NCT02152995
NCT02156362,thyroid cancer,Determination of Pronostics Factors for Advanced Thyroid Carcinoma (pT3 pT4 or M1 at Diagnosis),Thyroid Cancer,2012-05-29,2023-05-31,2023-05-31,Interventional,"Active, not recruiting",Not Applicable,Hospices Civils de Lyon,Hospices Civils de Lyon,Hospices Civils de Lyon-Centre de Médecine Nucléaire Groupement Hospitalier Est 59 boulevard Pinel,Other,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02156362
NCT02185560,thyroid carcinoma,Drug Use Investigation of Sorafenib/ NEXAVAR® for Unresectable Differentiated Thyroid Carcinoma (DTC),Thyroid Carcinoma,2014-07-04,2020-02-27,2024-06-30,Observational,"Active, not recruiting",,Bayer,Bayer,,Drug,Japan,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02185560
NCT02203682,hyperthyroidism,The Effect of Subantimicrobial Dose Doxycycline in Mild Thyroid-Associated Ophthalmopathy,"Autoimmune Diseases|Endocrine System Diseases|Eye Diseases, Hereditary|Graves Disease|Graves Ophthalmopathy|Hyperthyroidism|Immune System Diseases|Thyroid-associated Ophthalmopathy|Thyroid Diseases",2014-07-28,2022-07-31,2022-07-31,Interventional,Recruiting,Phase 2,Sun Yat-sen University,Sun Yat-sen University,Zhongshan Ophthalmic Center,Drug|Drug,China,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02203682
NCT02203682,graves disease,The Effect of Subantimicrobial Dose Doxycycline in Mild Thyroid-Associated Ophthalmopathy,"Autoimmune Diseases|Endocrine System Diseases|Eye Diseases, Hereditary|Graves Disease|Graves Ophthalmopathy|Hyperthyroidism|Immune System Diseases|Thyroid-associated Ophthalmopathy|Thyroid Diseases",2014-07-28,2022-07-31,2022-07-31,Interventional,Recruiting,Phase 2,Sun Yat-sen University,Sun Yat-sen University,Zhongshan Ophthalmic Center,Drug|Drug,China,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT02203682
NCT02203682,graves ophthalmopathy,The Effect of Subantimicrobial Dose Doxycycline in Mild Thyroid-Associated Ophthalmopathy,"Autoimmune Diseases|Endocrine System Diseases|Eye Diseases, Hereditary|Graves Disease|Graves Ophthalmopathy|Hyperthyroidism|Immune System Diseases|Thyroid-associated Ophthalmopathy|Thyroid Diseases",2014-07-28,2022-07-31,2022-07-31,Interventional,Recruiting,Phase 2,Sun Yat-sen University,Sun Yat-sen University,Zhongshan Ophthalmic Center,Drug|Drug,China,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT02203682
NCT02203682,thyroid diseases,The Effect of Subantimicrobial Dose Doxycycline in Mild Thyroid-Associated Ophthalmopathy,"Autoimmune Diseases|Endocrine System Diseases|Eye Diseases, Hereditary|Graves Disease|Graves Ophthalmopathy|Hyperthyroidism|Immune System Diseases|Thyroid-associated Ophthalmopathy|Thyroid Diseases",2014-07-28,2022-07-31,2022-07-31,Interventional,Recruiting,Phase 2,Sun Yat-sen University,Sun Yat-sen University,Zhongshan Ophthalmic Center,Drug|Drug,China,18.0,70.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT02203682
NCT02208544,thyroid neoplasms,Efficacy of [18F]-2-fluoro-2-deoxy-D-glucose Positron Emission Tomography (FDG-PET) in Evaluation of Cytological Indeterminate Thyroid Nodules Prior to Surgery: a Multicentre Cost-effectiveness Study,Thyroid Neoplasms|Thyroid Nodule,2014-07-22,2020-01-01,2021-11-01,Interventional,"Active, not recruiting",Not Applicable,Radboud University Medical Center,Dutch Cancer Society|Radboud University Medical Center,Radboudumc|MUMC|AMC|VUmc|MeanderMC|LUMC|ErasmusMC|Onze Lieve Vrouwe Gasthuis|Rijnstate|Reinier de Graaf Ziekenhuis|UMCG|St. Antonius|HagaZiekenhuis|UMCU|Isala Klinieken,Procedure|Device|Radiation,Netherlands,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02208544
NCT02208544,thyroid nodule,Efficacy of [18F]-2-fluoro-2-deoxy-D-glucose Positron Emission Tomography (FDG-PET) in Evaluation of Cytological Indeterminate Thyroid Nodules Prior to Surgery: a Multicentre Cost-effectiveness Study,Thyroid Neoplasms|Thyroid Nodule,2014-07-22,2020-01-01,2021-11-01,Interventional,"Active, not recruiting",Not Applicable,Radboud University Medical Center,Dutch Cancer Society|Radboud University Medical Center,Radboudumc|MUMC|AMC|VUmc|MeanderMC|LUMC|ErasmusMC|Onze Lieve Vrouwe Gasthuis|Rijnstate|Reinier de Graaf Ziekenhuis|UMCG|St. Antonius|HagaZiekenhuis|UMCU|Isala Klinieken,Procedure|Device|Radiation,Netherlands,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT02208544
NCT02210741,graves disease,Next-generation Sequencing (NGS) of Peripheral Blood Immune Repertoire in Graves' Disease,Graves Disease,2014-08-04,2024-02-29,2024-02-29,Observational,Not yet recruiting,,National Taiwan University Hospital,National Taiwan University Hospital,National Taiwan University Hospital,,Taiwan,20.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT02210741
NCT02244463,anaplastic thyroid cancer,A Phase II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer,Anaplastic Thyroid Cancer|Thyroid Cancer,2014-09-17,2022-12-31,2023-12-31,Interventional,"Active, not recruiting",Phase 2,Dana-Farber Cancer Institute,"Dana-Farber Cancer Institute|Millennium Pharmaceuticals, Inc.",Hoag Memorial Hospital Presbyterian|Dana-Farber Cancer Institute|University of Michigan Medical School,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT02244463
NCT02393690,poorly differentiated thyroid gland carcinoma,Randomized Double-Blind Phase II Study of Radioactive Iodine (RAI) in Combination With Placebo or Selumetinib for the Treatment of RAI-Avid Recurrent/Metastatic Thyroid Cancers,Metastatic Thyroid Gland Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Recurrent Thyroid Gland Carcinoma|Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7|Stage IV Thyroid Gland Follicular Carcinoma AJCC v7|Stage IV Thyroid Gland Papillary Carcinoma AJCC v7,2015-03-16,2020-07-17,2022-12-31,Interventional,"Active, not recruiting",Phase 2,Academic and Community Cancer Research United,Academic and Community Cancer Research United|National Cancer Institute (NCI),UC San Diego Moores Cancer Center|Hoag Memorial Hospital|University of Colorado Hospital|MedStar Georgetown University Hospital|Dana-Farber Cancer Institute|Mayo Clinic in Rochester|Memorial Sloan Kettering Cancer Center|Duke University Medical Center|Ohio State University Comprehensive Cancer Center|Vanderbilt University/Ingram Cancer Center|M D Anderson Cancer Center,Radiation|Other|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Poorly differentiated thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02393690
NCT02393690,metastatic thyroid gland carcinoma,Randomized Double-Blind Phase II Study of Radioactive Iodine (RAI) in Combination With Placebo or Selumetinib for the Treatment of RAI-Avid Recurrent/Metastatic Thyroid Cancers,Metastatic Thyroid Gland Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Recurrent Thyroid Gland Carcinoma|Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7|Stage IV Thyroid Gland Follicular Carcinoma AJCC v7|Stage IV Thyroid Gland Papillary Carcinoma AJCC v7,2015-03-16,2020-07-17,2022-12-31,Interventional,"Active, not recruiting",Phase 2,Academic and Community Cancer Research United,Academic and Community Cancer Research United|National Cancer Institute (NCI),UC San Diego Moores Cancer Center|Hoag Memorial Hospital|University of Colorado Hospital|MedStar Georgetown University Hospital|Dana-Farber Cancer Institute|Mayo Clinic in Rochester|Memorial Sloan Kettering Cancer Center|Duke University Medical Center|Ohio State University Comprehensive Cancer Center|Vanderbilt University/Ingram Cancer Center|M D Anderson Cancer Center,Radiation|Other|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Metastatic Thyroid Cancer,https://clinicaltrials.gov/ct2/show/NCT02393690
NCT02465060,thyroid gland carcinoma,Molecular Analysis for Therapy Choice (MATCH),Advanced Malignant Solid Neoplasm|Bladder Carcinoma|Breast Carcinoma|Cervical Carcinoma|Colon Carcinoma|Colorectal Carcinoma|Endometrial Carcinoma|Esophageal Carcinoma|Gastric Carcinoma|Glioma|Head and Neck Carcinoma|Kidney Carcinoma|Liver and Intrahepatic Bile Duct Carcinoma|Lung Carcinoma|Lymphoma|Malignant Uterine Neoplasm|Melanoma|Ovarian Carcinoma|Pancreatic Carcinoma|Plasma Cell Myeloma|Prostate Carcinoma|Rectal Carcinoma|Recurrent Bladder Carcinoma|Recurrent Breast Carcinoma|Recurrent Cervical Carcinoma|Recurrent Colon Carcinoma|Recurrent Colorectal Carcinoma|Recurrent Esophageal Carcinoma|Recurrent Gastric Carcinoma|Recurrent Glioma|Recurrent Head and Neck Carcinoma|Recurrent Liver Carcinoma|Recurrent Lung Carcinoma|Recurrent Lymphoma|Recurrent Malignant Solid Neoplasm|Recurrent Melanoma|Recurrent Ovarian Carcinoma|Recurrent Pancreatic Carcinoma|Recurrent Plasma Cell Myeloma|Recurrent Prostate Carcinoma|Recurrent Rectal Carcinoma|Recurrent Skin Carcinoma|Recurrent Thyroid Gland Carcinoma|Recurrent Uterine Corpus Cancer|Refractory Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Plasma Cell Myeloma|Skin Carcinoma|Thyroid Gland Carcinoma|Uterine Corpus Cancer,2015-06-03,2025-12-31,2025-12-31,Interventional,Recruiting,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),University of Alabama at Birmingham Cancer Center|Thomas Hospital|Mobile Infirmary Medical Center|University of South Alabama Mitchell Cancer Institute|Anchorage Associates in Radiation Medicine|Anchorage Radiation Therapy Center|Alaska Breast Care and Surgery LLC|Alaska Oncology and Hematology LLC|Alaska Regional Hospital|Alaska Women's Cancer Care|Anchorage Oncology Centre|Katmai Oncology Group|Providence Alaska Medical Center|Fairbanks Memorial Hospital|CTCA at Western Regional Medical Center|Kingman Regional Medical Center|Cancer Center at Saint Joseph's|Saint Joseph's Hospital and Medical Center|Mayo Clinic Hospital in Arizona|Mayo Clinic in Arizona|Mercy Hospital Fort Smith|CHI Saint Vincent Cancer Center Hot Springs|Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro|University of Arkansas for Medical Sciences|Kaiser Permanente-Anaheim|Kaiser Permanente-Deer Valley Medical Center|Mission Hope Medical Oncology - Arroyo Grande|PCR Oncology|Sutter Auburn Faith Hospital|Sutter Cancer Centers Radiation Oncology Services-Auburn|AIS Cancer Center at San Joaquin Community Hospital|Kaiser Permanente-Baldwin Park|Kaiser Permanente-Bellflower|Alta Bates Summit Medical Center-Herrick Campus|Providence Saint Joseph Medical Center/Disney Family Cancer Center|Mills-Peninsula Medical Center|Sutter Cancer Centers Radiation Oncology Services-Cameron Park|Eden Hospital Medical Center|Community Cancer Institute|University Oncology Associates|John Muir Medical Center-Concord Campus|City of Hope Corona|UC Irvine Health Cancer Center-Newport|Sutter Davis Hospital|City of Hope Comprehensive Cancer Center|Epic Care-Dublin|Kaiser Permanente Dublin|Bay Area Breast Surgeons Inc|Epic Care Partners in Cancer Care|Kaiser Permanente-Fontana|Kaiser Permanente-Fremont|Palo Alto Medical Foundation-Fremont|Fresno Cancer Center|Kaiser Permanente-Fresno|Saint Jude Medical Center|Marin Cancer Care Inc|Marin General Hospital|Kaiser Permanente - Harbor City|Kaiser Permanente-Irvine|UC San Diego Moores Cancer Center|Loma Linda University Medical Center|Kaiser Permanente Los Angeles Medical Center|Los Angeles County-USC Medical Center|USC / Norris Comprehensive Cancer Center|Kaiser Permanente West Los Angeles|Cedars Sinai Medical Center|Contra Costa Regional Medical Center|Fremont - Rideout Cancer Center|Memorial Medical Center|Kaiser Permanente-Modesto|Community Hospital of Monterey Peninsula|Pacific Cancer Care-Monterey|Palo Alto Medical Foundation-Camino Division|Palo Alto Medical Foundation-Gynecologic Oncology|USC Norris Oncology/Hematology-Newport Beach|Sutter Cancer Research Consortium|Alta Bates Summit Medical Center - Summit Campus|Bay Area Tumor Institute|Kaiser Permanente Oakland-Broadway|Kaiser Permanente-Oakland|Kaiser Permanente-Ontario|Saint Joseph Hospital - Orange|UC Irvine Health/Chao Family Comprehensive Cancer Center|Desert Regional Medical Center|Palo Alto Medical Foundation Health Care|Stanford Cancer Institute Palo Alto|VA Palo Alto Health Care System|Kaiser Permanente - Panorama City|Keck Medical Center of USC Pasadena|Kaiser Permanente-Rancho Cordova Cancer Center|Eisenhower Medical Center|Kaiser Permanente- Marshall Medical Offices|Kaiser Permanente-Redwood City|Kaiser Permanente-Richmond|Kaiser Permanente-Riverside|Rohnert Park Cancer Center|Kaiser Permanente-Roseville|Sutter Cancer Centers Radiation Oncology Services-Roseville|Sutter Roseville Medical Center|The Permanente Medical Group-Roseville Radiation Oncology|Kaiser Permanente Downtown Commons|Sutter Medical Center Sacramento|University of California Davis Comprehensive Cancer Center|Kaiser Permanente-South Sacramento|South Sacramento Cancer Center|Kaiser Permanente - Sacramento|Saint Helena Hospital|UC San Diego Medical Center - Hillcrest|Kaiser Permanente-San Diego Mission|Kaiser Permanente-San Diego Zion|Rady Children's Hospital - San Diego|Sharp Memorial Hospital|Naval Medical Center -San Diego|California Pacific Medical Center-Pacific Campus|Kaiser Permanente-San Francisco|Kaiser Permanente-Santa Teresa-San Jose|Kaiser Permanente San Leandro|Pacific Central Coast Health Center-San Luis Obispo|Kaiser Permanente-San Marcos|Mills Health Center|Kaiser Permanente-San Rafael|Kaiser San Rafael-Gallinas|Kaiser Permanente Medical Center - Santa Clara|Palo Alto Medical Foundation-Santa Cruz|Mission Hope Medical Oncology - Santa Maria|Kaiser Permanente-Santa Rosa|Sutter Pacific Medical Foundation|Kaiser Permanente Cancer Treatment Center|Kaiser Permanente-South San Francisco|Saint Joseph's Medical Center|Kaiser Permanente-Stockton|Palo Alto Medical Foundation-Sunnyvale|Gene Upshaw Memorial Tahoe Forest Cancer Center|City of Hope Upland|Sutter Cancer Centers Radiation Oncology Services-Vacaville|Kaiser Permanente Medical Center-Vacaville|Kaiser Permanente-Vallejo|Sutter Solano Medical Center/Cancer Center|Kaiser Permanente-Walnut Creek|Epic Care Cyberknife Center|John Muir Medical Center-Walnut Creek|City of Hope West Covina|Presbyterian Intercommunity Hospital|Kaiser Permanente-Woodland Hills|Rocky Mountain Cancer Centers-Aurora|The Medical Center of Aurora|University of Colorado Hospital|Boulder Community Hospital|Boulder Community Foothills Hospital|Rocky Mountain Cancer Centers-Boulder|Rocky Mountain Cancer Centers - Centennial|Penrose-Saint Francis Healthcare|Rocky Mountain Cancer Centers-Penrose|UCHealth Memorial Hospital Central|Memorial Hospital North|Saint Francis Cancer Center|Cancer Center of Colorado at Sloan's Lake|Denver Health Medical Center|Kaiser Permanente-Franklin|National Jewish Health-Main Campus|The Women's Imaging Center|Porter Adventist Hospital|Colorado Blood Cancer Institute|Presbyterian - Saint Lukes Medical Center - Health One|Rocky Mountain Cancer Centers-Midtown|SCL Health Saint Joseph Hospital|Rocky Mountain Cancer Centers-Rose|Rose Medical Center|Mercy Medical Center|Southwest Oncology PC|Mountain Blue Cancer Care Center - Swedish|Rocky Mountain Cancer Centers - Swedish|Swedish Medical Center|Poudre Valley Hospital|Mountain Blue Cancer Care Center|National Jewish Health-Western Hematology Oncology|Saint Mary's Hospital and Regional Medical Center|Grand Valley Oncology|North Colorado Medical Center|Rocky Mountain Cancer Centers-Greenwood Village|Good Samaritan Medical Center|Kaiser Permanente-Rock Creek|Rocky Mountain Cancer Centers-Lakewood|Saint Anthony Hospital|Rocky Mountain Cancer Centers-Littleton|Littleton Adventist Hospital|Kaiser Permanente-Lone Tree|Rocky Mountain Cancer Centers-Sky Ridge|Sky Ridge Medical Center|Longmont United Hospital|Rocky Mountain Cancer Centers-Longmont|McKee Medical Center|Parker Adventist Hospital|Rocky Mountain Cancer Centers-Parker|Saint Mary Corwin Medical Center|Rocky Mountain Cancer Centers - Pueblo|National Jewish Health-Northern Hematology Oncology|Rocky Mountain Cancer Centers-Thornton|SCL Health Lutheran Medical Center|Smilow Cancer Hospital-Derby Care Center|Smilow Cancer Hospital Care Center-Fairfield|Smilow Cancer Hospital Care Center at Glastonbury|Smilow Cancer Hospital Care Center at Greenwich|Smilow Cancer Hospital Care Center - Guiford|Smilow Cancer Hospital Care Center at Saint Francis|Smilow Cancer Center/Yale-New Haven Hospital|Yale University|Yale-New Haven Hospital North Haven Medical Center|Eastern Connecticut Hematology and Oncology Associates|Smilow Cancer Hospital-Orange Care Center|Stamford Hospital/Bennett Cancer Center|Smilow Cancer Hospital-Torrington Care Center|Smilow Cancer Hospital Care Center-Trumbull|Smilow Cancer Hospital-Waterbury Care Center|Smilow Cancer Hospital Care Center - Waterford|Veterans Affairs Connecticut Healthcare System-West Haven Campus|Beebe South Coastal Health Campus|Beebe Medical Center|Christiana Gynecologic Oncology LLC|Delaware Clinical and Laboratory Physicians PA|Helen F Graham Cancer Center|Medical Oncology Hematology Consultants PA|Christiana Care Health System-Christiana Hospital|Beebe Health Campus|TidalHealth Nanticoke / Allen Cancer Center|Christiana Care Health System-Wilmington Hospital|MedStar Georgetown University Hospital|MedStar Washington Hospital Center|Sibley Memorial Hospital|Mount Sinai Comprehensive Cancer Center at Aventura|UM Sylvester Comprehensive Cancer Center at Coral Gables|UM Sylvester Comprehensive Cancer Center at Coral Springs|Broward Health North|UM Sylvester Comprehensive Cancer Center at Deerfield Beach|Holy Cross Hospital|Broward Health Medical Center|University of Florida Health Science Center - Gainesville|Memorial Regional Hospital/Joe DiMaggio Children's Hospital|UM Sylvester Comprehensive Cancer Center at Hollywood|Mayo Clinic in Florida|The Watson Clinic|Mount Sinai Medical Center|University of Miami Miller School of Medicine-Sylvester Cancer Center|Miami Cancer Institute|UM Sylvester Comprehensive Cancer Center at Kendall|Health Central|Orlando Health Cancer Institute|Memorial Hospital West|UM Sylvester Comprehensive Cancer Center at Plantation|Saint Joseph's Hospital/Children's Hospital-Tampa|Moffitt Cancer Center|Indian River Medical Center|University Cancer and Blood Center LLC|Emory University Hospital Midtown|Piedmont Hospital|Emory University Hospital/Winship Cancer Institute|Emory Saint Joseph's Hospital|Northside Hospital|Augusta University Medical Center|Northeast Georgia Medical Center Braselton|John B Amos Cancer Center|Northside Hospital-Forsyth|Dekalb Medical Center|Northside Hospital - Duluth|Northeast Georgia Medical Center-Gainesville|The Longstreet Clinic - Gainesville|Northside Hospital - Gwinnett|Central Georgia Gynecologic Oncology|Medical Center of Central Georgia|CTCA at Southeastern Regional Medical Center|Harbin Clinic Medical Oncology and Clinical Research|Low Country Cancer Care|Memorial Health University Medical Center|Summit Cancer Care-Memorial|Lewis Cancer and Research Pavilion at Saint Joseph's/Candler|Summit Cancer Care-Candler|Suburban Hematology Oncology Associates - Snellville|Lewis Hall Singletary Oncology Center|South Georgia Medical Center/Pearlman Cancer Center|Hawaii Cancer Care - Savio|Pali Momi Medical Center|Queen's Cancer Center - Pearlridge|Straub Pearlridge Clinic|The Cancer Center of Hawaii-Pali Momi|The Queen's Medical Center - West Oahu|Hawaii Cancer Care Inc - Waterfront Plaza|Island Urology|Queen's Cancer Cenrer - POB I|Queen's Medical Center|Straub Clinic and Hospital|University of Hawaii Cancer Center|Hawaii Cancer Care Inc-Liliha|Hawaii Diagnostic Radiology Services LLC|Kuakini Medical Center|Queen's Cancer Center - Kuakini|The Cancer Center of Hawaii-Liliha|Kaiser Permanente Moanalua Medical Center|Kapiolani Medical Center for Women and Children|Straub Medical Center - Kahului Clinic|Castle Medical Center|Wilcox Memorial Hospital and Kauai Medical Clinic|Saint Alphonsus Cancer Care Center-Boise|Saint Luke's Cancer Institute - Boise|Saint Alphonsus Cancer Care Center-Caldwell|Kootenai Health - Coeur d'Alene|Walter Knox Memorial Hospital|Saint Luke's Cancer Institute - Fruitland|Idaho Urologic Institute-Meridian|Saint Luke's Cancer Institute - Meridian|Saint Alphonsus Medical Center-Nampa|Saint Luke's Cancer Institute - Nampa|Kootenai Clinic Cancer Services - Post Falls|Kootenai Cancer Clinic|Saint Luke's Cancer Institute - Twin Falls|Saint Anthony's Health|Rush - Copley Medical Center|Saint Joseph Medical Center|Illinois CancerCare-Bloomington|Illinois CancerCare-Canton|Memorial Hospital of Carbondale|SIH Cancer Institute|Illinois CancerCare-Carthage|Centralia Oncology Clinic|Mount Sinai Hospital Medical Center|Northwestern University|John H Stroger Jr Hospital of Cook County|Rush University Medical Center|University of Illinois|Swedish Covenant Hospital|University of Chicago Comprehensive Cancer Center|Advocate Illinois Masonic Medical Center|AMG Crystal Lake - Oncology|Carle on Vermilion|Cancer Care Specialists of Illinois - Decatur|Decatur Memorial Hospital|Northwestern Medicine Cancer Center Kishwaukee|Illinois CancerCare-Dixon|Carle Physician Group-Effingham|Crossroads Cancer Center|AMITA Health Alexian Brothers Medical Center|Elmhurst Memorial Hospital|Illinois CancerCare-Eureka|NorthShore University HealthSystem-Evanston Hospital|Saint Francis Hospital|Illinois CancerCare-Galesburg|Western Illinois Cancer Treatment Center|Northwestern Medicine Cancer Center Delnor|NorthShore University HealthSystem-Glenbrook Hospital|Ingalls Memorial Hospital|NorthShore University HealthSystem-Highland Park Hospital|Duly Health and Care Joliet|Presence Saint Mary's Hospital|Illinois CancerCare-Kewanee Clinic|Northwestern Medicine Lake Forest Hospital|AMG Libertyville - Oncology|Illinois CancerCare-Macomb|Carle Physician Group-Mattoon/Charleston|Loyola University Medical Center|Marjorie Weinberg Cancer Center at Loyola-Gottlieb|Trinity Medical Center|Good Samaritan Regional Health Center|Edward Hospital/Cancer Center|UC Comprehensive Cancer Center at Silver Cross|Cancer Care Center of O'Fallon|University of Chicago Medicine-Orland Park|Illinois CancerCare-Ottawa Clinic|Radiation Oncology of Northern Illinois|Illinois CancerCare-Pekin|OSF Saint Francis Radiation Oncology at Pekin Cancer Treatment Center|Illinois CancerCare-Peoria|OSF Saint Francis Radiation Oncology at Peoria Cancer Center|Methodist Medical Center of Illinois|OSF Saint Francis Medical Center|Illinois CancerCare-Peru|Valley Radiation Oncology|Edward Hospital/Cancer Center?Plainfield|Illinois CancerCare-Princeton|Hematology Oncology Associates of Illinois - Skokie|North Shore Medical Center|Central Illinois Hematology Oncology Center|Southern Illinois University School of Medicine|Springfield Clinic|Memorial Medical Center|Southwest Illinois Health Services LLP|Carle Cancer Center|The Carle Foundation Hospital|Northwestern Medicine Cancer Center Warrenville|Illinois CancerCare - Washington|Rush-Copley Healthcare Center|Midwestern Regional Medical Center|Michiana Hematology Oncology PC-Crown Point|Michiana Hematology Oncology PC-Elkhart|Deaconess Clinic Downtown|Indiana University/Melvin and Bren Simon Cancer Center|Sidney and Lois Eskenazi Hospital|Community Cancer Center East|Community Cancer Center South|Community Cancer Center North|Springmill Medical Center|Community Howard Regional Health|IU Health Arnett Cancer Care|Franciscan Saint Anthony Health-Michigan City|Woodland Cancer Care Center|Memorial Regional Cancer Center Day Road|Michiana Hematology Oncology PC-Mishawaka|Baptist Health Floyd|Chancellor Center for Oncology|Michiana Hematology Oncology PC-Plymouth|Reid Health|Memorial Hospital of South Bend|Michiana Hematology Oncology PC-Westville|Mary Greeley Medical Center|McFarland Clinic PC - Ames|McFarland Clinic PC-Boone|Saint Anthony Regional Hospital|Physicians' Clinic of Iowa PC|Mercy Hospital|Oncology Associates at Mercy Medical Center|Medical Oncology and Hematology Associates-West Des Moines|Mercy Cancer Center-West Lakes|Jennie Edmundson Memorial Hospital|Alegent Health Mercy Hospital|Heartland Oncology and Hematology LLP|Greater Regional Medical Center|Iowa Methodist Medical Center|Medical Oncology and Hematology Associates-Des Moines|Broadlawns Medical Center|Medical Oncology and Hematology Associates-Laurel|Mercy Medical Center - Des Moines|Iowa Lutheran Hospital|JCHC McCreery Cancer Center|McFarland Clinic PC-Trinity Cancer Center|Trinity Regional Medical Center|McFarland Clinic PC-Jefferson|McFarland Clinic PC-Marshalltown|Ottumwa Regional Health Center|Siouxland Regional Cancer Center|Methodist West Hospital|Mercy Medical Center-West Lakes|Coffeyville Regional Medical Center|Newman Regional Health|University of Kansas Clinical Research Center|Central Care Cancer Center - Garden City|Saint Catherine Hospital|Central Care Cancer Center - Great Bend|Saint Rose Ambulatory and Surgery Center|HaysMed University of Kansas Health System|University of Kansas Cancer Center-West|University of Kansas Cancer Center|Lawrence Memorial Hospital|Kansas Institute of Medicine Cancer and Blood Center|Minimally Invasive Surgery Hospital|Olathe Health Cancer Center|Menorah Medical Center|University of Kansas Cancer Center-Overland Park|Saint Luke's South Hospital|Ascension Via Christi - Pittsburg|Salina Regional Health Center|University of Kansas Health System Saint Francis Campus|University of Kansas Hospital-Westwood Cancer Center|Flaget Memorial Hospital|Baptist Health Corbin|Commonwealth Cancer Center-Corbin|Oncology Hematology Care Inc-Crestview|Saint Elizabeth Medical Center South|Baptist Health Hardin|Saint Elizabeth Fort Thomas|Baptist Health Lexington|Saint Joseph Radiation Oncology Resource Center|Saint Joseph Hospital East|University of Kentucky/Markey Cancer Center|Saint Joseph London|Jewish Hospital|The James Graham Brown Cancer Center at University of Louisville|Baptist Health Louisville|Saints Mary and Elizabeth Hospital|UofL Health Medical Center Northeast|Baptist Health Madisonville/Merle Mahr Cancer Center|Baptist Health Paducah|Jewish Hospital Medical Center South|LSU Health Baton Rouge-North Clinic|Baton Rouge General Medical Center|Our Lady of The Lake|Hematology/Oncology Clinic PLLC|Louisiana Hematology Oncology Associates LLC|Mary Bird Perkins Cancer Center|Ochsner Health Center-Summa|Our Lady of the Lake Physicians Group - Medical Oncology|The NeuroMedical Center-Clinic|Medical Center of Baton Rouge|Our Lady of the Lake Medical Oncology|Ochsner High Grove|Mary Bird Perkins Cancer Center - Covington|Northshore Oncology Associates-Covington|Ochsner Hematology Oncology North Shore - Covington (West Region)|Women's Cancer Care-Covington|Ochsner Medical Center West Bank|Mary Bird Perkins Cancer Center - Houma|Oncology Center of The South Incorporated|Terrebonne General Medical Center|Ochsner Medical Center Kenner|West Jefferson Medical Center|East Jefferson General Hospital|Robert Veith MD LLC|Ochsner LSU Health Monroe Medical Center|Louisiana State University Health Science Center|Tulane University Health Sciences Center|University Medical Center New Orleans|Ochsner Medical Center Jefferson|LSU Health Sciences Center at Shreveport|CHRISTUS Highland Medical Center|Harold Alfond Center for Cancer Care|Eastern Maine Medical Center|Waldo County General Hospital|MaineHealth/SMHC Cancer Care and Blood Disorders-Biddeford|Lafayette Family Cancer Center-EMMC|Maine Center for Cancer Medicine-Kennebunk|Stephens Memorial Hospital|Penobscot Bay Medical Center|MaineHealth/SMHC Cancer Care and Blood Disorders-Sanford|Maine Center for Cancer Medicine-Scarborough|Maine Medical Center- Scarborough Campus|Maine Medical Partners - South Portland|Maine Center for Cancer Medicine-Topsham|Anne Arundel Medical Center|University of Maryland/Greenebaum Cancer Center|Greater Baltimore Medical Center|Sinai Hospital of Baltimore|MedStar Union Memorial Hospital|MedStar Franklin Square Medical Center/Weinberg Cancer Institute|MedStar Good Samaritan Hospital|Johns Hopkins University/Sidney Kimmel Cancer Center|Walter Reed National Military Medical Center|National Institutes of Health Clinical Center|Western Maryland Regional Medical Center|University of Maryland Shore Medical Center at Easton|Christiana Care - Union Hospital|Frederick Memorial Hospital|FMH James M Stockman Cancer Institute|MedStar Montgomery Medical Center|Northwest Hospital Center|TidalHealth Peninsula Regional|Holy Cross Hospital|William E Kahlert Regional Cancer Center/Sinai Hospital|Beverly Hospital|Tufts Medical Center|Massachusetts General Hospital Cancer Center|Boston Medical Center|Beth Israel Deaconess Medical Center|Dana-Farber Cancer Institute|Lahey Hospital and Medical Center|Simonds-Sinon Regional Cancer Center|MetroWest Medical Center-Framingham Union Hospital|Addison Gilbert Hospital|Lowell General Hospital|Lahey Medical Center-Peabody|Mercy Medical Center|Baystate Medical Center|Winchester Hospital|UMass Memorial Medical Center - University Campus|Hickman Cancer Center|Saint Joseph Mercy Hospital|C S Mott Children's Hospital|University of Michigan Comprehensive Cancer Center|Bronson Battle Creek|IHA Hematology Oncology Consultants-Brighton|Saint Joseph Mercy Brighton|Henry Ford Cancer Institute-Downriver|IHA Hematology Oncology Consultants-Canton|Saint Joseph Mercy Canton|Caro Cancer Center|IHA Hematology Oncology Consultants-Chelsea|Saint Joseph Mercy Chelsea|Hematology Oncology Consultants-Clarkston|Newland Medical Associates-Clarkston|Henry Ford Macomb Hospital-Clinton Township|Beaumont Hospital - Dearborn|Henry Ford Medical Center-Fairlane|Wayne State University/Karmanos Cancer Institute|Henry Ford Hospital|Ascension Saint John Hospital|Great Lakes Cancer Management Specialists-Doctors Park|Michigan State University Clinical Center|Green Bay Oncology - Escanaba|Beaumont Hospital - Farmington Hills|Genesee Cancer and Blood Disease Treatment Center|Genesee Hematology Oncology PC|Genesys Hurley Cancer Institute|Hurley Medical Center|Helen DeVos Children's Hospital at Spectrum Health|Mercy Health Saint Mary's|Spectrum Health at Butterworth Campus|Academic Hematology Oncology Specialists|Great Lakes Cancer Management Specialists-Van Elslander Cancer Center|Michigan Breast Specialists-Grosse Pointe Woods|William Beaumont Hospital-Grosse Pointe|Allegiance Health|Bronson Methodist Hospital|West Michigan Cancer Center|Borgess Medical Center|Karmanos Cancer Institute at McLaren Greater Lansing|Sparrow Hospital|Hope Cancer Clinic|Saint Mary Mercy Hospital|Great Lakes Cancer Management Specialists-Macomb Medical Campus|Michigan Breast Specialists-Macomb Township|Saint Mary's Oncology/Hematology Associates of Marlette|Mid-Michigan Medical Center - Midland|Monroe Cancer Center|Toledo Clinic Cancer Centers-Monroe|Mercy Health Mercy Campus|Lakeland Hospital Niles|Cancer and Hematology Centers of Western Michigan - Norton Shores|Ascension Providence Hospitals - Novi|Henry Ford Medical Center-Columbus|21st Century Oncology-Pontiac|Hope Cancer Center|Newland Medical Associates-Pontiac|Saint Joseph Mercy Oakland|Huron Medical Center PC|Lake Huron Medical Center|Spectrum Health Reed City Hospital|Great Lakes Cancer Management Specialists-Rochester Hills|Michigan Cancer Specialists|Oakland Colon Rectal Associates|Beaumont Children's Hospital-Royal Oak|Cancer Care Associates PC|Comprehensive Medical Center PLLC|Hematology Oncology Consultants PC|Oakland Medical Group|William Beaumont Hospital-Royal Oak|Ascension Saint Mary's Hospital|Oncology Hematology Associates of Saginaw Valley PC|Lakeland Medical Center Saint Joseph|Marie Yeager Cancer Center|Henry Ford Macomb Health Center - Shelby Township|Ascension Providence Hospitals - Southfield|Bhadresh Nayak MD PC-Sterling Heights|Premier Hematology Oncology Care|Mitchell Folbe MD PC|Ascension Saint Joseph Hospital|Munson Medical Center|Michigan Institute of Urology-Town Center|Claudia BR Herke MD PC|William Beaumont Hospital - Troy|Hematology Oncology Consultants PC-Troy|Advanced Breast Care Center PLLC|Great Lakes Cancer Management Specialists-Macomb Professional Building|Macomb Hematology Oncology PC|Michigan Breast Specialists-Warren|Saint John Macomb-Oakland Hospital|Henry Ford West Bloomfield Hospital|Saint Mary's Oncology/Hematology Associates of West Branch|Henry Ford Wyandotte Hospital|Metro Health Hospital|Huron Gastroenterology PC|IHA Hematology Oncology Consultants-Ann Arbor|Riverwood Healthcare Center|Sanford Joe Lueken Cancer Center|Essentia Health Saint Joseph's Medical Center|Fairview Ridges Hospital|Minnesota Oncology - Burnsville|Cambridge Medical Center|Mercy Hospital|Essentia Health - Deer River Clinic|Essentia Health Saint Mary's - Detroit Lakes Clinic|Essentia Health Cancer Center|Essentia Health Saint Mary's Medical Center|Miller-Dwan Hospital|Fairview Southdale Hospital|Lake Region Healthcare Corporation-Cancer Care|Essentia Health - Fosston|Unity Hospital|Essentia Health Hibbing Clinic|Fairview Clinics and Surgery Center Maple Grove|Minnesota Oncology Hematology PA-Maplewood|Saint John's Hospital - Healtheast|Abbott-Northwestern Hospital|Hennepin County Medical Center|Health Partners Inc|University of Minnesota/Masonic Cancer Center|Monticello Cancer Center|New Ulm Medical Center|Essentia Health - Park Rapids|Fairview Northland Medical Center|North Memorial Medical Health Center|Mayo Clinic in Rochester|Park Nicollet Clinic - Saint Louis Park|Regions Hospital|United Hospital|Essentia Health Sandstone|Saint Francis Regional Medical Center|Lakeview Hospital|Essentia Health Virginia Clinic|Ridgeview Medical Center|Rice Memorial Hospital|Minnesota Oncology Hematology PA-Woodbury|Sanford Cancer Center Worthington|Fairview Lakes Medical Center|Baptist Memorial Hospital and Cancer Center-Golden Triangle|Baptist Cancer Center-Grenada|Hattiesburg Clinic - Hematology/Oncology Clinic|Forrest General Hospital / Cancer Center|University of Mississippi Medical Center|Baptist Memorial Hospital and Cancer Center-Union County|Baptist Memorial Hospital and Cancer Center-Oxford|Singing River Hospital|Baptist Memorial Hospital and Cancer Center-Desoto|Central Care Cancer Center - Bolivar|Parkland Health Center-Bonne Terre|Cox Cancer Center Branson|Saint Francis Medical Center|Southeast Cancer Center|Saint Luke's Hospital|University of Missouri - Ellis Fischel|Siteman Cancer Center at West County Hospital|Parkland Health Center - Farmington|Centerpoint Medical Center LLC|Capital Region Southwest Campus|Freeman Health System|Mercy Hospital Joplin|Truman Medical Centers|Saint Luke's Hospital of Kansas City|The University of Kansas Cancer Center-South|Research Medical Center|University of Kansas Cancer Center - North|University of Kansas Cancer Center - Lee's Summit|Saint Luke's East - Lee's Summit|Liberty Radiation Oncology Center|University of Kansas Cancer Center at North Kansas City Hospital|Delbert Day Cancer Institute at PCRMC|Mercy Clinic-Rolla-Cancer and Hematology|Heartland Regional Medical Center|Saint Louis Cancer and Breast Institute-South City|Washington University School of Medicine|Mercy Hospital South|Siteman Cancer Center-South County|Missouri Baptist Medical Center|Siteman Cancer Center at Christian Hospital|Mercy Hospital Saint Louis|Siteman Cancer Center at Saint Peters Hospital|Sainte Genevieve County Memorial Hospital|Mercy Hospital Springfield|CoxHealth South Hospital|Missouri Baptist Sullivan Hospital|Missouri Baptist Outpatient Center-Sunset Hills|Community Hospital of Anaconda|Billings Clinic Cancer Center|Saint Vincent Healthcare|Saint Vincent Frontier Cancer Center|Bozeman Deaconess Hospital|Saint James Community Hospital and Cancer Treatment Center|Benefis Healthcare- Sletten Cancer Institute|Saint Peter's Community Hospital|Kalispell Regional Medical Center|Saint Patrick Hospital - Community Hospital|Community Medical Hospital|Nebraska Medicine-Bellevue|CHI Health Saint Francis|Heartland Hematology and Oncology|CHI Health Good Samaritan|Nebraska Hematology and Oncology|Nebraska Cancer Research Center|Saint Elizabeth Regional Medical Center|Southeast Nebraska Cancer Center - 68th Street Place|Faith Regional Health Services Carson Cancer Center|Great Plains Health Callahan Cancer Center|Nebraska Cancer Specialists/Oncology Hematology West PC - MECC|Nebraska Methodist Hospital|Nebraska Medicine-Village Pointe|Alegent Health Immanuel Medical Center|Hematology and Oncology Consultants PC|Alegent Health Bergan Mercy Medical Center|Nebraska Cancer Specialists - Omaha|Alegent Health Lakeside Hospital|Oncology Hematology West PC|Creighton University Medical Center|University of Nebraska Medical Center|Midlands Community Hospital|Regional West Medical Center Cancer Center|Carson Tahoe Regional Medical Center|Cancer and Blood Specialists-Henderson|Comprehensive Cancer Centers of Nevada - Henderson|Comprehensive Cancer Centers of Nevada-Horizon Ridge|Las Vegas Cancer Center-Henderson|OptumCare Cancer Care at Seven Hills|Comprehensive Cancer Centers of Nevada-Southeast Henderson|GenesisCare USA - Henderson|Las Vegas Urology - Green Valley|Las Vegas Urology - Pebble|Urology Specialists of Nevada - Green Valley|Las Vegas Urology - Pecos|Desert West Surgery|OptumCare Cancer Care at Charleston|University Medical Center of Southern Nevada|Cancer and Blood Specialists-Shadow|Radiation Oncology Centers of Nevada Central|Urology Specialists of Nevada - Central|GenesisCare USA - Las Vegas|HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway|Sunrise Hospital and Medical Center|HealthCare Partners Medical Group Oncology/Hematology-San Martin|Las Vegas Prostate Cancer Center|Las Vegas Urology - Sunset|Urology Specialists of Nevada - Southwest|Radiation Oncology Centers of Nevada Southeast|Cancer Therapy and Integrative Medicine|Ann M Wierman MD LTD|Cancer and Blood Specialists-Tenaya|Comprehensive Cancer Centers of Nevada - Northwest|GenesisCare USA - Vegas Tenaya|HealthCare Partners Medical Group Oncology/Hematology-Tenaya|Las Vegas Urology - Cathedral Rock|Las Vegas Urology - Smoke Ranch|OptumCare Cancer Care at MountainView|Urology Specialists of Nevada - Northwest|Alliance for Childhood Diseases/Cure 4 the Kids Foundation|Comprehensive Cancer Centers of Nevada - Town Center|Comprehensive Cancer Centers of Nevada-Summerlin|Summerlin Hospital Medical Center|Las Vegas Cancer Center-Medical Center|Comprehensive Cancer Centers of Nevada|GenesisCare USA - Fort Apache|OptumCare Cancer Care at Fort Apache|HealthCare Partners Medical Group Oncology/Hematology-Centennial Hills|Comprehensive Cancer Centers of Nevada - Central Valley|Hope Cancer Care of Nevada-Pahrump|Center of Hope at Renown Medical Center|Renown Regional Medical Center|Saint Mary's Regional Medical Center|Radiation Oncology Associates|New Hampshire Oncology Hematology PA-Concord|Dartmouth Hitchcock Medical Center|Norris Cotton Cancer Center-Manchester|Elliot Hospital|Solinsky Center for Cancer Care|Norris Cotton Cancer Center-Nashua|Ocean Medical Center|AtlantiCare Health Park-Cape May Court House|AtlantiCare Surgery Center|Trinitas Hospital and Comprehensive Cancer Center - Williamson Street Campus|Hunterdon Medical Center|Hackensack University Medical Center|Bayshore Community Hospital|Monmouth Medical Center Southern Campus|Saint Barnabas Medical Center|Monmouth Medical Center|Southern Ocean County Medical Center|Memorial Sloan Kettering Monmouth|Morristown Medical Center|Inspira Medical Center Mullica Hill|Jersey Shore Medical Center|Rutgers Cancer Institute of New Jersey|Newark Beth Israel Medical Center|Capital Health Medical Center-Hopewell|Riverview Medical Center/Booker Cancer Center|Sidney Kimmel Cancer Center Washington Township|Overlook Hospital|Inspira Medical Center Vineland|Lovelace Medical Center-Downtown|University of New Mexico Cancer Center|Southwest Gynecologic Oncology Associates Inc|New Mexico Oncology Hematology Consultants|Presbyterian Kaseman Hospital|Memorial Medical Center - Las Cruces|Presbyterian Rust Medical Center/Jorgensen Cancer Center|Christus Saint Vincent Regional Cancer Center|South Shore University Hospital|Montefiore Medical Center-Einstein Campus|Montefiore Medical Center-Weiler Hospital|Children's Hospital at Montefiore|Montefiore Medical Center - Moses Campus|State University of New York Downstate Medical Center|Roswell Park Cancer Institute|Arnot Ogden Medical Center/Falck Cancer Center|Glens Falls Hospital|Memorial Sloan Kettering Westchester|Northwell Health/Center for Advanced Medicine|North Shore University Hospital|Long Island Jewish Medical Center|Lenox Hill Hospital|Mount Sinai Hospital|NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center|Manhattan Eye Ear and Throat Hospital|Memorial Sloan Kettering Cancer Center|NYP/Weill Cornell Medical Center|Rochester General Hospital|University of Rochester|Stony Brook University Medical Center|State University of New York Upstate Medical University|SUNY Upstate Medical Center-Community Campus|Dickstein Cancer Treatment Center|Mission Hospital|AdventHealth Infusion Center Asheville|Messino Cancer Centers|Hope Women's Cancer Centers-Asheville|Waverly Hematology Oncology|UNC Lineberger Comprehensive Cancer Center|Novant Health Presbyterian Medical Center|Novant Health Carolina Surgical - Randolph|Oncology Specialists of Charlotte|Southern Oncology Specialists-Charlotte|Southeastern Medical Oncology Center-Clinton|AdventHealth Infusion Center Haywood|Durham VA Medical Center|Duke University Medical Center|Southeastern Medical Oncology Center-Goldsboro|Wayne Memorial Hospital|Novant Health Breast Surgery - Greensboro|Hendersonville Hematology and Oncology at Pardee|Margaret R Pardee Memorial Hospital|AdventHealth Hendersonville|Novant Health Cancer Institute - Huntersville|Novant Health Presbyterian Medical Center Huntersville|Southern Oncology Specialists-Huntersville|Onslow Memorial Hospital|Southeastern Medical Oncology Center-Jacksonville|Novant Health Cancer Institute - Kernersville|Matthews Radiation Oncology Center|Novant Health Cancer Specialists-Matthews|Lake Norman Radiation Oncology Center-Mooresville|Novant Health Cancer Institute - Mooresville|Novant Health Cancer Institute - Mount Airy|FirstHealth of the Carolinas-Moore Regional Hospital|Duke Raleigh Hospital|Novant Health Cancer Institute - Rowan|Rowan Regional Medical Center|Novant Health Cancer Institute - Statesville|Novant Health Cancer Institute - Thomasville|Marion L Shepard Cancer Center at Vidant Beaufort Hospital|AdventHealth Infusion Center Weaverville|Novant Health Cancer Institute - Wilkesboro|Novant Health Forsyth Medical Center|Novant Health Oncology Specialists|Winston-Salem Health Care|Wake Forest University Health Sciences|Sanford Bismarck Medical Center|Essentia Health Cancer Center-South University Clinic|Sanford South University Medical Center|Sanford Broadway Medical Center|Sanford Clinic North-Fargo|Sanford Roger Maris Cancer Center|Essentia Health - Jamestown Clinic|Trinity Cancer Care Center|Aultman Alliance Community Hospital|UHHS-Chagrin Highlands Medical Center|Indu and Raj Soin Medical Center|Strecker Cancer Center-Belpre|Saint Elizabeth Boardman Hospital|Cleveland Clinic Mercy Hospital|Mercy Hematology and Oncology Associates Inc|Aultman Health Foundation|Dayton Physicians LLC-Miami Valley South|Miami Valley Hospital South|Geauga Hospital|Adena Regional Medical Center|Oncology Hematology Care Inc-Eden Park|Oncology Hematology Care Inc-Mercy West|The Christ Hospital|Good Samaritan Hospital - Cincinnati|Cincinnati Children's Hospital Medical Center|Oncology Hematology Care Inc-Anderson|Oncology Hematology Care Inc-Kenwood|Bethesda North Hospital|Oncology Hematology Care Inc-Blue Ash|TriHealth Cancer Institute-Westside|TriHealth Cancer Institute-Anderson|Case Western Reserve University|MetroHealth Medical Center|Cleveland Clinic Foundation|Ohio State University Comprehensive Cancer Center|Mount Carmel East Hospital|Columbus Oncology and Hematology Associates Inc|Riverside Methodist Hospital|Grant Medical Center|The Mark H Zangmeister Center|Mount Carmel Health Center West|Doctors Hospital|Good Samaritan Hospital - Dayton|Miami Valley Hospital|Dayton Physician LLC-Miami Valley Hospital North|Miami Valley Hospital North|Delaware Health Center-Grady Cancer Center|Delaware Radiation Oncology|Grady Memorial Hospital|Columbus Oncology and Hematology Associates|Dublin Methodist Hospital|Hematology Oncology Center Incorporated|Mercy Cancer Center-Elyria|Oncology Hematology Care Inc-Healthplex|Armes Family Cancer Center|Blanchard Valley Hospital|Orion Cancer Care|Atrium Medical Center-Middletown Regional Hospital|Dayton Physicians LLC-Atrium|Dayton Physicians LLC-Wayne|Wayne Hospital|Mount Carmel Grove City Hospital|Greater Dayton Cancer Center|First Dayton Cancer Care|Kettering Medical Center|Fairfield Medical Center|Saint Rita's Medical Center|Marietta Memorial Hospital|OhioHealth Marion General Hospital|Toledo Clinic Cancer Centers-Maumee|Toledo Radiation Oncology at Northwest Ohio Onocolgy Center|UH Seidman Cancer Center at Landerbrook Health Center|UH Seidman Cancer Center at Lake Health Mentor Campus|UH Seidman Cancer Center at Southwest General Hospital|Dayton Physicians LLC-Signal Point|Knox Community Hospital|Licking Memorial Hospital|Newark Radiation Oncology|Saint Charles Hospital|University Hospitals Parma Medical Center|Mercy Health Perrysburg Cancer Center|Southern Ohio Medical Center|UH Seidman Cancer Center at Firelands Regional Medical Center|Dayton Physicians LLC-Wilson|Springfield Regional Cancer Center|Springfield Regional Medical Center|Trinity's Tony Teramana Cancer Center|ProMedica Flower Hospital|ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital|Saint Vincent Mercy Medical Center|University of Toledo|Mercy Health - Saint Anne Hospital|Toledo Clinic Cancer Centers-Toledo|Dayton Physicians LLC-Upper Valley|Upper Valley Medical Center|University Hospitals Sharon Health Center|Saint Joseph Warren Hospital|Saint Ann's Hospital|UH Seidman Cancer Center at Saint John Medical Center|UHHS-Westlake Medical Center|Saint Elizabeth Youngstown Hospital|Genesis Healthcare System Cancer Care Center|Cancer Centers of Southwest Oklahoma Research|University of Oklahoma Health Sciences Center|Integris Southwest Medical Center|Mercy Hospital Oklahoma City|Integris Cancer Institute of Oklahoma|Cancer Treatment Centers of America|Oklahoma Cancer Specialists and Research Institute-Tulsa|Saint Alphonsus Medical Center-Baker City|Saint Charles Health System|Clackamas Radiation Oncology Center|Providence Cancer Institute Clackamas Clinic|Bay Area Hospital|Good Samaritan Hospital|Legacy Mount Hood Medical Center|Providence Newberg Medical Center|Saint Alphonsus Medical Center-Ontario|Providence Willamette Falls Medical Center|Legacy Good Samaritan Hospital and Medical Center|Providence Portland Medical Center|Providence Saint Vincent Medical Center|Kaiser Permanente Northwest|Oregon Health and Science University|Saint Charles Health System-Redmond|Legacy Meridian Park Hospital|Jefferson Abington Hospital|Lehigh Valley Hospital-Cedar Crest|UPMC Altoona|UPMC-Heritage Valley Health System Beaver|Lehigh Valley Hospital - Muhlenberg|Bryn Mawr Hospital|UPMC Hillman Cancer Center at Butler Health System|UPMC Camp Hill|Carlisle Regional Cancer Center|Christiana Care Health System-Concord Health Center|Chambersburg Hospital|Main Line Health Center-Collegeville|UPMC Hillman Cancer Center - Passavant - Cranberry|Geisinger Medical Center|Doylestown Hospital|Pocono Medical Center|Easton Hospital|Ephrata Cancer Center|Ephrata Community Hospital|UPMC Hillman Cancer Center Erie|UPMC Hamot|Main Line Health Center-Exton|UPMC Cancer Center at UPMC Horizon|Adams Cancer Center|UPMC Cancer Centers - Arnold Palmer Pavilion|Oncology Hematology Associates|Cherry Tree Cancer Center|UPMC Pinnacle Harrisburg|UPMC Pinnacle Cancer Center/Community Osteopathic Campus|Geisinger Medical Center-Cancer Center Hazleton|Lehigh Valley Hospital-Hazleton|Penn State Milton S Hershey Medical Center|IRMC Cancer Center|UPMC-Johnstown/John P. Murtha Regional Cancer Center|Armstrong Center for Medicine and Health|Lancaster General Ann B Barshinger Cancer Institute|Lancaster General Hospital|Sechler Family Cancer Center|Geisinger Medical Oncology-Lewisburg|Lewistown Hospital|UPMC Cancer Center at UPMC McKeesport|Holy Redeemer Hospital and Medical Center|UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion|Riddle Memorial Hospital|Forbes Hospital|UPMC Hillman Cancer Center - Monroeville|UPMC-Coraopolis/Heritage Valley Radiation Oncology|UPMC Hillman Cancer Center - Part of Frick Hospital|Arnold Palmer Cancer Center Medical Oncology Norwin|Allegheny Valley Hospital|UPMC Cancer Center-Natrona Heights|UPMC Hillman Cancer Center - New Castle|Suburban Community Hospital and Cancer Center|Paoli Memorial Hospital|Drexel University School of Medicine|Thomas Jefferson University Hospital|Fox Chase Cancer Center|Jefferson Torresdale Hospital|Eastern Regional Medical Center|Nazareth Hospital|Phoenixville Hospital|Allegheny General Hospital|UPMC-Magee Womens Hospital|Oncology Hematology Association|UPMC-Saint Margaret|UPMC-Mercy Hospital|West Penn Hospital|University of Pittsburgh Cancer Institute (UPCI)|UPMC-Passavant Hospital|UPMC-Saint Clair Hospital Cancer Center|Geisinger Cancer Services-Pottsville|Penn State Health Saint Joseph Medical Center|Guthrie Medical Group PC-Robert Packer Hospital|Hematology and Oncology Associates of North East Pennsylvania|Community Medical Center|Geisinger Medical Oncology-Selinsgrove|UPMC Cancer Center at UPMC Northwest|Geisinger Medical Group|Mount Nittany Medical Center|UPMC Cancer Center-Uniontown|UPMC Cancer Center-Washington|Chester County Hospital|UPMC West Mifflin-Cancer Center Jefferson|Reading Hospital|Geisinger Wyoming Valley/Henry Cancer Center|UPMC Susquehanna|Divine Providence Hospital|Asplundh Cancer Pavilion|Lankenau Medical Center|WellSpan Health-York Cancer Center|WellSpan Health-York Hospital|UPMC Memorial|Newport Hospital|Rhode Island Hospital|Women and Infants Hospital|Miriam Hospital|Smilow Cancer Hospital Care Center - Westerly|AnMed Health Cancer Center|Beaufort Memorial Hospital|Prisma Health Cancer Institute - Spartanburg|Roper Hospital|Charleston Oncology - Roper|Lowcountry Hematology Oncology PA-North Charleston|Bon Secours Saint Francis Hospital|Charleston Oncology - Saint Francis|Lowcountry Hematology Oncology PA-West Ashley|Medical University of South Carolina|Prisma Health Cancer Institute - Easley|McLeod Regional Medical Center|Gibbs Cancer Center-Gaffney|Tidelands Georgetown Memorial Hospital|Greenville Health System Cancer Institute-Andrews|Saint Francis Hospital|Prisma Health Cancer Institute - Butternut|Prisma Health Cancer Institute - Faris|Prisma Health Greenville Memorial Hospital|Saint Francis Cancer Center|Prisma Health Cancer Institute - Eastside|Self Regional Healthcare|Prisma Health Cancer Institute - Greer|Gibbs Cancer Center-Pelham|South Carolina Cancer Specialists PC|The Radiation Oncology Center-Hilton Head/Bluffton|Lowcountry Hematology Oncology PA-Mount Pleasant|Prisma Health Cancer Institute - Seneca|North Grove Medical Park|Spartanburg Medical Center|Spartanburg Medical Center - Mary Black Campus|MGC Hematology Oncology-Union|Avera Cancer Institute-Aberdeen|Rapid City Regional Hospital|Sanford Cancer Center Oncology Clinic|Avera Cancer Institute|Sanford USD Medical Center - Sioux Falls|Memorial Hospital|Integrity Oncology PLLC-Collierville|Cookeville Regional Medical Center|Vanderbilt-Ingram Cancer Center Cool Springs|Pulmonary Medicine Center of Chattanooga-Hixson|Tennessee Cancer Specialists-Dowell Springs|Thompson Cancer Survival Center|Thompson Cancer Survival Center - West|Thompson Oncology Group-Maryville|Baptist Memorial Hospital and Cancer Center-Memphis|Family Cancer Center-Memphis|Vanderbilt Breast Center at One Hundred Oaks|Meharry Medical College|Vanderbilt University/Ingram Cancer Center|Thompson Oncology Group-Oak Ridge|Memorial GYN Plus|Dell Seton Medical Center at The University of Texas|Saint Joseph Regional Cancer Center|MD Anderson in The Woodlands|Parkland Memorial Hospital|Baylor University Medical Center|UT Southwestern/Simmons Cancer Center-Dallas|UT Southwestern/Simmons Cancer Center-Fort Worth|Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center|Houston Methodist Hospital|M D Anderson Cancer Center|Memorial Hermann Texas Medical Center|MD Anderson West Houston|Memorial Hermann Northeast Hospital|MD Anderson League City|Covenant Medical Center-Lakeside|UT Southwestern Clinical Center at Richardson/Plano|Cancer Therapy and Research Center at The UT Health Science Center at San Antonio|Methodist Children's Hospital of South Texas|University Hospital|University of Texas Health Science Center at San Antonio|MD Anderson in Sugar Land|Memorial Hermann The Woodlands Hospital|American Fork Hospital / Huntsman Intermountain Cancer Center|Sandra L Maxwell Cancer Center|Farmington Health Center|Logan Regional Hospital|Intermountain Medical Center|McKay-Dee Hospital Center|Utah Valley Regional Medical Center|Riverton Hospital|Dixie Medical Center Regional Cancer Center|Utah Cancer Specialists-Salt Lake City|Huntsman Cancer Institute/University of Utah|LDS Hospital|South Jordan Health Center|Central Vermont Medical Center/National Life Cancer Treatment|University of Vermont Medical Center|University of Vermont and State Agricultural College|Norris Cotton Cancer Center-North|Danville Regional Medical Center|Inova Schar Cancer Institute|Inova Fair Oaks Hospital|Inova Fairfax Hospital|Augusta Health Center for Cancer and Blood Disorders|Hematology Oncology Associates of Fredericksburg Inc|Centra Lynchburg Hematology-Oncology Clinic Inc|Sovah Health Martinsville|Bon Secours Memorial Regional Medical Center|Bon Secours Westchester Emergency Center|Bon Secours Saint Francis Medical Center|Children's Hospital of The King's Daughters|Bon Secours Saint Mary's Hospital|Virginia Cancer Institute|Bon Secours Cancer Institute at Reynolds Crossing|VCU Massey Cancer Center at Stony Point|Virginia Commonwealth University/Massey Cancer Center|Providence Regional Cancer System-Aberdeen|Cancer Care Center at Island Hospital|MultiCare Auburn Medical Center|Virginia Mason Bainbridge Island Medical Center|Overlake Medical Center|Swedish Cancer Institute-Eastside Oncology Hematology|PeaceHealth Saint Joseph Medical Center|Harrison HealthPartners Hematology and Oncology-Bremerton|Harrison Medical Center|Highline Medical Center-Main Campus|Providence Regional Cancer System-Centralia|Swedish Cancer Institute-Edmonds|Saint Elizabeth Hospital|Providence Regional Cancer Partnership|Virginia Mason Federal Way Medical Center|Saint Francis Hospital|Tacoma/Valley Radiation Oncology Centers-Gig Harbor|MultiCare Gig Harbor Medical Park|Swedish Cancer Institute-Issaquah|Kadlec Clinic Hematology and Oncology|Northwest Cancer Clinic|Providence Regional Cancer System-Lacey|Saint Clare Hospital|PeaceHealth Saint John Medical Center|Virginia Mason Lynnwood Medical Center|Skagit Valley Hospital Regional Cancer Care Center|Skagit Valley Hospital|Jefferson Healthcare|Harrison HealthPartners Hematology and Oncology-Poulsbo|Peninsula Cancer Center|MultiCare Good Samaritan Hospital|Tacoma/Valley Radiation Oncology Centers-Puyallup|Valley Medical Center|Virginia Mason Medical Center|Minor and James Medical PLLC|Pacific Gynecology Specialists|Swedish Medical Center-Ballard Campus|Fred Hutchinson Cancer Research Center|Seattle Cancer Care Alliance|Kaiser Permanente Washington|Swedish Medical Center-First Hill|Swedish Medical Center-Cherry Hill|University of Washington Medical Center - Montlake|PeaceHealth United General Medical Center|Providence Regional Cancer System-Shelton|MultiCare Deaconess Cancer and Blood Specialty Center - Valley|MultiCare Deaconess Cancer and Blood Specialty Center - Downtown|Providence Sacred Heart Medical Center and Children's Hospital|Spokane Valley Cancer Center-Mayfair|Spokane Valley Cancer Center-Mission|Evergreen Hematology and Oncology PS|MultiCare Deaconess Cancer and Blood Specialty Center - North|Tacoma/Valley Radiation Oncology Centers-Jackson Hall|Franciscan Research Center-Northwest Medical Plaza|Mary Bridge Children's Hospital and Health Center|MultiCare Tacoma General Hospital|Northwest Medical Specialties PLLC|Tacoma/Valley Radiation Oncology Centers-Saint Joe's|PeaceHealth Southwest Medical Center|Legacy Cancer Institute Medical Oncology and Day Treatment|Legacy Salmon Creek Hospital|Providence Saint Mary Regional Cancer Center|Wenatchee Valley Hospital and Clinics|North Star Lodge Cancer Center at Yakima Valley Memorial Hospital|Providence Regional Cancer System-Yelm|United Hospital Center|West Virginia University Charleston Division|Edwards Comprehensive Cancer Center|WVUH-Berkely Medical Center|Monongalia Hospital|West Virginia University Healthcare|Camden Clark Medical Center|Langlade Hospital and Cancer Center|Ascension Saint Elizabeth Hospital|Duluth Clinic Ashland|Northwest Wisconsin Cancer Center|Ascension Southeast Wisconsin Hospital - Elmbrook Campus|Aurora Cancer Care-Southern Lakes VLCC|Ascension Calumet Hospital|Marshfield Clinic-Chippewa Center|Aurora Saint Luke's South Shore|HSHS Sacred Heart Hospital|Marshfield Clinic Cancer Center at Sacred Heart|Marshfield Medical Center-EC Cancer Center|Aurora Health Center-Fond du Lac|Ascension Saint Francis - Reiman Cancer Center|Ascension Southeast Wisconsin Hospital - Franklin|Aurora Health Care Germantown Health Center|Aurora Cancer Care-Grafton|Green Bay Oncology at Saint Vincent Hospital|Saint Vincent Hospital Cancer Center Green Bay|Green Bay Oncology Limited at Saint Mary's Hospital|Saint Vincent Hospital Cancer Center at Saint Mary's|Aurora BayCare Medical Center|Mercyhealth Hospital and Cancer Center - Janesville|Aurora Cancer Care-Kenosha South|Gundersen Lutheran Medical Center|Marshfield Clinic - Ladysmith Center|University of Wisconsin Hospital and Clinics|Holy Family Memorial Hospital|Aurora Bay Area Medical Group-Marinette|Saint Vincent Hospital Cancer Center at Marinette|Marshfield Medical Center-Marshfield|Marshfield Medical Center|Aspirus Medford Hospital|Ascension Columbia Saint Mary's Hospital Ozaukee|Aurora Cancer Care-Milwaukee|Ascension Southeast Wisconsin Hospital - Saint Joseph Campus|Ascension Columbia Saint Mary's Hospital - Milwaukee|Ascension Saint Francis Hospital|Aurora Saint Luke's Medical Center|Medical College of Wisconsin|Aurora Sinai Medical Center|Marshfield Clinic-Minocqua Center|ProHealth D N Greenwald Center|Cancer Center of Western Wisconsin|ProHealth Oconomowoc Memorial Hospital|Saint Vincent Hospital Cancer Center at Oconto Falls|Ascension Mercy Hospital|Vince Lombardi Cancer Clinic - Oshkosh|Ascension All Saints Hospital|Aurora Cancer Care-Racine|Ascension Saint Mary's Hospital|Saint Mary's Hospital|Lakeview Medical Center-Marshfield Clinic|Marshfield Medical Center-Rice Lake|HSHS Saint Nicholas Hospital|Vince Lombardi Cancer Clinic-Sheboygan|Ascension Saint Michael's Hospital|Marshfield Clinic Stevens Point Center|Saint Vincent Hospital Cancer Center at Sturgeon Bay|Green Bay Oncology - Sturgeon Bay|Aurora Medical Center in Summit|Vince Lombardi Cancer Clinic-Two Rivers|Aurora Cancer Care-Waukesha|ProHealth Waukesha Memorial Hospital|UW Cancer Center at ProHealth Care|Aspirus Regional Cancer Center|Marshfield Clinic-Wausau Center|Ascension Medical Group Southeast Wisconsin - Mayfair Road|Aurora Cancer Care-Milwaukee West|Aurora West Allis Medical Center|Diagnostic and Treatment Center|Marshfield Medical Center - Weston|Aspirus Cancer Care - Wisconsin Rapids|Marshfield Clinic - Wisconsin Rapids Center|Cheyenne Regional Medical Center-West|Big Horn Basin Cancer Center|Billings Clinic-Cody|Welch Cancer Center|FHP Health Center-Guam|Cancer Center-Metro Medical Center Bayamon|Doctors Cancer Center|San Juan Community Oncology Group|San Juan City Hospital,Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Other|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Other|Drug|Drug|Biological|Drug|Drug|Biological|Drug|Biological|Drug|Drug|Drug|Drug|Biological|Biological|Drug|Drug,Guam|Puerto Rico|United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02465060
NCT02567877,hypothyroidism,Is Levothyroxine Alone Adequate Thyroid Hormone Replacement for All Patients?,Hypothyroidism|Postsurgical Hypothyroidism,2015-10-01,2025-06-30,2025-06-30,Observational,Recruiting,,"University of Colorado, Denver","Charite University, Berlin, Germany|University of Colorado, Denver",University of Colorado Anschutz Medical Campus,Procedure|Drug,United States,18.0,75.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT02567877
NCT02568267,papillary thyroid cancer,"An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements","Adult Solid Tumor|Breast Cancer|Cholangiocarcinoma|Colorectal Cancer|Head and Neck Neoplasms|Lymphoma, Large-Cell, Anaplastic|Melanoma|Neuroendocrine Tumors|Non-Small Cell Lung Cancer|Ovarian Cancer|Pancreatic Cancer|Papillary Thyroid Cancer|Primary Brain Tumors|Renal Cell Carcinoma|Salivary Gland Cancers|Sarcomas",2015-10-02,2024-12-31,2025-04-01,Interventional,Recruiting,Phase 2,Hoffmann-La Roche,Hoffmann-La Roche,"Western Regional Medical Center at Cancer Treatment Centers of America|Dignity Health St Joseph's Hospital and Medical Center|Mayo Clinic|City of Hope Cancer Center; Division of Medical Oncology & Experimental Therapeutics|Scripps Clinic|University of California San Diego Moores Cancer Center; Dept of Lung Cancer|University of Southern California Medical Center|Univ Of California Irvine College Of Medicine; 300194620|Southern California Kaiser Permanente|UCSF Mount Zion Medical Ctr|Sarcoma Oncology Center|University of Colorado Cancer Center|Yale University|Georgetown University Medical Center Lombardi Cancer Center|Florida Cancer Specialists - Sarasota|H. Lee Moffitt Cancer Center and Research Inst.|Cleveland Clinic Florida|University Cancer & Blood Center, LLC; Research|Winship Cancer Institute|Southeastern Regional Medical Center, Inc.|University of Hawaii Cancer Center|Northwestern University|Advocate Medical Group - Park Ridge, Luther Lane - Oncology|Midwestern Regional Medical Center|Weinberg Cancer Institution at Franklin Square|Massachusetts General Hospital|Beth Israel Deaconess Medical Center|Dana Farber Cancer Institute|University of Michigan Comprehensive Cancer Center; Clinical Trials Office|Karmanos Cancer Center|Henry Ford Hospital|Regents of the University of Minnesota|Washington University|Comprehensive Cancer Centers of Nevada (CCCN) - Central Valley|Dartmouth Hitchcock Medical Center|North Shore Hem Onc Associates|Memorial Sloan Kettering Cancer Center|Levine Cancer Institute|Duke Cancer Institute|Cleveland Clinic|OSU, James Cancer Hospital|Cancer Treatment Centers of America; Tulsa|Providence Portland Medical Center|Oregon Health & Science Univ|Cancer Treatment Centers of America - Eastern Regional Medical Center|Mary Crowley Medical Research Center|University Hospital Medical Oncology Clinic; Harold C. Simmons Comprehensive Cancer Center|University of Texas MD Anderson Cancer Center|Baylor Scott & White Health|University of Utah Hospitals & Clinics|Virginia Cancer Specialists, PC|Virginia Oncology Associates - Hampton|University of Washington Seattle Cancer Care Alliance|Wheaton Franciscan Cancer Care-All Saints|Border Medical Oncology Research Unit|Liverpool Hospital|Newcastle Private Hospital|Flinders Medical Centre|Austin Health|Antwerp University Hospital|Beijing Cancer Hospital|Sichuan Provincial Cancer Hospital|Cancer Center of Guangzhou Medical University|Harbin Medical University Cancer Hospital|Fudan University Shanghai Cancer Center|Shanghai chest hospital|Shenzhen People's Hospital|Tianjin Cancer Hospital|Union Hospital Tongji Medical College Huazhong University of Science and Technology|Zhejiang Cancer Hospital|Institut de Cancerologie de l Ouest|Institut Bergonie; Oncologie|Centre Oscar Lambret; Chir Cancerologie General|Centre Leon Berard; Departement Oncologie Medicale|Hôpital de la Timone; Oncologie Médicale Hématologie & Soins Palliatifs|Hôpital Nord - AP-HM Marseille#; Service d'Oncologie Multidisciplinaire|Institut de Recherche en Cancérologie de Montpellier|Hôpital Européen Georges Pompidou; Hématologie Oncologie|Institut Curie; Oncologie Medicale|Institut De Cancerologie De L'ouest - Rene Gauducheau - Biology|Institut Claudius Regaud; Departement Oncologie Medicale|Institut Gustave Roussy; Pathologie Thoracique|Charite Universitaetsmedizin Berlin - Campus Charite Mitte ; Charite Comprehensive Cancer Center|Evang. Lungenklinik Berlin Klinik für Pneumologie|Universitaetsklinikum Carl Gustav Carus TU Dresden|Asklepios-Fachkliniken Muenchen-Gauting; Onkologie|Universitaetsmedizin Goettingen; Abteilung Haematologie und Onkologie|NCT Uniklinikum Heidelberg; Medizinische Onkologie|Universitaetsklinikum Koeln; Innere Medizin I, Haematologie|Hong Kong Integrated Oncology Centre|Princess Margaret Hospital|The University of Hong Kong|Queen Elizabeth Hospital|The Chinese University of Hong Kong|Seconda Università degli Studi di Napoli; Servizio Epato-Gastroenterologia|Università Campus Bio-Medico di Roma; Oncologia Medica|Azienda Ospedaliero Universitaria San Martino; Lung Cancer Unit|Fondazione IRCCS Istituto Nazionale dei Tumori|Azienda Socio Sanitaria Territoriale Niguarda (Ospedale Niguarda Ca' Granda); Oncologico -Onc.Falck|Fondazione del Piemonte per l'Oncologia - IRCCS;Ematologia|Azienda Ospedaliero-Universitaria S.Luigi Gonzaga; SSD Oncologia Polmonare|A.O Città della Salute e della Scienza di Torino; Colorectal Cancer Unit (CRCU) - SSCVD|Azienda Ospedaliero Universitaria Pisana; Uff. Sperim. Clin. U.O. Farmaceutica|Azienda Ospedaliera di Perugia Ospedale S. Maria della Misericordia ; S.C. Oncologia Medica|IOV - Istituto Oncologico Veneto - IRCCS; Oncologia Medica II|Aichi Cancer Center Hospital; Respiratory Medicine|NHO Shikoku Cancer Center; Dept of Respiratory Medicine|NHO Kyushu Cancer Center|Hyogo Cancer Center, Dept of Respiratory Medicine|National Cancer Center Hospital; Dept of Respiratory Medicine|Miyagi Cancer Center; Respiratory Medicine|Niigata Cancer Center Hospital; Internal Medicine|OSAKA CITY GENERAL HOSPITAL;Medical Oncology|Kindai University Hospital; Medical Oncology|Shizuoka Cancer Center; Respiratory Internal Medicine|Chungbuk National University Hospital|Seoul National University Hospital|Severance Hospital, Yonsei University Health System|Samsung Medical Center|Asan Medical Center.|NKI The Netherlands Cancer Institute|Leids Universitair Medisch Centrum|Uniwersyteckie Centrum Kliniczne; Klinika Onkologii i Radioterapii|Centrum Onkologii-Instytut im.M.Sklodowskiej Curie; Dept of Nuclear Med. and Endocrine Oncology|Mazowieckie Centrum Leczenia Chorob Pluc i Gruzlicy; Dept of Pulmonology & subdiv. of oncology|Szpital Kliniczny Przemienienia Panskiego Uni. Medycznego im. Karola Marcinkowskiego; Chemotherapy|Centrum Onkologii Instytut im. M. Sklodowskiej-Curie, Klinika Nowotworow Ukladu Chlonnego|National University Hospital; Haematology/Oncology|National Cancer Centre|Centro Nacional de Investigaciones Oncológicas(CNIO); Gastrointestinal Cancer Clinical Research Unit|Vall d´Hebron Institute of Oncology (VHIO), Barcelona|Hospital Universitario de La Princesa; Servicio de Oncologia|Hospital Universitario Ramon y Cajal; Servicio de Farmacia|Hospital Universitario Clínico San Carlos; Servicio de Oncologia|Hospital Universitario 12 de Octubre; Servicio de Oncologia|Hospital Universitario La Paz; Servicio de Oncologia|Centro Integral Oncologico Clara Campal; Servicio de Oncología|Hospital Clinico Universitario Virgen de la Victoria; Servicio de Oncologia|Hospital Universitario Virgen del Rocio; Servicio de Oncologia|Changhua Christian Hospital|National Cheng Kung University Hospital|Taipei Veterans General Hospital|National Taiwan University Hospital|Taichung Veterans General Hospital|Addenbrookes Hospital|Sarah Cannon Research Institute|Christie Hospital Nhs Trust; Medical Oncology",Drug,"Australia|Belgium|China|France|Germany|Hong Kong|Italy|Japan|Korea, Republic of|Netherlands|Poland|Singapore|Spain|Taiwan|United Kingdom|United States",18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT02568267
NCT02592356,thyroid gland medullary carcinoma,Effects of Tyrosine Kinase Inhibitors on Body Composition in Endocrine Tumors -- A Pilot Study,Differentiated Thyroid Gland Carcinoma|Malignant Adrenal Gland Pheochromocytoma|Malignant Paraganglioma|Thyroid Gland Medullary Carcinoma,2015-10-27,2022-11-30,2022-11-30,Interventional,"Active, not recruiting",Not Applicable,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center|National Cancer Institute (NCI),M D Anderson Cancer Center,Procedure|Procedure|Procedure|Other|Other|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, medullary",https://clinicaltrials.gov/ct2/show/NCT02592356
NCT02628067,thyroid carcinoma,A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158),Advanced Cancer|Advanced Solid Tumors|Anal Cancer|Anal Carcinoma|Bile Duct Cancer|Biliary Cancer|Carcinoid Tumor|Cervical Cancer|Cervical Carcinoma|Cholangiocarcinoma|Colorectal Carcinoma|Endometrial Cancer|Endometrial Carcinoma|Mesothelioma|Neuroendocrine Tumor|Parotid Gland Cancer|Salivary Cancer|Salivary Gland Cancer|Salivary Gland Carcinoma|Small Cell Lung Cancer (SCLC)|Small Cell Lung Carcinoma|Thyroid Cancer|Thyroid Carcinoma|Vulvar Cancer|Vulvar Carcinoma,2015-12-09,2026-06-18,2026-06-18,Interventional,Recruiting,Phase 2,Merck Sharp & Dohme Corp.,Merck Sharp & Dohme Corp.,"Call for Information (Investigational Site 0202)|Call for Information (Investigational Site 0017)|Call for Information (Investigational Site 0015)|Call for Information (Investigational Site 0207)|Call for Information (Investigational Site 0010)|Call for Information (Investigational Site 0209)|Call for Information (Investigational Site 0008)|Call for Information (Investigational Site 0004)|Merck Sharp & Dohme|MSD Brasil|Merck Canada|Merck Sharp & Dohme (China) Ltd.|MDS Colombia SAS|Merck Sharp & Dohme|MSD France|MSD Sharp & Dohme GmbH|Merck Sharp & Dohme Co. Ltd.|MSD Italia S.r.l.|MSD K.K.|MSD Korea LTD|Merck Sharp & Dohme BV|MSD Norge A/S|Merck Sharp & Dohme (I.A.) Corporation|Merck Sharp & Dohme IDEA, Inc.|MSD (Pty) LTD South Africa|Merck Sharp and Dohme de Espana S.A.|Merck Sharp & Dohme (I.A.) Corp.",Biological|Biological,"Australia|Brazil|Canada|China|Colombia|Denmark|France|Germany|Israel|Italy|Japan|Korea, Republic of|Netherlands|Norway|Philippines|Russian Federation|South Africa|Spain|Taiwan|United States",18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02628067
NCT02657551,thyroid cancer,A Phase II Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer,Thyroid Cancer,2015-11-09,2022-12-31,2023-12-31,Interventional,Recruiting,Phase 2,Dana-Farber Cancer Institute,Bayer|Dana-Farber Cancer Institute,Yale Cancer Center|Dana-Farber Cancer Institute,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02657551
NCT02713269,thyroid gland carcinoma,A Phase II Clinical Trial Evaluating the Efficacy of Combining Thermal Ablation and Spine Stereotactic Radiosurgery for Patients With Spine Metastases With Moderate to Severe Epidural Involvement,Malignant Digestive System Neoplasm|Metastatic Head and Neck Carcinoma|Metastatic Kidney Carcinoma|Metastatic Malignant Neoplasm in the Spine|Metastatic Malignant Neoplasm of Unknown Primary|Metastatic Melanoma|Prostate Carcinoma Metastatic in the Bone|Sarcoma|Solid Neoplasm|Spinal Cord Compression|Stage IV Breast Cancer AJCC v6 and v7|Stage IV Lung Non-Small Cell Cancer AJCC v7|Thyroid Gland Carcinoma,2016-03-15,2022-07-01,2022-07-01,Interventional,Recruiting,Phase 2,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center|National Cancer Institute (NCI),M D Anderson Cancer Center,Procedure|Other|Other|Radiation|Procedure,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02713269
NCT02747888,thyroid cancer,Hereditary Risk Factors for Thyroid Cancer,Thyroid Cancer,2016-03-31,2022-03-01,2022-03-01,Interventional,Recruiting,Not Applicable,Dana-Farber Cancer Institute,Dana-Farber Cancer Institute,Dana Farber Cancer Institute,Genetic,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02747888
NCT02834013,thyroid gland carcinoma,DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors,"Acinar Cell Carcinoma|Adenoid Cystic Carcinoma|Adrenal Cortex Carcinoma|Adrenal Gland Pheochromocytoma|Anal Canal Neuroendocrine Carcinoma|Anal Canal Undifferentiated Carcinoma|Angiosarcoma|Apocrine Neoplasm|Appendix Mucinous Adenocarcinoma|Bartholin Gland Transitional Cell Carcinoma|Basal Cell Carcinoma|Bladder Adenocarcinoma|Breast Metaplastic Carcinoma|Cervical Adenocarcinoma|Cholangiocarcinoma|Chordoma|Colorectal Squamous Cell Carcinoma|Desmoid Fibromatosis|Endometrial Transitional Cell Carcinoma|Endometrioid Adenocarcinoma|Esophageal Neuroendocrine Carcinoma|Esophageal Undifferentiated Carcinoma|Extrahepatic Bile Duct Carcinoma|Extramammary Paget Disease|Fallopian Tube Adenocarcinoma|Fallopian Tube Transitional Cell Carcinoma|Fibromyxoid Tumor|Gallbladder Carcinoma|Gastric Neuroendocrine Carcinoma|Gastric Squamous Cell Carcinoma|Gastric Undifferentiated Carcinoma|Gastrointestinal Stromal Tumor|Gestational Trophoblastic Tumor|Giant Cell Carcinoma|Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type|Intestinal Neuroendocrine Carcinoma|Intrahepatic Cholangiocarcinoma|Lung Carcinoid Tumor|Lung Sarcomatoid Carcinoma|Major Salivary Gland Carcinoma|Malignant Odontogenic Neoplasm|Malignant Peripheral Nerve Sheath Tumor|Malignant Solid Neoplasm|Malignant Testicular Sex Cord-Stromal Tumor|Metastatic Malignant Neoplasm of Unknown Primary|Minimally Invasive Lung Adenocarcinoma|Mixed Mesodermal (Mullerian) Tumor|Mucinous Adenocarcinoma|Mucinous Cystadenocarcinoma|Nasal Cavity Adenocarcinoma|Nasal Cavity Carcinoma|Nasopharyngeal Carcinoma|Nasopharyngeal Papillary Adenocarcinoma|Nasopharyngeal Undifferentiated Carcinoma|Oral Cavity Carcinoma|Oropharyngeal Undifferentiated Carcinoma|Ovarian Adenocarcinoma|Ovarian Germ Cell Tumor|Ovarian Mucinous Adenocarcinoma|Ovarian Squamous Cell Carcinoma|Ovarian Transitional Cell Carcinoma|Pancreatic Acinar Cell Carcinoma|Pancreatic Neuroendocrine Carcinoma|Paraganglioma|Paranasal Sinus Adenocarcinoma|Paranasal Sinus Carcinoma|Parathyroid Gland Carcinoma|PEComa|Peritoneal Mesothelioma|Pituitary Gland Carcinoma|Placental Choriocarcinoma|Primary Peritoneal High Grade Serous Adenocarcinoma|Pseudomyxoma Peritonei|Rare Disorder|Scrotal Squamous Cell Carcinoma|Seminal Vesicle Adenocarcinoma|Seminoma|Serous Cystadenocarcinoma|Small Intestinal Adenocarcinoma|Small Intestinal Squamous Cell Carcinoma|Spindle Cell Neoplasm|Squamous Cell Carcinoma of the Penis|Teratoma With Somatic-Type Malignancy|Testicular Non-Seminomatous Germ Cell Tumor|Thyroid Gland Carcinoma|Tracheal Carcinoma|Transitional Cell Carcinoma|Ureter Adenocarcinoma|Ureter Squamous Cell Carcinoma|Urethral Adenocarcinoma|Urethral Squamous Cell Carcinoma|Vaginal Adenocarcinoma|Vaginal Squamous Cell Carcinoma, Not Otherwise Specified|Vulvar Carcinoma",2016-07-13,2023-10-31,2023-10-31,Interventional,Recruiting,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),University of Alabama at Birmingham Cancer Center|University of South Alabama Mitchell Cancer Institute|Anchorage Associates in Radiation Medicine|Anchorage Radiation Therapy Center|Alaska Breast Care and Surgery LLC|Alaska Oncology and Hematology LLC|Alaska Women's Cancer Care|Anchorage Oncology Centre|Katmai Oncology Group|Providence Alaska Medical Center|Fairbanks Memorial Hospital|CTCA at Western Regional Medical Center|Kingman Regional Medical Center|Cancer Center at Saint Joseph's|Highlands Oncology Group PA - Fayetteville|Mercy Hospital Fort Smith|CHI Saint Vincent Cancer Center Hot Springs|Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro|University of Arkansas for Medical Sciences|Highlands Oncology Group|Highlands Oncology Group - Springdale|Kaiser Permanente-Anaheim|Kaiser Permanente-Deer Valley Medical Center|Mission Hope Medical Oncology - Arroyo Grande|PCR Oncology|Sutter Auburn Faith Hospital|Sutter Cancer Centers Radiation Oncology Services-Auburn|AIS Cancer Center at San Joaquin Community Hospital|Kaiser Permanente-Baldwin Park|Kaiser Permanente-Bellflower|Alta Bates Summit Medical Center-Herrick Campus|Providence Saint Joseph Medical Center/Disney Family Cancer Center|Mills-Peninsula Medical Center|Sutter Cancer Centers Radiation Oncology Services-Cameron Park|Eden Hospital Medical Center|UC Irvine Health Cancer Center-Newport|Sutter Davis Hospital|City of Hope Comprehensive Cancer Center|Epic Care-Dublin|Kaiser Permanente Dublin|Bay Area Breast Surgeons Inc|Epic Care Partners in Cancer Care|Kaiser Permanente-Fontana|Kaiser Permanente-Fremont|Palo Alto Medical Foundation-Fremont|Kaiser Permanente-Fresno|Kaiser Permanente - Harbor City|Keck Medicine of USC Huntington Beach|Kaiser Permanente-Irvine|UC San Diego Moores Cancer Center|Loma Linda University Medical Center|Kaiser Permanente Los Angeles Medical Center|Los Angeles County-USC Medical Center|USC / Norris Comprehensive Cancer Center|Kaiser Permanente West Los Angeles|Cedars Sinai Medical Center|Contra Costa Regional Medical Center|Fremont - Rideout Cancer Center|Mercy UC Davis Cancer Center|Memorial Medical Center|Kaiser Permanente-Modesto|Palo Alto Medical Foundation-Camino Division|Palo Alto Medical Foundation-Gynecologic Oncology|Providence Queen of The Valley|USC Norris Oncology/Hematology-Newport Beach|Sutter Cancer Research Consortium|Alta Bates Summit Medical Center - Summit Campus|Bay Area Tumor Institute|Kaiser Permanente-Oakland|Kaiser Permanente-Ontario|Saint Joseph Hospital - Orange|UC Irvine Health/Chao Family Comprehensive Cancer Center|Desert Regional Medical Center|Palo Alto Medical Foundation Health Care|Kaiser Permanente - Panorama City|Keck Medical Center of USC Pasadena|Eisenhower Medical Center|Kaiser Permanente- Marshall Medical Offices|Kaiser Permanente-Redwood City|Kaiser Permanente-Richmond|Kaiser Permanente-Riverside|Kaiser Permanente-Roseville|Sutter Cancer Centers Radiation Oncology Services-Roseville|Sutter Roseville Medical Center|Kaiser Permanente Downtown Commons|Sutter Medical Center Sacramento|University of California Davis Comprehensive Cancer Center|Kaiser Permanente-South Sacramento|Kaiser Permanente - Sacramento|Kaiser Permanente-San Diego Mission|Kaiser Permanente-San Diego Zion|Sharp Memorial Hospital|California Pacific Medical Center-Pacific Campus|Kaiser Permanente-San Francisco|Kaiser Permanente-Santa Teresa-San Jose|Kaiser Permanente San Leandro|Pacific Central Coast Health Center-San Luis Obispo|Kaiser Permanente-San Marcos|Mills Health Center|Kaiser Permanente-San Rafael|Kaiser San Rafael-Gallinas|Kaiser Permanente Medical Center - Santa Clara|Palo Alto Medical Foundation-Santa Cruz|Mission Hope Medical Oncology - Santa Maria|Kaiser Permanente-Santa Rosa|Providence Medical Foundation - Santa Rosa|Sutter Pacific Medical Foundation|Providence Santa Rosa Memorial Hospital|Kaiser Permanente-South San Francisco|Kaiser Permanente-Stockton|Palo Alto Medical Foundation-Sunnyvale|Gene Upshaw Memorial Tahoe Forest Cancer Center|Sutter Cancer Centers Radiation Oncology Services-Vacaville|Kaiser Permanente Medical Center-Vacaville|Kaiser Permanente-Vallejo|Sutter Solano Medical Center/Cancer Center|Kaiser Permanente-Walnut Creek|Epic Care Cyberknife Center|Kaiser Permanente-Woodland Hills|Rocky Mountain Cancer Centers-Aurora|The Medical Center of Aurora|University of Colorado Hospital|Boulder Community Hospital|Boulder Community Foothills Hospital|Rocky Mountain Cancer Centers-Boulder|Rocky Mountain Cancer Centers - Centennial|Penrose-Saint Francis Healthcare|Rocky Mountain Cancer Centers-Penrose|UCHealth Memorial Hospital Central|Memorial Hospital North|Saint Francis Cancer Center|Cancer Center of Colorado at Sloan's Lake|Denver Health Medical Center|Kaiser Permanente-Franklin|National Jewish Health-Main Campus|The Women's Imaging Center|Porter Adventist Hospital|Colorado Blood Cancer Institute|Presbyterian - Saint Lukes Medical Center - Health One|Rocky Mountain Cancer Centers-Midtown|SCL Health Saint Joseph Hospital|Rocky Mountain Cancer Centers-Rose|Rose Medical Center|Mercy Medical Center|Southwest Oncology PC|Mountain Blue Cancer Care Center - Swedish|Rocky Mountain Cancer Centers - Swedish|Swedish Medical Center|The Melanoma and Skin Cancer Institute|Poudre Valley Hospital|Valley View Hospital Cancer Center|Mountain Blue Cancer Care Center|National Jewish Health-Western Hematology Oncology|Saint Mary's Hospital and Regional Medical Center|Grand Valley Oncology|North Colorado Medical Center|Rocky Mountain Cancer Centers-Greenwood Village|Good Samaritan Medical Center|Kaiser Permanente-Rock Creek|Rocky Mountain Cancer Centers-Lakewood|Saint Anthony Hospital|Rocky Mountain Cancer Centers-Littleton|Littleton Adventist Hospital|Kaiser Permanente-Lone Tree|Rocky Mountain Cancer Centers-Sky Ridge|Sky Ridge Medical Center|Longmont United Hospital|Rocky Mountain Cancer Centers-Longmont|McKee Medical Center|Parker Adventist Hospital|Rocky Mountain Cancer Centers-Parker|Saint Mary Corwin Medical Center|Rocky Mountain Cancer Centers - Pueblo|National Jewish Health-Northern Hematology Oncology|Rocky Mountain Cancer Centers-Thornton|SCL Health Lutheran Medical Center|Smilow Cancer Hospital-Derby Care Center|Smilow Cancer Hospital Care Center-Fairfield|Smilow Cancer Hospital Care Center - Guiford|Smilow Cancer Hospital Care Center at Saint Francis|Smilow Cancer Center/Yale-New Haven Hospital|Yale University|Yale-New Haven Hospital North Haven Medical Center|Stamford Hospital/Bennett Cancer Center|Smilow Cancer Hospital Care Center-Trumbull|Smilow Cancer Hospital-Waterbury Care Center|Veterans Affairs Connecticut Healthcare System-West Haven Campus|Beebe South Coastal Health Campus|Beebe Medical Center|Delaware Clinical and Laboratory Physicians PA|Helen F Graham Cancer Center|Medical Oncology Hematology Consultants PA|Christiana Care Health System-Christiana Hospital|Beebe Health Campus|TidalHealth Nanticoke / Allen Cancer Center|Christiana Care Health System-Wilmington Hospital|MedStar Georgetown University Hospital|Sibley Memorial Hospital|AdventHealth Altamonte|Mount Sinai Comprehensive Cancer Center at Aventura|Holy Cross Hospital|University of Florida Health Science Center - Gainesville|Memorial Regional Hospital/Joe DiMaggio Children's Hospital|AdventHealth Kissimmee|Mount Sinai Medical Center|AdventHealth Medical Group Urology at Orlando|AdventHealth Orlando|Orlando Health Cancer Institute|AdventHealth East Orlando|Memorial Hospital West|Moffitt Cancer Center-International Plaza|Moffitt Cancer Center - McKinley Campus|Moffitt Cancer Center|AdventHealth Winter Park|Emory University Hospital Midtown|Piedmont Hospital|Emory University Hospital/Winship Cancer Institute|Emory Saint Joseph's Hospital|John B Amos Cancer Center|Atlanta VA Medical Center|Piedmont Fayette Hospital|Harbin Clinic Medical Oncology and Clinical Research|Low Country Cancer Care|Lewis Cancer and Research Pavilion at Saint Joseph's/Candler|Summit Cancer Care-Candler|South Georgia Medical Center/Pearlman Cancer Center|Hawaii Cancer Care - Savio|Pali Momi Medical Center|Queen's Cancer Center - Pearlridge|The Cancer Center of Hawaii-Pali Momi|The Queen's Medical Center - West Oahu|Hawaii Cancer Care Inc - Waterfront Plaza|Island Urology|Queen's Cancer Cenrer - POB I|Queen's Medical Center|Straub Clinic and Hospital|University of Hawaii Cancer Center|Hawaii Cancer Care Inc-Liliha|Hawaii Diagnostic Radiology Services LLC|Kuakini Medical Center|Queen's Cancer Center - Kuakini|The Cancer Center of Hawaii-Liliha|Kaiser Permanente Moanalua Medical Center|Kapiolani Medical Center for Women and Children|Straub Medical Center - Kahului Clinic|Castle Medical Center|Wilcox Memorial Hospital and Kauai Medical Clinic|Saint Alphonsus Cancer Care Center-Boise|Saint Luke's Cancer Institute - Boise|Saint Alphonsus Cancer Care Center-Caldwell|Kootenai Health - Coeur d'Alene|Walter Knox Memorial Hospital|Saint Luke's Cancer Institute - Fruitland|Idaho Urologic Institute-Meridian|Saint Luke's Cancer Institute - Meridian|Saint Alphonsus Medical Center-Nampa|Saint Luke's Cancer Institute - Nampa|Kootenai Clinic Cancer Services - Post Falls|Kootenai Cancer Clinic|Saint Luke's Cancer Institute - Twin Falls|Saint Anthony's Health|Rush - Copley Medical Center|Saint Joseph Medical Center|Illinois CancerCare-Bloomington|Loyola Center for Health at Burr Ridge|Illinois CancerCare-Canton|Memorial Hospital of Carbondale|SIH Cancer Institute|Illinois CancerCare-Carthage|Centralia Oncology Clinic|Mount Sinai Hospital Medical Center|Northwestern University|John H Stroger Jr Hospital of Cook County|Rush University Medical Center|University of Chicago Comprehensive Cancer Center|Advocate Illinois Masonic Medical Center|Carle on Vermilion|Cancer Care Specialists of Illinois - Decatur|Decatur Memorial Hospital|Northwestern Medicine Cancer Center Kishwaukee|Illinois CancerCare-Dixon|Carle Physician Group-Effingham|Crossroads Cancer Center|Illinois CancerCare-Eureka|Illinois CancerCare-Galesburg|Western Illinois Cancer Treatment Center|Northwestern Medicine Cancer Center Delnor|Ingalls Memorial Hospital|Loyola Medicine Homer Glen|Presence Saint Mary's Hospital|Illinois CancerCare-Kewanee Clinic|Northwestern Medicine Lake Forest Hospital|Illinois CancerCare-Macomb|Carle Physician Group-Mattoon/Charleston|Loyola University Medical Center|Marjorie Weinberg Cancer Center at Loyola-Gottlieb|Good Samaritan Regional Health Center|UC Comprehensive Cancer Center at Silver Cross|Cancer Care Center of O'Fallon|University of Chicago Medicine-Orland Park|Illinois CancerCare-Ottawa Clinic|Illinois CancerCare-Pekin|OSF Saint Francis Radiation Oncology at Pekin Cancer Treatment Center|Illinois CancerCare-Peoria|OSF Saint Francis Radiation Oncology at Peoria Cancer Center|Methodist Medical Center of Illinois|OSF Saint Francis Medical Center|Illinois CancerCare-Peru|Valley Radiation Oncology|Illinois CancerCare-Princeton|Southern Illinois University School of Medicine|Springfield Clinic|Memorial Medical Center|Southwest Illinois Health Services LLP|Carle Cancer Center|The Carle Foundation Hospital|Northwestern Medicine Cancer Center Warrenville|Illinois CancerCare - Washington|Rush-Copley Healthcare Center|Midwestern Regional Medical Center|IU Health West Hospital|IU Health North Hospital|Deaconess Clinic Downtown|Parkview Regional Medical Center|Indiana University/Melvin and Bren Simon Cancer Center|Sidney and Lois Eskenazi Hospital|Springmill Medical Center|Memorial Regional Cancer Center Day Road|Chancellor Center for Oncology|Reid Health|Memorial Hospital of South Bend|Mary Greeley Medical Center|McFarland Clinic PC - Ames|McFarland Clinic PC-Boone|Saint Anthony Regional Hospital|Mercy Hospital|Oncology Associates at Mercy Medical Center|Medical Oncology and Hematology Associates-West Des Moines|Mercy Cancer Center-West Lakes|Alegent Health Mercy Hospital|Greater Regional Medical Center|Iowa Methodist Medical Center|Medical Oncology and Hematology Associates-Des Moines|Broadlawns Medical Center|Medical Oncology and Hematology Associates-Laurel|Mercy Medical Center - Des Moines|Iowa Lutheran Hospital|McFarland Clinic PC-Trinity Cancer Center|Trinity Regional Medical Center|McFarland Clinic PC-Jefferson|McFarland Clinic PC-Marshalltown|Methodist West Hospital|Mercy Medical Center-West Lakes|Cancer Center of Kansas - Chanute|Coffeyville Regional Medical Center|Cancer Center of Kansas - Dodge City|Cancer Center of Kansas - El Dorado|University of Kansas Clinical Research Center|Cancer Center of Kansas - Fort Scott|Central Care Cancer Center - Garden City|Saint Catherine Hospital|Central Care Cancer Center - Great Bend|HaysMed University of Kansas Health System|Cancer Center of Kansas-Independence|University of Kansas Cancer Center-West|University of Kansas Cancer Center|Cancer Center of Kansas-Kingman|Lawrence Memorial Hospital|Cancer Center of Kansas-Liberal|Cancer Center of Kansas-Manhattan|Cancer Center of Kansas - McPherson|Cancer Center of Kansas - Newton|Olathe Health Cancer Center|University of Kansas Cancer Center-Overland Park|University of Kansas Hospital-Indian Creek Campus|Cancer Center of Kansas - Parsons|Ascension Via Christi - Pittsburg|Cancer Center of Kansas - Pratt|Cancer Center of Kansas - Salina|Salina Regional Health Center|University of Kansas Health System Saint Francis Campus|Cancer Center of Kansas - Wellington|University of Kansas Hospital-Westwood Cancer Center|Associates In Womens Health|Cancer Center of Kansas-Wichita Medical Arts Tower|Ascension Via Christi Hospitals Wichita|Cancer Center of Kansas - Wichita|Wesley Medical Center|Cancer Center of Kansas - Winfield|Flaget Memorial Hospital|Commonwealth Cancer Center-Corbin|Saint Joseph Radiation Oncology Resource Center|Saint Joseph Hospital East|Saint Joseph London|Jewish Hospital|Saints Mary and Elizabeth Hospital|UofL Health Medical Center Northeast|Jewish Hospital Medical Center South|Baton Rouge General Medical Center|Hematology/Oncology Clinic PLLC|Ochsner Health Center-Summa|Medical Center of Baton Rouge|Ochsner High Grove|Ochsner Medical Center Kenner|East Jefferson General Hospital|LSU Healthcare Network / Metairie Multi-Specialty Clinic|Louisiana State University Health Science Center|Tulane University Health Sciences Center|University Medical Center New Orleans|Ochsner Medical Center Jefferson|Eastern Maine Medical Center|Lafayette Family Cancer Center-EMMC|Greater Baltimore Medical Center|Johns Hopkins University/Sidney Kimmel Cancer Center|National Institutes of Health Clinical Center|Western Maryland Regional Medical Center|Frederick Memorial Hospital|FMH James M Stockman Cancer Institute|Lahey Hospital and Medical Center|Lahey Medical Center-Peabody|Mercy Medical Center|Baystate Medical Center|Hickman Cancer Center|Saint Joseph Mercy Hospital|University of Michigan Comprehensive Cancer Center|Bronson Battle Creek|IHA Hematology Oncology Consultants-Brighton|Saint Joseph Mercy Brighton|University of Michigan - Brighton Center for Specialty Care|Henry Ford Cancer Institute-Downriver|IHA Hematology Oncology Consultants-Canton|Saint Joseph Mercy Canton|Caro Cancer Center|IHA Hematology Oncology Consultants-Chelsea|Saint Joseph Mercy Chelsea|Hematology Oncology Consultants-Clarkston|Newland Medical Associates-Clarkston|Henry Ford Macomb Hospital-Clinton Township|Beaumont Hospital - Dearborn|Henry Ford Medical Center-Fairlane|Henry Ford Hospital|Ascension Saint John Hospital|Great Lakes Cancer Management Specialists-Doctors Park|Green Bay Oncology - Escanaba|Genesee Cancer and Blood Disease Treatment Center|Genesee Hematology Oncology PC|Genesys Hurley Cancer Institute|Hurley Medical Center|Helen DeVos Children's Hospital at Spectrum Health|Mercy Health Saint Mary's|Spectrum Health at Butterworth Campus|Academic Hematology Oncology Specialists|Great Lakes Cancer Management Specialists-Van Elslander Cancer Center|Michigan Breast Specialists-Grosse Pointe Woods|Allegiance Health|Bronson Methodist Hospital|West Michigan Cancer Center|Ascension Borgess Cancer Center|Borgess Medical Center|Sparrow Hospital|Hope Cancer Clinic|Saint Mary Mercy Hospital|Great Lakes Cancer Management Specialists-Macomb Medical Campus|Michigan Breast Specialists-Macomb Township|Green Bay Oncology-Manistique|Saint Mary's Oncology/Hematology Associates of Marlette|Monroe Cancer Center|Toledo Clinic Cancer Centers-Monroe|Mercy Health Mercy Campus|Lakeland Hospital Niles|Cancer and Hematology Centers of Western Michigan - Norton Shores|Ascension Providence Hospitals - Novi|Henry Ford Medical Center-Columbus|21st Century Oncology-Pontiac|Hope Cancer Center|Newland Medical Associates-Pontiac|Saint Joseph Mercy Oakland|Huron Medical Center PC|Lake Huron Medical Center|Spectrum Health Reed City Hospital|Great Lakes Cancer Management Specialists-Rochester Hills|Ascension Saint Mary's Hospital|Oncology Hematology Associates of Saginaw Valley PC|Lakeland Medical Center Saint Joseph|Marie Yeager Cancer Center|Henry Ford Macomb Health Center - Shelby Township|Ascension Providence Hospitals - Southfield|Bhadresh Nayak MD PC-Sterling Heights|Ascension Saint Joseph Hospital|Munson Medical Center|Advanced Breast Care Center PLLC|Great Lakes Cancer Management Specialists-Macomb Professional Building|Macomb Hematology Oncology PC|Michigan Breast Specialists-Warren|Saint John Macomb-Oakland Hospital|Henry Ford West Bloomfield Hospital|Saint Mary's Oncology/Hematology Associates of West Branch|Henry Ford Wyandotte Hospital|Metro Health Hospital|Huron Gastroenterology PC|IHA Hematology Oncology Consultants-Ann Arbor|Riverwood Healthcare Center|Sanford Joe Lueken Cancer Center|Essentia Health Saint Joseph's Medical Center|Fairview Ridges Hospital|Minnesota Oncology - Burnsville|Cambridge Medical Center|Mercy Hospital|Essentia Health - Deer River Clinic|Essentia Health Saint Mary's - Detroit Lakes Clinic|Essentia Health Cancer Center|Essentia Health Saint Mary's Medical Center|Miller-Dwan Hospital|Fairview Southdale Hospital|Lake Region Healthcare Corporation-Cancer Care|Essentia Health - Fosston|Unity Hospital|Essentia Health Hibbing Clinic|Fairview Clinics and Surgery Center Maple Grove|Minnesota Oncology Hematology PA-Maplewood|Saint John's Hospital - Healtheast|Abbott-Northwestern Hospital|Hennepin County Medical Center|Health Partners Inc|Monticello Cancer Center|New Ulm Medical Center|Essentia Health - Park Rapids|Fairview Northland Medical Center|North Memorial Medical Health Center|Park Nicollet Clinic - Saint Louis Park|Regions Hospital|United Hospital|Essentia Health Sandstone|Saint Francis Regional Medical Center|Lakeview Hospital|Sanford Thief River Falls Medical Center|Essentia Health Virginia Clinic|Ridgeview Medical Center|Rice Memorial Hospital|Minnesota Oncology Hematology PA-Woodbury|Sanford Cancer Center Worthington|Fairview Lakes Medical Center|Baptist Memorial Hospital and Cancer Center-Golden Triangle|Baptist Cancer Center-Grenada|Gulfport Memorial Hospital|Hattiesburg Clinic - Hematology/Oncology Clinic|Forrest General Hospital / Cancer Center|University of Mississippi Medical Center|Baptist Memorial Hospital and Cancer Center-Union County|Baptist Memorial Hospital and Cancer Center-Oxford|Baptist Memorial Hospital and Cancer Center-Desoto|Saint Louis Cancer and Breast Institute-Ballwin|Central Care Cancer Center - Bolivar|Parkland Health Center-Bonne Terre|Cox Cancer Center Branson|Saint Francis Medical Center|Southeast Cancer Center|Saint Luke's Hospital|Siteman Cancer Center at West County Hospital|Parkland Health Center - Farmington|Capital Region Southwest Campus|Freeman Health System|Mercy Hospital Joplin|Truman Medical Centers|Kansas City Veterans Affairs Medical Center|The University of Kansas Cancer Center-South|University of Kansas Cancer Center - North|University of Kansas Cancer Center - Lee's Summit|Delbert Day Cancer Institute at PCRMC|Mercy Clinic-Rolla-Cancer and Hematology|Heartland Regional Medical Center|Saint Louis Cancer and Breast Institute-South City|Washington University School of Medicine|Mercy Hospital South|Siteman Cancer Center-South County|Missouri Baptist Medical Center|Siteman Cancer Center at Christian Hospital|Mercy Hospital Saint Louis|Siteman Cancer Center at Saint Peters Hospital|Sainte Genevieve County Memorial Hospital|Mercy Hospital Springfield|CoxHealth South Hospital|Missouri Baptist Sullivan Hospital|Missouri Baptist Outpatient Center-Sunset Hills|Mercy Hospital Washington|Community Hospital of Anaconda|Billings Clinic Cancer Center|Saint Vincent Healthcare|Saint Vincent Frontier Cancer Center|Bozeman Deaconess Hospital|Saint James Community Hospital and Cancer Treatment Center|Benefis Healthcare- Sletten Cancer Institute|Great Falls Clinic|Saint Peter's Community Hospital|Kalispell Regional Medical Center|Community Medical Hospital|CHI Health Saint Francis|Heartland Hematology and Oncology|CHI Health Good Samaritan|Saint Elizabeth Regional Medical Center|Nebraska Cancer Specialists/Oncology Hematology West PC - MECC|Nebraska Methodist Hospital|Alegent Health Immanuel Medical Center|Hematology and Oncology Consultants PC|Alegent Health Bergan Mercy Medical Center|Alegent Health Lakeside Hospital|Creighton University Medical Center|Midlands Community Hospital|Carson Tahoe Regional Medical Center|Cancer and Blood Specialists-Henderson|Comprehensive Cancer Centers of Nevada - Henderson|Comprehensive Cancer Centers of Nevada-Horizon Ridge|Las Vegas Cancer Center-Henderson|OptumCare Cancer Care at Seven Hills|Comprehensive Cancer Centers of Nevada-Southeast Henderson|GenesisCare USA - Henderson|Las Vegas Urology - Green Valley|Las Vegas Urology - Pebble|Urology Specialists of Nevada - Green Valley|Las Vegas Urology - Pecos|Desert West Surgery|OptumCare Cancer Care at Charleston|University Medical Center of Southern Nevada|Hope Cancer Care of Nevada|Cancer and Blood Specialists-Shadow|Radiation Oncology Centers of Nevada Central|Urology Specialists of Nevada - Central|GenesisCare USA - Las Vegas|HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway|Sunrise Hospital and Medical Center|HealthCare Partners Medical Group Oncology/Hematology-San Martin|Las Vegas Prostate Cancer Center|Las Vegas Urology - Sunset|Urology Specialists of Nevada - Southwest|Radiation Oncology Centers of Nevada Southeast|Cancer Therapy and Integrative Medicine|Ann M Wierman MD LTD|Cancer and Blood Specialists-Tenaya|Comprehensive Cancer Centers of Nevada - Northwest|GenesisCare USA - Vegas Tenaya|HealthCare Partners Medical Group Oncology/Hematology-Tenaya|Las Vegas Urology - Cathedral Rock|Las Vegas Urology - Smoke Ranch|OptumCare Cancer Care at MountainView|Urology Specialists of Nevada - Northwest|Alliance for Childhood Diseases/Cure 4 the Kids Foundation|Comprehensive Cancer Centers of Nevada - Town Center|Comprehensive Cancer Centers of Nevada-Summerlin|Summerlin Hospital Medical Center|Las Vegas Cancer Center-Medical Center|Comprehensive Cancer Centers of Nevada|GenesisCare USA - Fort Apache|OptumCare Cancer Care at Fort Apache|HealthCare Partners Medical Group Oncology/Hematology-Centennial Hills|Comprehensive Cancer Centers of Nevada - Central Valley|University Cancer Center|Hope Cancer Care of Nevada-Pahrump|Renown Regional Medical Center|Saint Mary's Regional Medical Center|Radiation Oncology Associates|Dartmouth Hitchcock Medical Center|Norris Cotton Cancer Center-Manchester|Norris Cotton Cancer Center-Nashua|Morristown Medical Center|Chilton Medical Center|Overlook Hospital|Inspira Medical Center Vineland|Lovelace Medical Center-Saint Joseph Square|University of New Mexico Cancer Center|Southwest Gynecologic Oncology Associates Inc|New Mexico Oncology Hematology Consultants|Presbyterian Kaseman Hospital|Memorial Medical Center - Las Cruces|Presbyterian Rust Medical Center/Jorgensen Cancer Center|Christus Saint Vincent Regional Cancer Center|Montefiore Medical Center-Einstein Campus|Montefiore Medical Center-Weiler Hospital|Montefiore Medical Center - Moses Campus|Roswell Park Cancer Institute|Arnot Ogden Medical Center/Falck Cancer Center|Glens Falls Hospital|Laura and Isaac Perlmutter Cancer Center at NYU Langone|University of Rochester|Stony Brook University Medical Center|AdventHealth Infusion Center Asheville|Southeastern Medical Oncology Center-Clinton|AdventHealth Infusion Center Haywood|Southeastern Medical Oncology Center-Goldsboro|Wayne Memorial Hospital|Margaret R Pardee Memorial Hospital|AdventHealth Hendersonville|Onslow Memorial Hospital|Southeastern Medical Oncology Center-Jacksonville|Vidant Oncology-Kenansville|Vidant Oncology-Kinston|Vidant Oncology-Richlands|AdventHealth Infusion Center Weaverville|Sanford Bismarck Medical Center|Essentia Health Cancer Center-South University Clinic|Sanford South University Medical Center|Sanford Broadway Medical Center|Sanford Roger Maris Cancer Center|Essentia Health - Jamestown Clinic|Indu and Raj Soin Medical Center|Strecker Cancer Center-Belpre|Saint Elizabeth Boardman Hospital|Cleveland Clinic Mercy Hospital|Mercy Hematology and Oncology Associates Inc|Dayton Physicians LLC-Miami Valley South|Miami Valley Hospital South|Adena Regional Medical Center|Good Samaritan Hospital - Cincinnati|Oncology Hematology Care Inc-Kenwood|Bethesda North Hospital|TriHealth Cancer Institute-Westside|TriHealth Cancer Institute-Anderson|MetroHealth Medical Center|Cleveland Clinic Foundation|Ohio State University Comprehensive Cancer Center|Mount Carmel East Hospital|Columbus Oncology and Hematology Associates Inc|Riverside Methodist Hospital|Grant Medical Center|The Mark H Zangmeister Center|Mount Carmel Health Center West|Doctors Hospital|Good Samaritan Hospital - Dayton|Miami Valley Hospital|Dayton Physician LLC-Miami Valley Hospital North|Miami Valley Hospital North|Delaware Health Center-Grady Cancer Center|Delaware Radiation Oncology|Grady Memorial Hospital|Columbus Oncology and Hematology Associates|Dublin Methodist Hospital|Armes Family Cancer Center|Blanchard Valley Hospital|Orion Cancer Care|Atrium Medical Center-Middletown Regional Hospital|Dayton Physicians LLC-Atrium|Dayton Physicians LLC-Wayne|Wayne Hospital|Mount Carmel Grove City Hospital|Greater Dayton Cancer Center|First Dayton Cancer Care|Kettering Medical Center|Fairfield Medical Center|Saint Rita's Medical Center|OhioHealth Mansfield Hospital|Marietta Memorial Hospital|OhioHealth Marion General Hospital|Toledo Clinic Cancer Centers-Maumee|Toledo Radiation Oncology at Northwest Ohio Onocolgy Center|Dayton Physicians LLC-Signal Point|Knox Community Hospital|Licking Memorial Hospital|Newark Radiation Oncology|Mercy Health Perrysburg Cancer Center|Southern Ohio Medical Center|North Coast Cancer Care|Dayton Physicians LLC-Wilson|Springfield Regional Cancer Center|Springfield Regional Medical Center|ProMedica Flower Hospital|ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital|Saint Vincent Mercy Medical Center|Mercy Health - Saint Anne Hospital|Toledo Clinic Cancer Centers-Toledo|Dayton Physicians LLC-Upper Valley|Upper Valley Medical Center|South Pointe Hospital|Saint Joseph Warren Hospital|Saint Ann's Hospital|Saint Elizabeth Youngstown Hospital|Genesis Healthcare System Cancer Care Center|Cancer Centers of Southwest Oklahoma Research|University of Oklahoma Health Sciences Center|Mercy Hospital Oklahoma City|Cancer Treatment Centers of America|Oklahoma Cancer Specialists and Research Institute-Tulsa|Saint Alphonsus Medical Center-Baker City|Saint Charles Health System|Clackamas Radiation Oncology Center|Providence Cancer Institute Clackamas Clinic|Bay Area Hospital|Legacy Mount Hood Medical Center|Providence Newberg Medical Center|Saint Alphonsus Medical Center-Ontario|Providence Willamette Falls Medical Center|Legacy Good Samaritan Hospital and Medical Center|Providence Portland Medical Center|Providence Saint Vincent Medical Center|Kaiser Permanente Northwest|Oregon Health and Science University|Saint Charles Health System-Redmond|Legacy Meridian Park Hospital|Lehigh Valley Hospital-Cedar Crest|UPMC-Heritage Valley Health System Beaver|Lehigh Valley Hospital - Muhlenberg|Christiana Care Health System-Concord Health Center|UPMC Hillman Cancer Center - Passavant - Cranberry|Doylestown Hospital|Pocono Medical Center|Saint Vincent Hospital|UPMC Cancer Centers - Arnold Palmer Pavilion|Lehigh Valley Hospital-Hazleton|Jefferson Hospital|UPMC-Johnstown/John P. Murtha Regional Cancer Center|UPMC Cancer Center at UPMC McKeesport|Forbes Hospital|UPMC Hillman Cancer Center - Monroeville|UPMC-Coraopolis/Heritage Valley Radiation Oncology|UPMC Hillman Cancer Center - Part of Frick Hospital|Arnold Palmer Cancer Center Medical Oncology Norwin|Thomas Jefferson University Hospital|Eastern Regional Medical Center|Temple University Hospital|Allegheny General Hospital|UPMC-Magee Womens Hospital|UPMC-Presbyterian Hospital|UPMC-Saint Margaret|West Penn Hospital|University of Pittsburgh Cancer Institute (UPCI)|UPMC-Shadyside Hospital|UPMC-Passavant Hospital|UPMC-Saint Clair Hospital Cancer Center|Pottstown Hospital|UPMC Cancer Center at UPMC Northwest|UPMC Uniontown Hospital Radiation Oncology|UPMC Cancer Center-Washington|UPMC Washington Hospital Radiation Oncology|UPMC West Mifflin-Cancer Center Jefferson|Wexford Health and Wellness Pavilion|Prisma Health Cancer Institute - Spartanburg|Medical University of South Carolina|Prisma Health Cancer Institute - Laurens|Prisma Health Cancer Institute - Easley|Gibbs Cancer Center-Gaffney|Tidelands Georgetown Memorial Hospital|Saint Francis Hospital|Prisma Health Cancer Institute - Butternut|Prisma Health Cancer Institute - Faris|Prisma Health Greenville Memorial Hospital|Saint Francis Cancer Center|Prisma Health Cancer Institute - Eastside|Prisma Health Cancer Institute - Greer|Gibbs Cancer Center-Pelham|Prisma Health Cancer Institute - Seneca|North Grove Medical Park|Spartanburg Medical Center|Spartanburg Medical Center - Mary Black Campus|MGC Hematology Oncology-Union|Sanford Cancer Center Oncology Clinic|Sanford USD Medical Center - Sioux Falls|Memorial Hospital|Baptist Memorial Hospital and Cancer Center-Collierville|Vanderbilt-Ingram Cancer Center Cool Springs|Pulmonary Medicine Center of Chattanooga-Hixson|Baptist Memorial Hospital and Cancer Center-Memphis|Vanderbilt Breast Center at One Hundred Oaks|Meharry Medical College|Vanderbilt University/Ingram Cancer Center|Memorial GYN Plus|Saint Joseph Regional Cancer Center|Parkland Memorial Hospital|Baylor University Medical Center|UT Southwestern/Simmons Cancer Center-Dallas|UT Southwestern/Simmons Cancer Center-Fort Worth|Lyndon Baines Johnson General Hospital|M D Anderson Cancer Center|UT Southwestern Clinical Center at Richardson/Plano|University Hospital|University of Texas Health Science Center at San Antonio|American Fork Hospital / Huntsman Intermountain Cancer Center|Sandra L Maxwell Cancer Center|Farmington Health Center|Logan Regional Hospital|Intermountain Medical Center|McKay-Dee Hospital Center|Utah Valley Regional Medical Center|Riverton Hospital|Dixie Medical Center Regional Cancer Center|Utah Cancer Specialists-Salt Lake City|Huntsman Cancer Institute/University of Utah|LDS Hospital|South Jordan Health Center|Central Vermont Medical Center/National Life Cancer Treatment|University of Vermont Medical Center|University of Vermont and State Agricultural College|Norris Cotton Cancer Center-North|Virginia Commonwealth University/Massey Cancer Center|Providence Regional Cancer System-Aberdeen|Cancer Care Center at Island Hospital|MultiCare Auburn Medical Center|Virginia Mason Bainbridge Island Medical Center|Overlake Medical Center|PeaceHealth Saint Joseph Medical Center|Harrison HealthPartners Hematology and Oncology-Bremerton|Harrison Medical Center|Highline Medical Center-Main Campus|Providence Regional Cancer System-Centralia|Swedish Cancer Institute-Edmonds|Saint Elizabeth Hospital|Providence Regional Cancer Partnership|Virginia Mason Federal Way Medical Center|Saint Francis Hospital|Tacoma/Valley Radiation Oncology Centers-Gig Harbor|MultiCare Gig Harbor Medical Park|Swedish Cancer Institute-Issaquah|Kadlec Clinic Hematology and Oncology|Northwest Cancer Clinic|Providence Regional Cancer System-Lacey|Saint Clare Hospital|PeaceHealth Saint John Medical Center|Virginia Mason Lynnwood Medical Center|Skagit Valley Hospital Regional Cancer Care Center|Skagit Valley Hospital|Jefferson Healthcare|Harrison HealthPartners Hematology and Oncology-Poulsbo|Peninsula Cancer Center|MultiCare Good Samaritan Hospital|Tacoma/Valley Radiation Oncology Centers-Puyallup|Valley Medical Center|Virginia Mason Medical Center|Pacific Gynecology Specialists|Swedish Medical Center-Ballard Campus|Fred Hutchinson Cancer Research Center|Seattle Cancer Care Alliance|Kaiser Permanente Washington|Swedish Medical Center-First Hill|University of Washington Medical Center - Montlake|PeaceHealth United General Medical Center|Providence Regional Cancer System-Shelton|MultiCare Deaconess Cancer and Blood Specialty Center - Valley|MultiCare Deaconess Cancer and Blood Specialty Center - Downtown|Spokane Valley Cancer Center-Mayfair|Spokane Valley Cancer Center-Mission|MultiCare Deaconess Cancer and Blood Specialty Center - North|Tacoma/Valley Radiation Oncology Centers-Jackson Hall|Franciscan Research Center-Northwest Medical Plaza|Mary Bridge Children's Hospital and Health Center|MultiCare Tacoma General Hospital|Northwest Medical Specialties PLLC|Tacoma/Valley Radiation Oncology Centers-Saint Joe's|PeaceHealth Southwest Medical Center|Legacy Cancer Institute Medical Oncology and Day Treatment|Legacy Salmon Creek Hospital|Providence Saint Mary Regional Cancer Center|Wenatchee Valley Hospital and Clinics|North Star Lodge Cancer Center at Yakima Valley Memorial Hospital|Providence Regional Cancer System-Yelm|Edwards Comprehensive Cancer Center|Ascension Saint Elizabeth Hospital|Duluth Clinic Ashland|Northwest Wisconsin Cancer Center|Ascension Southeast Wisconsin Hospital - Elmbrook Campus|Ascension Calumet Hospital|Marshfield Clinic-Chippewa Center|Marshfield Clinic Cancer Center at Sacred Heart|Marshfield Medical Center-EC Cancer Center|Ascension Saint Francis - Reiman Cancer Center|Ascension Southeast Wisconsin Hospital - Franklin|Saint Vincent Hospital Cancer Center Green Bay|Saint Vincent Hospital Cancer Center at Saint Mary's|Gundersen Lutheran Medical Center|Marshfield Clinic - Ladysmith Center|Holy Family Memorial Hospital|Saint Vincent Hospital Cancer Center at Marinette|Marshfield Medical Center-Marshfield|Ascension Columbia Saint Mary's Hospital Ozaukee|Ascension Southeast Wisconsin Hospital - Saint Joseph Campus|Ascension Columbia Saint Mary's Hospital - Milwaukee|Ascension Saint Francis Hospital|Marshfield Clinic-Minocqua Center|Cancer Center of Western Wisconsin|Saint Vincent Hospital Cancer Center at Oconto Falls|Ascension Mercy Hospital|Ascension All Saints Hospital|Ascension Saint Mary's Hospital|Marshfield Medical Center-Rice Lake|HSHS Saint Nicholas Hospital|Ascension Saint Michael's Hospital|Marshfield Clinic Stevens Point Center|Saint Vincent Hospital Cancer Center at Sturgeon Bay|Marshfield Clinic-Wausau Center|Ascension Medical Group Southeast Wisconsin - Mayfair Road|Marshfield Medical Center - Weston|Marshfield Clinic - Wisconsin Rapids Center|Cheyenne Regional Medical Center-West|Billings Clinic-Cody|Welch Cancer Center|FHP Health Center-Guam,Procedure|Biological|Biological,Guam|United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02834013
NCT02838927,hypoparathyroidism,Epi-Hypo: Survey on Epidemiology of Hypoparathyroidism in France,Hypoparathyroidism,2016-07-09,2030-09-30,2031-09-30,Observational,Recruiting,,European Georges Pompidou Hospital,European Georges Pompidou Hospital|Oscar - Filière Santé Maladies Rares,"Felix Guyon Hospital|Hôpital Privé de Provence|Amiens University Hospital|Clinic Auch Area|Henri Mondor Hospital|Jean Minjoz Hospital|Avicenne Hospital, AP-HP|Jean Verdier Hospital, AP-HP|University Hospital|Bourgoin Jallieu Hospital|La Cavale Blanche Hospital|Côte de Nacre Hospital|Henri Mondor Hospital, APHP|Dax-Côte d'Argent Hospital|University Hospital|Grenoble Alpes Hospital|CHD Vendée|Kremlin-Bicêtre Hospital, APHP|Le Mans Hospital|Libourne Hospital|Claude Huriez Hospital|Edouard Herriot Hospital, HCL|La Conception Hospital, AP-HM|Clinic Metz Area|Mercy Hospital|Arnaud de Villeneuve Hospital|Clinic area|Brabois Hospital|University Hospital|University Hospital|Georges Renon Hospital|Caremeau Hospital|European Georges Pompidou Hospital, APHP|Clinic Paris Area|Cochin Hospital, APHP|Lariboisière Hospital, APHP|Necker Hospital, AP-HP|Pitié-Salpêtrière Hospital, APHP|Tenon Hospital, APHP|Clinic Poitiers Area|Laennec Hospital|Reims University Hospital|Clinic Rennes Area|Charles Nicolle Hospital|Clinic Area|Clinique du Landy|Hautepierre Hospital|Sainte Anne Hospital, HIA|Larrey Hospital|Guy Chatiliez Hospital|Bretonneau Hospital|Valenciennes Hospital|CHIV - Lucie et Raymond Aubrac",Other,France,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT02838927
NCT02867592,thyroid gland medullary carcinoma,"Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors",Adrenal Cortex Carcinoma|Alveolar Soft Part Sarcoma|Central Nervous System Neoplasm|Childhood Clear Cell Sarcoma of Soft Tissue|Clear Cell Sarcoma of Soft Tissue|Ewing Sarcoma|Hepatoblastoma|Hepatocellular Carcinoma|Osteosarcoma|Recurrent Adrenal Cortex Carcinoma|Recurrent Alveolar Soft Part Sarcoma|Recurrent Ewing Sarcoma|Recurrent Hepatoblastoma|Recurrent Hepatocellular Carcinoma|Recurrent Malignant Solid Neoplasm|Recurrent Osteosarcoma|Recurrent Primary Malignant Central Nervous System Neoplasm|Recurrent Renal Cell Carcinoma|Recurrent Rhabdomyosarcoma|Recurrent Soft Tissue Sarcoma|Recurrent Thyroid Gland Medullary Carcinoma|Refractory Ewing Sarcoma|Refractory Malignant Solid Neoplasm|Refractory Osteosarcoma|Refractory Primary Malignant Central Nervous System Neoplasm|Refractory Rhabdomyosarcoma|Refractory Soft Tissue Sarcoma|Renal Cell Carcinoma|Rhabdomyosarcoma|Solid Neoplasm|Thyroid Gland Medullary Carcinoma|Wilms Tumor,2016-08-15,2021-06-30,2022-07-01,Interventional,"Active, not recruiting",Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),Children's Hospital of Alabama|Providence Alaska Medical Center|Arkansas Children's Hospital|Kaiser Permanente-Anaheim|Kaiser Permanente-Bellflower|Kaiser Permanente Downey Medical Center|Kaiser Permanente-Fontana|Loma Linda University Medical Center|Children's Hospital Los Angeles|Kaiser Permanente Los Angeles Medical Center|Valley Children's Hospital|UCSF Benioff Children's Hospital Oakland|Kaiser Permanente-Oakland|Children's Hospital of Orange County|Lucile Packard Children's Hospital Stanford University|University of California Davis Comprehensive Cancer Center|Kaiser Permanente-San Diego Mission|Rady Children's Hospital - San Diego|UCSF Medical Center-Mission Bay|Children's Hospital Colorado|Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center|Connecticut Children's Medical Center|Yale University|Alfred I duPont Hospital for Children|Kaiser Permanente-Capitol Hill Medical Center|MedStar Georgetown University Hospital|Children's National Medical Center|Golisano Children's Hospital of Southwest Florida|University of Florida Health Science Center - Gainesville|Nemours Children's Clinic-Jacksonville|University of Miami Miller School of Medicine-Sylvester Cancer Center|Nicklaus Children's Hospital|AdventHealth Orlando|Arnold Palmer Hospital for Children|Nemours Children's Hospital|Nemours Children's Clinic - Pensacola|Johns Hopkins All Children's Hospital|Children's Healthcare of Atlanta - Egleston|Straub Clinic and Hospital|Kaiser Permanente Moanalua Medical Center|Kapiolani Medical Center for Women and Children|Saint Luke's Cancer Institute - Boise|Lurie Children's Hospital-Chicago|University of Illinois|University of Chicago Comprehensive Cancer Center|Carle on Vermilion|Carle Physician Group-Effingham|Carle Physician Group-Mattoon/Charleston|Saint Jude Midwest Affiliate|Carle Cancer Center|The Carle Foundation Hospital|Riley Hospital for Children|Saint Vincent Hospital and Health Care Center|Blank Children's Hospital|Iowa Methodist Medical Center|Iowa Lutheran Hospital|University of Iowa/Holden Comprehensive Cancer Center|University of Kentucky/Markey Cancer Center|Norton Children's Hospital|Children's Hospital New Orleans|Eastern Maine Medical Center|Lafayette Family Cancer Center-EMMC|Sinai Hospital of Baltimore|Johns Hopkins University/Sidney Kimmel Cancer Center|National Institutes of Health Clinical Center|Massachusetts General Hospital Cancer Center|Dana-Farber Cancer Institute|C S Mott Children's Hospital|Wayne State University/Karmanos Cancer Institute|Ascension Saint John Hospital|Huron Medical Center PC|Beaumont Children's Hospital-Royal Oak|Children's Hospitals and Clinics of Minnesota - Minneapolis|University of Minnesota/Masonic Cancer Center|Mayo Clinic in Rochester|University of Mississippi Medical Center|Siteman Cancer Center at West County Hospital|Children's Mercy Hospitals and Clinics|Cardinal Glennon Children's Medical Center|Barnes-Jewish Hospital|Washington University School of Medicine|Siteman Cancer Center-South County|Mercy Hospital Saint Louis|Siteman Cancer Center at Saint Peters Hospital|Children's Hospital and Medical Center of Omaha|University of Nebraska Medical Center|Comprehensive Cancer Centers of Nevada-Horizon Ridge|Sunrise Hospital and Medical Center|Alliance for Childhood Diseases/Cure 4 the Kids Foundation|Summerlin Hospital Medical Center|Hope Cancer Care of Nevada-Pahrump|Radiation Oncology Associates|Dartmouth Hitchcock Medical Center|Hackensack University Medical Center|Morristown Medical Center|Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital|Roswell Park Cancer Institute|NYU Winthrop Hospital|The Steven and Alexandra Cohen Children's Medical Center of New York|Laura and Isaac Perlmutter Cancer Center at NYU Langone|NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center|State University of New York Upstate Medical University|UNC Lineberger Comprehensive Cancer Center|Carolinas Medical Center/Levine Cancer Institute|Southeastern Medical Oncology Center-Clinton|Duke University Medical Center|Southeastern Medical Oncology Center-Goldsboro|Wayne Memorial Hospital|East Carolina University|Southeastern Medical Oncology Center-Jacksonville|Cincinnati Children's Hospital Medical Center|Rainbow Babies and Childrens Hospital|MetroHealth Medical Center|Cleveland Clinic Foundation|Nationwide Children's Hospital|Dayton Children's Hospital|ProMedica Flower Hospital|ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital|University of Oklahoma Health Sciences Center|Oregon Health and Science University|Children's Hospital of Philadelphia|Children's Hospital of Pittsburgh of UPMC|Medical University of South Carolina|Saint Francis Hospital|BI-LO Charities Children's Cancer Center|Saint Francis Cancer Center|East Tennessee Childrens Hospital|Saint Jude Children's Research Hospital|The Children's Hospital at TriStar Centennial|Medical City Dallas Hospital|UT Southwestern/Simmons Cancer Center-Dallas|El Paso Children's Hospital|Texas Tech University Health Sciences Center-El Paso|Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center|Children's Hospital of San Antonio|University of Vermont and State Agricultural College|University of Virginia Cancer Center|Children's Hospital of The King's Daughters|Seattle Children's Hospital|Providence Sacred Heart Medical Center and Children's Hospital|Gundersen Lutheran Medical Center|University of Wisconsin Hospital and Clinics|Children's Hospital of Wisconsin,Drug|Drug|Other,United States,2.0,30.0,[0-17]|[18-65],Thyroid neoplasms,"Thyroid cancer, medullary",https://clinicaltrials.gov/ct2/show/NCT02867592
NCT02869620,thyroid neoplasms,Institut Paoli Calmettes Thyroid Cancer Database,Thyroid Neoplasms,2016-08-11,2030-01-31,2030-12-31,Observational [Patient Registry],Recruiting,,Institut Paoli-Calmettes,Institut Paoli-Calmettes,Institut Paoli-Calmettes,Other,France,18.0,95.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02869620
NCT02886949,thyrotoxicosis,"The Relationship of Vascular Cell Adhesion Molecule 1, C-reactive Protein, Brain-derived Neurotrophic Factor, Orexin and Depressive Symptoms in the Subjects With Thyroid Disease",THYROTOXICOSIS,2015-09-02,2020-12-31,2024-12-31,Observational,Recruiting,,Taichung Veterans General Hospital,Taichung Veterans General Hospital,"Division of Endocrinology and Metabolism, Department of Internal Medicine, Taichung Veterans General Hospital",,Taiwan,20.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02886949
NCT02938702,thyroid cancer,,Papillary Thyroid Microcarcinoma|Thyroid Cancer,2016-02-17,2025-03-31,2030-03-31,Observational,"Active, not recruiting",,Seoul National University Hospital,Seoul National University Hospital,Seoul National University Hospital,,"Korea, Republic of",18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02938702
NCT02947035,thyroid cancer,Molecular Testing to Direct Extent of Initial Thyroid Surgery,Thyroid Cancer,2016-10-20,2023-02-01,2023-02-28,Interventional,Recruiting,Phase 2,University of Pittsburgh,University of Pittsburgh,University of Pittsburgh|Medical College of Wisconsin,Procedure|Procedure,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02947035
NCT02973997,tall cell variant thyroid gland papillary carcinoma,"Combination Targeted Therapy With Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers: A Phase II Study",Columnar Cell Variant Thyroid Gland Papillary Carcinoma|Follicular Variant Thyroid Gland Papillary Carcinoma|Metastatic Thyroid Gland Follicular Carcinoma|Metastatic Thyroid Gland Papillary Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Recurrent Differentiated Thyroid Gland Carcinoma|Recurrent Thyroid Gland Follicular Carcinoma|Recurrent Thyroid Gland Papillary Carcinoma|Stage III Differentiated Thyroid Gland Carcinoma AJCC v7|Stage III Thyroid Gland Follicular Carcinoma AJCC v7|Stage III Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v7|Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v7|Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVC Differentiated Thyroid Gland Carcinoma AJCC v7|Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7|Stage IV Thyroid Gland Follicular Carcinoma AJCC v7|Stage IV Thyroid Gland Papillary Carcinoma AJCC v7|Tall Cell Variant Thyroid Gland Papillary Carcinoma|Thyroid Gland Hurthle Cell Carcinoma|Unresectable Differentiated Thyroid Gland Carcinoma|Unresectable Thyroid Gland Carcinoma,2016-11-23,2022-10-08,2024-09-30,Interventional,"Active, not recruiting",Phase 2,Academic and Community Cancer Research United,Academic and Community Cancer Research United|National Cancer Institute (NCI),Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center|University of Colorado Hospital|Massachusetts General Hospital Cancer Center|University of Michigan Comprehensive Cancer Center|Memorial Sloan Kettering Cancer Center|Ohio State University Comprehensive Cancer Center|M D Anderson Cancer Center,Other|Drug|Drug|Biological,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT02973997
NCT02973997,thyroid gland hurthle cell carcinoma,"Combination Targeted Therapy With Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers: A Phase II Study",Columnar Cell Variant Thyroid Gland Papillary Carcinoma|Follicular Variant Thyroid Gland Papillary Carcinoma|Metastatic Thyroid Gland Follicular Carcinoma|Metastatic Thyroid Gland Papillary Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Recurrent Differentiated Thyroid Gland Carcinoma|Recurrent Thyroid Gland Follicular Carcinoma|Recurrent Thyroid Gland Papillary Carcinoma|Stage III Differentiated Thyroid Gland Carcinoma AJCC v7|Stage III Thyroid Gland Follicular Carcinoma AJCC v7|Stage III Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v7|Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v7|Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVC Differentiated Thyroid Gland Carcinoma AJCC v7|Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7|Stage IV Thyroid Gland Follicular Carcinoma AJCC v7|Stage IV Thyroid Gland Papillary Carcinoma AJCC v7|Tall Cell Variant Thyroid Gland Papillary Carcinoma|Thyroid Gland Hurthle Cell Carcinoma|Unresectable Differentiated Thyroid Gland Carcinoma|Unresectable Thyroid Gland Carcinoma,2016-11-23,2022-10-08,2024-09-30,Interventional,"Active, not recruiting",Phase 2,Academic and Community Cancer Research United,Academic and Community Cancer Research United|National Cancer Institute (NCI),Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center|University of Colorado Hospital|Massachusetts General Hospital Cancer Center|University of Michigan Comprehensive Cancer Center|Memorial Sloan Kettering Cancer Center|Ohio State University Comprehensive Cancer Center|M D Anderson Cancer Center,Other|Drug|Drug|Biological,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Hurthle cell thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02973997
NCT02973997,poorly differentiated thyroid gland carcinoma,"Combination Targeted Therapy With Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers: A Phase II Study",Columnar Cell Variant Thyroid Gland Papillary Carcinoma|Follicular Variant Thyroid Gland Papillary Carcinoma|Metastatic Thyroid Gland Follicular Carcinoma|Metastatic Thyroid Gland Papillary Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Recurrent Differentiated Thyroid Gland Carcinoma|Recurrent Thyroid Gland Follicular Carcinoma|Recurrent Thyroid Gland Papillary Carcinoma|Stage III Differentiated Thyroid Gland Carcinoma AJCC v7|Stage III Thyroid Gland Follicular Carcinoma AJCC v7|Stage III Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v7|Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v7|Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVC Differentiated Thyroid Gland Carcinoma AJCC v7|Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7|Stage IV Thyroid Gland Follicular Carcinoma AJCC v7|Stage IV Thyroid Gland Papillary Carcinoma AJCC v7|Tall Cell Variant Thyroid Gland Papillary Carcinoma|Thyroid Gland Hurthle Cell Carcinoma|Unresectable Differentiated Thyroid Gland Carcinoma|Unresectable Thyroid Gland Carcinoma,2016-11-23,2022-10-08,2024-09-30,Interventional,"Active, not recruiting",Phase 2,Academic and Community Cancer Research United,Academic and Community Cancer Research United|National Cancer Institute (NCI),Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center|University of Colorado Hospital|Massachusetts General Hospital Cancer Center|University of Michigan Comprehensive Cancer Center|Memorial Sloan Kettering Cancer Center|Ohio State University Comprehensive Cancer Center|M D Anderson Cancer Center,Other|Drug|Drug|Biological,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Poorly differentiated thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02973997
NCT03013257,graves disease,"A Randomized, Open-label, Parallel-group Study to Explore the Efficacy of High-intensity Focused Ultrasound (HIFU) Versus Fixed-dose Radioiodine-131 in the Treatment of Relapsed Graves' Disease",Graves Disease,2017-01-04,2022-04-30,2022-12-31,Interventional,Recruiting,Not Applicable,The University of Hong Kong,The University of Hong Kong,Queen Mary Hospital,Device,Hong Kong,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT03013257
NCT03029429,pseudohypoparathyroidism,Phase 2 Study of Theophylline Treatment for Pseudohypoparathyroidism,Albright Hereditary Osteodystrophy|Pseudohypoparathyroidism,2017-01-18,2023-07-01,2023-11-01,Interventional,Recruiting,Phase 2,Vanderbilt University Medical Center,Harvard University|Vanderbilt University Medical Center,Ashley Shoemaker,Drug|Drug,United States,13.0,99.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,pseudohypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03029429
NCT03037385,"thyroid cancer, papillary","A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors","Adenocarcinoma|Adenocarcinoma, Papillary|Bronchial Neoplasms|Carcinoma|Carcinoma, Bronchogenic|Carcinoma, Neuroendocrine|Carcinoma, Non-Small-Cell Lung|Colonic Diseases|Colonic Neoplasms|Colorectal Neoplasms|Digestive System Disease|Digestive System Neoplasm|Endocrine Gland Neoplasm|Endocrine System Diseases|Gastrointestinal Disease|Gastrointestinal Neoplasms|Head and Neck Neoplasms|Intestinal Disease|Intestinal Neoplasms|Lung Diseases|Lung Neoplasm|Medullary Thyroid Cancer|Neoplasms|Neoplasms by Histologic Type|Neoplasms by Site|Neoplasms, Germ Cell and Embryonal|Neoplasms, Glandular and Epithelial|Neoplasms, Nerve Tissue|Neuroectodermal Tumors|Neuroendocrine Tumors|Respiratory Tract Disease|Respiratory Tract Neoplasms|RET-altered Colon Cancer|RET-altered Non Small Cell Lung Cancer|RET-altered Papillary Thyroid Cancer|RET-altered Solid Tumors|Thoracic Neoplasms|Thyroid Cancer, Papillary|Thyroid Diseases|Thyroid Neoplasm",2017-01-20,2023-12-31,2024-02-29,Interventional,"Active, not recruiting",Phase 1/Phase 2,Hoffmann-La Roche,Hoffmann-La Roche,"Mayo Clinic|UC Irvine Medical Center|University of Colorado Cancer Center|Georgetown University Medical Center|Mayo Clinic|University of Miami Hospitals and Clinics, Sylvester Comprehensive Cancer Center|Maryland Oncology Hematology, PA - Columbia|Massachusetts General Hospital|University of Michigan|Mayo Clinic|Washington University School of Medicine, Siteman Cancer Center|Albany Medical Center|Jack D. Weiler Hospital|Cornell University|Oregon Health and Science University|University of Pennsylvania Hospital|UPMC CancerCenter|Texas Oncology - Austin|Texas Oncology - Baylor Charles A. Sammons Cancer Center|University of Texas MD Anderson Cancer Center|University of Washington, Seattle Cancer Care Alliance|Antwerp University Hospital|Beijing Cancer Hospital|West China Hospital, Sichuan University|Sichuan Cancer Hospital & Institute|Chongqing Cancer Hospital|Fujian Provincial Cancer Hospital|First Affiliated Hospital of Gannan Medical University|Sun Yat-sen University Cancer Center|Guangdong Provincial People's Hospital|Nanfang Hospital of Southern Medical University|Zhejiang Provincial People's Hospital|Zhejiang Cancer Hospital|Anhui Provincial Cancer Hospital|Jinan Central Hospital|Gansu Provincial Cancer Hospital|Fudan University Shanghai Cancer Center|Liaoning Cancer Hospital & Institute|Tianjin Medical University Cancer Institute and Hospital|Union Hospital, Tongji Medical College, Huazhong University of Science and Technology|Henan Cancer Hospital|Institut Bergonié|CHRU de Lille - Hôpital Claude Hurier Servide d'Endocrinologie et Diabétologie|Centre Leon Berard|Centre Antoine Lacassagne|Hospital Tenon|Institut Curie|CHU de Rennes - Hôpital Pontchaillou|Insitut Claudius Regaud|Gustave Roussy|HELIOS Klinikum Emil von Behring|Universitätsklinikum Essen|Thoraxklinik Heidelberg|Klinikum der Universitat Munchen|Pius-Hospital Oldenberg|The Chinese University of Hong Kong|Istituto Europeo di Oncologia Sviluppo Nuovi Farmaci per Terapie Innovative|Grande Ospedale Metropolitano Niguarda|Ospedale Santa Maria delle Croci|Istituto Nazionale Tumori Regina Elena|Seoul National University Hospital|Severance Hospital|Asan Medical Center|Samsung Medical Center|Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis|University Medical Center Groningen|National Cancer Centre Singapore|Hospital Universitari Vall d'Hebron|Hospital Clinic Barcelona|Hospital Duran I Reynals|Hospital Universitario Ramon y Cajal|Hospital Universitario 12 de Octubre Servicio de Oncologia Medica|National Taiwan University Hospital|Taipei Veterans General Hospital|NHS Grampian - Aberdeen Royal Infirmary|Sarah Cannon Research Institute|Guy's Hospital St. Thomas NHS Foundation Trust|NIHR UCLH Clinical Research Facility, University College of London NHS Foundation Trust|The Christie NHS Foundation Trust",Drug,"Belgium|China|France|Germany|Hong Kong|Italy|Korea, Republic of|Netherlands|Singapore|Spain|Taiwan|United Kingdom|United States",18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT03037385
NCT03037385,medullary thyroid cancer,"A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors","Adenocarcinoma|Adenocarcinoma, Papillary|Bronchial Neoplasms|Carcinoma|Carcinoma, Bronchogenic|Carcinoma, Neuroendocrine|Carcinoma, Non-Small-Cell Lung|Colonic Diseases|Colonic Neoplasms|Colorectal Neoplasms|Digestive System Disease|Digestive System Neoplasm|Endocrine Gland Neoplasm|Endocrine System Diseases|Gastrointestinal Disease|Gastrointestinal Neoplasms|Head and Neck Neoplasms|Intestinal Disease|Intestinal Neoplasms|Lung Diseases|Lung Neoplasm|Medullary Thyroid Cancer|Neoplasms|Neoplasms by Histologic Type|Neoplasms by Site|Neoplasms, Germ Cell and Embryonal|Neoplasms, Glandular and Epithelial|Neoplasms, Nerve Tissue|Neuroectodermal Tumors|Neuroendocrine Tumors|Respiratory Tract Disease|Respiratory Tract Neoplasms|RET-altered Colon Cancer|RET-altered Non Small Cell Lung Cancer|RET-altered Papillary Thyroid Cancer|RET-altered Solid Tumors|Thoracic Neoplasms|Thyroid Cancer, Papillary|Thyroid Diseases|Thyroid Neoplasm",2017-01-20,2023-12-31,2024-02-29,Interventional,"Active, not recruiting",Phase 1/Phase 2,Hoffmann-La Roche,Hoffmann-La Roche,"Mayo Clinic|UC Irvine Medical Center|University of Colorado Cancer Center|Georgetown University Medical Center|Mayo Clinic|University of Miami Hospitals and Clinics, Sylvester Comprehensive Cancer Center|Maryland Oncology Hematology, PA - Columbia|Massachusetts General Hospital|University of Michigan|Mayo Clinic|Washington University School of Medicine, Siteman Cancer Center|Albany Medical Center|Jack D. Weiler Hospital|Cornell University|Oregon Health and Science University|University of Pennsylvania Hospital|UPMC CancerCenter|Texas Oncology - Austin|Texas Oncology - Baylor Charles A. Sammons Cancer Center|University of Texas MD Anderson Cancer Center|University of Washington, Seattle Cancer Care Alliance|Antwerp University Hospital|Beijing Cancer Hospital|West China Hospital, Sichuan University|Sichuan Cancer Hospital & Institute|Chongqing Cancer Hospital|Fujian Provincial Cancer Hospital|First Affiliated Hospital of Gannan Medical University|Sun Yat-sen University Cancer Center|Guangdong Provincial People's Hospital|Nanfang Hospital of Southern Medical University|Zhejiang Provincial People's Hospital|Zhejiang Cancer Hospital|Anhui Provincial Cancer Hospital|Jinan Central Hospital|Gansu Provincial Cancer Hospital|Fudan University Shanghai Cancer Center|Liaoning Cancer Hospital & Institute|Tianjin Medical University Cancer Institute and Hospital|Union Hospital, Tongji Medical College, Huazhong University of Science and Technology|Henan Cancer Hospital|Institut Bergonié|CHRU de Lille - Hôpital Claude Hurier Servide d'Endocrinologie et Diabétologie|Centre Leon Berard|Centre Antoine Lacassagne|Hospital Tenon|Institut Curie|CHU de Rennes - Hôpital Pontchaillou|Insitut Claudius Regaud|Gustave Roussy|HELIOS Klinikum Emil von Behring|Universitätsklinikum Essen|Thoraxklinik Heidelberg|Klinikum der Universitat Munchen|Pius-Hospital Oldenberg|The Chinese University of Hong Kong|Istituto Europeo di Oncologia Sviluppo Nuovi Farmaci per Terapie Innovative|Grande Ospedale Metropolitano Niguarda|Ospedale Santa Maria delle Croci|Istituto Nazionale Tumori Regina Elena|Seoul National University Hospital|Severance Hospital|Asan Medical Center|Samsung Medical Center|Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis|University Medical Center Groningen|National Cancer Centre Singapore|Hospital Universitari Vall d'Hebron|Hospital Clinic Barcelona|Hospital Duran I Reynals|Hospital Universitario Ramon y Cajal|Hospital Universitario 12 de Octubre Servicio de Oncologia Medica|National Taiwan University Hospital|Taipei Veterans General Hospital|NHS Grampian - Aberdeen Royal Infirmary|Sarah Cannon Research Institute|Guy's Hospital St. Thomas NHS Foundation Trust|NIHR UCLH Clinical Research Facility, University College of London NHS Foundation Trust|The Christie NHS Foundation Trust",Drug,"Belgium|China|France|Germany|Hong Kong|Italy|Korea, Republic of|Netherlands|Singapore|Spain|Taiwan|United Kingdom|United States",18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, medullary",https://clinicaltrials.gov/ct2/show/NCT03037385
NCT03037385,thyroid diseases,"A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors","Adenocarcinoma|Adenocarcinoma, Papillary|Bronchial Neoplasms|Carcinoma|Carcinoma, Bronchogenic|Carcinoma, Neuroendocrine|Carcinoma, Non-Small-Cell Lung|Colonic Diseases|Colonic Neoplasms|Colorectal Neoplasms|Digestive System Disease|Digestive System Neoplasm|Endocrine Gland Neoplasm|Endocrine System Diseases|Gastrointestinal Disease|Gastrointestinal Neoplasms|Head and Neck Neoplasms|Intestinal Disease|Intestinal Neoplasms|Lung Diseases|Lung Neoplasm|Medullary Thyroid Cancer|Neoplasms|Neoplasms by Histologic Type|Neoplasms by Site|Neoplasms, Germ Cell and Embryonal|Neoplasms, Glandular and Epithelial|Neoplasms, Nerve Tissue|Neuroectodermal Tumors|Neuroendocrine Tumors|Respiratory Tract Disease|Respiratory Tract Neoplasms|RET-altered Colon Cancer|RET-altered Non Small Cell Lung Cancer|RET-altered Papillary Thyroid Cancer|RET-altered Solid Tumors|Thoracic Neoplasms|Thyroid Cancer, Papillary|Thyroid Diseases|Thyroid Neoplasm",2017-01-20,2023-12-31,2024-02-29,Interventional,"Active, not recruiting",Phase 1/Phase 2,Hoffmann-La Roche,Hoffmann-La Roche,"Mayo Clinic|UC Irvine Medical Center|University of Colorado Cancer Center|Georgetown University Medical Center|Mayo Clinic|University of Miami Hospitals and Clinics, Sylvester Comprehensive Cancer Center|Maryland Oncology Hematology, PA - Columbia|Massachusetts General Hospital|University of Michigan|Mayo Clinic|Washington University School of Medicine, Siteman Cancer Center|Albany Medical Center|Jack D. Weiler Hospital|Cornell University|Oregon Health and Science University|University of Pennsylvania Hospital|UPMC CancerCenter|Texas Oncology - Austin|Texas Oncology - Baylor Charles A. Sammons Cancer Center|University of Texas MD Anderson Cancer Center|University of Washington, Seattle Cancer Care Alliance|Antwerp University Hospital|Beijing Cancer Hospital|West China Hospital, Sichuan University|Sichuan Cancer Hospital & Institute|Chongqing Cancer Hospital|Fujian Provincial Cancer Hospital|First Affiliated Hospital of Gannan Medical University|Sun Yat-sen University Cancer Center|Guangdong Provincial People's Hospital|Nanfang Hospital of Southern Medical University|Zhejiang Provincial People's Hospital|Zhejiang Cancer Hospital|Anhui Provincial Cancer Hospital|Jinan Central Hospital|Gansu Provincial Cancer Hospital|Fudan University Shanghai Cancer Center|Liaoning Cancer Hospital & Institute|Tianjin Medical University Cancer Institute and Hospital|Union Hospital, Tongji Medical College, Huazhong University of Science and Technology|Henan Cancer Hospital|Institut Bergonié|CHRU de Lille - Hôpital Claude Hurier Servide d'Endocrinologie et Diabétologie|Centre Leon Berard|Centre Antoine Lacassagne|Hospital Tenon|Institut Curie|CHU de Rennes - Hôpital Pontchaillou|Insitut Claudius Regaud|Gustave Roussy|HELIOS Klinikum Emil von Behring|Universitätsklinikum Essen|Thoraxklinik Heidelberg|Klinikum der Universitat Munchen|Pius-Hospital Oldenberg|The Chinese University of Hong Kong|Istituto Europeo di Oncologia Sviluppo Nuovi Farmaci per Terapie Innovative|Grande Ospedale Metropolitano Niguarda|Ospedale Santa Maria delle Croci|Istituto Nazionale Tumori Regina Elena|Seoul National University Hospital|Severance Hospital|Asan Medical Center|Samsung Medical Center|Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis|University Medical Center Groningen|National Cancer Centre Singapore|Hospital Universitari Vall d'Hebron|Hospital Clinic Barcelona|Hospital Duran I Reynals|Hospital Universitario Ramon y Cajal|Hospital Universitario 12 de Octubre Servicio de Oncologia Medica|National Taiwan University Hospital|Taipei Veterans General Hospital|NHS Grampian - Aberdeen Royal Infirmary|Sarah Cannon Research Institute|Guy's Hospital St. Thomas NHS Foundation Trust|NIHR UCLH Clinical Research Facility, University College of London NHS Foundation Trust|The Christie NHS Foundation Trust",Drug,"Belgium|China|France|Germany|Hong Kong|Italy|Korea, Republic of|Netherlands|Singapore|Spain|Taiwan|United Kingdom|United States",18.0,120.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT03037385
NCT03048877,differentiated thyroid cancer,"A Randomized, Double-Blind, Placebo-Controlled Study of Apatinib in Locally Advanced or Metastatic Radioactive Iodine-refractory Differentiated Thyroid Cancer",Differentiated Thyroid Cancer,2017-02-03,2020-03-25,2022-07-31,Interventional,"Active, not recruiting",Phase 3,Peking Union Medical College Hospital,Peking Union Medical College Hospital,Nanjing PLA 81 Hospital|Peking Union Medical College Hospital,Drug|Drug,China,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Differentiated thyroid cancer, all",https://clinicaltrials.gov/ct2/show/NCT03048877
NCT03053115,hypothyroidism,"Combined Replacement Therapy With Levothyroxine and Liothyronine in Thyroidectomized Patients: Effects on Peripheral Tissues. A Prospective, Randomized, Controlled, Double-blind Study",Hypothyroidism,2016-11-25,2021-12-31,2021-12-31,Interventional,"Active, not recruiting",Phase 2/Phase 3,Azienda USL Modena,Azienda USL Modena,AziendaUSLModena,Drug|Drug|Drug,Italy,18.0,120.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT03053115
NCT03053999,hyperparathyroidism,Variables That Are Correlated to Developing Multiple Endocrine Neoplasia (MEN) and Pancreatic Neuroendocrine Tumors (PNET),Hyperparathyroidism|Multiple Endocrine Neoplasia|Pancreatic Neuroendocrine Tumors,2017-02-13,2022-10-31,2023-10-31,Observational,Recruiting,,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center,University of Texas MD Anderson Cancer Center,Other|Other,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT03053999
NCT03064542,hyperthyroidism,"The Role of Thyroid Status in Regulating Brown Adipose Tissue Activity, White Adipose Tissue Partitioning and Resting Energy Expenditure",Hyperthyroidism,2017-02-09,2024-10-24,2024-10-24,Observational [Patient Registry],"Active, not recruiting",,"Clinical Nutrition Research Centre, Singapore","Agency for Science, Technology and Research|Clinical Nutrition Research Centre, Singapore","Tan Tock Seng Hospital, Endocrinology Clinic",Drug,Singapore,21.0,50.0,[18-65],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03064542
NCT03085056,anaplastic thyroid cancer,A Pilot Study of Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer,Anaplastic Thyroid Cancer,2017-03-15,2023-09-30,2023-09-30,Interventional,"Active, not recruiting",Early Phase 1,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center|Novartis,Memoral Sloan Kettering Basking Ridge (Limited Protocol Activities)|Memoral Sloan Kettering Monmouth (Limited Protocol Activities)|Memorial Sloan Kettering Bergen (Limited Protocol Activities)|Memorial Sloan Kettering Cancer Center @ Commack (Limited Protocol Activities)|Memoral Sloan Kettering Westchester (Limited Protocol Activities)|Memorial Sloan Kettering Cancer Center|Memorial Sloan Kettering Nassau (Limited Protocol Activities),Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT03085056
NCT03099356,metastatic thyroid cancer,"An Open Label Phase II Trial Evaluating the Efficacy of Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer",Metastatic Thyroid Cancer,2017-03-28,2022-05-12,2023-05-12,Interventional,Recruiting,Phase 2,University of Michigan Rogel Cancer Center,University of Michigan Rogel Cancer Center,University of Michigan Cancer Center,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Metastatic Thyroid Cancer,https://clinicaltrials.gov/ct2/show/NCT03099356
NCT03122847,graves ophthalmopathy,The Effect of 4.5 Gram Methylprednisolone Administered Once Weekly for 12 Weeks on Bone Metabolism in Graves´ Ophthalmopathy,Graves Ophthalmopathy,2017-04-18,2022-07-31,2023-07-31,Observational,"Active, not recruiting",,Aarhus University Hospital,Odense University Hospital|Torben Harsløf,Aarhus University Hospital|Odense University Hospital,Drug,Denmark,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT03122847
NCT03131726,graves ophthalmopathy,Treatment of Graves´Ophthalmopathy With Simvastatin (GO-DS),Graves Ophthalmopathy|Thyroid Associated Ophthalmopathy|Thyroid Associated Orbitopathy,2017-03-10,2024-01-26,2024-03-30,Interventional,Recruiting,Phase 3,Lund University,Lund University,"Dpt. of Endocrinology, SUS Malmö",Drug,Sweden,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT03131726
NCT03157128,medullary thyroid cancer,"A Phase 1/2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)",Any Solid Tumor|Colon Cancer|Medullary Thyroid Cancer|Non-Small Cell Lung Cancer,2017-05-09,2022-11-21,2023-11-21,Interventional,Recruiting,Phase 1/Phase 2,Eli Lilly and Company,"Eli Lilly and Company|Loxo Oncology, Inc.","Mayo Clinic of Scottsdale|City of Hope National Medical Center|University of California - San Diego|UCLA Medical Center|Hoag Memorial Hospital Presbyterian|Irvine Medical Center|UCSF Medical Center at Mission Bay|Kaiser Permanente|Kaiser Permanente Medical Center|Sarah Cannon Research Institute at HealthOne|Yale Cancer Center|Johns Hopkins University|Mayo Clinic in Florida|Memorial Hospital Pembroke|Emory University|University of Chicago Medicine-Comprehensive Cancer Center|Ochsner Clinic Foundation|University of Maryland Medical Center|Massachusetts General Hospital|Dana-Farber Cancer Institute|University of Michigan|START Midwest|Mayo Clinic|Washington University Medical School|Comprehensive Cancer Centers of Nevada|Roswell Park Cancer Institute|NYU Langone|Memorial Sloan Kettering Cancer Center|University of North Carolina|Cleveland Clinic Foundation|Ohio State University Hospital|Oregon Health and Science University|University of Pennsylvania Hospital|Thomas Jefferson University|Sarah Cannon Research Institute SCRI|Vanderbilt University Medical Center|University of Texas Southwestern Medical Center at Dallas|University of Texas MD Anderson Cancer Center|Huntsman Cancer Institute|Virginia Cancer Specialists, PC|University of Wisconsin-Madison Hospital and Health Clinic|Royal North Shore Hospital|Peter MacCallum Cancer Centre|BC Cancer Vancouver|Rigshospitalet|Hôpital Européen Georges Pompidou|Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest|Centre Leon Berard|APHM Hôpital de la Timone|Institut du Cancer de Montpellier - Val d'aurelle|Gustave Roussy|Universitätsklinikum Würzburg A. ö. R.|Universitätsklinikum Köln|Prince of Wales Hospital|Sheba Medical Center|Shaare Zedek Medical Center|Soroka Medical Center - Pediatric Outpatient Clinic|Hadassah Medical Center|Istituto Nazionale dei Tumori|Nagoya University Hospital|National Cancer Center Hospital East|Hokkaido University Hospital|Hyogo Cancer Center|Kanazawa University Hospital|Kindai University Hospital|Shizuoka Cancer Center|National Cancer Center Hospital|Japanese Foundation for Cancer Research|Tottori University Hospital|National Hospital Organization Kyushu Cancer Center|Okayama University Hospital|Osaka City General Hospital|National Cancer Center|Seoul National University Bundang Hospital|Asan Medical Center|Samsung Medical Center|Severance Hospital, Yonsei University Health System|National Cancer Centre Singapore|Hospital Universitari Vall d'Hebron|Hospital Universitario Fundación Jiménez Díaz|Hospital Madrid Norte Sanchinarro|Kantonsspital Luzern|Taichung Veterans General Hospital|National Taiwan University Hospital|Royal Marsden Hospital",Drug,"Australia|Canada|Denmark|France|Germany|Hong Kong|Israel|Italy|Japan|Korea, Republic of|Singapore|Spain|Switzerland|Taiwan|United Kingdom|United States",12.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, medullary",https://clinicaltrials.gov/ct2/show/NCT03157128
NCT03160274,thyroid neoplasms,"Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions",Associated Conditions|Bone Cancer|Inherited Cancer Syndrome|Kidney Neoplasms|Other Cancer|Paraganglioma|Pheochromocytoma|Thyroid Neoplasms,2017-05-05,2030-12-31,2030-12-31,Observational [Patient Registry],Recruiting,,The University of Texas Health Science Center at San Antonio,National Institute of General Medical Sciences (NIGMS)|The University of Texas Health Science Center at San Antonio,University of Texas Health Science Center,Genetic,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03160274
NCT03170960,differentiated thyroid cancer,A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors,Castration-resistant Prostate Cancer|Colorectal Cancer|Differentiated Thyroid Cancer|Endometrial Cancer|Gastric Cancer|Gastroesophageal Junction Adenocarcinoma|Head and Neck Cancer|Hepatocellular Carcinoma|Lower Esophageal Cancer|Non-Small Cell Lung Cancer|Ovarian Cancer|Renal Cell Carcinoma|Triple Negative Breast Cancer|Urothelial Carcinoma,2017-05-23,2022-12-31,2022-12-31,Interventional,Recruiting,Phase 1/Phase 2,Exelixis,Exelixis,Exelixis Clinical Site #53|Exelixis Clinical Site #18|Exelixis Clinical Site #1|Exelixis Clinical Site #20|Exelixis Clinical Site #46|Exelixis Clinical Site #51|Exelixis Clinical Site #62|Exelixis Clinical Site #21|Exelixis Clinical Site #34|Exelixis Clinical Site #50|Exelixis Clinical Site #42|Exelixis Clinical Site #48|Exelixis Clinical Site #16|Exelixis Clinical Site #76|Exelixis Clinical Site #60|Exelixis Clinical Site #79|Exelixis Clinical Site #32|Exelixis Clinical Site #23|Exelixis Clinical Site #57|Exelixis Clinical Site #24|Exelixis Clinical Site #10|Exelixis Clinical Site #3|Exelixis Clinical Site #17|Exelixis Clinical Site #65|Exelixis Clinical Site #43|Exelixis Clinical Site #35|Exelixis Clinical Site #59|Exelixis Clinical Site #61|Exelixis Clinical Site #38|Exelixis Clinical Site #27|Exelixis Clinical Site #31|Exelixis Clinical Site #37|Exelixis Clinical Site #40|Exelixis Clinical Site #11|Exelixis Clinical Site #67|Exelixis Clinical Site #49|Exelixis Clinical Site #64|Exelixis Clinical Site #71|Exelixis Clinical Site #6|Exelixis Clinical Site #102|Exelixis Clinical Site #45|Exelixis Clinical Site #41|Exelixis Clinical Site #15|Exelixis Clinical Site #55|Exelixis Clinical Site #66|Exelixis Clinical Site #95|Exelixis Clinical Site #13|Exelixis Clinical Site #26|Exelixis Clinical Site #114|Exelixis Clinical Site #29|Exelixis Clinical Site #39|Exelixis Clinical Site #44|Exelixis Clinical Site #33|Exelixis Clinical Site #63|Exelixis Clinical Site #2|Exelixis Clinical Site #30|Exelixis Clinical Site #14|Exelixis Clinical Site #98|Exelixis Clinical Site #101|Exelixis Clinical Site #115|Exelixis Clinical Site #112|Exelixis Clinical Site #123|Exelixis Clinical Site #99|Exelixis Clinical Site #52|Exelixis Clinical Site #54|Exelixis Clinical Site #88|Exelixis Clinical Site #8|Exelixis Clinical Site #92|Exelixis Clinical Site #93|Exelixis Clinical Site #87|Exelixis Clinical Site #69|Exelixis Clinical Site #97|Exelixis Clinical Site #89|Exelixis Clinical Site #109|Exelixis Clinical Site #104|Exelixis Clinical Site #80|Exelixis Clinical Site #78|Exelixis Clinical Site #7|Exelixis Clinical Site #68|Exelixis Clinical Site #72|Exelixis Clinical Site #82|Exelixis Clinical Site #119|Exelixis Clinical Site #107|Exelixis Clinical Site #105|Exelixis Clinical Site #56|Exelixis Clinical Site #36|Exelixis Clinical Site #84|Exelixis Clinical Site #47|Exelixis Clinical Site #108|Exelixis Clinical Site #103|Exelixis Clinical Site #25|Exelixis Clinical Site #4|Exelixis Clinical Site #85|Exelixis Clinical Site #121|Exelixis Clinical Site #110|Exelixis Clinical Site #12|Exelixis Clinical Site #74|Exelixis Clinical Site #91|Exelixis Clinical Site #94|Exelixis Clinical Site #70|Exelixis Clinical Site #113|Exelixis Clinical Site #116|Exelixis Clinical Site #96|Exelixis Clinical Site #90|Exelixis Clinical Site #117|Exelixis Clinical Site #75|Exelixis Clinical Site #58|Exelixis Clinical Site #83|Exelixis Clinical Site #86|Exelixis Clinical Site #28|Exelixis Clinical Site #9|Exelixis Clinical Site #73|Exelixis Clinical Site #118|Exelixis Clinical Site #77|Exelixis Clinical Site #106|Exelixis Clinical Site #111|Exelixis Clinical Site #22|Exelixis Clinical Site #5|Exelixis Clinical Site #81|Exelixis Clinical Site #100|Exelixis Clinical Site #122|Exelixis Clinical Site #120|Exelixis Clinical Site #124|Exelixis Clinical Site #19,Drug|Drug|Drug|Drug,Australia|Belgium|France|Germany|Italy|Netherlands|Spain|United Kingdom|United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Differentiated thyroid cancer, all",https://clinicaltrials.gov/ct2/show/NCT03170960
NCT03181100,poorly differentiated thyroid gland carcinoma,Atezolizumab Combinations With Chemotherapy for Anaplastic and Poorly Differentiated Thyroid Carcinomas,Metastatic Thyroid Gland Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Stage IVA Thyroid Gland Anaplastic Carcinoma AJCC v8|Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8|Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8|Thyroid Gland Anaplastic Carcinoma|Unresectable Thyroid Gland Carcinoma,2017-06-06,2023-07-27,2023-07-27,Interventional,Recruiting,Phase 2,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center|National Cancer Institute (NCI),M D Anderson Cancer Center,Drug|Biological|Drug|Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Poorly differentiated thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03181100
NCT03181100,thyroid gland anaplastic carcinoma,Atezolizumab Combinations With Chemotherapy for Anaplastic and Poorly Differentiated Thyroid Carcinomas,Metastatic Thyroid Gland Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Stage IVA Thyroid Gland Anaplastic Carcinoma AJCC v8|Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8|Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8|Thyroid Gland Anaplastic Carcinoma|Unresectable Thyroid Gland Carcinoma,2017-06-06,2023-07-27,2023-07-27,Interventional,Recruiting,Phase 2,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center|National Cancer Institute (NCI),M D Anderson Cancer Center,Drug|Biological|Drug|Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT03181100
NCT03181100,metastatic thyroid gland carcinoma,Atezolizumab Combinations With Chemotherapy for Anaplastic and Poorly Differentiated Thyroid Carcinomas,Metastatic Thyroid Gland Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Stage IVA Thyroid Gland Anaplastic Carcinoma AJCC v8|Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8|Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8|Thyroid Gland Anaplastic Carcinoma|Unresectable Thyroid Gland Carcinoma,2017-06-06,2023-07-27,2023-07-27,Interventional,Recruiting,Phase 2,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center|National Cancer Institute (NCI),M D Anderson Cancer Center,Drug|Biological|Drug|Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Metastatic Thyroid Cancer,https://clinicaltrials.gov/ct2/show/NCT03181100
NCT03196518,thyroid cancer,PET Imaging of Thyroid Tissue Expressing Sodium-iodine Symporter Using the New Tracer 18F-tetrafluoroborate (18F-TFB),Thyroid Cancer,2017-06-21,2023-06-30,2023-06-30,Interventional,Recruiting,Not Applicable,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Procedure|Other,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03196518
NCT03215095,thyroid cancer,"Radioiodine (RAI) in Combination With Durvalumab (Medi4736) for RAI-avid, Recurrent/Metastatic Thyroid Cancers",Thyroid Cancer,2017-07-11,2023-07-31,2023-07-31,Interventional,"Active, not recruiting",Early Phase 1,Memorial Sloan Kettering Cancer Center,AstraZeneca|MedImmune LLC|Memorial Sloan Kettering Cancer Center,Memoral Sloan Kettering Basking Ridge|Memoral Sloan Kettering Monmouth|Memorial Sloan Kettering Bergen|Memorial Sloan Kettering Commack|Memorial Sloan Kettering Westchester|Memorial Sloan Kettering Cancer Center|Memorial Sloan Kettering Nassau,Drug|Radiation,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03215095
NCT03246958,thyroid cancer,"A Phase 2 Study of Nivolumab Plus Ipilimumab in RAI Refractory, Aggressive Thyroid Cancer With Exploratory Cohorts in Medullary and Anaplastic Thyroid Cancer",Thyroid Cancer,2017-08-08,2022-12-31,2025-03-31,Interventional,"Active, not recruiting",Phase 2,Dana-Farber Cancer Institute,Bristol-Myers Squibb|Dana-Farber Cancer Institute,Dana Farber Cancer Institute,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03246958
NCT03285230,thyroid cancer,The French E3N Prospective Cohort Study (Etude Epidémiologique auprès de Femmes de la Mutuelle Générale de l'Education Nationale),Asthma|Breast Cancer|Cardiovascular Diseases|Colo-rectal Cancer|Crohn Disease|Depression|Diabetes|Endometrial Cancer|Endometriosis|Hypertension|Inflammatory Bowel Diseases|Melanoma|Parkinson Disease|Thyroid Cancer,2017-07-27,1991-11-15,2025-12-15,Observational,"Active, not recruiting",,"Institut National de la Santé Et de la Recherche Médicale, France","Gustave Roussy, Cancer Campus, Grand Paris|Institut National de la Santé Et de la Recherche Médicale, France|Ligue contre le cancer, France|Université Paris-Sud",,,,40.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03285230
NCT03324880,hypoparathyroidism,"A Randomized, Double-blind, Placebo-controlled, Adaptive Study to Evaluate Symptom Improvement and Metabolic Control Among Adult Subjects With Symptomatic Hypoparathyroidism Treated With Recombinant Human Parathyroid Hormone [rhPTH(1-84)]",Hypoparathyroidism,2017-10-10,2022-05-10,2022-05-10,Interventional,Recruiting,Phase 4,Takeda,Shire,"University of Chicago|Michigan Bone and Mineral Clinic|Mayo Clinic - PPDS|Physicians East PA|Ohio State University Wexner Medical Center|Children's Hospital of Philadelphia|UZ Gent|UZ Leuven|Nova Scotia Health Authority (Capital District Health Authority)|Bone Research and Education Centre|CHU de Quebec-Universite Laval|Eastern Health - Health Sciences Center- General Hospital|Aarhus Universitetshospital|Odense Universitetshospital|CHU Angers|Hopital Jean Minjoz|CHU Bicêtre|CHRU Lille|Universitätsklinikum Carl Gustav Carus an der TU Dresden|Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico|Universita di Firenze, Dipartimento di Chirurgia e Medicina Traslazionale (DCMT)|Università Campus Bio Medico Di Roma|VU Medisch Centrum|Leids Universitair Medisch Centrum|Erasmus MC|Haukeland Universitetssykehus|Oslo Universitetssykehus HF Rikshospitalet|Oslo Universitetssykehus Aker|Centro Hospitalar E Universitário de Coimbra EPE|Unidade Local de Saúde de Matosinhos SA|Centro Hospitalar de São João, E.P.E.|C.H. Regional Reina Sofia - PPDS|Hospital Universitario Quironsalud Madrid|Hospital Universitario Fundacion Jimenez Diaz|Hospital Universitario 12 de Octubre|Karolinska Universitetssjukhuset Solna|Sahlgrenska Universitetssjukhuset|Skanes Universitetssjukhus Lund|Ninewells Hospital - PPDS|Norfolk and Norwich University Hospital|Queen Elizabeth Hospital|Leicester Royal Infirmary|Manchester Royal Infirmary - PPDS",Biological|Biological,Belgium|Canada|Denmark|France|Germany|Italy|Netherlands|Norway|Portugal|Spain|Sweden|United Kingdom|United States,18.0,85.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT03324880
NCT03324893,"hyperparathyroidism, primary",18F-Fluorocholine PET/MRI for the Localization of Parathyroid Adenomas,"18F-fluorocholine|Hyperparathyroidism, Primary|Positron-Emission Tomography",2017-10-17,2021-06-30,2021-06-30,Interventional,"Active, not recruiting",Not Applicable,"University Health Network, Toronto","University Health Network, Toronto",UHN,Diagnostic Test,Canada,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT03324893
NCT03360890,thyroid cancer,Synergy of Pembrolizumab Anti-PD-1 Immunotherapy With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors. The iPRIME Study.,Salivary Gland Cancer|Thyroid Cancer,2017-11-20,2022-09-30,2022-09-30,Interventional,Recruiting,Phase 2,University of Chicago,University of Chicago,University of Chicago Comprehensive Cancer Center,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03360890
NCT03377829,thyroid cancer,A Multicenter Prospective Controlled Trial of Laser Ablation Versus Surgery for the Treatment of Papillary Thyroid Microcarcinoma,Thyroid Cancer|Treatment Related Cancer,2017-11-26,2021-08-31,2022-12-31,Interventional,Recruiting,Not Applicable,Ruijin Hospital,WeiWei Zhan,"Ultrasound Department, Chinese PLA General Hospital|Ultrasound Department of the Third Hospital Affiliated to Zhongshan University|Ultrasound Department, the Second Affiliated Hospital of Harbin Medical Univercity|Ultrasound Department, the Xiangya Third Hospital of Zhongnan University|Ultrasound Department, the First Affliction Hospital of Nanjing Medical University|Ultrasound Department, the First Affiliated Hospital of Soochow University|Ultrasound Department, First people's Hospital Affiliated to Medical School of Shanghai Jiaotong University|Ultrasound Department, Ruijin Hospital Affiliated to Medical School of Shanghai Jiaotong University|The department of ultrasound ,second affiliated hospital of xi'an jiaotong university|Department of Ultrasonography, Zhejiang Cancer Hospital|Department of Ultrasound Medicine, the First Hospital Affiliated to Medical School of Zhejiang University|Department of Endocrinology, Regina Apostolorum Hospital|Diagnostic Imaging, Regina Apostolorum Hospital",Procedure|Procedure,China|Italy,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03377829
NCT03395925,thyroid nodule,Evaluation of the Thyroid Volume After Radiofrequency Ablation of Thyroid Nodules and Recurrent Thyroid,Thyroid Nodule,2017-12-17,2021-10-30,2022-01-30,Interventional,"Active, not recruiting",Not Applicable,Olympus Surgical Technologies Europe,Olympus Surgical Technologies Europe,Johann-Wolfgang Goethe University,Device,Germany,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT03395925
NCT03432299,thyroid cancer,Radiofrequency Ablation of Low Risk Papillary Thyroid Microcarcinoma: Safety and Efficacy,Papillary Thyroid Microcarcinoma|Thyroid Cancer,2018-01-22,2023-07-31,2023-12-31,Interventional,Recruiting,Not Applicable,Seoul National University Hospital,Seoul National University Hospital,Seoul National University Hospital,Procedure,"Korea, Republic of",19.0,60.0,[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03432299
NCT03449108,poorly differentiated thyroid gland carcinoma,Clinical Study to Assess Efficacy and Safety of LN-145/LN-145-S1 (Autologous Centrally Manufactured Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types,Bone Sarcoma|Dedifferentiated Chondrosarcoma|Giant Cell Tumor of Bone|Malignancy in Giant Cell Tumor of Bone|Malignant Solid Neoplasm|Ovarian Carcinosarcoma|Platinum-Resistant Ovarian Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Recurrent Osteosarcoma|Recurrent Ovarian Carcinoma|Refractory Osteosarcoma|Soft Tissue Sarcoma|Thyroid Gland Anaplastic Carcinoma|Thyroid Gland Squamous Cell Carcinoma|Undifferentiated High Grade Pleomorphic Sarcoma of Bone,2018-02-22,2023-06-30,2024-06-30,Interventional,Recruiting,Phase 2,M.D. Anderson Cancer Center,"Iovance Biotherapeutics, Inc.|M.D. Anderson Cancer Center|National Cancer Institute (NCI)",M D Anderson Cancer Center,Biological|Biological|Biological|Drug|Drug|Biological|Biological|Other|Other,United States,16.0,70.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Poorly differentiated thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03449108
NCT03449108,thyroid gland anaplastic carcinoma,Clinical Study to Assess Efficacy and Safety of LN-145/LN-145-S1 (Autologous Centrally Manufactured Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types,Bone Sarcoma|Dedifferentiated Chondrosarcoma|Giant Cell Tumor of Bone|Malignancy in Giant Cell Tumor of Bone|Malignant Solid Neoplasm|Ovarian Carcinosarcoma|Platinum-Resistant Ovarian Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Recurrent Osteosarcoma|Recurrent Ovarian Carcinoma|Refractory Osteosarcoma|Soft Tissue Sarcoma|Thyroid Gland Anaplastic Carcinoma|Thyroid Gland Squamous Cell Carcinoma|Undifferentiated High Grade Pleomorphic Sarcoma of Bone,2018-02-22,2023-06-30,2024-06-30,Interventional,Recruiting,Phase 2,M.D. Anderson Cancer Center,"Iovance Biotherapeutics, Inc.|M.D. Anderson Cancer Center|National Cancer Institute (NCI)",M D Anderson Cancer Center,Biological|Biological|Biological|Drug|Drug|Biological|Biological|Other|Other,United States,16.0,70.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT03449108
NCT03449108,thyroid gland squamous cell carcinoma,Clinical Study to Assess Efficacy and Safety of LN-145/LN-145-S1 (Autologous Centrally Manufactured Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types,Bone Sarcoma|Dedifferentiated Chondrosarcoma|Giant Cell Tumor of Bone|Malignancy in Giant Cell Tumor of Bone|Malignant Solid Neoplasm|Ovarian Carcinosarcoma|Platinum-Resistant Ovarian Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Recurrent Osteosarcoma|Recurrent Ovarian Carcinoma|Refractory Osteosarcoma|Soft Tissue Sarcoma|Thyroid Gland Anaplastic Carcinoma|Thyroid Gland Squamous Cell Carcinoma|Undifferentiated High Grade Pleomorphic Sarcoma of Bone,2018-02-22,2023-06-30,2024-06-30,Interventional,Recruiting,Phase 2,M.D. Anderson Cancer Center,"Iovance Biotherapeutics, Inc.|M.D. Anderson Cancer Center|National Cancer Institute (NCI)",M D Anderson Cancer Center,Biological|Biological|Biological|Drug|Drug|Biological|Biological|Other|Other,United States,16.0,70.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid Gland Squamous Cell Carcinoma,https://clinicaltrials.gov/ct2/show/NCT03449108
NCT03469011,papillary thyroid cancer,A Phase I Dose Escalation Trial to Determine if Imatinib Treatment Restores Sodium Iodide Symporter Function and Sensitivity to Radioiodine Treatment in Metastatic Thyroid Cancer Patients,Papillary Thyroid Cancer,2018-03-12,2021-12-31,2021-12-31,Interventional,Recruiting,Phase 1,AHS Cancer Control Alberta,AHS Cancer Control Alberta|Alberta Cancer Foundation,Cross Cancer Institute,Drug,Canada,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT03469011
NCT03475953,thyroid cancer,A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors,"Biliary Tract Cancer|Colorectal Cancer Not MSI-H or MMR-deficient|Gastro-enteropancreatic Neuroendocrine Tumor|GIST|Hepatocellular Carcinoma|Non-small Cell Lung Cancer|Oesophageal or Gastric Carcinoma|Soft-tissue Sarcoma|Solid Tumor, Adult|Thyroid Cancer",2018-02-20,2020-12-31,2022-12-31,Interventional,Recruiting,Phase 1/Phase 2,Institut Bergonié,"Bayer|Institut Bergonié|Merck KGaA, Darmstadt, Germany",Institut Bergonié|Centre Hospitalier Régional Universitaire - CHU Morvan|Centre Léon Bérard|Institut de Cancérologie de Montpellier|Institut Curie|IUCT Oncopôle - Institut Claudius Regaud|Institut Gustave Roussy,Drug|Drug|Drug|Drug|Drug,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03475953
NCT03483337,thyroid cancer,Quantitative Imaging Tools to Derive DW-MRI Oncological Biomarkers,Head and Neck Cancer|Thyroid Cancer,2018-03-19,2024-03-31,2024-03-31,Observational,Recruiting,,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Other|Other,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03483337
NCT03484884,thyroid cancer,A Feasibility Study of Non-Invasive Cerenkov Luminescence Imaging in Patients With Cancer,Thyroid Cancer,2018-03-20,2023-03-31,2023-03-31,Observational,Recruiting,,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Memorial Sloan - Kettering Cancer Center,Diagnostic Test,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03484884
NCT03488134,thyroid cancer,"A Prospective Study of Predicting Prognosis and Recurrence of Thyroid Cancer Via New Biomarkers, Urinary Exosomal Thyroglobulin and Galectin-3",Thyroid Cancer,2018-03-28,2022-01-31,2023-07-31,Observational [Patient Registry],"Active, not recruiting",,National Taiwan University Hospital,National Taiwan University Hospital,National Taiwan University Hospital,,Taiwan,20.0,80.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03488134
NCT03517579,graves disease,Personalized Treatment Planning for Radio-iodine Therapy of Thyroid Disease,Graves Disease|Thyroid Cancer,2018-04-03,2024-10-15,2024-12-15,Interventional,Recruiting,Not Applicable,Johns Hopkins University,Johns Hopkins University,Johns Hopkins Hospital,Device,United States,21.0,65.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT03517579
NCT03517579,thyroid cancer,Personalized Treatment Planning for Radio-iodine Therapy of Thyroid Disease,Graves Disease|Thyroid Cancer,2018-04-03,2024-10-15,2024-12-15,Interventional,Recruiting,Not Applicable,Johns Hopkins University,Johns Hopkins University,Johns Hopkins Hospital,Device,United States,21.0,65.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03517579
NCT03570021,thyroid cancer,ESTIMation of the ABiLity of Prophylactic Central Compartment Neck Dissection to Modify Outcomes in Low-risk Differentiated Thyroid Cancer,Thyroid Cancer,2018-06-15,2026-06-30,2026-06-30,Interventional,Recruiting,Phase 3,"Gustave Roussy, Cancer Campus, Grand Paris","Gustave Roussy, Cancer Campus, Grand Paris",Gustave Roussy,Procedure|Procedure,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03570021
NCT03573960,thyroid neoplasms,"Prospective Single Arm Post Marketing Phase IV Study to Assess the Safety and Efficacy of Lenvatinib in Subjects With Locally Recurrent or Metastatic, Progressive, Radioiodine Refractory Differentiated Thyroid Cancer",Thyroid Neoplasms,2018-06-19,2022-12-31,2022-12-31,Interventional,"Active, not recruiting",Phase 4,Eisai Inc.,Eisai Pharmaceuticals India Pvt. Ltd,"All India Institute of Medical Sciences|Indraprastha Apollo Hospital|Shetty's Hospital|Deenanath Mangeshkar Hospital|All India Institute of Medical Sciences|S. P. Medical College & A. G. Hospitals|Tata Memorial Hospital|BL Kapoor Hospital, New Delhi|Indrayani Hospital, Alandi|City Cancer Centre",Drug,India,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03573960
NCT03624751,thyroid cancer,Follow up for Patients With Thyroid Cancer Planed for Radioiodine Scan or Treatment,Thyroid Cancer,2018-05-24,2028-06-30,2030-06-30,Observational,Recruiting,,Taichung Veterans General Hospital,Taichung Veterans General Hospital,Division of Endocrinology and Metabolism in Taichung Veterans General Hospital,Radiation,Taiwan,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03624751
NCT03631771,hypothyroidism,"A Multicenter, Prospective Study to Evaluate the Risk of Hypothyroidism in Pediatric Patients Administered Intravascular Iohexol, Iodixanol, Iopromide, or Ioversol. THYROPED.",Hypothyroidism,2018-08-13,2024-08-31,2025-02-28,Interventional,Not yet recruiting,Phase 4,GE Healthcare,Bayer|GE Healthcare|Guerbet/Liebel-Flarsheim,,Drug|Drug|Drug|Drug,,0.0,3.0,[0-17],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT03631771
NCT03633708,secondary hyperparathyroidism,"Phase 3, Randomized, Open-label, Controlled, Multiple Dose, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Etelcalcetide in Pediatric Subjects 28 Days to < 18 Years of Age With Secondary Hyperparathyroidism and Chronic Kidney Disease Receiving Maintenance Hemodialysis",Chronic Kidney Disease|Secondary Hyperparathyroidism,2018-08-14,2023-01-31,2023-01-31,Interventional,Recruiting,Phase 3,Amgen,Amgen,Childrens Hospital of Los Angeles|Childrens Hospital Colorado|Childrens Mercy Hospital|Mount Sinai Kidney Center - B1 Renal Treatment|Cincinnati Childrens Hospital Medical Center|Cleveland Clinic|The Childrens Hospital at Oklahoma University Medical Center|Childrens Hospital of Philadelphia|Childrens Medical Center Dallas|Primary Childrens Hospital Outpatient Services|Hospital Italiano|Fresenius Escobar|Centro Infantil Del Rinon|Fortis Flt Lt Rajan Dhall Hospital|All India Institute of Medical Sciences|Sir Ganga Ram Hospital|Manipal Hospital|KLES Dr Prabhakar Kore Hospital and Medical Research Centre|NRS Medical College and Hospital|Seoul National University Hospital|Pusan National University Yangsan Hospital|Hospital Raja Perempuan Zainab II|Hospital TuanKu Jaafar|Hospital Wanita Dan Kanak-Kanak Kuala Lumpur|SBHI Pediatrics city clinical hospital of Saint Vladimir|Municipal Children Hospital 1|State Budgetary Healthcare Institution Samara Regional Clinical Hospital na V D Seredavin|National University Hospital|Kaohsiung Veterans General Hospital|National Cheng Kung University Hospital|National Taiwan University Hospital|Linkou Chang Gung Memorial Hospital|Hacettepe Universitesi Tip Fakultesi Ihsan Dogramaci Cocuk Hastanesi|Baskent Universitesi Ankara Hastanesi|Gazi Universitesi Tip Fakultesi|Istanbul Universitesi Cerrahpasa Tip Fakultesi|Ege Universitesi Tip Fakultesi|Erciyes Universitesi Tip Fakultesi Mustafa Eraslan ve Fevzi Mercan Cocuk Hastanesi|National Childrens Specializated Hospital OKHMATDIT,Drug,"Argentina|India|Korea, Republic of|Malaysia|Russian Federation|Singapore|Taiwan|Turkey|Ukraine|United States",0.0,18.0,[0-17]|[18-65],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT03633708
NCT03639662,follicular thyroid cancer,Psychological Impact of a Sophrological Accompaniment During the Announcement of Thyroid Cancer Compared With Usual Initial Management: Multicenter Randomized Prospective Study,Follicular Thyroid Cancer,2018-08-17,2022-03-31,2022-11-30,Interventional,Not yet recruiting,Not Applicable,Assistance Publique Hopitaux De Marseille,Assistance Publique Hopitaux De Marseille,Assistance Publique Des Hopitaux de Marseille,Other,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, follicular",https://clinicaltrials.gov/ct2/show/NCT03639662
NCT03643055,medullary thyroid cancer,Diagnostic Value of 18F-Fluorocholine PET/CT for the Detection of Medullary Thyroid Cancer,Medullary Thyroid Cancer,2018-08-20,2021-03-03,2024-09-03,Observational,"Active, not recruiting",,University Medical Centre Ljubljana,Institute of Oncology Ljubljana|University Medical Centre Ljubljana,"Department for nuclear medicine, University medical centre Ljubljana",Diagnostic Test,Slovenia,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, medullary",https://clinicaltrials.gov/ct2/show/NCT03643055
NCT03647358,thyroid carcinoma,Lesion Dosimetry With Iodine-124 in Metastatic Thyroid Carcinoma,Metastatic Thyroid Carcinoma|Thyroid Carcinoma,2018-08-22,2022-08-31,2022-08-31,Interventional,Recruiting,Phase 1,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center|Weill Cornell Medical Center,Device|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03647358
NCT03657654,thyroid cancer,Voice Outcomes Following Thyroidectomy Compared to Surgeries That Do Not Involve Risk to the Laryngeal Nerves,Thyroid Cancer|Thyroid Nodule,2018-08-29,2021-12-15,2021-12-15,Observational,Recruiting,,University of Virginia,University of Virginia,University of Virginia,Other,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03657654
NCT03657654,thyroid nodule,Voice Outcomes Following Thyroidectomy Compared to Surgeries That Do Not Involve Risk to the Laryngeal Nerves,Thyroid Cancer|Thyroid Nodule,2018-08-29,2021-12-15,2021-12-15,Observational,Recruiting,,University of Virginia,University of Virginia,University of Virginia,Other,United States,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT03657654
NCT03676348,thyroid cancer,"Health Related Quality of Life in Thyroid Cancer Patients, and in Patients With Thyroid Nodules Suspicious of Cancer",Quality of Life|Thyroid Cancer|Thyroid Nodule,2018-09-17,2023-04-30,2028-04-30,Observational,Recruiting,,Oslo University Hospital,Oslo University Hospital,"ENT department, Oslo University Hospital",,Norway,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03676348
NCT03676348,thyroid nodule,"Health Related Quality of Life in Thyroid Cancer Patients, and in Patients With Thyroid Nodules Suspicious of Cancer",Quality of Life|Thyroid Cancer|Thyroid Nodule,2018-09-17,2023-04-30,2028-04-30,Observational,Recruiting,,Oslo University Hospital,Oslo University Hospital,"ENT department, Oslo University Hospital",,Norway,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT03676348
NCT03676647,thyroid gland nodule,Retrospective-Prospective Collection of Thyroid Specimens After FNA,Thyroid Gland Nodule,2018-09-17,2023-12-31,2023-12-31,Observational,Recruiting,,City of Hope Medical Center,City of Hope Medical Center|National Cancer Institute (NCI),City of Hope Medical Center,Other,United States,19.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT03676647
NCT03690388,differentiated thyroid cancer,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects With Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy",Differentiated Thyroid Cancer,2018-09-26,2020-08-19,2022-12-31,Interventional,"Active, not recruiting",Phase 3,Exelixis,Exelixis,Exelixis Clinical Site #2|Exelixis Clinical Site #98|Exelixis Clinical Site #69|Exelixis Clinical Site #10|Exelixis Clinical Site #3|Exelixis Clinical Site #9|Exelixis Clinical Site #21|Exelixis Clinical Site #4|Exelixis Clinical Site #94|Exelixis Clinical Site #93|Exelixis Clinical Site #6|Exelixis Clinical Site #164|Exelixis Clinical Site #54|Exelixis Clinical Site #153|Exelixis Clinical Site #80|Exelixis Clinical Site #78|Exelixis Clinical Site #22|Exelixis Clinical Site #63|Exelixis Clinical Site #42|Exelixis Clinical Site #11|Exelixis Clinical Site #118|Exelixis Clinical Site #76|Exelixis Clinical Site #19|Exelixis Clinical Site #7|Exelixis Clinical Site #5|Exelixis Clinical Site #1|Exelixis Clinical Site #75|Exelixis Clinical Site #134|Exelixis Clinical Site #68|Exelixis Clinical Site #8|Exelixis Clinical Site #113|Exelixis Clinical Site #96|Exelixis Clinical Site #97|Exelixis Clinical Site #129|Exelixis Clinical Site #17|Exelixis Clinical Site #25|Exelixis Clinical Site #86|Exelixis Clinical Site #24|Exelixis Clinical Site #12|Exelixis Clinical Site #62|Exelixis Clinical Site #119|Exelixis Clinical Site #90|Exelixis Clinical Site #31|Exelixis Clinical Site #26|Exelixis Clinical Site #74|Exelixis Clinical Site #100|Exelixis Clinical Site #27|Exelixis Clinical Site #35|Exelixis Clinical Site #39|Exelixis Clinical Site #140|Exelixis Clinical Site #38|Exelixis Clinical Site #40|Exelixis Clinical Site #116|Exelixis Clinical Site #92|Exelixis Clinical Site #47|Exelixis Clinical Site #20|Exelixis Clinical Site #18|Exelixis Clinical Site #107|Exelixis Clinical Site #83|Exelixis Clinical Site #145|Exelixis Clinical Site #137|Exelixis Clinical Site #138|Exelixis Clinical Site #105|Exelixis Clinical Site #104|Exelixis Clinical Site #32|Exelixis Clinical Site #44|Exelixis Clinical Site #67|Exelixis Clinical Site #45|Exelixis Clinical Site #72|Exelixis Clinical Site #102|Exelixis Clinical Site #91|Exelixis Clinical Site #82|Exelixis Clinical Site #152|Exelixis Clinical Site #95|Exelixis Clinical Site #121|Exelixis Clinical Site #156|Exelixis Clinical Site #125|Exelixis Clinical Site #163|Exelixis Clinical Site #124|Exelixis Clinical Site #151|Exelixis Clinical Site #155|Exelixis Clinical Site #131|Exelixis Clinical Site #154|Exelixis Clinical Site #160|Exelixis Clinical Site #159|Exelixis Clinical Site #139|Exelixis Clinical Site #28|Exelixis Clinical Site #46|Exelixis Clinical Site #37|Exelixis Clinical Site #43|Exelixis Clinical Site #41|Exelixis Clinical Site #58|Exelixis Clinical Site #109|Exelixis Clinical Site #135|Exelixis Clinical Site #132|Exelixis Clinical Site #144|Exelixis Clinical Site #143|Exelixis Clinical Site #29|Exelixis Clinical Site #120|Exelixis Clinical Site #103|Exelixis Clinical Site #110|Exelixis Clinical Site #115|Exelixis Clinical Site #108|Exelixis Clinical Site #56|Exelixis Clinical Site #123|Exelixis Clinical Site #87|Exelixis Clinical Site #127|Exelixis Clinical Site #111|Exelixis Clinical Site #70|Exelixis Clinical Site #79|Exelixis Clinical Site #36|Exelixis Clinical Site #34|Exelixis Clinical Site #158|Exelixis Clinical Site #133|Exelixis Clinical Site #147|Exelixis Clinical Site #148|Exelixis Clinical Site #161|Exelixis Clinical Site #128|Exelixis Clinical Site #117|Exelixis Clinical Site #15|Exelixis Clinical Site #61|Exelixis Clinical Site #59|Exelixis Clinical Site #149|Exelixis Clinical Site #150|Exelixis Clinical Site #142|Exelixis Clinical Site #146|Exelixis Clinical Site #48|Exelixis Clinical Site #55|Exelixis Clinical Site #157|Exelixis Clinical Site #49|Exelixis Clinical Site #53|Exelixis Clinical Site #84|Exelixis Clinical Site #85|Exelixis Clinical Site #106|Exelixis Clinical Site #89|Exelixis Clinical Site #52|Exelixis Clinical Site #66|Exelixis Clinical Site #14|Exelixis Clinical Site #99|Exelixis Clinical Site #114|Exelixis Clinical Site #30|Exelixis Clinical Site #13|Exelixis Clinical Site #16|Exelixis Clinical Site #33|Exelixis Clinical Site #73|Exelixis Clinical Site #23|Exelixis Clinical Site #81|Exelixis Clinical Site #136|Exelixis Clinical Site #112|Exelixis Clinical Site #77|Exelixis Clinical Site #101|Exelixis Clinical Site #126|Exelixis Clinical Site #122|Exelixis Clinical Site #141|Exelixis Clinical Site #130|Exelixis Clinical Site #88|Exelixis Clinical Site #71|Exelixis Clinical Site #162|Exelixis Clinical Site #51|Exelixis Clinical Site #64|Exelixis Clinical Site #50|Exelixis Clinical Site #60|Exelixis Clinical Site #65|Exelixis Clinical Site #57,Drug|Drug,"Argentina|Australia|Austria|Belgium|Brazil|Canada|Croatia|Czechia|France|Germany|Hong Kong|Hungary|Israel|Italy|Korea, Republic of|Mexico|Netherlands|Poland|Romania|Russian Federation|Spain|Taiwan|Thailand|United Kingdom|United States",16.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,"Differentiated thyroid cancer, all",https://clinicaltrials.gov/ct2/show/NCT03690388
NCT03708627,graves ophthalmopathy,The Role of Bimatoprost in Graves' Periorbitopathy,Graves Ophthalmopathy,2018-10-13,2022-05-31,2022-06-30,Interventional,Recruiting,Early Phase 1,Johns Hopkins University,Johns Hopkins University,University of Washington,Drug,United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT03708627
NCT03713671,primary hyperparathyroidism,The Effect of Quadriceps Femoris Muscle Fatigue Protocol on Gait and Balance Parameters Before and After Parathyroidectomy in Patients With Primary Hyperparathyroidism,Primary Hyperparathyroidism,2018-10-18,2022-01-10,2022-01-30,Interventional,Recruiting,Not Applicable,Recep Tayyip Erdogan University Training and Research Hospital,Ankara Education and Research Hospital|Hacettepe University|Recep Tayyip Erdogan University Training and Research Hospital,Ankara Education and Research Hospital,Diagnostic Test,Turkey,45.0,65.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT03713671
NCT03753919,metastatic thyroid cancer,"A Phase II Study of Durvalumab (MEDI4736) Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma - The DUTHY Trial",Metastatic Thyroid Cancer|Metastatic Thyroid Follicular Carcinoma|Metastatic Thyroid Papillary Carcinoma,2018-11-20,2022-07-31,2022-12-31,Interventional,Recruiting,Phase 2,Grupo Espanol de Tumores Neuroendocrinos,Grupo Espanol de Tumores Neuroendocrinos|MFAR,Instituto Catalán de Oncología de Hospitalet|Hospital Provincial de Castellón|Hospital Clínic Barcelona|Hospital Universitari Vall d'Hebron|MD Anderson Cancer Center|Hospital Clínico San Carlos|Hospital Universitario 12 de Octubre|Hospital Universitario HM Sanchinarro|Hospital Universitario La Paz|Hospital Universitario Ramón y Cajal|Hospital General Universitario Morales Meseguer|Hospital Universitario Virgen de la Victoria|Clínica Universidad de Navarra|Instituto Valenciano de Oncología|Complejo Hospitalario Universitario de Vigo (CHUVI),Drug|Drug,Spain,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Metastatic Thyroid Cancer,https://clinicaltrials.gov/ct2/show/NCT03753919
NCT03757637,differentiated thyroid cancer,"Yeur-Hur Lai, PhD, RN, School of Nursing, College of Medicine, National Taiwan University",Differentiated Thyroid Cancer,2018-11-27,2022-12-31,2022-12-31,Interventional,Recruiting,Not Applicable,National Taiwan University Hospital,National Taiwan University Hospital,"Department of Surgery, National Taiwan University Hospital, No.7, Chung-Shan South Road, Taipei, TAIWAN, R.O.C.",Other|Other,Taiwan,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,"Differentiated thyroid cancer, all",https://clinicaltrials.gov/ct2/show/NCT03757637
NCT03765333,thyroid cancer,"Descriptive Observational Epidemiological Study on the Characteristics of Thyroid Cancer in Patients Treated in Oncology Services of Spanish Centers: National Registry of Thyroid Cancer - Differentiated, Medullary and Anaplastic",Thyroid Cancer,2018-11-20,2021-09-30,2021-11-30,Observational,Recruiting,,Grupo Espanol de Tumores Neuroendocrinos,Grupo Espanol de Tumores Neuroendocrinos,Hospital Universitari Vall d'Hebron,,Spain,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03765333
NCT03779906,hypothyroidism,"A Prospective, Multicenter Observational Study to Evaluate Thyroid Function of Pediatric Subjects From Birth to 3 Years Exposed to ISOVUE® (Iopamidol Injection)",Hypothyroidism,2018-12-17,2024-12-01,2025-01-31,Interventional,Recruiting,Phase 4,"Bracco Diagnostics, Inc","Bracco Diagnostics, Inc",Children's Hospital and Medical Center,Drug,United States,0.0,3.0,[0-17],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT03779906
NCT03822507,secondary hyperparathyroidism,"A Phase 3, Randomized, Double-Blind, Intra-Subject Dose-Adjustment, Parallel-Group Study of KHK7580 and Cinacalcet Hydrochloride in Subjects With Secondary Hyperparathyroidism Receiving Hemodialysis",Secondary Hyperparathyroidism,2019-01-29,2021-09-30,2022-03-31,Interventional,Recruiting,Phase 3,"Kyowa Kirin Co., Ltd.","Kyowa Hakko Kirin China Pharmaceutical Co., LTD.|Kyowa Kirin Co., Ltd.|Kyowa Kirin Korea Co., Ltd.",Research site_29|Research site_34|Research site_25|Research site_22|Research site_23|Research site_30|Research site_28|Research site_32|Research site_33|Research site_24|Research site_26|Research site_27|Research site_31|Research site_11|Research site_21|Research site_13|Research site_15|Research site_12|Research site_18|Research site_14|Research site_17|Research site_19|Research site_20|Research site_16|Research site_2|Research site_3|Research site_5|Research site_9|Research site_4|Research site_7|Research site_10|Research site_1|Research site_6|Research site_8,Drug|Drug,"China|Hong Kong|Korea, Republic of|Taiwan",18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT03822507
NCT03823859,hyperthyroidism,Metabolomics of Thyroid Hormones,Central Hypothyroidism|Hyperthyroidism|Hypothyroidism,2019-01-28,2021-07-28,2021-12-31,Observational [Patient Registry],"Active, not recruiting",,"University Hospital, Basel, Switzerland","ETH Zurich|University Hospital, Basel, Switzerland","University Hospital Basel, Department of Endocrinology",Diagnostic Test|Diagnostic Test|Diagnostic Test,Switzerland,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03823859
NCT03823859,central hypothyroidism,Metabolomics of Thyroid Hormones,Central Hypothyroidism|Hyperthyroidism|Hypothyroidism,2019-01-28,2021-07-28,2021-12-31,Observational [Patient Registry],"Active, not recruiting",,"University Hospital, Basel, Switzerland","ETH Zurich|University Hospital, Basel, Switzerland","University Hospital Basel, Department of Endocrinology",Diagnostic Test|Diagnostic Test|Diagnostic Test,Switzerland,18.0,80.0,[18-65]|[65 and more],Hypothyroidism,Secondary hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT03823859
NCT03831620,primary hyperparathyroidism,The Crosstalk Between Calcium-sensing Receptor Signaling and Endocannabinoid System in Primary Hyperparathyroidism,Primary Hyperparathyroidism,2019-01-25,2022-07-31,2022-07-31,Observational [Patient Registry],Recruiting,,"University Hospital Inselspital, Berne","University Hospital Inselspital, Berne","Department of visceral surgery and transplant surgery, Berne University Hospital",,Switzerland,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT03831620
NCT03841617,thyroid cancer,The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer,Thyroid Cancer,2019-02-13,2024-02-01,2029-02-01,Interventional,Recruiting,Phase 2,National Institutes of Health Clinical Center (CC),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),National Institutes of Health Clinical Center,Drug|Radiation|Radiation|Other,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03841617
NCT03884140,thyroid nodule,Clinical Diagnostic Evaluation of Thyroid Nodules,Thyroid Nodule,2019-03-19,2022-06-01,2022-09-01,Observational [Patient Registry],Not yet recruiting,,Assiut University,Assiut University,,,,18.0,75.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT03884140
NCT03892993,thyroid gland medullary carcinoma,"Designing a Decision Aid to Help People With Medullary Thyroid Cancer Make Decisions With Their Doctors About Whether to Start or Stop New Drugs, Enroll in Clinical Trials, or Continue With Active Surveillance",Thyroid Gland Medullary Carcinoma,2019-02-21,2023-04-19,2024-04-19,Interventional,Recruiting,Not Applicable,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center|National Cancer Institute (NCI),M D Anderson Cancer Center,Other|Other,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, medullary",https://clinicaltrials.gov/ct2/show/NCT03892993
NCT03899792,papillary thyroid cancer,A Phase 1/2 Study of the Oral RET Inhibitor LOXO 292 in Pediatric Patients With Advanced RET-Altered Solid or Primary Central Nervous System Tumors,Infantile Fibrosarcoma|Infantile Myofibromatosis|Medullary Thyroid Cancer|Papillary Thyroid Cancer|Soft Tissue Sarcoma,2019-02-06,2023-03-26,2024-03-26,Interventional,Recruiting,Phase 1/Phase 2,Eli Lilly and Company,"Eli Lilly and Company|Loxo Oncology, Inc.",Childrens Hospital of Los Angeles|Lucile Packard Children's Hospital|The Children's Hospital for Cancer and Blood Disorders|Nemours Children's Health|Dana-Farber Cancer Institute|University of Minnesota Hospital|Memorial Sloan Kettering Cancer Center|Cincinnati Children's Hospital Medical Center|Children's Hospital of Philadelphia|St. Jude Children's Research Hospital|University of Texas Southwestern Medical Center at Dallas|Texas Childrens Hospital|Seattle Children's Hospital Research Foundation|The Children's Hospital at Westmead|Royal Children's Hospital|The Hospital for Sick Children|Rigshospitalet|Gustave Roussy|Universitätsklinikum Heidelberg|Fondazione IRCCS Istituto Nazionale dei Tumori|Hokkaido University Hospital|National Cancer Center Hospital|Hiroshima University Hospital|Kyoto University Hospital|Seoul National University Hospital|Hospital Universitari Vall d'Hebron|University College Hospital - London,Drug,"Australia|Canada|Denmark|France|Germany|Italy|Japan|Korea, Republic of|Spain|United Kingdom|United States",6.0,21.0,[0-17]|[18-65],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT03899792
NCT03899792,medullary thyroid cancer,A Phase 1/2 Study of the Oral RET Inhibitor LOXO 292 in Pediatric Patients With Advanced RET-Altered Solid or Primary Central Nervous System Tumors,Infantile Fibrosarcoma|Infantile Myofibromatosis|Medullary Thyroid Cancer|Papillary Thyroid Cancer|Soft Tissue Sarcoma,2019-02-06,2023-03-26,2024-03-26,Interventional,Recruiting,Phase 1/Phase 2,Eli Lilly and Company,"Eli Lilly and Company|Loxo Oncology, Inc.",Childrens Hospital of Los Angeles|Lucile Packard Children's Hospital|The Children's Hospital for Cancer and Blood Disorders|Nemours Children's Health|Dana-Farber Cancer Institute|University of Minnesota Hospital|Memorial Sloan Kettering Cancer Center|Cincinnati Children's Hospital Medical Center|Children's Hospital of Philadelphia|St. Jude Children's Research Hospital|University of Texas Southwestern Medical Center at Dallas|Texas Childrens Hospital|Seattle Children's Hospital Research Foundation|The Children's Hospital at Westmead|Royal Children's Hospital|The Hospital for Sick Children|Rigshospitalet|Gustave Roussy|Universitätsklinikum Heidelberg|Fondazione IRCCS Istituto Nazionale dei Tumori|Hokkaido University Hospital|National Cancer Center Hospital|Hiroshima University Hospital|Kyoto University Hospital|Seoul National University Hospital|Hospital Universitari Vall d'Hebron|University College Hospital - London,Drug,"Australia|Canada|Denmark|France|Germany|Italy|Japan|Korea, Republic of|Spain|United Kingdom|United States",6.0,21.0,[0-17]|[18-65],Thyroid neoplasms,"Thyroid cancer, medullary",https://clinicaltrials.gov/ct2/show/NCT03899792
NCT03905369,thyroid cancer,Focus on Values to Stimulate Shared Decisions in Patients With Thyroid Cancer: A Multifaceted COMmunication BOoster (COMBO),Thyroid Cancer,2019-03-21,2022-09-01,2023-03-01,Interventional,Recruiting,Not Applicable,Radboud University Medical Center,Dutch Cancer Society|Radboud University Medical Center,Rijnstate hospital|CWZ|Radboudumc|MUMC|Catharina hospital|AUMC|AVL|Haga|LUMC|UMCG|UMC Utrecht,Other|Other,Netherlands,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03905369
NCT03926585,hypothyroidism,Longtime Effect of Combination Treatment With L-thyroxine (L-T4) and Liothyronine (L-T3) in Patients With Persistent Hypothyroid Symptoms - Relation to Polymorphisms (SNP) in the DIO2 and the MCT10 Gene,Hypothyroidism,2019-04-15,2022-04-30,2022-04-30,Observational,Recruiting,,Herlev Hospital,Birte Nygaard,Herlev Hospital,,Denmark,18.0,80.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT03926585
NCT03931109,primary hyperparathyroidism,Circulating microRNA Signatures in Primary Hyperparathyroidism,"Osteoporosis, Postmenopausal|Primary Hyperparathyroidism",2019-04-15,2022-04-30,2022-04-30,Observational [Patient Registry],"Active, not recruiting",,University of Pennsylvania,University of Pennsylvania,Perelman Center for Advanced Medicine/ Hospital of the University of Pennsylvania,,United States,50.0,100.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT03931109
NCT03937349,secondary hyperparathyroidism,Impact of Parathyroidectomy on Cardiovascular Calcification in Dialysis-dependent Patients: a Prospective Cohort Study,Chronic Kidney Disease Mineral and Bone Disorder|Dialysis|Secondary Hyperparathyroidism|Vascular Calcification,2019-05-01,2022-12-31,2022-12-31,Observational,Recruiting,,"Saint Petersburg State University, Russia","Saint Petersburg State University, Russia","Saint-Petersburg State University, Clinic of advanced medical technologies n.a. N.I.Pirogov",,Russian Federation,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT03937349
NCT03942380,thyroid neoplasms,Cell-free Tumor DNAand HPV-DNA in Blood Samples From Newly Diagnosed Patients With Head and Neck Cancer,Head and Neck Cancer|Head and Neck Neoplasms|Head and Neck Squamous Cell Carcinoma|Hypopharynx Cancer|Hypopharynx Carcinoma|Hypopharynx Neoplasm|Larynx Cancer|Larynx Carcinoma|Larynx Neoplasm|Nasopharyngeal Cancer|Nasopharyngeal Carcinoma|Nasopharynx Neoplasm|Oral Cancer|Oral Cavity Cancer|Oral Neoplasm|Oropharynx Cancer|Oropharynx Carcinoma|Oropharynx Neoplasm|Salivary Gland Cancer|Salivary Gland Carcinoma|Salivary Gland Neoplasms|Sinonasal Cancer|Sinonasal Carcinoma|Sinonasal Neoplasm|Thyroid Cancer|Thyroid Carcinoma|Thyroid Neoplasms,2019-04-15,2025-02-01,2025-02-01,Interventional,Recruiting,Not Applicable,"Rigshospitalet, Denmark","Christian von Buchwald|Copenhagen University Hospital, Denmark|Department of Otorhinolaryngology, Head and Neck Surgery and Audiology","University Hospital of Copenhagen, Rigshospitalet",Diagnostic Test,Denmark,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03942380
NCT03969329,secondary hyperparathyroidism,"Phase 3, Single-arm, Open-label, Multidose, Titration, Pharmacokinetic, Pharmacodynamic, and Safety Study of Etelcalcetide in Children and Adolescents ≥ 2 to < 18 Years of Age With Secondary Hyperparathyroidism and Chronic Kidney Disease Receiving Maintenance Hemodialysis",Secondary Hyperparathyroidism,2019-05-29,2026-08-02,2026-08-02,Interventional,Recruiting,Phase 3,Amgen,Amgen,"Universitair Ziekenhuis Gent|Fakultni nemocnice v Motole|Hospices Civils de Lyon Hopital Femme Mere Enfant|Hôpital Armand Trousseau|Kindernierenzentrum Bonn|Universitätsklinikum Hamburg-Eppendorf|Medizinische Hochschule Hannover|Zentrum für Kinder und Jugendmedizin des Universitätsklinikums Heidelberg|Universitätsklinikum Köln|General Children Hospital Panagioti and Aglaias Kyriakou|Ippokrateio General Hospital of Thessaloniki|Semmelweis Egyetem|Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont Altalanos Orvostudomanyi Kar|Azienda Ospedaliera Universitaria Meyer|Childrens Hospital, Affiliate of Vilnius University Hospital Santaros Klinikos|Uniwersytecki Szpital Dzieciecy w Krakowie|Centro Hospitalar Universitario do Porto - Hospital de Santo Antonio|Hospital Universitari Vall d Hebron|Royal Hospital for Sick Children|Great Ormond Street Hospital for Children",Drug,Belgium|Czechia|France|Germany|Greece|Hungary|Italy|Lithuania|Poland|Portugal|Spain|United Kingdom,2.0,17.0,[0-17],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT03969329
NCT03973450,endocrine neoplasia,"Epidemiology of Pituitary Tumours: Prevalence of Associated Endocrine and Non-endocrine Tumours and Potential Implications in the Management and Follow-up of Patients""",Endocrine Neoplasia|Familial Tumor Syndrome|Hyperparathyroidism|Pituitary Tumor|Solid Tumor,2019-05-25,2021-11-30,2022-02-28,Observational,Recruiting,,Neuromed IRCCS,Neuromed IRCCS,Neuromed,Other,Italy,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03973450
NCT03973450,hyperparathyroidism,"Epidemiology of Pituitary Tumours: Prevalence of Associated Endocrine and Non-endocrine Tumours and Potential Implications in the Management and Follow-up of Patients""",Endocrine Neoplasia|Familial Tumor Syndrome|Hyperparathyroidism|Pituitary Tumor|Solid Tumor,2019-05-25,2021-11-30,2022-02-28,Observational,Recruiting,,Neuromed IRCCS,Neuromed IRCCS,Neuromed,Other,Italy,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT03973450
NCT03975231,thyroid gland anaplastic carcinoma,A Phase I Trial of Concurrent Intensity Modulated Radiation Therapy (IMRT) and Dabrafenib/Trametinib in BRAF Mutated Anaplastic Thyroid Cancer,BRAF NP_004324.2:p.V600E|BRAF V600K Mutation Present|Thyroid Gland Anaplastic Carcinoma,2019-06-03,2025-04-30,2025-04-30,Interventional,"Active, not recruiting",Phase 1,City of Hope Medical Center,City of Hope Medical Center|National Cancer Institute (NCI),City of Hope Medical Center|Ohio State University Comprehensive Cancer Center,Drug|Radiation|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT03975231
NCT03977207,hypothyroidism,A Randomized Controlled Trial of Thyroid Hormone Supplementation in Hemodialysis Patients,Hemodialysis|Hypothyroidism|Thyroid; Functional Disturbance,2019-05-28,2024-06-30,2024-06-30,Interventional,Recruiting,Not Applicable,"University of California, Irvine","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|University of California, Irvine",University of California Irvine,Drug|Drug,United States,18.0,75.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT03977207
NCT04000880,thyroid cancer,Adapting MultiPLe Behavior Interventions That eFfectively Improve (AMPLIFI) Cancer Survivor Health,Breast Cancer|Colorectal Cancer|Endometrial Cancer|Kidney Cancer|Multiple Myeloma|Non-Hodgkin Lymphoma|Ovary Cancer|Prostate Cancer|Thyroid Cancer,2019-06-21,2024-08-31,2024-08-31,Interventional,Recruiting,Not Applicable,University of Alabama at Birmingham,National Cancer Institute (NCI)|University of Alabama at Birmingham|University of Tennessee Health Science Center,University of Alabama at Birmingham|University of Tennessee Health Science Center,Behavioral|Other|Other|Other,United States,50.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04000880
NCT04009291,parathyroid diseases,"PaTH Forward: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial With an Open-Label Extension, Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Subcutaneously Daily in Adults With Hypoparathyroidism",Endocrine System Diseases|Hypoparathyroidism|Parathyroid Diseases,2019-06-20,2020-03-06,2023-03-31,Interventional,"Active, not recruiting",Phase 2,Ascendis Pharma A/S,Ascendis Pharma A/S,Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site,Combination Product|Combination Product,Canada|Denmark|Germany|Italy|Norway|United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT04009291
NCT04013100,primary hyperparathyroidism,Cohort Trial on Perioperative Localization Techniques of Parathyroid Adenomas,Primary Hyperparathyroidism,2019-07-05,2029-12-31,2029-12-31,Observational [Patient Registry],Not yet recruiting,,IHU Strasbourg,IHU Strasbourg,,Diagnostic Test,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT04013100
NCT04028479,thyroid cancer,The Registry of Oncology Outcomes Associated With Testing and Treatment (ROOT),"Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Adenocarcinoma|Adenocystic Carcinoma|Adrenal Cancer|Anal Cancer|Appendix Cancer|Astrocytoma|Bile Duct Cancer|Bladder Cancer|Bone Cancer|Brain Stem Neoplasms|Brain Tumor|Breast Cancer|Cancer, Advanced|Cancer of Colon|Cancer of Pancreas|Carcinoid Tumor|Cervical Cancer|Cholangiocarcinoma|Chondrosarcoma|Chronic Myeloid Leukemia|CNS Cancer|Colon Cancer|Colorectal Cancer|Esophageal Cancer|Esophagus Cancer|Fallopian Tube Cancer|Gestational Trophoblastic Tumor|Glioblastoma|Head and Neck Neoplasms|Hepatic Cancer|Kidney Cancer|Larynx Cancer|Liposarcoma|Liver Cancer|Lung Cancer|Melanoma|Mesothelioma|Multiple Endocrine Neoplasia|Multiple Myeloma|Nasopharyngeal Carcinoma|Neuroendocrine Tumors|Non Hodgkin Lymphoma|Osteosarcoma|Ovarian Cancer|Pancreatic Cancer|Parathyroid Neoplasms|Parotid Tumor|Penile Cancer|Pharynx Cancer|Pheochromocytoma|Prostate Cancer|Pulmonary Carcinoma|Rectal Cancer|Renal Cell Carcinoma|Salivary Gland Cancer|Sarcoma|Sarcoma, Kaposi|Sarcoma,Soft Tissue|Skin Cancer|Small Bowel Cancer|Small Cell Carcinoma|Stomach Cancer|Synovial Sarcoma|Testicular Cancer|Testis Cancer|Thymus Cancer|Thyroid Cancer|Tongue Cancer|Unknown Primary Tumors|Ureter Cancer|Uterine Cancer|Vaginal Cancer|Vulvar Cancer|Waldenstrom Macroglobulinemia",2019-07-17,2029-10-01,2031-10-01,Observational [Patient Registry],Recruiting,,Taproot Health,Taproot Health,Teton Cancer Institute,Diagnostic Test|Drug|Other,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04028479
NCT04028479,parathyroid neoplasms,The Registry of Oncology Outcomes Associated With Testing and Treatment (ROOT),"Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Adenocarcinoma|Adenocystic Carcinoma|Adrenal Cancer|Anal Cancer|Appendix Cancer|Astrocytoma|Bile Duct Cancer|Bladder Cancer|Bone Cancer|Brain Stem Neoplasms|Brain Tumor|Breast Cancer|Cancer, Advanced|Cancer of Colon|Cancer of Pancreas|Carcinoid Tumor|Cervical Cancer|Cholangiocarcinoma|Chondrosarcoma|Chronic Myeloid Leukemia|CNS Cancer|Colon Cancer|Colorectal Cancer|Esophageal Cancer|Esophagus Cancer|Fallopian Tube Cancer|Gestational Trophoblastic Tumor|Glioblastoma|Head and Neck Neoplasms|Hepatic Cancer|Kidney Cancer|Larynx Cancer|Liposarcoma|Liver Cancer|Lung Cancer|Melanoma|Mesothelioma|Multiple Endocrine Neoplasia|Multiple Myeloma|Nasopharyngeal Carcinoma|Neuroendocrine Tumors|Non Hodgkin Lymphoma|Osteosarcoma|Ovarian Cancer|Pancreatic Cancer|Parathyroid Neoplasms|Parotid Tumor|Penile Cancer|Pharynx Cancer|Pheochromocytoma|Prostate Cancer|Pulmonary Carcinoma|Rectal Cancer|Renal Cell Carcinoma|Salivary Gland Cancer|Sarcoma|Sarcoma, Kaposi|Sarcoma,Soft Tissue|Skin Cancer|Small Bowel Cancer|Small Cell Carcinoma|Stomach Cancer|Synovial Sarcoma|Testicular Cancer|Testis Cancer|Thymus Cancer|Thyroid Cancer|Tongue Cancer|Unknown Primary Tumors|Ureter Cancer|Uterine Cancer|Vaginal Cancer|Vulvar Cancer|Waldenstrom Macroglobulinemia",2019-07-17,2029-10-01,2031-10-01,Observational [Patient Registry],Recruiting,,Taproot Health,Taproot Health,Teton Cancer Institute,Diagnostic Test|Drug|Other,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04028479
NCT04031339,thyroid neoplasms,"Multicenter, Prospective, Observational Study of Clinical Outcomes of Thyroid Cancer",Thyroid Neoplasms,2019-06-25,2025-01-31,2025-01-31,Observational,Recruiting,,University of Roma La Sapienza,Catholic University of the Sacred Heart|Italian Thyroid Cancer Observatory (ITCO) Foundation|University of Roma La Sapienza,"Ospedali Riuniti di Ancona|Università degli Studi di Bari|Azienda Unità Sanitaria di Bologna - Ospedale Maggiore|University of Bologna, S. Orsola Malpighi Hospital|ASST Valle Olona - Ospedale di Busto Arsizio|University of Florence|Ente Ospedaliero Ospedali Galliera|Sapienza University of Rome, Santa Maria Goretti Hospital|Tinchi Pisticci Hospital|University of Milan, Fondazione IRCCS, National Cancer Institute of Milan|University of Modena and Reggio Emilia|University of Naples Federico II|University of Parma|Bio-Medical Campus University|Sapienza University of Rome, Sant'Andrea Hospital|Sapienza University of Rome|University of Siena|University of Turin, Gradenigo Hospital|University of Turin, Molinette Hospital",Procedure,Italy,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04031339
NCT04040673,thyroid cancer,Evaluation of the Role of Vibrational Spectroscopy in the Diagnosis of Premalignant and Malignant Disease of the Thyroid RAFTER (RAman For Thyroid cancER),Thyroid Cancer|Thyroid Diseases,2019-07-29,2022-10-01,2022-10-01,Observational,Not yet recruiting,,Gloucestershire Hospitals NHS Foundation Trust,Gloucestershire Hospitals NHS Foundation Trust,Biophotonics Research Unit,Procedure|Device,United Kingdom,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04040673
NCT04040673,thyroid diseases,Evaluation of the Role of Vibrational Spectroscopy in the Diagnosis of Premalignant and Malignant Disease of the Thyroid RAFTER (RAman For Thyroid cancER),Thyroid Cancer|Thyroid Diseases,2019-07-29,2022-10-01,2022-10-01,Observational,Not yet recruiting,,Gloucestershire Hospitals NHS Foundation Trust,Gloucestershire Hospitals NHS Foundation Trust,Biophotonics Research Unit,Procedure|Device,United Kingdom,18.0,120.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT04040673
NCT04040946,hyperparathyroidism,Phase III Trial Comparing 2 Diagnostic Strategies for Preoperative Localization of Parathyroid Adenoma in Primary Hyperparathyroidism:TEMP / CT With Tc99m-sestaMIBI or PET / CT With F18-choline in First Intention,F18-choline|Hyperparathyroidism|Parathyroid Adenoma,2019-07-29,2022-09-30,2023-03-31,Interventional,Recruiting,Phase 3,Centre Francois Baclesse,Centre Francois Baclesse|Fondation de l'Avenir,CHU Brest|Centre François Baclesse|Centre Eugène Marquis|CHU,Diagnostic Test|Diagnostic Test,France,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT04040946
NCT04051099,hyperparathyroidism,Bilateral Superficial Cervical Plexus Block Combined With Intravenous Sedation Versus General Anesthesia in Selected Patients for Thyroid/Parathyroid Surgery ; a Prospective Randomized Control Trial,Benign Tumor of Thyroid|Hyperparathyroidism,2018-03-27,2021-09-30,2021-12-15,Interventional,Recruiting,Not Applicable,Mahidol University,Mahidol University,"Faculty of Medicine Siriraj Hospital, Mahidol University",Procedure|Drug|Procedure|Procedure,Thailand,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT04051099
NCT04061980,metastatic thyroid gland carcinoma,Encorafenib/Binimetinib With or Without Nivolumab for Patients With Metastatic BRAF V600 Mutant Thyroid Cancer,BRAF NP_004324.2:p.V600M|BRAF V600E Mutation Present|Metastatic Thyroid Gland Carcinoma|Refractory Thyroid Gland Carcinoma|Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v8|Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v8|Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8,2019-08-18,2022-07-30,2024-08-01,Interventional,Recruiting,Phase 2,Providence Health & Services,Providence Health & Services,Providence Portland Medical Center,Drug|Drug|Biological,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Metastatic Thyroid Cancer,https://clinicaltrials.gov/ct2/show/NCT04061980
NCT04076514,papillary thyroid cancer,The Role of Central Neck Dissection in Stage N0 Papillary Thyroid Carcinoma,Papillary Thyroid Cancer,2019-08-28,2020-09-30,2020-11-01,Observational,Recruiting,,Assiut University,Assiut University,Ahmed Kamel,Procedure,Egypt,16.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT04076514
NCT04080505,graves disease,Does the Use of Pre-operative SSKI Actually Reduce Vascularity and Improve Surgical Outcomes for Total Thyroidectomy in Graves' Disease?,Graves Disease,2019-09-04,2021-12-31,2022-12-31,Interventional,Recruiting,Phase 3,Columbia University,Columbia University,Columbia University Medical Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04080505
NCT04104529,thyroid cancer,Establishment of a Monocentric and Prospective Clinico-biological Database in Patients Treated With Metabolic Radiotherapy in the Nuclear Medicine Department,Neuroendocrine Tumors|Prostate Cancer|Thyroid Cancer,2019-09-24,2024-10-31,2024-10-31,Interventional,Recruiting,Not Applicable,Institut du Cancer de Montpellier - Val d'Aurelle,Institut du Cancer de Montpellier - Val d'Aurelle,Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle,Other,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04104529
NCT04126954,"hyperparathyroidism, secondary",Multicentric Retrospective Study on the Use of Cinacalcet in an Off-label Phosphocalcic Context,"Hyperparathyroidism, Primary|Hyperparathyroidism, Secondary",2019-10-11,2021-01-31,2023-12-31,Observational,Not yet recruiting,,Hospices Civils de Lyon,Hospices Civils de Lyon,"Endocrinologie Diabète et Maladies Métaboliques - Hôpital Gabriel Montpied|Service de Néphrologie Pédiatrique -Hôpital Jeanne de Flandre|Service d'Endocrinologie Pédiatrique - Hôpital de la mère et de l'Enfant|Pole Femme Mère Enfant - Pédiatrie spécialisée - Centre Hospitalier Universitaire|Service de Néphrologie pédiatrique - Clinique Médicale Pédiatrique|Service d'endocrinologie et Diabétologie Pédiatrique-Hôpital Robert Debré|Service de Diabétologie et endocrinologie pédiatriques - Centre Hospitalier Universitaire|Pôle Néphrologie-Urologie-Diabétologie-Endocrinologie|Service d'Endocrinologie, Maladies Osseuses, Gynécologie, Génétique|Unité Endocrinologie, Nutrition, Diabétologie -Hôpital Bretonneau",Other,France,0.0,99.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT04126954
NCT04129411,papillary thyroid cancer,Pilot Study for the Treatment of Papillary Thyroid Carcinoma With Radiofrequency Ablation,Papillary Thyroid Cancer|Papillary Thyroid Microcarcinoma,2019-10-04,2022-03-31,2022-03-31,Interventional,Recruiting,Not Applicable,Mayo Clinic,Mayo Clinic,Mayo Clinic,Device,United States,18.0,85.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT04129411
NCT04135573,graves disease,Mechanism of NK Cell Disfunction in Graves' Disease,Graves Disease,2019-01-03,2022-06-30,2022-06-30,Observational [Patient Registry],"Active, not recruiting",,Shandong Provincial Hospital,Shandong Provincial Hospital,Shandong Provincial Hospital,,China,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04135573
NCT04136912,thyroid cancer,High Frame Rate 3-D Super Resolution Ultrasound Microvascular Imaging,Breast Cancer|Thyroid Cancer,2019-10-21,2023-12-31,2023-12-31,Interventional,Not yet recruiting,Phase 2,UNC Lineberger Comprehensive Cancer Center,National Cancer Institute (NCI)|UNC Lineberger Comprehensive Cancer Center,Univeristy of North Carolina Chapel Hill,Drug|Device,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04136912
NCT04137185,differentiated thyroid cancer,"Phase I/II Clinical Trial of Dose-tolerance, Pharmacokinetics and Iodine Uptake For Recombinant Human Thyroid Stimulating Hormone In Post-thyroidectomized Patients",Differentiated Thyroid Cancer,2019-09-20,2022-12-30,2022-12-30,Interventional,Recruiting,Phase 1/Phase 2,"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","Suzhou Zelgen Biopharmaceuticals Co.,Ltd",Peking Union Medical College Hospital,Drug,China,18.0,75.0,[18-65]|[65 and more],Thyroid neoplasms,"Differentiated thyroid cancer, all",https://clinicaltrials.gov/ct2/show/NCT04137185
NCT04161391,medullary thyroid cancer,"A Phase 1/2 Study of TPX-0046, A Novel Oral RET/SRC Inhibitor in Adult Subjects With Advanced/Metastatic Solid Tumors Harboring Oncogenic RET Fusions or Mutations",Advanced Solid Tumor|Medullary Thyroid Cancer|Metastatic Solid Tumor|Non Small Cell Lung Cancer|RET Gene Mutation,2019-11-11,2025-12-31,2026-11-30,Interventional,Recruiting,Phase 1/Phase 2,"Turning Point Therapeutics, Inc.","Turning Point Therapeutics, Inc.","UCI Health - Chao Family Comprehensive Cancer Center|UC San Diego Moores Cancer Center|University of Colorado, Denver|Sarah Cannon Research Institute at HealthONE|Georgetown University Medical Center|Moffitt Cancer Center|Winship Cancer Institute, Emory University|University of Chicago Medical Center|Massachusetts General Hospital|Karmanos Cancer Institute|Memorial Sloan Kettering Cancer Center|Fox Chase Cancer Center|MD Anderson Cancer Center|Virginia Cancer Specialists|The University of Washington, Seattle Cancer Care Alliance|Severance Hospital, Yonsei University Health System",Drug,"Korea, Republic of|United States",18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, medullary",https://clinicaltrials.gov/ct2/show/NCT04161391
NCT04171622,poorly differentiated thyroid gland carcinoma,Lenvatinib in Combination With Pembrolizumab for Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer,Metastatic Thyroid Gland Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8|Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8|Thyroid Gland Squamous Cell Carcinoma|Unresectable Thyroid Gland Carcinoma,2019-11-19,2022-08-31,2022-08-31,Interventional,Not yet recruiting,Phase 2,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center|National Cancer Institute (NCI),M D Anderson Cancer Center,Drug|Biological,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Poorly differentiated thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04171622
NCT04171622,thyroid gland squamous cell carcinoma,Lenvatinib in Combination With Pembrolizumab for Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer,Metastatic Thyroid Gland Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8|Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8|Thyroid Gland Squamous Cell Carcinoma|Unresectable Thyroid Gland Carcinoma,2019-11-19,2022-08-31,2022-08-31,Interventional,Not yet recruiting,Phase 2,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center|National Cancer Institute (NCI),M D Anderson Cancer Center,Drug|Biological,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid Gland Squamous Cell Carcinoma,https://clinicaltrials.gov/ct2/show/NCT04171622
NCT04171622,metastatic thyroid gland carcinoma,Lenvatinib in Combination With Pembrolizumab for Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer,Metastatic Thyroid Gland Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8|Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8|Thyroid Gland Squamous Cell Carcinoma|Unresectable Thyroid Gland Carcinoma,2019-11-19,2022-08-31,2022-08-31,Interventional,Not yet recruiting,Phase 2,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center|National Cancer Institute (NCI),M D Anderson Cancer Center,Drug|Biological,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Metastatic Thyroid Cancer,https://clinicaltrials.gov/ct2/show/NCT04171622
NCT04197960,papillary thyroid carcinoma,A Prospective Multicenter Study to Compare the Therapeutic Outcomes of Microwave Ablation With Surgical Resection for Micropapillary Thyroid Carcinoma,Papillary Thyroid Carcinoma,2019-12-04,2020-09-30,2022-12-31,Interventional,Not yet recruiting,Not Applicable,Chinese PLA General Hospital,Chinese PLA General Hospital,Chinese PLA General Hospital,Procedure|Procedure,China,18.0,75.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT04197960
NCT04211337,medullary thyroid cancer,"A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)",Medullary Thyroid Cancer,2019-12-24,2024-05-20,2026-11-13,Interventional,Recruiting,Phase 3,Eli Lilly and Company,"Eli Lilly and Company|Loxo Oncology, Inc.","University of Alabama at Birmingham|Mayo Clinic Hospital|City of Hope National Medical Center|UCLA Medical Center|University of California, Davis - Health Systems|UCSF Medical Center at Mission Bay|Los Angeles Biomedical Research Institute at Harbor - UCLA Medical|Mayo Clinic in Florida|Emory University|University of Chi Med Center|Massachusetts General Hospital|University of Michigan|Mayo Clinic|Washington University Medical School|Memorial Sloan Kettering Cancer Center|University of Cincinnati Cancer Institute|Ohio State University Medical Center|University of Pennsylvania Hospital|Thomas Jefferson University|University of Texas MD Anderson Cancer Center|University of Wisconsin-Madison Hospital and Health Clinic|Chris O'Brien Lifehouse|Royal North Shore Hospital|Peter MacCallum Cancer Centre|The Alfred Hospital|Sir Charles Gairdner Hospital|Universitair Ziekenhuis Antwerpen|Centre Hospitalier Universitaire Sart Tilman|Oncocentro BH|Hospital de Cancer de Londrina|Hospital de Clinicas de Porto Alegre|Instituto de de Educação, pesquisa e Gestão em Saúde|Fundação Pio XII - Hospital de Câncer de Barretos|Clinica Onco Star|Hospital PUC-CAMPINAS|Hospital das Clinicas da FMRP|INCA Hospital do Câncer III|Oncoclinicas Rio de Janeiro S.A.|Soc. Beneficente de Senhoras Hospital Sirio Libanes-Oncology|Icesp - Instituto Do Câncer Do Estado de São Paulo|Centro Paulista de Oncologia|London Health Science Centre - Victoria Hospital|Princess Margaret Hospital|Anhui Provincial Hospital|Beijing Tongren Hospital affiliated to Capital Medical Unive|The First Affiliated Hospital of Fujian Medical University|Gansu Province Cancer Hospital|Sun Yat-sen University Cancer Center|Harbin Medical University Cancer Hospital|Henan Cancer Hospital|Hunan Cancer Hospital|Jilin Cancer Hospital|Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School|Jinan Central Hospital|Fudan University Shanghai Cancer Center|West China Hospital of Sichuan University|First Affiliated Hospital of Kunming Medical University|Zhejiang Provincial People's Hospital|Sir Run Run Shaw Hospital|Zhejiang Cancer Hospital|Chongqing Cancer Hospital|Tianjin Medical University Cancer Institute and Hospital|Fakultni nemocnice Brno|Fakultni nemocnice Olomouc|Fakultni Nemocnice v Motole|Assistance Publique Hôpitaux de Marseille - Hôpital Nord|Centre Georges François Leclerc|Centre Hospitalier Universitaire d'Angers|Centre Jean Perrin - Centre Régional de Lutte contre le Cancer d'Auvergne|Centre Leon Berard|Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest|Centre François Baclesse|Hôpital C. HURIEZ|Hopital Pitie Salpetriere -Unité Thyroïde-Tumeurs Endocrines|Institut de cancérologie Strasbourg Europe|Institut Claudius Regaud|Gustave Roussy|Klinikum der Universität München Großhadern|Universitätsklinikum Würzburg A. ö. R.|Medizinische Hochschule Hanover|Universitätsmedizin Johannes Gutenberg Universität Mainz|Charité Campus Mitte|Universitaetsklinikum Essen|Studiengesellschaft Hämato-Onkologie Hamburg - Prof Laack & Partner|Otto-von-Guericke-Universität|Alexandra General Hospital of Athens|University General Hospital of Heraklion|European Interbalkan Medical Center|Regional Cancer Centre|HCG Manavata Cancer Centre|Ruby Hall Clinic and Grant Medical Foundation|Deenanath Mangeshkar Hospital & Research Centre|Apollo Gleneagles Hospitals Kolkata|Postgraduate Institute of Medical Education & Research|Hadassah Medical Center|Rabin Medical Center|Sheba Medical Center|Istituto Nazionale dei Tumori|Ospedale San Luca, IRCCS Istituto Auxologico|Polic.Umberto I -Univ. La Sapienza|A.O.U. Senese Policlinico Santa Maria alle Scotte|Istituto Oncologico Veneto IRCCS|Ospedale Garibaldi-Nesima|Azienda Ospedaliera Universitaria Federico II|Azienda Ospedlaliero-Univeristaria Pisana, Stabilimento Ospedaliero di Cisanello|I.F.O. Istituto Nazionale Tumori Regina Elena|Azienda Ospedaliero-Universitaria S.Giovanni Battista|Aichi Cancer Center Hospital|National Cancer Center Hospital East|Hokkaido University Hospital|Kobe University Hospital|Yokohama City University Hospital|Osaka University Hospital|Japanese Foundation for Cancer Research|National Hospital Organization Kyushu Medical Center|National Cancer Center|Seoul National University Bundang Hospital|Chonnam National University Hwasun Hospital|Asan Medical Center|Seoul National University Hospital|Severance Hospital, Yonsei University Health System|Samsung Medical Center|Nederlands Kanker Instituut - Antoni van Leeuwenhoek|University Medical Center Groningen|Leids Universitair Medisch Centrum|Maastricht UMC+|Erasmus Medisch Centrum|Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie|Swietokrzyskie Centrum Onkologii, Samodzielny Publiczny Zaklad Opieki Zdrowotnej|National medical research center of radiology Obninsk|Clinic of advanced medical technologies n. a. Nicolay I. Pirogov (policlinic, hospital)|LLC Evimed|Blokhin Cancer Research Center|National Medical Research Center of Endocrinology of Ministry of Health Dept|Saint-Petersburg City Clinical Oncology Dispensary|Hospital Universitario Virgen de la Victoria|Hospital Universitari Vall d'Hebron|Hospital Universitari de Girona Dr. Josep Trueta|Hospital Universitario Ramón y Cajal|Clinica Universitaria De Navarra|Institut Catala d'Oncologia|Hospital General Universitario Gregorio Marañon|Clinica Universidad de Navarra|Hospital Clinico San Carlos|Hospital Universitario 12 de Octubre|Hospital Universitario La Paz|Hospital Universitario Miguel Servet|China Medical University Hospital|National Cheng-Kung Uni. Hosp.|National Taiwan University Hospital|Gartnavel General Hospital|University College Hospital - London|Royal Marsden NHS Trust|Velindre Cancer Centre|Weston Park Hospital|Royal Marsden Hospital",Drug|Drug|Drug,"Australia|Belgium|Brazil|Canada|China|Czechia|France|Germany|Greece|India|Israel|Italy|Japan|Korea, Republic of|Netherlands|Poland|Russian Federation|Spain|Taiwan|United Kingdom|United States",12.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, medullary",https://clinicaltrials.gov/ct2/show/NCT04211337
NCT04224792,thyroid cancer,Effects of Exercise Training on Fatigue in Thyroid Cancer Survivors,Thyroid Cancer,2020-01-08,2024-09-30,2024-12-30,Interventional,Not yet recruiting,Not Applicable,Mayo Clinic,Mayo Clinic,Mayo Clinic in Rochester,Other|Other,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04224792
NCT04238624,anaplastic thyroid cancer,"A Pilot Study of the Addition of Cemiplimab, an Antibody to PD-1, to the Treatment of Subjects With BRAF-Mutant Anaplastic Thyroid Cancer Who Are No Longer Responding to Dabrafenib and Trametinib",Anaplastic Thyroid Cancer|BRAF Gene Mutation|BRAF Mutation-Related Tumors|Thyroid Cancer,2020-01-21,2022-06-20,2022-06-20,Interventional,Recruiting,Phase 2,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Memoral Sloan Kettering Basking Ridge (Limited Protocol Activities)|Memoral Sloan Kettering Monmouth (Limited Protocol Activities)|Memorial Sloan Kettering Bergen (Limited Protocol Activities)|Memorial Sloan Kettering Cancer Center @ Commack (Limited Protocol Activities)|Memoral Sloan Kettering Westchester (Limited Protocol Activities)|Memorial Sloan Kettering Cancer Center|Memorial Sloan Kettering Nassau (Limited Protocol Activities),Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT04238624
NCT04239521,graves disease,"The Epidemiology, Management, and the Associated Burden of Mental Health, Atopic and Autoimmune Conditions, and Common Infections in Alopecia Areata",Acute Bronchitis|Allergic Rhinitis|Alopecia Areata|Ankylosing Spondylitis|Anxiety Disorders|Asthma|Atopic Dermatitis|Celiac Disease|Crohn Disease|Depressive Episode|Gastrointestinal Infection|Genital Infection|Graves Disease|Hashimoto Thyroiditis|Herpes Simplex|Herpes Zoster|Infection|Infection Viral|Influenza|Lower Resp Tract Infection|Multiple Sclerosis|Pernicious Anemia|Pneumonia|Polymyalgia Rheumatica|Psoriasis|Psoriatic Arthritis|Recurrent Depressive Disorder|Rheumatoid Arthritis|Sjogren's Syndrome|Skin Infection|Systemic Lupus Erythematosus|Type 1 Diabetes|Ulcerative Colitis|Upper Respiratory Tract Infection|Urinary Tract Infections|Vitiligo,2020-01-09,2021-10-31,2021-12-31,Observational,"Active, not recruiting",,Momentum Data,Momentum Data|Pfizer|University of Oxford|University of Surrey,Momentum Data Ltd,Other,United Kingdom,0.0,120.0,[0-17]|[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04239521
NCT04252001,thyroid dysgenesis,Growing up With the Young Endocrine Support System (YESS!): Innovative E-technology to Improve Transition From Paediatric to Adult Care,Addison's Disease|Androgen Insensitivity Syndrome|Combined Pituitary Hormone Deficiency|Congenital Adrenal Hyperplasia|Growth Hormone Deficiency|Hypogonadotropic Hypogonadism|Klinefelter Syndrome|Thyroid Dysgenesis|Turner Syndrome,2020-01-21,2022-12-01,2023-12-01,Interventional,Not yet recruiting,Not Applicable,Erasmus Medical Center,dr. Laura C. G. de Graaff-Herder,Ghent University Hospital|Erasmus Medical Center|Hospital Infantil Universitario Niño Jesús|Queen Elizabeth University Hospital|Royal Hospital for Children|The Royal London Hospital (Barts Health NHS Trust)|University College London Hospital (UCL Institute of Child Health),Device|Device|Other,Belgium|Netherlands|Spain|United Kingdom,15.0,20.0,[0-17]|[18-65],Hypothyroidism,Congenital hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT04252001
NCT04280081,medullary thyroid cancer,"A Phase 2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including Rearranged in Transfection (RET) Fusion-Positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation",Medullary Thyroid Cancer|Solid Tumor,2020-02-20,2021-03-25,2025-11-20,Interventional,"Active, not recruiting",Phase 2,Eli Lilly and Company,"Eli Lilly and Company|Loxo Oncology, Inc.","Nanfang Affiliated Hospital South Medical University|The First Affiated Hospital Of Guangzhou Medical Collage|Hunan Cancer Hospital|Jilin Province Tumor Hospital|Jinan Central Hospital|Shanghai Chest Hospital|Zhejiang Cancer Hospital|First Affiliated Hosp of College of Med, Zhejiang University|Zhejiang Provincial People's Hospital|Beijing Cancer Hospital|Fudan University Shanghai Cancer Center|Shanghai East Hospital|Tianjin Medical University Cancer Institute & Hospital",Drug,China,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, medullary",https://clinicaltrials.gov/ct2/show/NCT04280081
NCT04281875,thyroid neoplasms,Assessing Benefits of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Total Thyroidectomy.,Postoperative Hypoparathyroidism|Thyroid Cancer|Thyroid Neoplasms,2020-02-19,2022-03-31,2023-02-28,Interventional,Recruiting,Not Applicable,Vanderbilt-Ingram Cancer Center,National Cancer Institute (NCI)|Vanderbilt-Ingram Cancer Center,Vanderbilt University Medical Center,Device,United States,18.0,99.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04281875
NCT04285476,thyroid cancer,Study of the Predictive Value of a Signature of 10 microRNA in Thyroid Cytologies of Undetermined Type,Thyroid Cancer,2020-02-24,2022-07-31,2023-03-31,Interventional,Recruiting,Not Applicable,Institut du Cancer de Montpellier - Val d'Aurelle,Institut du Cancer de Montpellier - Val d'Aurelle,CHU de Toulouse|Institut régional du Cancer de Montpellier,Diagnostic Test,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04285476
NCT04290663,thyroid cancer,Multicentric Phase III Trial Comparing Two Strategies in Intermediate-risk Differentiated Thyroid Cancer Patients: Systematic Radioiodine Administration (3.7 GBq I131 After rhTSH) Versus Decision of Radioiodine Treatment Guided by a Post-operative Work-up Based on Serum Tg Values and Diagnostic RAI Scintigraphy,Intermediate Risk|Thyroid Cancer,2020-02-20,2026-02-28,2028-02-29,Interventional,Recruiting,Phase 3,Centre Francois Baclesse,Centre Francois Baclesse|French cancer Institute INCa,Centre Francois Baclesse,Drug|Other,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04290663
NCT04299425,primary hyperparathyroidism,Evaluating Impact of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy,Hypercalcemia|Parathyroid Adenoma|Parathyroid Cancer|Parathyroid Hyperplasia|Parathyroid Neoplasms|Primary Hyperparathyroidism,2020-03-04,2022-03-31,2023-02-28,Interventional,Recruiting,Not Applicable,Vanderbilt-Ingram Cancer Center,National Cancer Institute (NCI)|Vanderbilt-Ingram Cancer Center,Vanderbilt University Medical Center,Device,United States,18.0,99.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT04299425
NCT04299425,parathyroid neoplasms,Evaluating Impact of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy,Hypercalcemia|Parathyroid Adenoma|Parathyroid Cancer|Parathyroid Hyperplasia|Parathyroid Neoplasms|Primary Hyperparathyroidism,2020-03-04,2022-03-31,2023-02-28,Interventional,Recruiting,Not Applicable,Vanderbilt-Ingram Cancer Center,National Cancer Institute (NCI)|Vanderbilt-Ingram Cancer Center,Vanderbilt University Medical Center,Device,United States,18.0,99.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04299425
NCT04305561,primary hyperparathyroidism,Comparison of CEUS With Conventional Ultrasound (US) to Dual-tracer 99mTcO4-/99mTc-MIBI Subtraction Scintigraphy With SPECT/CT Combined With US for Localizing Pathological Parathyroid Glands in Patients With Primary Hyperparathyroidism,Primary Hyperparathyroidism,2020-01-24,2021-12-31,2025-03-31,Interventional,Recruiting,Not Applicable,Odense University Hospital,Odense University Hospital,Odense University Hospital,Procedure,Denmark,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT04305561
NCT04309136,thyroid cancer,The Efficacy and Safety of Anlotinib in Neoadjuvant Treatment in Locally Advanced Thyroid Cancer: a Single-arm Phase II Clinical Trial,Thyroid Cancer,2020-03-12,2021-02-01,2022-06-01,Interventional,"Active, not recruiting",Phase 2,Fudan University,Fudan University,Fudan University Shanghai Cancer Center,Drug|Procedure|Procedure,China,14.0,80.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04309136
NCT04311606,thyroid eye disease,Anti-VEGF Therapy for Acute Thyroid Eye Disease (AcTED Study),Thyroid Eye Disease,2020-03-12,2025-09-30,2027-01-01,Interventional,Recruiting,Phase 2,Massachusetts Eye and Ear Infirmary,Massachusetts Eye and Ear Infirmary|Regeneron Pharmaceuticals,Mass Eye and Ear,Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT04311606
NCT04312087,thyroid cancer,Lateral Neck Lymph Node Mapping in Papillary Thyroid Carcinoma,Thyroid Cancer,2020-03-14,2021-08-01,2022-12-31,Interventional,Recruiting,Not Applicable,Fudan University,Fudan University,Fudan University Shanghai Cancer Center,Procedure|Procedure|Procedure,China,14.0,80.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04312087
NCT04320901,thyroid cancer,Comparative Analysis Between Harmonic Versus LigaSure in Transoral Endoscopic Thyroidectomy: A Randomized Controlled Trial,Thyroid Cancer|Thyroid Nodule,2020-03-20,2022-12-31,2023-02-28,Interventional,Recruiting,Not Applicable,Inha University Hospital,Inha University Hospital,Inha University Hospital,Device|Device,"Korea, Republic of",20.0,70.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04320901
NCT04320901,thyroid nodule,Comparative Analysis Between Harmonic Versus LigaSure in Transoral Endoscopic Thyroidectomy: A Randomized Controlled Trial,Thyroid Cancer|Thyroid Nodule,2020-03-20,2022-12-31,2023-02-28,Interventional,Recruiting,Not Applicable,Inha University Hospital,Inha University Hospital,Inha University Hospital,Device|Device,"Korea, Republic of",20.0,70.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT04320901
NCT04321954,differentiated thyroid cancer,A Phase 2 Study of Neoadjuvant Lenvatinib in Locally Advanced Invasive Thyroid Cancer,Advanced Cancer|Differentiated Thyroid Cancer,2020-03-24,2023-09-30,2024-03-31,Interventional,Recruiting,Phase 2,Massachusetts Eye and Ear Infirmary,Eisai Inc.|Massachusetts Eye and Ear Infirmary,Massachusetts General Hospital Cancer Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Differentiated thyroid cancer, all",https://clinicaltrials.gov/ct2/show/NCT04321954
NCT04327999,thyroid carcinoma,Effect of Artificial Tears on Radioiodine Levels in the Nasolacrimal Duct System of Patients Following Radioiodine Therapy for Thyroid Carcinoma,Radioactive Iodine Level|Thyroid Carcinoma,2020-03-04,2023-07-31,2024-07-31,Interventional,Recruiting,Phase 2,Vanderbilt-Ingram Cancer Center,Vanderbilt-Ingram Cancer Center,Vanderbilt University Medical Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04327999
NCT04339478,thyroid cancer,Does Parathyroid Autofluorescence Reduces Unintensional Parathyroidectomy During Total Thyroidectomy With Central Lymph Node Compartment Dissection,Thyroid Cancer|Thyroidectomy With Central Lymph Node Dissection,2020-04-06,2022-03-30,2022-08-30,Observational,Recruiting,,Aristotle University Of Thessaloniki,Aristotle University Of Thessaloniki|The Hashemite University|Umraniye Education and Research Hospital,"1st Propedeutic Department of Surgery, AHEPA University General Hospital, Aristotle University of Thessaloniki|Department of Surgery, Faculty of Medicine, Hashemite University|Umraniye Education and Research Hospital",,Greece|Jordan|Turkey,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04339478
NCT04354324,papillary thyroid cancer,Treatment Efficacy and Safety of Low-dose Radioiodine Ablation for Intermediate-risk Differentiated Thyroid Carcinoma Patients Without Metastasis: a Double-blind Randomized Clinical Trial,Papillary Thyroid Cancer,2020-03-01,2024-06-30,2024-06-30,Interventional,Not yet recruiting,Not Applicable,Zhujiang Hospital,Zhujiang Hospital,,Drug,,16.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT04354324
NCT04359979,thyroid eye disease,Treatment With Tamsulosin for Upper Eyelid Retraction Related to Thyroid Eye Disease.,Eyelid Diseases|Thyroid Eye Disease,2020-04-21,2021-05-31,2021-12-31,Interventional,Recruiting,Not Applicable,Sheba Medical Center,Sheba Medical Center,Sheba Medical Center,Drug,Israel,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT04359979
NCT04391244,differentiated thyroid cancer,Investigating National Solutions for Personalised Iodine-131 Radiation Exposure - Measuring Absorbed Dose to Tumour and Organs at Risk Following Routine Iodine Ablation Therapy,Differentiated Thyroid Cancer,2020-05-12,2022-07-31,2022-07-31,Observational,Recruiting,,Royal Marsden NHS Foundation Trust,European Commission|Royal Marsden NHS Foundation Trust,The Royal Marsden NHS Foundation Trust,,United Kingdom,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Differentiated thyroid cancer, all",https://clinicaltrials.gov/ct2/show/NCT04391244
NCT04396912,"thyroid cancer, papillary","Post-thyroidectomy Vocal Cord Paralysis Along With Hypocalcemia: Prospective, Matched-randomized Observational Cohort Compatible With STROBE Guidelines","Calcium Deficiency|Iatrogenic Hypocalcemia|Iatrogenic Hypoparathyroidism|Multinodular Goiter|PTH|Thyroid Cancer|Thyroid Cancer, Papillary|Thyroid Neoplasms|Thyroid Nodule|Vocal Cord; Injury, Superficial|Vocal Cord Paralysis|Vocal Cord Paresis",2020-05-15,2021-06-01,2021-06-01,Observational,Recruiting,,Umraniye Education and Research Hospital,Umraniye Education and Research Hospital,"Umraniye Education and Research Hospital, Health Sciences University",Procedure,Turkey,17.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT04396912
NCT04396912,multinodular goiter,"Post-thyroidectomy Vocal Cord Paralysis Along With Hypocalcemia: Prospective, Matched-randomized Observational Cohort Compatible With STROBE Guidelines","Calcium Deficiency|Iatrogenic Hypocalcemia|Iatrogenic Hypoparathyroidism|Multinodular Goiter|PTH|Thyroid Cancer|Thyroid Cancer, Papillary|Thyroid Neoplasms|Thyroid Nodule|Vocal Cord; Injury, Superficial|Vocal Cord Paralysis|Vocal Cord Paresis",2020-05-15,2021-06-01,2021-06-01,Observational,Recruiting,,Umraniye Education and Research Hospital,Umraniye Education and Research Hospital,"Umraniye Education and Research Hospital, Health Sciences University",Procedure,Turkey,17.0,120.0,[0-17]|[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04396912
NCT04396912,thyroid nodule,"Post-thyroidectomy Vocal Cord Paralysis Along With Hypocalcemia: Prospective, Matched-randomized Observational Cohort Compatible With STROBE Guidelines","Calcium Deficiency|Iatrogenic Hypocalcemia|Iatrogenic Hypoparathyroidism|Multinodular Goiter|PTH|Thyroid Cancer|Thyroid Cancer, Papillary|Thyroid Neoplasms|Thyroid Nodule|Vocal Cord; Injury, Superficial|Vocal Cord Paralysis|Vocal Cord Paresis",2020-05-15,2021-06-01,2021-06-01,Observational,Recruiting,,Umraniye Education and Research Hospital,Umraniye Education and Research Hospital,"Umraniye Education and Research Hospital, Health Sciences University",Procedure,Turkey,17.0,120.0,[0-17]|[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT04396912
NCT04400474,anaplastic thyroid cancer,Exploratory Basket Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. CABATEN Study,Adenocarcinoma|Anaplastic Thyroid Cancer|Neuroendocrine Tumor|Paraganglioma|Pheochromocytoma,2020-05-12,2023-03-31,2024-03-31,Interventional,Recruiting,Phase 2,Grupo Espanol de Tumores Neuroendocrinos,Grupo Espanol de Tumores Neuroendocrinos|Ipsen|Roche Pharma AG,Hospital Germans Trias i Pujol - ICO Badalona|Hospital Duran i Reynals - ICO L'Hospitalet|Hospital General Universitario Elche|Hospital Universitari Vall d'Hebron|MD Anderson Cancer Center|Hospital Universitario Ramón y Cajal|Hospital Universitario 12 de Octubre|Hospital Universitario La Paz|Hospital General Universitario Morales Meseguer|Hospital Universitario Virgen de la Victoria|Hospital Universitario Central de Asturias|Hospital Universitario Marqués de Valdecilla|Hospital Universitario Virgen del Rocío|Hospital Universitario de Canarias|Hospital Universitario Miguel Servet,Drug,Spain,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT04400474
NCT04410601,thyroiditis,Pre-and Post-operative Risk Factors Affecting the Incidence and Severity of Dysphagia Following Total Thyroidectomy: An International Multi-centric Prospective Randomized Controlled Clinical Trial (RCT),"Dysphagia Comes and Goes|Dysphagia, Esophageal|Dysphagia, Oral Phase|Thyroid Cancer|Thyroid Goiter|Thyroiditis|Thyroid Neoplasms|Thyroid Nodule (Benign)",2020-05-15,2021-06-30,2021-06-30,Interventional,Recruiting,Not Applicable,Umraniye Education and Research Hospital,Umraniye Education and Research Hospital,"Umraniye Education and Research Hospital, Health Sciences University",Procedure,Turkey,17.0,120.0,[0-17]|[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT04410601
NCT04410601,thyroid neoplasms,Pre-and Post-operative Risk Factors Affecting the Incidence and Severity of Dysphagia Following Total Thyroidectomy: An International Multi-centric Prospective Randomized Controlled Clinical Trial (RCT),"Dysphagia Comes and Goes|Dysphagia, Esophageal|Dysphagia, Oral Phase|Thyroid Cancer|Thyroid Goiter|Thyroiditis|Thyroid Neoplasms|Thyroid Nodule (Benign)",2020-05-15,2021-06-30,2021-06-30,Interventional,Recruiting,Not Applicable,Umraniye Education and Research Hospital,Umraniye Education and Research Hospital,"Umraniye Education and Research Hospital, Health Sciences University",Procedure,Turkey,17.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04410601
NCT04420754,anaplastic thyroid cancer,A Multi Center Phase I Study of AIC100 in Relapsed and/or Refractory Advanced Thyroid Cancer and Anaplastic Thyroid Cancer,Anaplastic Thyroid Cancer|Relapsed/Refractory Poorly Differentiated Thyroid Cancer,2020-06-03,2023-07-31,2024-07-31,Interventional,Recruiting,Phase 1,"AffyImmune Therapeutics, Inc.","AffyImmune Therapeutics, Inc.",Weill Cornell Medical College,Biological,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT04420754
NCT04447183,differentiated thyroid cancer,A Phase II Study of the Safety and Effectiveness of rhTSH in Radioiodine Treatment for Patients With Differentiated Thyroid Cancer.,Differentiated Thyroid Cancer,2020-06-23,2022-02-28,2022-10-31,Interventional,Recruiting,Phase 2,"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","Suzhou Zelgen Biopharmaceuticals Co.,Ltd",Peking Union Medical College Hospital,Drug|Other,China,18.0,75.0,[18-65]|[65 and more],Thyroid neoplasms,"Differentiated thyroid cancer, all",https://clinicaltrials.gov/ct2/show/NCT04447183
NCT04458233,thyroid nodule,FNA Guided Ultrasonography Needle Technique Axial Vs Lateral Approach Study,Thyroid Nodule,2020-06-30,2021-06-01,2021-07-01,Interventional,Recruiting,Not Applicable,Ziv Hospital,Ziv Hospital,Ziv Medical Center,Procedure,Israel,18.0,85.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT04458233
NCT04459273,thyroid gland carcinoma,PET Biodistribution Study of 68Ga-FAPI-46 in Patients With Different Malignancies: An Exploratory Biodistribution Study With Histopathology Validation,Bladder Carcinoma|Cervical Carcinoma|Cholangiocarcinoma|Hematopoietic and Lymphoid Cell Neoplasm|Hepatocellular Carcinoma|Malignant Adrenal Gland Neoplasm|Malignant Brain Neoplasm|Malignant Pleural Neoplasm|Malignant Skin Neoplasm|Malignant Solid Neoplasm|Malignant Testicular Neoplasm|Malignant Thymus Neoplasm|Neuroendocrine Neoplasm|Thyroid Gland Carcinoma|Urothelial Carcinoma,2020-07-01,2023-07-01,2024-07-01,Interventional,Recruiting,Phase 1,Jonsson Comprehensive Cancer Center,Jonsson Comprehensive Cancer Center,UCLA / Jonsson Comprehensive Cancer Center,Procedure|Drug|Procedure,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04459273
NCT04462471,"thyroid cancer, papillary",A Phase Ib Trial of Vemurafenib Plus Copanlisib to Enhance Radioiodine Avidity in Radioiodine-Refractory Thyroid Cancers,"BRAF V600E Mutation Positive|Thyroid Cancer|Thyroid Cancer, Follicular|Thyroid Cancer (Follicular Cell)|Thyroid Cancer, Papillary|Thyroid Carcinoma",2020-07-02,2023-12-31,2024-12-31,Interventional,Recruiting,Phase 1,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Memoral Sloan Kettering Basking Ridge (Limited Protocol Activities)|Memoral Sloan Kettering Monmouth (Limited protocol activities)|Memorial Sloan Kettering Bergen (Limited Protocol Activities)|Memorial Sloan Kettering Cancer Center @ Commack (Limited Protocol Activities)|Memoral Sloan Kettering Westchester (Limited protocol activities)|Memorial Sloan-Kettering Cancer Center (All protocol activities)|Memorial Sloan Kettering Nassau (Limited protocol activities),Diagnostic Test|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT04462471
NCT04462471,thyroid cancer (follicular cell),A Phase Ib Trial of Vemurafenib Plus Copanlisib to Enhance Radioiodine Avidity in Radioiodine-Refractory Thyroid Cancers,"BRAF V600E Mutation Positive|Thyroid Cancer|Thyroid Cancer, Follicular|Thyroid Cancer (Follicular Cell)|Thyroid Cancer, Papillary|Thyroid Carcinoma",2020-07-02,2023-12-31,2024-12-31,Interventional,Recruiting,Phase 1,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Memoral Sloan Kettering Basking Ridge (Limited Protocol Activities)|Memoral Sloan Kettering Monmouth (Limited protocol activities)|Memorial Sloan Kettering Bergen (Limited Protocol Activities)|Memorial Sloan Kettering Cancer Center @ Commack (Limited Protocol Activities)|Memoral Sloan Kettering Westchester (Limited protocol activities)|Memorial Sloan-Kettering Cancer Center (All protocol activities)|Memorial Sloan Kettering Nassau (Limited protocol activities),Diagnostic Test|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, follicular",https://clinicaltrials.gov/ct2/show/NCT04462471
NCT04463719,thyroid cancer,Adequate Selection of Patients for Thyroid Biopsy: Evaluation of a Shared Decision Making Conversation Aid,Thyroid Cancer|Thyroid Nodules,2020-07-06,2022-06-30,2025-06-30,Interventional,Not yet recruiting,Not Applicable,University of Florida,National Cancer Institute (NCI)|University of Florida,University of Florida|Mayo Clinic,Behavioral|Behavioral,United States,18.0,99.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04463719
NCT04472026,thyroid cancer,Adequate Selection of Patients for Thyroid Biopsy: Evaluation of a Shared Decision Making Conversation Aid,Thyroid Cancer|Thyroid Nodules,2020-07-10,2022-06-30,2025-06-30,Interventional,Recruiting,Not Applicable,University of Florida,National Cancer Institute (NCI)|University of Florida,University of Florida|Mayo Clinic,Behavioral,United States,18.0,99.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04472026
NCT04477798,thyroid nodule,Protein Classifier for Thyroid Indeterminate Nodules： a Multi-center Prospective Clinical Study,Thyroid Nodule,2020-07-10,2021-07-01,2021-12-31,Interventional,Recruiting,Not Applicable,Zhejiang University,Luo Dingcun,Hangzhou First People's Hospital Affiliated to Zhejiang University Medical College,Diagnostic Test,China,18.0,70.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT04477798
NCT04481893,thyroid cancer,Interest of the Virtual Reality Headset in the Management of Perioperative Stress in Patients Candidates for Total Thyroidectomy,Thyroid Cancer|Thyroidectomy,2020-07-07,2022-04-30,2022-04-30,Interventional,Recruiting,Not Applicable,Centre Francois Baclesse,Centre Francois Baclesse,Centre François Baclesse,Behavioral,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04481893
NCT04521348,thyroid cancer,A Phase II Study to Explore the Safety and Efficacy of Multiple Target Kinase Inhibitor(mTKI) Combined With Anti-Programmed Death-1(PD-1) Antibody in the Treatment of Advanced Thyroid Cancer,Thyroid Cancer,2019-10-25,2022-06-30,2023-06-30,Interventional,Recruiting,Phase 2,Fudan University,Fudan University,Fudan University Shanghai Cancer Center,Drug,China,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04521348
NCT04522570,medullary thyroid cancer,Ultrasound Guided Percutaneous Thermal Ablation of Cervical Metastases From Thyroid Carcinoma,Lymph Node Metastases|Medullary Thyroid Cancer|Thyroid Neoplasia|Well-Differentiated Thyroid Cancer,2020-08-10,2022-12-31,2023-12-31,Interventional,Recruiting,Not Applicable,Instituto do Cancer do Estado de São Paulo,Instituto do Cancer do Estado de São Paulo,Instituto do Cancer do Estado de São Paulo,Device|Device|Device,Brazil,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, medullary",https://clinicaltrials.gov/ct2/show/NCT04522570
NCT04524884,thyroid cancer,The Efficacy and Safety of Anti-PD-1 Antibody Toripalimab Combined With Surufatinib for Locally Advanced Thyroid Cancer: a Phase II Study,Thyroid Cancer,2020-08-20,2022-04-30,2022-09-30,Interventional,Not yet recruiting,Phase 2,Fudan University,Fudan University,"270 Dongan Road, Fudan University Shanghai Cancer Center",Drug|Drug,China,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04524884
NCT04544111,papillary thyroid cancer,Phase II Study of PDR001 in Combination With MAPK Pathway Inhibitors in Patients With Radioiodine-Refractory Thyroid Cancer,"Follicular Thyroid Cancer|Hurthle Cell Thyroid Neoplasia|Hurthle Cell Tumor|Papillary Thyroid Cancer|Poorly Differentiated Thyroid Gland Carcinoma|Thyroid Cancer|Thyroid Cancer, Follicular",2020-09-03,2022-09-02,2022-09-02,Interventional,Recruiting,Phase 2,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Memoral Sloan Kettering Basking Ridge (Limited Protocol Activities)|Memoral Sloan Kettering Monmouth (Limited protocol activities)|Memorial Sloan Kettering Bergen (Limited Protocol Activities)|Memorial Sloan Kettering Cancer Center @ Suffolk - Commack (Limited Protocol Activities)|Memoral Sloan Kettering Westchester (Limited protocol activities)|Memorial Sloan Kettering Cancer Center (All Protocol Activities)|Memorial Sloan Kettering Nassau (Limited protocol activities),Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT04544111
NCT04544111,"thyroid cancer, follicular",Phase II Study of PDR001 in Combination With MAPK Pathway Inhibitors in Patients With Radioiodine-Refractory Thyroid Cancer,"Follicular Thyroid Cancer|Hurthle Cell Thyroid Neoplasia|Hurthle Cell Tumor|Papillary Thyroid Cancer|Poorly Differentiated Thyroid Gland Carcinoma|Thyroid Cancer|Thyroid Cancer, Follicular",2020-09-03,2022-09-02,2022-09-02,Interventional,Recruiting,Phase 2,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Memoral Sloan Kettering Basking Ridge (Limited Protocol Activities)|Memoral Sloan Kettering Monmouth (Limited protocol activities)|Memorial Sloan Kettering Bergen (Limited Protocol Activities)|Memorial Sloan Kettering Cancer Center @ Suffolk - Commack (Limited Protocol Activities)|Memoral Sloan Kettering Westchester (Limited protocol activities)|Memorial Sloan Kettering Cancer Center (All Protocol Activities)|Memorial Sloan Kettering Nassau (Limited protocol activities),Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, follicular",https://clinicaltrials.gov/ct2/show/NCT04544111
NCT04544111,hurthle cell tumor,Phase II Study of PDR001 in Combination With MAPK Pathway Inhibitors in Patients With Radioiodine-Refractory Thyroid Cancer,"Follicular Thyroid Cancer|Hurthle Cell Thyroid Neoplasia|Hurthle Cell Tumor|Papillary Thyroid Cancer|Poorly Differentiated Thyroid Gland Carcinoma|Thyroid Cancer|Thyroid Cancer, Follicular",2020-09-03,2022-09-02,2022-09-02,Interventional,Recruiting,Phase 2,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Memoral Sloan Kettering Basking Ridge (Limited Protocol Activities)|Memoral Sloan Kettering Monmouth (Limited protocol activities)|Memorial Sloan Kettering Bergen (Limited Protocol Activities)|Memorial Sloan Kettering Cancer Center @ Suffolk - Commack (Limited Protocol Activities)|Memoral Sloan Kettering Westchester (Limited protocol activities)|Memorial Sloan Kettering Cancer Center (All Protocol Activities)|Memorial Sloan Kettering Nassau (Limited protocol activities),Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Hurthle cell thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04544111
NCT04544111,poorly differentiated thyroid gland carcinoma,Phase II Study of PDR001 in Combination With MAPK Pathway Inhibitors in Patients With Radioiodine-Refractory Thyroid Cancer,"Follicular Thyroid Cancer|Hurthle Cell Thyroid Neoplasia|Hurthle Cell Tumor|Papillary Thyroid Cancer|Poorly Differentiated Thyroid Gland Carcinoma|Thyroid Cancer|Thyroid Cancer, Follicular",2020-09-03,2022-09-02,2022-09-02,Interventional,Recruiting,Phase 2,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Memoral Sloan Kettering Basking Ridge (Limited Protocol Activities)|Memoral Sloan Kettering Monmouth (Limited protocol activities)|Memorial Sloan Kettering Bergen (Limited Protocol Activities)|Memorial Sloan Kettering Cancer Center @ Suffolk - Commack (Limited Protocol Activities)|Memoral Sloan Kettering Westchester (Limited protocol activities)|Memorial Sloan Kettering Cancer Center (All Protocol Activities)|Memorial Sloan Kettering Nassau (Limited protocol activities),Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Poorly differentiated thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04544111
NCT04551170,pseudohypoparathyroidism,Phase 2 Study of Theophylline Treatment for Pseudohypoparathyroidism,Albright Hereditary Osteodystrophy|Pseudohypoparathyroidism|Pseudohypoparathyroidism Type 1a,2020-09-09,2025-06-30,2025-06-30,Interventional,Recruiting,Phase 2,Vanderbilt University Medical Center,Vanderbilt University Medical Center,Vanderbilt University Medical Center,Drug|Drug,United States,2.0,12.0,[0-17],Parathyroid diseases,pseudohypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04551170
NCT04552769,undifferentiated thyroid cancer,Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer,Anaplastic Thyroid Cancer|Thyroid Cancer|Undifferentiated Thyroid Cancer,2020-09-11,2022-09-30,2023-09-30,Interventional,Recruiting,Phase 2,Stanford University,Stanford University,Stanford University,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT04552769
NCT04554680,thyroid cancer,Phase II Clinical Trial in Radioactive Iodine-Refractory Advanced Thyroid Carcinoma Evaluating BRAF & MEK Blockade Therapy for Re-differentiation- Applying a Novel Time-Dependent Concept,Thyroid Cancer,2020-08-29,2021-12-31,2022-04-30,Interventional,Recruiting,Phase 2,"National University Hospital, Singapore","National University Hospital, Singapore|Singapore General Hospital",National University Hospital,Drug,Singapore,21.0,99.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04554680
NCT04560426,thyroid cancer,Protective Effect of Intraoperative Parathyroid Gland Auxiliary Recognition System in Thyroid Malignant Tumor Operation,Intraoperative Monitoring|Parathyroid|Thyroid Cancer,2020-08-29,2021-10-31,2022-10-31,Interventional,Not yet recruiting,Not Applicable,Fudan University,Fudan University,Fudan University Shanghai Cancer Center,Device,China,20.0,50.0,[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04560426
NCT04563780,differentiated thyroid cancer,The Prognostic Value of Post Thyroidectomy 99mTCpertechnetate Thyroid Scan in Patient With Differentiated Thyroid Cancer,Differentiated Thyroid Cancer,2020-09-21,2021-12-31,2021-12-31,Observational,Recruiting,,Assiut University,Assiut University,Aya Khaled Mahmoud,Device,Egypt,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,"Differentiated thyroid cancer, all",https://clinicaltrials.gov/ct2/show/NCT04563780
NCT04569513,parathyroid diseases,The Analysis of Thyroidectomy and Parathyroidectomy,Parathyroid Diseases|Thyroid Diseases,2020-05-11,2024-06-30,2024-12-31,Observational,Recruiting,,National Taiwan University Hospital,National Taiwan University Hospital,Ting-Chun Kuo,Biological,Taiwan,20.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT04569513
NCT04569513,thyroid diseases,The Analysis of Thyroidectomy and Parathyroidectomy,Parathyroid Diseases|Thyroid Diseases,2020-05-11,2024-06-30,2024-12-31,Observational,Recruiting,,National Taiwan University Hospital,National Taiwan University Hospital,Ting-Chun Kuo,Biological,Taiwan,20.0,120.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT04569513
NCT04574817,anaplastic thyroid cancer,"A Single-arm, Open-lable, Multicenter, Phase II Clinical Study of HX008 in Subjects With Anaplastic Thyroid Cancer",Anaplastic Thyroid Cancer,2020-09-29,2022-05-30,2023-05-30,Interventional,Not yet recruiting,Phase 2,Taizhou Hanzhong biomedical co. LTD,Taizhou Hanzhong biomedical co. LTD,"Cancer Hospital, Chinese Academy of Medical Sciences",Drug,China,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT04574817
NCT04574947,parathyroid neoplasms,Intravenous Or Topical Lidocaine And Neuromonitoring in Thyroid Surgery (IOLANT Study),Anesthesia|Parathyroid Neoplasms|Thyroid Neoplasm,2020-09-24,2021-11-15,2021-12-01,Interventional,Recruiting,Phase 4,"Saint Petersburg State University, Russia","Saint Petersburg State University, Russia",St. Petersburg State University Hospital,Drug|Drug|Procedure|Procedure,Russian Federation,45.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04574947
NCT04579757,anaplastic thyroid cancer,An Open-Label Phase Ib/II Study of Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors,Anaplastic Thyroid Cancer|Colorectal Cancer|Gastric Cancer|Metastatic Solid Tumor|Neuroendocrine Tumors|Small Cell Lung Cancer|Soft Tissue Sarcoma,2020-09-02,2024-04-30,2024-06-30,Interventional,Recruiting,Phase 1/Phase 2,Hutchison Medipharma Limited,BeiGene|Hutchison Medipharma Limited,"Arizona Oncology Associated, PC-HOPE|City of Hope|Rocky Mountain Cancer Centers Midtown|Johns Hopkins University - Sibley Memorial Hospital|Emory University - Winship Cancer Institute|Holden Comprehensive Cancer Center, University of Iowa|Memorial Sloan Kettering Cancer Center|University Hospitals Cleveland Medical Center|University of Pennsylvania, Perelman Center for Advanced Medicine|Prisma Health - Upstate (ITOR)|Sarah Cannon|Vanderbilt University Medical Center|Mary Crowley Cancer Research|Texas Oncology - Baylor Charles A. Sammons Cancer Center|Texas Oncology, P.A.|The University of Texas MD Anderson Cancer Center|Texas Oncology, P.A.|Virginia Cancer Specialists, PC",Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT04579757
NCT04580199,thyroid nodule,"Surgical (Total or Hemithyroidectomy)Versus Non Surgical (Ethanol Ablation ,RF Ablation ,Laser Ablation) Management of Thyroid Nodule",Thyroid Nodule,2020-10-02,2021-12-01,2022-12-01,Interventional,Not yet recruiting,Not Applicable,Assiut University,Mahmoud Fahd,,Procedure,,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT04580199
NCT04583735,thyroid eye disease,"A Phase 4, Randomized, Double-masked, Placebo-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of TEPEZZA® in Treating Patients With Chronic (Inactive) Thyroid Eye Disease",Chronic (Inactive) Thyroid Eye Disease|Thyroid Eye Disease,2020-10-06,2022-09-30,2023-04-30,Interventional,Recruiting,Phase 4,"Horizon Pharma USA, Inc.","Horizon Therapeutics USA, Inc.",Perlman Medical Offices / UCSD|MACRO Trials|Univ of Colorado Dept of Opthalmology|Bascom Palmer Eye Institute / Univ of Miami|Mayo Clinic|Washington University|Hamilton Eye Institute / U Tennessee|Medical College of Wisconsin,Biological|Drug,United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT04583735
NCT04589624,thyroid gland carcinoma,Pilot Study of Metabolic Guidance for Therapy in Patients With Thyroid Cancer,Thyroid Gland Carcinoma,2020-09-20,2022-12-31,2022-12-31,Interventional,Recruiting,Early Phase 1,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center|National Cancer Institute (NCI),M D Anderson Cancer Center,Drug|Procedure|Procedure,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04589624
NCT04589884,parathyroid diseases,Intraoperative EXamination Using MAChine-learning-based HYperspectral for diagNosis & Autonomous Anatomy Assessment,Digestive Cancer|Digestive Perfusion|Liver Cancer|Liver Metastases|Parathyroid Diseases|Thyroid Diseases,2020-10-09,2024-09-22,2024-10-22,Observational,Recruiting,,IHU Strasbourg,ARC Foundation for Cancer Research|IHU Strasbourg,"Service de Chirurgie Digestive et Endocrinienne, NHC",Other,France,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT04589884
NCT04589884,thyroid diseases,Intraoperative EXamination Using MAChine-learning-based HYperspectral for diagNosis & Autonomous Anatomy Assessment,Digestive Cancer|Digestive Perfusion|Liver Cancer|Liver Metastases|Parathyroid Diseases|Thyroid Diseases,2020-10-09,2024-09-22,2024-10-22,Observational,Recruiting,,IHU Strasbourg,ARC Foundation for Cancer Research|IHU Strasbourg,"Service de Chirurgie Digestive et Endocrinienne, NHC",Other,France,18.0,120.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT04589884
NCT04598815,graves ophthalmopathy,"A Phase II, Randomized, Superiority, Adaptive, Open-label, Single-center, Clinical Trial to Evaluate the Efficacy of Sirolimus (Rapamycin) in Patients With Graves' Disease and Moderate-to-severe and Active Graves' Orbitopathy (GO)",Graves Ophthalmopathy,2020-10-16,2025-01-01,2025-01-01,Interventional,Not yet recruiting,Phase 2,University of Pisa,University of Pisa,Ospedale Cisanello-Endocrinology II,Drug,Italy,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT04598815
NCT04612894,thyroid cancer,The Efficacy and Safety of Anti-PD-1 Antibody Camrelizumab Combined With Apatinib for Neoadjuvant Therapy in Locally Advanced Thyroid Cancer: a Phase II Study,Thyroid Cancer,2020-10-30,2022-12-01,2023-12-31,Interventional,Not yet recruiting,Phase 2,Fudan University,Fudan University,Fudan University Shanghai Cancer Center,Drug|Procedure|Procedure,China,14.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04612894
NCT04613323,hashimoto disease,Management of Thyroid Function in Hashimoto's Thyroiditis During Pregnancy: Real-word Experience in a Secondary Endocrine Centre in Italy,Hashimoto Disease|Pregnancy Related|Thyroid Dysfunction,2020-07-14,2022-07-01,2022-09-01,Observational,Not yet recruiting,,Centro Diagnostico Priamar,Centro Diagnostico Priamar,,,,18.0,120.0,[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT04613323
NCT04614389,thyroid nodule,Utility of Contrast-Enhanced Sonography and Shear Wave Elastography in Conjunction With ACR TI-RADS for the Evaluation of Thyroid Nodules,Thyroid Nodule,2019-09-25,2021-04-30,2021-07-01,Interventional,Recruiting,Not Applicable,University of Southern California,Siemens Medical Solutions USA - CSG|University of Southern California,USC Department of Radiology,Other|Other|Device,United States,18.0,70.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT04614389
NCT04619316,metastatic thyroid cancer,Enhancing Radioiodine Incorporation Into Radio Iodine Refractory Thyroid Cancers With MAPK Inhibition: A Single Center Pilot Study,Metastatic Thyroid Cancer,2020-11-01,2021-12-31,2022-06-30,Interventional,Recruiting,Phase 2,"University Hospital, Essen","University Hospital, Essen",Manuel M. Weber,Drug|Drug,Germany,18.0,85.0,[18-65]|[65 and more],Thyroid neoplasms,Metastatic Thyroid Cancer,https://clinicaltrials.gov/ct2/show/NCT04619316
NCT04623801,thyroid cancer,Pilot Study to Evaluate the Safety and Efficacy of Percutaneous Laser Ablation of Thyroid Papillary Microcarcinoma,Papillary Thyroid Microcarcinoma|Thyroid|Thyroid Cancer,2020-11-06,2022-10-31,2022-10-31,Interventional,Recruiting,Phase 2,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Procedure,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04623801
NCT04624477,papillary thyroid carcinoma,Active Surveillance or Surgery for Primary Management of Very Low Risk Papillary Thyroid Cancer: How Often Are the Long-term Disease Management Goals Achieved?,Papillary Microcarcinoma of the Thyroid|Papillary Thyroid Cancer|Papillary Thyroid Carcinoma,2020-10-27,2025-03-31,2030-03-31,Observational,Recruiting,,"University Health Network, Toronto","Canadian Cancer Society (CCS)|Canadian Institutes of Health Research (CIHR)|Centre hospitalier de l'Université de Montréal (CHUM)|CHU de Quebec-Universite Laval|Dalhousie University|Lawson Health Research Institute|McMaster University|Ottawa Hospital Research Institute|University Health Network, Toronto|University of British Columbia|University of Calgary",Nova Scotia Health|Lawson Health Research Institute|Ottawa Hospital Research Institute|University Health Network|CHU de Québec - Université Laval,,Canada,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT04624477
NCT04644315,"thyroid cancer, papillary","A Phase II, Open-Label, Single Arm Decentralized Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors","Brain Neoplasms|Bronchial Neoplasms|Carcinoma, Bronchogenic|Central Nervous System|Cholangiocarcinoma|Colonic Diseases|Colorectal Neoplasms|Digestive System Diseases|Digestive System Neoplasms|Gastrointestinal Diseases|Gastrointestinal Neoplasms|Head and Neck Neoplasms|Intestinal Diseases|Intestinal Neoplasms|Lymphoma, Large-Cell, Anaplastic|Melanoma|Neoplasms|Neoplasms by Site|Neuroendocrine Tumors|Ovarian Neoplasms|Pancreatic Neoplasms|Respiratory Tract Diseases|Respiratory Tract Neoplasms|Salivary Gland Neoplasms|Sarcoma|Thoracic Neoplasms|Thyroid Cancer, Papillary|Thyroid Neoplasms",2020-11-20,2025-12-01,2025-12-01,Interventional,Recruiting,Phase 2,Hoffmann-La Roche,Hoffmann-La Roche,"Science 37, Inc|Science 37-Basem; Dept 004- Basem|Science 37-Beg; Dept 001 Dr. M. Beg|Science 37-Ben; Dept 003-Ben|Science 37-Cannon; Dept 002-Cannon|Science 37-Kurzrock; Dept 005-Kurzrock|Science 37-Thomas; Dept 006-Thomas|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine",Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT04644315
NCT04664413,papillary thyroid cancer,Correlations Between Percentage of BRAFV600E Alleles and Outcome in Thyroid Carcinoma,Papillary Thyroid Cancer,2020-12-05,2021-04-30,2021-05-30,Observational,Not yet recruiting,,University of Salerno,University of Salerno,"Department of Medicine and Surgery, Univeristy of Salerno",,Italy,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT04664413
NCT04666103,thyroid carcinoma,Preserving Function Integrity of Neck Anatomy in Thyroid Surgery: A Randomized Clinical Trial,Ablation; Retina|Thyroid Carcinoma|Thyroid Nodule (Benign),2020-12-07,2021-12-31,2026-12-12,Interventional,Recruiting,Not Applicable,Wuhan University,Wuhan University,Zhongnan Hospital of Wuhan University,Procedure,China,18.0,75.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04666103
NCT04671719,hypoparathyroidism,Autotaxin in Patients With GNAS/PTH Abnormalities,Adult Children|Albright Syndrome|Fibrous Dysplasia|Hyperparathyroidism|Hypoparathyroidism|Pseudo Hypoparathyroidism,2020-12-11,2024-03-10,2024-03-10,Observational,Recruiting,,Hospices Civils de Lyon,Hospices Civils de Lyon,"Centre de compétence des maladies rares de l'insulino-sécrétion et de l'insulino-sensibilité|Centre de référence Dysplasie Fibreuse des os Service rhumatologie et pathologie osseuse Hôpital Edouard Herriot, Lyon|Centre de Référence des Maladies Rares du Métabolisme du Calcium et du Phosphate Service d'Endocrinologie et Diabète de l'Enfant Hôpital Bicêtre Paris Saclay",Biological,France,10.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT04671719
NCT04675710,thyroid gland anaplastic carcinoma,Pembrolizumab in Combination With Dabrafenib and Trametinib as a Neoadjuvant Strategy Prior to Surgery in BRAF-Mutated Anaplastic Thyroid Cancer,Thyroid Gland Anaplastic Carcinoma|Thyroid Gland Squamous Cell Carcinoma,2020-12-05,2024-06-30,2024-06-30,Interventional,Recruiting,Phase 2,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center,M D Anderson Cancer Center,Procedure|Drug|Radiation|Biological|Other|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT04675710
NCT04675710,thyroid gland squamous cell carcinoma,Pembrolizumab in Combination With Dabrafenib and Trametinib as a Neoadjuvant Strategy Prior to Surgery in BRAF-Mutated Anaplastic Thyroid Cancer,Thyroid Gland Anaplastic Carcinoma|Thyroid Gland Squamous Cell Carcinoma,2020-12-05,2024-06-30,2024-06-30,Interventional,Recruiting,Phase 2,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center,M D Anderson Cancer Center,Procedure|Drug|Radiation|Biological|Other|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid Gland Squamous Cell Carcinoma,https://clinicaltrials.gov/ct2/show/NCT04675710
NCT04680650,thyroid nodule,Comparison of Anesthesia Effects of Sevoflurane and Propofol Combined With Dexmedetomidine in Intraoperative Neuromonitoring During Thyroidectomy,Thyroid Nodule,2020-12-11,2021-03-31,2021-03-31,Interventional,"Active, not recruiting",Not Applicable,Affiliated Cancer Hospital & Institute of Guangzhou Medical University,Affiliated Cancer Hospital & Institute of Guangzhou Medical University,Cancer Center of Guangzhou Medical University,Drug|Drug,China,18.0,65.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT04680650
NCT04693377,metastatic thyroid gland carcinoma,Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases,Castration-Resistant Prostate Carcinoma|Metastatic Colorectal Carcinoma|Metastatic Malignant Neoplasm in the Bone|Metastatic Malignant Solid Neoplasm|Metastatic Melanoma|Metastatic Prostate Carcinoma|Metastatic Renal Cell Carcinoma|Metastatic Sarcoma|Metastatic Thyroid Gland Carcinoma|Metastatic Urothelial Carcinoma|Stage IVA Colorectal Cancer AJCC v8|Stage IVA Prostate Cancer AJCC v8|Stage IVB Colorectal Cancer AJCC v8|Stage IVB Prostate Cancer AJCC v8|Stage IVC Colorectal Cancer AJCC v8|Stage IV Colorectal Cancer AJCC v8|Stage IV Prostate Cancer AJCC v8|Stage IV Renal Cell Cancer AJCC v8,2020-10-13,2023-04-01,2023-04-01,Interventional,Recruiting,Not Applicable,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center,M D Anderson Cancer Center,Procedure|Other|Radiation,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Metastatic Thyroid Cancer,https://clinicaltrials.gov/ct2/show/NCT04693377
NCT04693936,hashimoto disease,Study of Metabolic Pathways for the Identification of Biomarkers in Hashimoto's Thyroiditis and Psoriasis,Hashimoto Disease|Psoriasis,2020-12-23,2023-01-31,2024-01-31,Interventional,Recruiting,Not Applicable,University of Crete,University of Crete,"Metabolomic Medicine, Private Health Clinics",Combination Product,Greece,18.0,60.0,[18-65],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT04693936
NCT04701203,parathyroid diseases,"PaTHway TRIAL: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial, With an Open-Label Extension, Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Subcutaneously Daily in Adults With Hypoparathyroidism",Endocrine System Diseases|Hypoparathyroidism|Parathyroid Diseases,2021-01-06,2022-02-28,2025-02-28,Interventional,"Active, not recruiting",Phase 3,Ascendis Pharma A/S,Ascendis Pharma Bone Diseases A/S,Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site,Combination Product|Combination Product,Canada|Denmark|Germany|Hungary|Italy|Norway|United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT04701203
NCT04704414,graves ophthalmopathy,Exophthalmometry With 3D Face Scanners,Exophthalmos|Graves Ophthalmopathy|Orbital Fractures|Orbital Tumor,2021-01-06,2021-12-31,2022-12-31,Interventional,Recruiting,Not Applicable,University of Zurich,University of Zurich,"Ophthalmology Department, University Hospital Zurich",Device,Switzerland,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT04704414
NCT04712760,congenital hypothyroidism,Congenital Hypothyroidism in Children With Eutopic Gland or Thyroid Hemiagenesis: Predictive Factors for Transient vs Permanent Hypothyroidism.,Congenital Hypothyroidism,2021-01-11,2021-03-01,2021-04-01,Observational,Recruiting,,"Central Hospital, Nancy, France","Central Hospital, Nancy, France",CHRU Nancy,,France,0.0,42.0,[0-17]|[18-65],Hypothyroidism,Congenital hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT04712760
NCT04730726,thyroid nodule,In Vivo Multispectral Optoacoustic Imaging of Thyroid Nodules,Thyroid Nodule,2021-01-26,2021-12-01,2022-04-01,Interventional,Recruiting,Not Applicable,University Medical Center Groningen,University Medical Center Groningen,University Medical Center Groningen,Device,Netherlands,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT04730726
NCT04731467,papillary thyroid cancer,"A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors",Colorectal Adenocarcinoma|Melanoma|Non Small Cell Lung Cancer|Ovarian Cancer|Pancreatic Cancer|Papillary Thyroid Cancer|Solid Tumor,2021-01-24,2024-02-29,2024-03-31,Interventional,Recruiting,Phase 1/Phase 2,Purple Biotech Ltd.,Bristol-Myers Squibb|Famewave Ltd.,HonorHealth Research Institute|Yale University|Barbara Ann Karmanos Cancer Institute|The University of Texas M.D. Anderson Cancer Center|Rambam Health Care Campus|Sheba Medical Center,Drug|Drug|Drug,Israel|United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT04731467
NCT04734457,congenital hypothyroidism,Final Height in Patients With Congenital Hypothyroidism Diagnosed by Neonatal Screening,Congenital Hypothyroidism,2021-01-11,2022-03-01,2022-04-01,Observational,Not yet recruiting,,Ain Shams University,Ain Shams University,Ain Shams University,Drug,Egypt,0.0,120.0,[0-17]|[18-65]|[65 and more],Hypothyroidism,Congenital hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT04734457
NCT04737330,thyroid eye disease,"A Two-year Multi-center Phase 3 Study to Investigate the Efficacy and Safety of Secukinumab in Adult Patients With Active, Moderate to Severe Thyroid Eye Disease (ORBIT), With a Randomized, Parallel-group, Double-blind, Placebo-controlled, 16-week Treatment Period, and a Follow-up/Retreatment Period",Graves Orbitopathy|Thyroid Eye Disease,2020-11-20,2023-04-27,2025-02-05,Interventional,Recruiting,Phase 3,Novartis,Novartis Pharmaceuticals,Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site,Drug|Drug,Germany,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT04737330
NCT04739566,thyroid gland anaplastic carcinoma,Dabrafenib and Trametinib Combination as a Neoadjuvant Strategy in BRAF-positive Anaplastic Thyroid Cancer (ANAPLAST-NEO),Thyroid Gland Anaplastic Carcinoma,2021-01-29,2024-01-22,2026-01-22,Interventional,Recruiting,Phase 2,"Saint Petersburg State University, Russia","Saint Petersburg State University, Russia",Saint-Petersburg State University (SPSU) N.I.Pirogov Clinic of High Medical Technologies,Drug|Drug,Russian Federation,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT04739566
NCT04742608,thyroid gland carcinoma,Isolation and Characterization of Extracellular Vesicles in Patients With Thyroid Nodules and Thyroid Cancer,Thyroid Gland Carcinoma|Thyroid Gland Nodule,2021-02-03,2023-02-01,2024-02-01,Observational,Recruiting,,Jonsson Comprehensive Cancer Center,Jonsson Comprehensive Cancer Center,UCLA / Jonsson Comprehensive Cancer Center,Procedure|Other,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04742608
NCT04742608,thyroid gland nodule,Isolation and Characterization of Extracellular Vesicles in Patients With Thyroid Nodules and Thyroid Cancer,Thyroid Gland Carcinoma|Thyroid Gland Nodule,2021-02-03,2023-02-01,2024-02-01,Observational,Recruiting,,Jonsson Comprehensive Cancer Center,Jonsson Comprehensive Cancer Center,UCLA / Jonsson Comprehensive Cancer Center,Procedure|Other,United States,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT04742608
NCT04742959,thyroid cancer,"A Phase Ib/II, Multicenter, Open-Label Study of TT-00420 Tablet, as Monotherapy or in Combination Regimens, in Patients With Advanced Solid Tumors",Advanced Solid Tumor|Bladder Cancer|Cholangiocarcinoma|Gallbladder Cancer|Gastric Cancer|HER2-negative Breast Cancer|Prostate Cancer|Sarcoma|Small-cell Lung Cancer|Thyroid Cancer|Triple Negative Breast Cancer,2021-02-02,2022-04-01,2022-12-01,Interventional,Recruiting,Phase 1/Phase 2,"TransThera Sciences (Nanjing), Inc.","TransThera Sciences (Nanjing), Inc.",City of Hope|The University of Chicago|Rutgers Cancer Institute|MD Anderson Cancer Center,Drug|Combination Product,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04742959
NCT04745793,parathyroid diseases,Precise Recognition With Enhanced Vision of Endocrine Neck Targets,Parathyroid Diseases|Thyroid Diseases,2021-02-04,2024-02-04,2024-03-04,Observational,Recruiting,,IHU Strasbourg,IHU Strasbourg,"Service de Chirurgie Digestive et Endocrinienne, NHC",Other,France,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT04745793
NCT04745793,thyroid diseases,Precise Recognition With Enhanced Vision of Endocrine Neck Targets,Parathyroid Diseases|Thyroid Diseases,2021-02-04,2024-02-04,2024-03-04,Observational,Recruiting,,IHU Strasbourg,IHU Strasbourg,"Service de Chirurgie Digestive et Endocrinienne, NHC",Other,France,18.0,120.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT04745793
NCT04747275,hypothyroidism,Use of Liquid Stable Levothyroxine in Trisomy 21 Pediatric Patients,Hypothyroidism|Trisomy 21,2021-02-03,2022-05-31,2022-07-31,Interventional,Recruiting,Phase 4,Children's Mercy Hospital Kansas City,Children's Mercy Hospital Kansas City,Children's Mercy Hospital,Drug|Drug,United States,2.0,4.0,[0-17],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT04747275
NCT04754607,thyroiditis,"Effects of Low-Level Laser Therapy on Oxidative Stress Levels, Fatigue and Quality of Life in Patients With Hashimoto Thyroiditis",Autoimmune Diseases|Autoimmune Thyroiditis|Hashimoto Thyroiditis|Thyroid Diseases|Thyroiditis,2021-02-12,2021-10-10,2021-11-30,Interventional,Recruiting,Not Applicable,Istanbul Medipol University Hospital,Istanbul Medipol University Hospital,Sumeyye TUNC,Other,Turkey,18.0,65.0,[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT04754607
NCT04754607,thyroid diseases,"Effects of Low-Level Laser Therapy on Oxidative Stress Levels, Fatigue and Quality of Life in Patients With Hashimoto Thyroiditis",Autoimmune Diseases|Autoimmune Thyroiditis|Hashimoto Thyroiditis|Thyroid Diseases|Thyroiditis,2021-02-12,2021-10-10,2021-11-30,Interventional,Recruiting,Not Applicable,Istanbul Medipol University Hospital,Istanbul Medipol University Hospital,Sumeyye TUNC,Other,Turkey,18.0,65.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT04754607
NCT04759911,thyroid gland papillary carcinoma,Neoadjuvant Treatment With Selpercatinib in RET-Altered Thyroid Cancers,Malignant Thyroid Gland Neoplasm|Poorly Differentiated Thyroid Gland Carcinoma|Recurrent Thyroid Gland Carcinoma|Thyroid Gland Anaplastic Carcinoma|Thyroid Gland Medullary Carcinoma|Thyroid Gland Papillary Carcinoma|Thyroid Gland Squamous Cell Carcinoma,2021-02-08,2024-09-10,2024-09-10,Interventional,Recruiting,Phase 2,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center,M D Anderson Cancer Center,Other|Other|Drug|Procedure,United States,12.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT04759911
NCT04759911,poorly differentiated thyroid gland carcinoma,Neoadjuvant Treatment With Selpercatinib in RET-Altered Thyroid Cancers,Malignant Thyroid Gland Neoplasm|Poorly Differentiated Thyroid Gland Carcinoma|Recurrent Thyroid Gland Carcinoma|Thyroid Gland Anaplastic Carcinoma|Thyroid Gland Medullary Carcinoma|Thyroid Gland Papillary Carcinoma|Thyroid Gland Squamous Cell Carcinoma,2021-02-08,2024-09-10,2024-09-10,Interventional,Recruiting,Phase 2,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center,M D Anderson Cancer Center,Other|Other|Drug|Procedure,United States,12.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Poorly differentiated thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04759911
NCT04759911,thyroid gland anaplastic carcinoma,Neoadjuvant Treatment With Selpercatinib in RET-Altered Thyroid Cancers,Malignant Thyroid Gland Neoplasm|Poorly Differentiated Thyroid Gland Carcinoma|Recurrent Thyroid Gland Carcinoma|Thyroid Gland Anaplastic Carcinoma|Thyroid Gland Medullary Carcinoma|Thyroid Gland Papillary Carcinoma|Thyroid Gland Squamous Cell Carcinoma,2021-02-08,2024-09-10,2024-09-10,Interventional,Recruiting,Phase 2,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center,M D Anderson Cancer Center,Other|Other|Drug|Procedure,United States,12.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT04759911
NCT04759911,thyroid gland squamous cell carcinoma,Neoadjuvant Treatment With Selpercatinib in RET-Altered Thyroid Cancers,Malignant Thyroid Gland Neoplasm|Poorly Differentiated Thyroid Gland Carcinoma|Recurrent Thyroid Gland Carcinoma|Thyroid Gland Anaplastic Carcinoma|Thyroid Gland Medullary Carcinoma|Thyroid Gland Papillary Carcinoma|Thyroid Gland Squamous Cell Carcinoma,2021-02-08,2024-09-10,2024-09-10,Interventional,Recruiting,Phase 2,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center,M D Anderson Cancer Center,Other|Other|Drug|Procedure,United States,12.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid Gland Squamous Cell Carcinoma,https://clinicaltrials.gov/ct2/show/NCT04759911
NCT04759911,thyroid gland medullary carcinoma,Neoadjuvant Treatment With Selpercatinib in RET-Altered Thyroid Cancers,Malignant Thyroid Gland Neoplasm|Poorly Differentiated Thyroid Gland Carcinoma|Recurrent Thyroid Gland Carcinoma|Thyroid Gland Anaplastic Carcinoma|Thyroid Gland Medullary Carcinoma|Thyroid Gland Papillary Carcinoma|Thyroid Gland Squamous Cell Carcinoma,2021-02-08,2024-09-10,2024-09-10,Interventional,Recruiting,Phase 2,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center,M D Anderson Cancer Center,Other|Other|Drug|Procedure,United States,12.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, medullary",https://clinicaltrials.gov/ct2/show/NCT04759911
NCT04760171,medullary thyroid cancer,An ex Vivo Study to Purify Amyloid Fibrils and Solve Their 3D Structures Using Amyloid Proteins From Medullary Thyroid Cancer and Laryngeal Amyloidosis,Alzheimer Disease|Amyloid|Dementia|Medullary Thyroid Cancer,2021-02-10,2023-02-28,2026-02-28,Observational,Not yet recruiting,,The Leeds Teaching Hospitals NHS Trust,The Leeds Teaching Hospitals NHS Trust|University of Leeds,,,,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, medullary",https://clinicaltrials.gov/ct2/show/NCT04760171
NCT04760288,thyroid cancer,"A Phase III, Randomized, Open-Label Study of Pralsetinib Versus Standard of Care for Treatment of RET-Mutated Medullary Thyroid Cancer.",Thyroid Cancer,2021-02-17,2026-04-15,2028-04-15,Interventional,Not yet recruiting,Phase 3,Hoffmann-La Roche,Hoffmann-La Roche,"The Lundquist Institute for BioMedical Innovation at Harbor-UCLA Medical Cente|Instituto de Investigaciones Metabolicas (Idim)|Centro Médico Privado CEMAIC|Instituto Medico de la Fundacion Estudios Clinicos|Sanatorio Britanico de Rosario|Centro de Investigación Clínica - Clínica Viedma|Macquarie University Hospital|Royal North Shore Hospital|Ashford Cancer Center Research|The Alfred Hospital;Clinical Trial Pharmacy|Medizinische Universität Graz; Klinische Abteilung für Allgemeine HNO|CETUS Hospital Dia Oncologia|Hospital de Clinicas de Porto Alegre (HCPA) - PPDS|Irmandade Da Santa Casa de Misericordia de Porto Alegre|Fundação Pio XII Hospital de Câncer de Barretos|Instituto Do Câncer Do Estado de São Paulo Octávio Frias de Oliveira|Multiprofile Hospital for Active Treatment Uni Hospital; Department of medicinal oncology|Complex Oncology Center Plovdiv; Department of Medical Oncology and Oncology Diseases in Pneumology|University Multiprofile Hospital For Active Treatment ""Sveti Ivan Rilski"" EAD; clinical hematology|Tom Baker Cancer Centre; Dept of Pathology|Cross Cancer Institute; Clinical Trials|McGill University Health Center; Glen-Cedars Cancer Centre, Oncology Pharmacy|Centre Hospitalier Universitaire de Sherbrooke; Pharmacie de Chimiotherapie|Clinical Hospital Centre Osijek; Hematology|Clinical Hospital Sestre Milosrdnice|Klinicki bolnicki centar Zagreb|Odense Universitetshospital, Onkologisk Afdeling, Klinisk Forsknings Enhed|Hôtel Dieu -Angers; Pharmacie / Secteur Essais Cliniques|EDOG - Institut Bergonie - PPDS|Centre Hospitalier Universitaire Lyon; Institut Hématologique et d'Oncologie Pédiatrique|CHU Nantes|Centre Antoine Lacassagne Centre Régional de Lutte Contre Le Cancer|Hopital Cochin|Institut Curie; Pharmacie|Hôpital Saint-Louis|ICANS|Institut Universitaire de Cancer de Toulouse Oncopole; IUCT- Oncopole|Attikon University General Hospital|University of Athens Medical School - Regional General Hospital Alexandra|Kianous Stavros|Semmelweis Egyetem, II. Belgyógyászati Klinika|Debreceni Egyetem Klinikai Kozpont|Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont|Panchshil Hospital|Unity Hospital-Surat|Tata Memorial Hospital; Dept of Medical Oncology|HCG NCHRI Cancer Center|Deenanath Mangeshkar Hospital & Research Centre|Sparsh Hospitals & Critical Care (P) Ltd.|Dayanand Medical College and Hospital|Hadassah Medical Center|C.H. Regional Reina Sofia - PPDS|National Cancer Center|Seoul National University Hospital|Samsung Medical Center - PPDS|VU Medisch Centrum|Saint Louis University Hospital of Sacred Heart|St. Luke's Medical Center - Quezon City|Centrum Onkologii-Instytut Im. Marii Skłodowskiej Curie; I Klinika Radioterapii i Chemioterapii|Centrum Onkologii Instytut im. Marii Sklodowskiej-Curie w Krakowie - Apteka/Pharmacy; Pharmacy|Instituto Português de Oncologia de Lisboa Francisco Gentil, E.P.E.|Instituto Portugues de Oncologia Do Porto Francisco Gentil Epe|Institutul National de Endocrinologie ""C. I. Parhon""; Sectorul 1 BUCUREȘTI|Prof Dr I Chiricuta Institute of Oncology; Oncology Department|Onco Clinic Consult SA|CHUS - H. Clinico U. de Santiago|Clinica Universidad Navarra; Servicio de Farmacia|Hospital Universitario Vall d'Hebron|Hospital Clinic de Barcelona|MD Anderson Cancer Center Madrid - España; Servicio de Farmacia|Hospital Universitario Ramon y Cajal|Hospital Universitario HM Sanchinarro - CIOCC; Farmacia - Ensayos Clínicos|Hospital Regional Universitario de Malaga|Hospital Universitario Virgen del Rocio|Phramongkutklao Hospital|Siriraj Hospital, Mahidol Uni ; Division of Rheumatology, Dept. of Medicine|Chulalongkorn University Hospital; Hematology|SI Institute for general and urgent surgery n.a. V.T.Zaitseva of NAMS of Ukraine|Municipal Non-profit Enterprise ""City Clinical Hospital # 4"" of Dnipro City Council - PPDS|Ukr. Scientific Practical Center of Endocrine Surgery,Transplantation of Endocrine organs&Tissues|Clinic Verum Expert LLC|Treatment and Diagnostic Center of LLC Specialized Clinic Prognosis Optima|St Bartholomew's Hospital|Guys Hospital; Guys Cancer Center|The Christie NHS Foundation Trust|The Royal Marsden NHS Foundation Trust - Royal Marsden Hospital (RMH) - Sutton",Drug|Drug|Drug,"Argentina|Australia|Austria|Brazil|Bulgaria|Canada|Croatia|Denmark|France|Greece|Hungary|India|Israel|Italy|Korea, Republic of|Netherlands|Philippines|Poland|Portugal|Romania|Spain|Thailand|Ukraine|United Kingdom|United States",12.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04760288
NCT04778865,hashimoto disease,Effect of Vitamin D Supplementation on Autoimmunity and Thyroid Function in Subjects With Hashimoto's Thyroiditis and Vitamin D Deficiency: Clinical Pilot Trial.,Hashimoto Disease|Treatment Levothyroxine|Vitamin D Deficiency,2021-02-24,2021-12-31,2021-12-31,Interventional,Recruiting,Not Applicable,Universidad de Valparaiso,Universidad de Valparaiso,Escuela de Nutrición. Facultad de Farmacia. Universidad de Valparaíso.,Dietary Supplement|Dietary Supplement,Chile,18.0,60.0,[18-65],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT04778865
NCT04782856,thyroid cancer,Energy Metabolism in Thyroidectomized Patients,Hypothyroidism|Thyroid Cancer|Thyroid Goiter,2021-03-01,2022-05-31,2022-05-31,Interventional,Recruiting,Phase 2,Virginia Commonwealth University,Virginia Commonwealth University,Virginia Commonwealth University,Drug|Drug|Drug,United States,18.0,89.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04782856
NCT04782856,hypothyroidism,Energy Metabolism in Thyroidectomized Patients,Hypothyroidism|Thyroid Cancer|Thyroid Goiter,2021-03-01,2022-05-31,2022-05-31,Interventional,Recruiting,Phase 2,Virginia Commonwealth University,Virginia Commonwealth University,Virginia Commonwealth University,Drug|Drug|Drug,United States,18.0,89.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT04782856
NCT04784208,hypothyroidism,A Study to Determine the Validity and Sensitivity of 'Questionnaire to Screen for HYpothyroidism' (Q'SHY),Healthy|Hypothyroidism,2021-02-25,2022-06-30,2022-06-30,Observational,Recruiting,,Abbott,Abbott,"Dr.Prasanna Kumar|Dr. MV Rama Mohan, MD, DM",Diagnostic Test,India,18.0,65.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT04784208
NCT04785443,thyroid diseases,Contribution of Indocyanine Green Angiography in the Detection of Parathyroids and the Prevention of Hypoparathyroidism Post Total Thyroidectomy,Thyroid Diseases,2021-02-25,2024-06-30,2025-03-31,Interventional,Recruiting,Phase 3,"University Hospital, Brest","University Hospital, Brest",CHRU de Brest,Drug|Procedure,France,18.0,120.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT04785443
NCT04787328,medullary thyroid carcinoma,"A Single-arm, Open-Label, Multicenter Phase II Study to Evaluate the Efficacy and Safety of HA121-28 Tablets in Patients With Medullary Thyroid Carcinoma (MTC)",Medullary Thyroid Carcinoma,2021-02-24,2023-03-31,2025-03-31,Interventional,Recruiting,Phase 2,"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","Beijing Tongren Hospital|Cancer Institute and Hospital, Chinese Academy of Medical Sciences|Fujian Cancer Hospital|Gansu Province Tumor Hospital|Sun Yat-Sen University Cancer Center|Henan Province Tumor Hospital|Jiangsu province tumor hospital|Cancer Hospital of Fudan University|Sichuan Cancer Hospital|Tianjin Medical University Cancer Institute and Hospital|Tianjin People's Hospital|The First Affiliated Hospital of Kunming Medical University|Zhejiang Provincial People's Hospital",Drug,China,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, medullary",https://clinicaltrials.gov/ct2/show/NCT04787328
NCT04795947,hypothyroidism,Correlation Between Thyroid Function and Quality of Life in Well-controlled Hypothyroidism Patients,Hypothyroidism,2021-03-10,2021-11-01,2021-11-01,Observational,"Active, not recruiting",,Beijing Chao Yang Hospital,Beijing Chao Yang Hospital,BeijingCYH,Behavioral,China,18.0,75.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT04795947
NCT04798092,primary hyperparathyroidism,Impact of Parathyroidectomy on Renal Function in Patients With Primary Hyperparathyroidism,Primary Hyperparathyroidism,2021-01-29,2022-01-31,2022-01-31,Observational,Recruiting,,"Central Hospital, Nancy, France","Central Hospital, Nancy, France",CHRU Nancy,Procedure,France,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT04798092
NCT04802876,thyroid carcinoma,Efficacy of Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors Defined by a Single and Pre-specified Cutoff,Anal Carcinoma|Bladder Carcinoma|Carcinoma of Unknown Primary|Cervical Carcinoma|Cholangiocarcinoma|Colorectal Adenocarcinoma|Esophageal Adenocarcinoma|Head and Neck Squamous Cell Carcinoma|Hepatocellular Carcinoma|HER2-positive Breast Cancer|Hormone Receptor Positive / HER2-negative Breast Cancer|Kidney Clear Cell Carcinoma|Lung Adenocarcinoma|Lung Adenocarcinoma EGFR-mutated/ ALK Traslocation|Lung Squamous Cell Carcinoma|Melanoma|Mesothelioma|MSI-H Colorectal Cancer|Other Histology|Ovarian Serous Cystadenocarcinoma|Pancreatic Adenocarcinoma|Prostate Adenocarcinoma|Sarcoma|Small Cell Lung Cancer|Squamous Esophageal Carcinoma|Stomach Adenocarcinoma|Thyroid Carcinoma|Triple Negative Breast Cancer|Uterine Carcinosarcoma|Uterine Endometrial Carcinoma|Uveal Melanoma,2021-03-14,2023-12-31,2024-12-11,Interventional,Recruiting,Phase 2,SOLTI Breast Cancer Research Group,Novartis|SOLTI Breast Cancer Research Group,Ico Badalona|Hospital Universitari Sant Joan de Reus|IOB - H. Quironsalud Barcelona|Hospital Vall Hebron|Hospital Clinic Barcelona|Complejo Asistencial Universitario de León|Fundación Jiménez Díaz|Hospital Universitario 12 de Octubre|Instituto Valenciano de Oncología (IVO)|Hospital Clínico Universitario de Valencia,Drug,Spain,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04802876
NCT04806269,thyrotoxicosis,"Clinical Application of Continuous Monitoring Data for the Pulse Rate, Exercise, and Symptom Survey by Wearable Device in the Patients With Thyroid Dysfunction",Hypothyroidism|Thyrotoxicosis,2021-01-26,2022-05-30,2022-12-31,Observational,Recruiting,,Seoul National University Bundang Hospital,Seoul National University Bundang Hospital,Seoul National University Bundang Hospital,Device,"Korea, Republic of",18.0,60.0,[18-65],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04806269
NCT04806269,hypothyroidism,"Clinical Application of Continuous Monitoring Data for the Pulse Rate, Exercise, and Symptom Survey by Wearable Device in the Patients With Thyroid Dysfunction",Hypothyroidism|Thyrotoxicosis,2021-01-26,2022-05-30,2022-12-31,Observational,Recruiting,,Seoul National University Bundang Hospital,Seoul National University Bundang Hospital,Seoul National University Bundang Hospital,Device,"Korea, Republic of",18.0,60.0,[18-65],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT04806269
NCT04821336,thyroid cancer,"Cholesterol Metabolites (Dendrogenin A or DDA, 6-oxo-cholestane-3β,5α-diol or OCDO,...) Quantification in Malignant Versus Normal Human Thyroid Tissue Refractory to Iodine",Thyroid Cancer,2021-03-25,2022-06-30,2022-06-30,Observational,Not yet recruiting,,Institut Claudius Regaud,Cancer Research Center of Toulouse|Institut Claudius Regaud,Institut Claudius regaud IUCT Oncopole,Other,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04821336
NCT04831957,hypothyroidism,Hypothyroidism After the TAVI Procedure in Elderly Patients,Hypothyroidism|TAVI,2021-03-19,2023-12-31,2023-12-31,Interventional,Recruiting,Not Applicable,Universitair Ziekenhuis Brussel,Universitair Ziekenhuis Brussel,UZ brussel,Diagnostic Test,Belgium,70.0,120.0,[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT04831957
NCT04844164,primary hyperparathyroidism,"Prospective Non-randomised Controlled Study of Vitamin D Metabolism in Patients With Endocrine Disorders (Acromegaly, Cushing's Disease, Primary Hyperparathyroidism, Diabetes Mellitus Type 1) Treated With Cholecalciferol Bolus Dose","Acromegaly|Diabetes Mellitus, Type 1|Pituitary ACTH Hypersecretion|Primary Hyperparathyroidism",2021-04-09,2021-05-15,2021-06-01,Interventional,Recruiting,Phase 1,"Endocrinology Research Centre, Moscow","Endocrinology Research Centre, Moscow|Russian Science Foundation","Endocrinology Research Centre, Moscow",Drug,Russian Federation,18.0,60.0,[18-65],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT04844164
NCT04853680,thyroid cancer,A Prospective Randomized Controlled Study of Whether Anti-adhesion Barrier Can Prevent Voice Quality After Thyroidectomy.,Thyroid Cancer|Thyroid Nodule|Voice Disorders,2021-04-11,2023-06-30,2023-07-30,Interventional,Recruiting,Not Applicable,Inha University Hospital,Inha University Hospital,Inha University Hospital,Device,"Korea, Republic of",20.0,70.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04853680
NCT04853680,thyroid nodule,A Prospective Randomized Controlled Study of Whether Anti-adhesion Barrier Can Prevent Voice Quality After Thyroidectomy.,Thyroid Cancer|Thyroid Nodule|Voice Disorders,2021-04-11,2023-06-30,2023-07-30,Interventional,Recruiting,Not Applicable,Inha University Hospital,Inha University Hospital,Inha University Hospital,Device,"Korea, Republic of",20.0,70.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT04853680
NCT04856488,hyperthyroidism,Preoperative Lugol's Solution in Graves' Disease and Toxic Nodular Goiter,Hyperthyroidism,2021-04-06,2023-08-31,2024-02-29,Interventional,Recruiting,Phase 3,Karolinska University Hospital,Jan Calissendorff,"Department of Endocrinology, Karolinska University Hospital",Drug,Sweden,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04856488
NCT04857086,differentiated thyroid cancer,A Multi-center Study to Observe Five-year Outcomes of the Initial Management in Patients With Differentiated Thyroid Cancer in the Real World in China (The Second Stage of DTCC),Differentiated Thyroid Cancer,2021-04-20,2022-07-30,2023-03-28,Observational,Recruiting,,Huazhong University of Science and Technology,"China-Japan Union Hospital, Jilin University|Chinese PLA General Hospital|First Hospital of China Medical University|Gansu Cancer Hospital|Huazhong University of Science and Technology|Sir Run Run Shaw Hospital|The First Affiliated Hospital of Kunming Medical College|Tongji Hospital|West China Hospital|Wuhan Union Hospital, China","Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",,China,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,"Differentiated thyroid cancer, all",https://clinicaltrials.gov/ct2/show/NCT04857086
NCT04858867,differentiated thyroid cancer,Reinducing Radioiodine-sensitivity in Radioiodine-refractory Differentiated Thyroid Cancer Using Lenvatinib (RESET),Differentiated Thyroid Cancer,2021-04-09,2023-09-01,2024-01-01,Interventional,Not yet recruiting,Not Applicable,Leiden University Medical Center,Leiden University Medical Center,Leiden University Medical Center,Radiation|Radiation,Netherlands,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Differentiated thyroid cancer, all",https://clinicaltrials.gov/ct2/show/NCT04858867
NCT04868045,thyroid cancer,Evaluation of The Development of Central Resistance to Thyroid Hormone After Prolonged Exposure to Excess Thyroid Hormone in Thyroid Cancer Patients,Thyroid Cancer,2021-04-28,2023-04-30,2023-04-30,Interventional,Recruiting,Phase 1,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Drug|Drug|Other,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04868045
NCT04876534,graves ophthalmopathy,"Multicenter, Randomized, Observer-blind, Controlled Study of the Anti-IL-6 Receptor Antibody Tocilizumab (TCZ) or Methylprednisolone (MP) Treatment in Patients With Active Moderate-severe Graves' Orbitopathy",Graves Ophthalmopathy,2021-05-03,2022-12-18,2023-12-18,Interventional,Recruiting,Phase 2,"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","Azienda Ospedaliera ""Sant'Andrea""|Azienda Ospedaliero, Universitaria Pisana|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|Istituto Auxologico Italiano|Mauriziano Umberto I Hospital","Istituto Auxologico Italiano|Azienda Ospedaliero, Universitaria Pisana|Azienda Ospedaliera ""Sant'Andrea""|Mauriziano Umberto I Hospital",Drug|Drug,Italy,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT04876534
NCT04878614,hypothyroidism,Comparison of Levothyroxine Formulation in Hypothyroid Patients With Enteral Feeding,Hypothyroidism,2021-05-04,2022-04-30,2023-04-30,Interventional,Recruiting,Phase 4,"University of California, Los Angeles","University of California, Los Angeles",UCLA Center for Human Nutrition,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT04878614
NCT04879355,thyroid nodule,The Use of Spinal Needles for Ultrasound-guided Fine Needle Aspiration From Thyroid Nodules - a Protocol for a Multicentre Randomised Controlled Trial,Thyroid Nodule,2021-03-07,2022-11-01,2023-12-01,Interventional,Not yet recruiting,Not Applicable,Zealand University Hospital,"Herlev Hospital|Preben Homøe|Rigshospitalet, Denmark",,Device|Device,,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT04879355
NCT04880798,differentiated thyroid cancer,Effect of Thyrotropin Level on Iodine Uptake: a Prospective 124I PET/CT Study in Metastatic Differentiated Thyroid Cancer,Differentiated Thyroid Cancer,2021-05-06,2022-12-31,2022-12-31,Interventional,Recruiting,Not Applicable,Peking Union Medical College Hospital,Beijing Cancer Hospital|Peking Union Medical College Hospital,Peking Union Medical College Hospital|Beijing Cancer Hospital,Diagnostic Test,China,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Differentiated thyroid cancer, all",https://clinicaltrials.gov/ct2/show/NCT04880798
NCT04892303,recurrent thyroid cancer,Combination Radiotherapy and Radiopharmaceutical Therapy Treatment Planning for Thyroid Cancer,Recurrent Thyroid Cancer,2021-05-03,2025-03-31,2025-08-31,Interventional,Recruiting,Phase 1,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,National Cancer Institute (NCI)|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,The Johns Hopkins SKCCC,Combination Product,United States,18.0,85.0,[18-65]|[65 and more],Thyroid neoplasms,Recurrent Thyroid Cancer,https://clinicaltrials.gov/ct2/show/NCT04892303
NCT04895631,"hyperparathyroidism, primary",18F-Fluorocholine Positron Emission Tomography (PET) for the Detection of Parathyroid Adenomas,"Hyperparathyroidism, Primary",2021-05-13,2026-06-30,2027-06-30,Interventional,Recruiting,Phase 3,"University of California, San Francisco",Thomas Hope,"University of California, San Francisco",Drug|Procedure,United States,13.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT04895631
NCT04922801,hyperthyroidism,OPTIMISING MOLECULAR RADIONUCLIDE THERAPY: The Role of Quantitative SPECT/CT & PET/CT and Radiation Dosimetry (SELFIE),Hyperthyroidism|Neuroendocrine Tumors|Thyroid Cancer|Thyroid Carcinoma,2021-05-17,2022-04-20,2022-06-30,Observational [Patient Registry],Recruiting,,King's College London,Guy's and St Thomas' NHS Foundation Trust|King's College London,Guy's and St Thomas Hospitals Foundation Trust,Diagnostic Test|Diagnostic Test|Diagnostic Test|Device|Diagnostic Test,United Kingdom,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04922801
NCT04922801,thyroid carcinoma,OPTIMISING MOLECULAR RADIONUCLIDE THERAPY: The Role of Quantitative SPECT/CT & PET/CT and Radiation Dosimetry (SELFIE),Hyperthyroidism|Neuroendocrine Tumors|Thyroid Cancer|Thyroid Carcinoma,2021-05-17,2022-04-20,2022-06-30,Observational [Patient Registry],Recruiting,,King's College London,Guy's and St Thomas' NHS Foundation Trust|King's College London,Guy's and St Thomas Hospitals Foundation Trust,Diagnostic Test|Diagnostic Test|Diagnostic Test|Device|Diagnostic Test,United Kingdom,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04922801
NCT04927468,graves ophthalmopathy,The Management of Large-angle Strabismus in Grave's Ophthalmopathy With Supramaximal Rectus Recession,"Graves Ophthalmopathy|Strabismus, Mechanical",2021-06-08,2023-07-01,2023-07-01,Interventional,Not yet recruiting,Not Applicable,Sun Yat-sen University,Sun Yat-sen University,,Procedure|Procedure,,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT04927468
NCT04931576,thyroid cancer,The Feasibility of no Drainage During Transoral Endoscopic Thyroidectomy Via the Vestibular Approach in Treatment of Papillary Thyroid Carcinoma,Drainage|Thyroid Cancer,2021-06-14,2023-06-01,2023-10-01,Interventional,Not yet recruiting,Not Applicable,"Second Affiliated Hospital, School of Medicine, Zhejiang University","Second Affiliated Hospital, School of Medicine, Zhejiang University",,Procedure,,18.0,55.0,[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04931576
NCT04932135,hyperthyroidism,Resting Heart Rate Monitoring for Optimized Treatment and Surveillance of Hyperthyroidism,Graves Disease|Hyperthyroidism,2021-06-14,2022-12-31,2023-03-31,Observational,Recruiting,,"University Hospital, Basel, Switzerland","University Hospital, Basel, Switzerland",University Hospital Basel,Diagnostic Test,Switzerland,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04932135
NCT04932135,graves disease,Resting Heart Rate Monitoring for Optimized Treatment and Surveillance of Hyperthyroidism,Graves Disease|Hyperthyroidism,2021-06-14,2022-12-31,2023-03-31,Observational,Recruiting,,"University Hospital, Basel, Switzerland","University Hospital, Basel, Switzerland",University Hospital Basel,Diagnostic Test,Switzerland,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04932135
NCT04940052,differentiated thyroid cancer,"A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Dabrafenib Plus Trametinib in Previously Treated Patients With Locally Advanced or Metastatic, Radio-active Iodine Refractory BRAFV600E Mutation-positive Differentiated Thyroid Cancer (DTC)",Differentiated Thyroid Cancer,2021-06-22,2024-02-19,2026-10-30,Interventional,Recruiting,Phase 3,Novartis,Novartis Pharmaceuticals,Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site,Drug|Drug|Drug|Drug,"China|Korea, Republic of|Malaysia|Taiwan|Turkey",18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Differentiated thyroid cancer, all",https://clinicaltrials.gov/ct2/show/NCT04940052
NCT04946123,hyperthyroidism,Association of Methimazole With L-carnitine and Selenium in Patients With Hyperthyroidism,Hyperthyroidism,2021-06-15,2022-06-30,2022-07-31,Interventional,Recruiting,Not Applicable,Lo.Li.Pharma s.r.l,Lo.Li.Pharma s.r.l,Azienda Ospedaliero-Universitaria Città della scienza e degli studi di Torino,Dietary Supplement,Italy,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04946123
NCT04948437,papillary thyroid cancer,Urinary Exosomal Biomarkers of Thyroglobulin and Galectin-3 for Prognosis and Follow-up in Patients of Well-differentiated Thyroid Cancer,Follicular Thyroid Cancer|Papillary Thyroid Cancer|Thyroid Cancer,2021-06-24,2024-10-31,2026-10-31,Observational,Recruiting,,National Taiwan University Hospital,National Taiwan University Hospital,"Chih-Yuan Wang, M.D",,Taiwan,20.0,80.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT04948437
NCT04948437,follicular thyroid cancer,Urinary Exosomal Biomarkers of Thyroglobulin and Galectin-3 for Prognosis and Follow-up in Patients of Well-differentiated Thyroid Cancer,Follicular Thyroid Cancer|Papillary Thyroid Cancer|Thyroid Cancer,2021-06-24,2024-10-31,2026-10-31,Observational,Recruiting,,National Taiwan University Hospital,National Taiwan University Hospital,"Chih-Yuan Wang, M.D",,Taiwan,20.0,80.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, follicular",https://clinicaltrials.gov/ct2/show/NCT04948437
NCT04948671,"hyperparathyroidism, primary",Primary Hyperparathyroidism and Gut Microbiota Unravelling an Unexpected Relationship: the HYPOGEUM Study,"Hyperparathyroidism, Primary",2021-06-28,2023-02-28,2024-02-28,Observational,Recruiting,,Centre Hospitalier Universitaire Vaudois,Centre Hospitalier Universitaire Vaudois|The Novartis Foundation,Patrizia D'amelio,Other,Switzerland,30.0,80.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT04948671
NCT04952012,"thyroiditis, autoimmune",The Effect of Thyroid Antibodies on Female Reproductive Function and Pregnancy Outcomes,"Thyroiditis, Autoimmune",2021-06-20,2021-11-30,2022-11-30,Observational,Recruiting,,"Second Affiliated Hospital, School of Medicine, Zhejiang University","Changxing People's Hospital|First People's Hospital of Yuhang|Second Affiliated Hospital, School of Medicine, Zhejiang University|Taizhou Women and Children's Hospital Affiliated to Wenzhou Medical University","Second Affiliated Hospital, School of Medicine, Zhejiang University",Drug,China,18.0,45.0,[18-65],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT04952012
NCT04952493,thyroid cancer,"The Efficacy and Safety of Anlotinib Hydrochloride or Penpulimab In Combination With RAI in Patients With Local Advanced or Metastatic Differentiated Thyroid Cancer: A Randomized, Open-label, Exploratory Clinical Trial",Thyroid Cancer,2021-06-27,2023-07-20,2024-07-20,Interventional,Recruiting,Phase 2,Peking Union Medical College Hospital,"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.|Peking Union Medical College Hospital",Peking Union Medical College Hospital,Drug|Drug|Drug,China,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04952493
NCT04964284,differentiated thyroid cancer,"A Randomized, Open-label, Multi-center, Controlled Phase Ⅲ Study to Evaluate the Safety and Efficacy of Recombinant Human Thryoid Stimulating Hormone（rhTSH） for Adjuvant Radioiodine Ablation Therapy in Postoperative Patients With Differentiated Thyroid Cancer",Differentiated Thyroid Cancer,2021-07-06,2022-09-30,2022-12-31,Interventional,Recruiting,Phase 3,"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","Suzhou Zelgen Biopharmaceuticals Co.,Ltd",Peking Union Medical College Hospital,Biological|Radiation,China,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Differentiated thyroid cancer, all",https://clinicaltrials.gov/ct2/show/NCT04964284
NCT04969926,primary hyperparathyroidism,Natural History Study of Parathyroid Disorders,"Inheritable Bone Diseases|Multiple Endocrine Neoplasia, Type 1|Parathyroid Cancer|Primary Hyperparathyroidism|Pseudohypoparathyroidism",2021-07-20,2031-01-22,2031-01-22,Observational,Recruiting,,National Institutes of Health Clinical Center (CC),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),National Institutes of Health Clinical Center,,United States,6.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT04969926
NCT04969926,pseudohypoparathyroidism,Natural History Study of Parathyroid Disorders,"Inheritable Bone Diseases|Multiple Endocrine Neoplasia, Type 1|Parathyroid Cancer|Primary Hyperparathyroidism|Pseudohypoparathyroidism",2021-07-20,2031-01-22,2031-01-22,Observational,Recruiting,,National Institutes of Health Clinical Center (CC),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),National Institutes of Health Clinical Center,,United States,6.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,pseudohypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04969926
NCT04970134,medullary thyroid carcinoma,Spanish Observational Study for MOLecular Characterization of THYroid Carcinoma MOLTHY Project,Differentiated Thyroid Carcinoma|Medullary Thyroid Carcinoma,2021-07-16,2023-03-31,2024-03-31,Observational,Recruiting,,Grupo Español de Tratamiento de Tumores de Cabeza y Cuello,Grupo Español de Tratamiento de Tumores de Cabeza y Cuello,Hospital Universitario Durán i Reinals|Fundació Althaia|Consorci Corporació Sanitària Parc Taulí de Sabadell|Hospital Universitario Vall d'Hebron|Hospital Clínic de Barcelona|Institut Català d'Oncologia Girona - ICO Girona|Hospital Universitario Ramón y Cajal|Hospital Universitario La Paz|Hospital universitario Marqués de Valdecilla|Hospital General Universitario de Valencia|Hospital Universitario y Politécnico La Fe|Hospital Universitario Miguel Servet,Other|Other|Other,Spain,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, medullary",https://clinicaltrials.gov/ct2/show/NCT04970134
NCT04971473,differentiated thyroid cancer,"An Open, Single-arm, Self-controlled, Multi-center Phase 3 Study to Compare the Efficacy and Safety of rhTSH as An Adjunctive Diagnostic Tool in Differentiated Thyroid Cancer Patients Who Had Been Thyroidectomized Vs. Patients Who After Thyroid Hormone Withdrawal",Differentiated Thyroid Cancer,2021-07-07,2023-06-30,2023-07-31,Interventional,Recruiting,Phase 3,"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","Suzhou Zelgen Biopharmaceuticals Co.,Ltd",Peking Union Medical College Hospital,Biological,China,18.0,75.0,[18-65]|[65 and more],Thyroid neoplasms,"Differentiated thyroid cancer, all",https://clinicaltrials.gov/ct2/show/NCT04971473
NCT04976816,thyroid eye disease,Local Betamethasone Versus Triamcinolone Injection in Management of Thyroid-Related Upper Lid Retraction With and Without Proptosis,Thyroid Eye Disease,2021-07-13,2022-12-31,2023-01-31,Interventional,Not yet recruiting,Phase 4,Assiut University,Assiut University,,Procedure|Procedure|Procedure|Procedure,,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT04976816
NCT04994080,secondary hyperparathyroidism,"A Multi-center, Randomized, Double-blind, Parallel Grouping, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Paricalcitol Soft Capsules in the Treatment of Secondary Hyperparathyroidism in Subjects With Stage 3 and Stage 4 Chronic Kidney Disease",Secondary Hyperparathyroidism,2021-07-21,2023-03-31,2023-03-31,Interventional,Not yet recruiting,Phase 3,"Chengdu Suncadia Medicine Co., Ltd.","Chengdu Suncadia Medicine Co., Ltd.",,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT04994080
NCT05002998,thyroid eye disease,"A Phase 3b/4, Double-masked, Randomized, International, Parallel-assignment, Multicenter Trial in Patients With Thyroid Eye Disease to Evaluate the Safety and Tolerability of Different Dosing Durations of Teprotumumab",Thyroid Eye Disease,2021-07-19,2025-08-31,2025-08-31,Interventional,Recruiting,Phase 4,"Horizon Pharma USA, Inc.","Horizon Therapeutics USA, Inc.",University of Colorado - Eye Center|Bascom Palmer Eye Institute,Drug|Drug,United States,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT05002998
NCT05003856,thyroid gland papillary carcinoma,Radiofrequency Ablation Use in Thyroid Nodule,Benign Thyroid Gland Neoplasm|Recurrent Thyroid Gland Carcinoma|Thyroid Gland Follicular Tumor of Uncertain Malignant Potential|Thyroid Gland Nodule|Thyroid Gland Papillary Carcinoma,2021-08-05,2025-06-30,2025-06-30,Interventional,Not yet recruiting,Phase 4,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center,M D Anderson Cancer Center,Other|Procedure,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT05003856
NCT05003856,thyroid gland nodule,Radiofrequency Ablation Use in Thyroid Nodule,Benign Thyroid Gland Neoplasm|Recurrent Thyroid Gland Carcinoma|Thyroid Gland Follicular Tumor of Uncertain Malignant Potential|Thyroid Gland Nodule|Thyroid Gland Papillary Carcinoma,2021-08-05,2025-06-30,2025-06-30,Interventional,Not yet recruiting,Phase 4,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center,M D Anderson Cancer Center,Other|Procedure,United States,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT05003856
NCT05012033,thyroid eye disease,Evaluation of High Dose Prednisolone Pharmacokinetics in the Acute and Chronic Setting,Asthma|COPD Exacerbation Acute|Inflammatory Disease|Thyroid Eye Disease|Vasculitis,2021-07-30,2026-03-26,2026-03-26,Observational,Not yet recruiting,,Imperial College London,Imperial College London,Imperial College Healthcare NHS Trust,Other,United Kingdom,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT05012033
NCT05014698,differentiated thyroid cancer,IDEntification of New Predisposition Genes in Differentiated THYroid Cancer,"Differentiated Thyroid Cancer|Thyroid Cancer, Nonmedullary",2021-08-05,2025-02-28,2025-02-28,Interventional,Recruiting,Not Applicable,Nantes University Hospital,Nantes University Hospital,Vendée Hospital|Nantes University Hospital,Genetic,France,8.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,"Differentiated thyroid cancer, all",https://clinicaltrials.gov/ct2/show/NCT05014698
NCT05015127,thyroid ophthalmopathy,"A Randomized, Double-blind, Placebo-controlled, Phase 2/3 Operational Seamless Design Clinical Study to Evaluate the Efficacy and Safety of HBM9161 Subcutaneous Injection in Chinese Patients With Active, Moderate to Severe Thyroid Eye Disease (TED)",Thyroid Ophthalmopathy,2021-08-03,2022-10-31,2022-12-31,Interventional,Recruiting,Phase 2/Phase 3,Harbour BioMed (Guangzhou) Co. Ltd.,Harbour BioMed (Guangzhou) Co. Ltd.,"Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine",Drug|Drug|Drug|Drug,China,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT05015127
NCT05015725,hypothyroidism,"A Single Center Cross-sectional Study to Evaluate the Relationship Between Serum rT3 Concentrations, T3/T4 Ratio, and Symptoms/Quality of Life in Treated Hypothyroid Patients",Hypothyroidism,2021-06-30,2022-07-05,2022-07-05,Observational,Recruiting,,Semmelweis University,Semmelweis University,Semmelweis University - Departement Medicine and Oncology,Diagnostic Test,Hungary,18.0,120.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT05015725
NCT05022641,primary hyperparathyroidism,Evaluating Impact of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy,Hypercalcemia|Parathyroid Adenoma|Parathyroid Cancer|Parathyroid Neoplasms|Primary Hyperparathyroidism,2021-08-22,2023-08-31,2023-08-31,Interventional,Recruiting,Not Applicable,University of Michigan,National Cancer Institute (NCI)|University of Michigan|Vanderbilt University,The University of Michigan,Device,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT05022641
NCT05022641,parathyroid neoplasms,Evaluating Impact of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy,Hypercalcemia|Parathyroid Adenoma|Parathyroid Cancer|Parathyroid Neoplasms|Primary Hyperparathyroidism,2021-08-22,2023-08-31,2023-08-31,Interventional,Recruiting,Not Applicable,University of Michigan,National Cancer Institute (NCI)|University of Michigan|Vanderbilt University,The University of Michigan,Device,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05022641
NCT05022667,thyroid neoplasms,Assessing Benefits of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Total Thyroidectomy,Endocrine Gland Neoplasms|Endocrine System Diseases|Head and Neck Neoplasms|Hypoparathyroidism|Neoplasms|Neoplasms by Site|Parathyroid Diseases|Thyroid Diseases|Thyroid Neoplasms,2021-08-22,2023-08-31,2023-08-31,Interventional,Recruiting,Not Applicable,University of Michigan,National Cancer Institute (NCI)|University of Michigan|Vanderbilt University,The University of Michigan,Device,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05022667
NCT05022667,parathyroid diseases,Assessing Benefits of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Total Thyroidectomy,Endocrine Gland Neoplasms|Endocrine System Diseases|Head and Neck Neoplasms|Hypoparathyroidism|Neoplasms|Neoplasms by Site|Parathyroid Diseases|Thyroid Diseases|Thyroid Neoplasms,2021-08-22,2023-08-31,2023-08-31,Interventional,Recruiting,Not Applicable,University of Michigan,National Cancer Institute (NCI)|University of Michigan|Vanderbilt University,The University of Michigan,Device,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT05022667
NCT05022667,thyroid diseases,Assessing Benefits of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Total Thyroidectomy,Endocrine Gland Neoplasms|Endocrine System Diseases|Head and Neck Neoplasms|Hypoparathyroidism|Neoplasms|Neoplasms by Site|Parathyroid Diseases|Thyroid Diseases|Thyroid Neoplasms,2021-08-22,2023-08-31,2023-08-31,Interventional,Recruiting,Not Applicable,University of Michigan,National Cancer Institute (NCI)|University of Michigan|Vanderbilt University,The University of Michigan,Device,United States,18.0,120.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT05022667
NCT05024929,papillary thyroid cancer,Targeted Therapy to Increase RAI Uptake in Patients With Metastatic Papillary Thyroid Cancer,Papillary Thyroid Cancer|Pediatric Cancer,2021-08-23,2031-02-01,2033-02-01,Observational,Recruiting,,Children's Hospital of Philadelphia,Children's Hospital of Philadelphia,Children's Hospital of Philadelphia,Procedure,United States,0.0,21.0,[0-17]|[18-65],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT05024929
NCT05025046,thyroid cancer,"Prospective, Blinded, Multi-center Clincal Study of NGS-based Thyroscan Genomic Classifier in the Diagnosis of Thyroid Nodules",Thyroid Cancer|Thyroid Nodule,2021-08-25,2022-06-30,2022-06-30,Observational,Recruiting,,Rigen Biotech,"Guangdong Provincial People's Hospital|RenJi Hospital|Rigen Biotech|Shenzhen People's Hospital|The First People's Hospital of Changzhou|Tianjin Medical University Cancer Institute and Hospital|Zhejiang Provincial People's Hospital|Zhongshan People's Hospital, Guangdong, China",Zhongshan City People's Hospital|The First Peple's Hospital of Changzhou|Guangdong Provincial People's Hospital|Zhejiang Provincial People's Hospital|Shanghai Jiaotong University School of Medicine|Shenzhen People's Hospital|Tianjin Medical University Center Hospital,Diagnostic Test,China,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05025046
NCT05025046,thyroid nodule,"Prospective, Blinded, Multi-center Clincal Study of NGS-based Thyroscan Genomic Classifier in the Diagnosis of Thyroid Nodules",Thyroid Cancer|Thyroid Nodule,2021-08-25,2022-06-30,2022-06-30,Observational,Recruiting,,Rigen Biotech,"Guangdong Provincial People's Hospital|RenJi Hospital|Rigen Biotech|Shenzhen People's Hospital|The First People's Hospital of Changzhou|Tianjin Medical University Cancer Institute and Hospital|Zhejiang Provincial People's Hospital|Zhongshan People's Hospital, Guangdong, China",Zhongshan City People's Hospital|The First Peple's Hospital of Changzhou|Guangdong Provincial People's Hospital|Zhejiang Provincial People's Hospital|Shanghai Jiaotong University School of Medicine|Shenzhen People's Hospital|Tianjin Medical University Center Hospital,Diagnostic Test,China,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT05025046
NCT05043584,hypoparathyroidism,Prevention of Postoperative Hypoparathyroidism Following Thyroid Surgery by Using Intraoperative Autofluorescence,Autofluorescence|Hypocalcemia|Hypoparathyroidism|Thyroidectomy,2021-09-05,2023-09-30,2024-03-31,Interventional,Recruiting,Not Applicable,Regional Hospital West Jutland,Hospital of South West Jutland|Regional Hospital West Jutland,"Department of Otorhinolaryngology, Hospital South West Jutland|Department of Otorhinolaryngology, Regional Hospital West Jutland",Device,Denmark,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT05043584
NCT05078853,differentiated thyroid cancer,Thyroglobulin Point of Care Assay for Rapid Detection of Metastatic Differentiated Thyroid Carcinoma- A Multi-Center Validation Study,Differentiated Thyroid Cancer|Lymph Node Metastases,2021-09-27,2022-12-31,2022-12-31,Observational,Recruiting,,Soroka University Medical Center,Soroka University Medical Center,Soroka University Medical Center,Device,Israel,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Differentiated thyroid cancer, all",https://clinicaltrials.gov/ct2/show/NCT05078853
NCT05088187,thyroid cancer,Longitudinal Evaluation of Objective Cognitive Function and Quality of Life in Patients Undergoing Surgery for Malignant and Benign Thyroid Nodules,"Cognitive Decline|Survivorship|Symptoms, Cognitive|Thyroid Cancer|Thyroid Nodule",2021-10-11,2023-11-01,2026-11-01,Observational,Not yet recruiting,,Karolinska University Hospital,Karolinska University Hospital|The Netherlands Cancer Institute,,,,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05088187
NCT05088187,thyroid nodule,Longitudinal Evaluation of Objective Cognitive Function and Quality of Life in Patients Undergoing Surgery for Malignant and Benign Thyroid Nodules,"Cognitive Decline|Survivorship|Symptoms, Cognitive|Thyroid Cancer|Thyroid Nodule",2021-10-11,2023-11-01,2026-11-01,Observational,Not yet recruiting,,Karolinska University Hospital,Karolinska University Hospital|The Netherlands Cancer Institute,,,,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT05088187
NCT05098600,autoimmune hyperthyroidism,"The Epidemiology, Management and Associated Conditions in Alopecia Areata in Czech Republic: A University-clinic-based Retrospective Cohort Study","Alopecia Areata|Alopecia Areata (& Ophiasis)|Alopecia Barbae|Alopecia Diffuse|Alopecia Totalis|Alopecia Universalis|Anemia, Pernicious|Ankylosing Spondylitis|Atopic Asthma|Atopic Dermatitis|Atopic Rhinitis|Autoimmune Diseases|Autoimmune Hyperthyroidism|Autoimmune Hypothyroidism|COVID-19 Pandemic|Crohn Disease|Diabetes Mellitus, Type 1|Down Syndrome|Infections|Inflammatory Bowel Diseases|Lupus Erythematosus|Multiple Sclerosis|Psoriasis|Rheumatoid Arthritis|Ulcerative Colitis|Vaccine Reaction|Vitiligo",2021-10-16,2021-12-31,2022-01-10,Observational,"Active, not recruiting",,Faculty Hospital Kralovske Vinohrady,Faculty Hospital Kralovske Vinohrady,Teaching Hospital of Royal Vineguards,Other,Czechia,0.0,120.0,[0-17]|[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT05098600
NCT05102292,anaplastic thyroid cancer,"An Open Label, Multicenter Phase Ib/II Clinical Study to Evaluate Efficacy , Safety and PK of HLX208 in Advanced Anaplastic Thyroid Cancer (ATC) With BRAF V600 Mutation",Anaplastic Thyroid Cancer|ATC,2021-10-20,2023-05-30,2024-12-30,Interventional,Recruiting,Phase 1/Phase 2,Shanghai Henlius Biotech,Shanghai Henlius Biotech,Fudan University Affiliated Oncology Hospital,Drug,China,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT05102292
NCT05103956,goiter,"Regular Treatment Versus Hemostatic Patch/Collagen Sealant and Polyethylene Glycol (Hemopatch) in the Immediate Postoperative of the Thyroidectomy, Unicentric Study, Non-inferiority, Open and Randomized (Tiropatch Study)",Goiter,2021-10-07,2022-04-01,2022-04-01,Observational,Recruiting,,Fundación Pública Andaluza para la gestión de la Investigación en Sevilla,Fundación Pública Andaluza para la gestión de la Investigación en Sevilla,Hospital Universitario Virgen del Rocío,,Spain,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT05103956
NCT05114980,hypoparathyroidism,Parathyroid Allotransplantation in Medically Refractory Hypoparathyroidism,Hypoparathyroidism,2021-10-29,2024-01-31,2025-01-31,Interventional,Recruiting,Not Applicable,University of Alabama at Birmingham,University of Alabama at Birmingham,University of Alabama at Birmingham,Procedure,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT05114980
NCT05117853,thyroid disease,The Use of Autofluorescence and Indocyanine Green to Avoid Hypocalcemia After Total Thyroidectomy: A Randomized Clinical Trial,Hypoparathyroidism Postprocedural|Thyroid Disease,2021-10-21,2024-10-31,2025-05-31,Interventional,Not yet recruiting,Phase 3,Onze Lieve Vrouw Hospital,Onze Lieve Vrouw Hospital,Onze Lieve Vrouw Hospital,Drug|Procedure,Belgium,18.0,120.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT05117853
NCT05124938,thyroid cancer,Assessment of CA19-9 in Patients' With Thyroid Malignancies,Thyroid Cancer,2021-10-26,2022-06-01,2022-12-01,Observational,Not yet recruiting,,Sohag University,Sohag University,Sohag faculty of medicine,Diagnostic Test,Egypt,1.0,80.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05124938
NCT05126147,graves ophthalmopathy,A Randomized Controlled Trial on the Effect of Hydroxychloroquine in Graves' Orbitopathy,Graves Ophthalmopathy,2021-10-05,2023-12-01,2024-12-01,Interventional,Not yet recruiting,Phase 4,National Taiwan University Hospital,National Taiwan University Hospital,National Taiwan University Hospital,Drug,Taiwan,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT05126147
NCT05132205,papillary thyroid cancer,Radiofrequency Ablation of Papillary Thyroid Microcarcinoma,Papillary Thyroid Cancer,2021-11-10,2024-09-28,2024-09-28,Interventional,Recruiting,Not Applicable,Johns Hopkins University,Johns Hopkins University,Johns Hopkins Hospital,Procedure,United States,18.0,100.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT05132205
NCT05132478,thyroid cancer,The Effect of Surgeon Emotional Support on Treatment Choice for Low-risk Thyroid Cancer: a Randomized Hypothetical Choice Experiment,Benign Thyroid Nodule|Thyroid Cancer|Thyroid Nodule,2021-11-12,2023-11-30,2023-11-30,Interventional,Recruiting,Not Applicable,"University of Wisconsin, Madison","National Cancer Institute (NCI)|University of Michigan|University of Wisconsin, Madison",University of Wisconsin Carbone Cancer Center,Other|Other,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05132478
NCT05132478,thyroid nodule,The Effect of Surgeon Emotional Support on Treatment Choice for Low-risk Thyroid Cancer: a Randomized Hypothetical Choice Experiment,Benign Thyroid Nodule|Thyroid Cancer|Thyroid Nodule,2021-11-12,2023-11-30,2023-11-30,Interventional,Recruiting,Not Applicable,"University of Wisconsin, Madison","National Cancer Institute (NCI)|University of Michigan|University of Wisconsin, Madison",University of Wisconsin Carbone Cancer Center,Other|Other,United States,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT05132478
NCT05143918,hypothyroidism,Assessment of Quality of Life Among Hypothyroid Patients in Assiut University Hospitals,Hypothyroidism,2021-11-23,2022-12-30,2023-12-30,Observational,Not yet recruiting,,Assiut University,Assiut University,,Other,,18.0,60.0,[18-65],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT05143918
NCT05152927,endocrine gland neoplasms,Evaluating Impact of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy,"Adenoma|Endocrine Gland Neoplasms|Hypercalcemia|Hyperparathyroidism|Hyperparathyroidism, Primary|Neoplasms, Glandular and Epithelial|Parathyroid Adenoma|Parathyroid Diseases|Parathyroid Dysfunction|Parathyroid Neoplasms",2021-11-29,2025-01-31,2025-01-31,Interventional,Recruiting,Not Applicable,"University of California, San Francisco","National Cancer Institute (NCI)|University of California, San Francisco|Vanderbilt University Medical Center","University of California, San Francisco",Device,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05152927
NCT05152927,parathyroid dysfunction,Evaluating Impact of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy,"Adenoma|Endocrine Gland Neoplasms|Hypercalcemia|Hyperparathyroidism|Hyperparathyroidism, Primary|Neoplasms, Glandular and Epithelial|Parathyroid Adenoma|Parathyroid Diseases|Parathyroid Dysfunction|Parathyroid Neoplasms",2021-11-29,2025-01-31,2025-01-31,Interventional,Recruiting,Not Applicable,"University of California, San Francisco","National Cancer Institute (NCI)|University of California, San Francisco|Vanderbilt University Medical Center","University of California, San Francisco",Device,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT05152927
NCT05152927,parathyroid neoplasms,Evaluating Impact of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy,"Adenoma|Endocrine Gland Neoplasms|Hypercalcemia|Hyperparathyroidism|Hyperparathyroidism, Primary|Neoplasms, Glandular and Epithelial|Parathyroid Adenoma|Parathyroid Diseases|Parathyroid Dysfunction|Parathyroid Neoplasms",2021-11-29,2025-01-31,2025-01-31,Interventional,Recruiting,Not Applicable,"University of California, San Francisco","National Cancer Institute (NCI)|University of California, San Francisco|Vanderbilt University Medical Center","University of California, San Francisco",Device,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05152927
NCT05172921,thyroid cancer,The Role of Environmental Factors in Thyroid Cancer,Thyroid Cancer,2021-12-23,2030-01-31,2030-01-31,Observational [Patient Registry],Recruiting,,Icahn School of Medicine at Mount Sinai,Icahn School of Medicine at Mount Sinai,Icahn School of Medicine at Mount Sinai,,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05172921
NCT05175404,thyroid cancer,Use of 18F-PSMA-11 PET for Detection of Lesions in Iodine Refractory Thyroid Cancers,Thyroid Cancer,2021-12-14,2022-12-31,2022-12-31,Interventional,Recruiting,Phase 2,"University Hospital, Ghent","University Hospital, Ghent",University hospital Ghent,Diagnostic Test,Belgium,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05175404
NCT05176639,thyroid eye disease,"A Multiple Ascending Dose (MAD) Safety, Tolerability and Efficacy Study of VRDN 001, a Humanized Monoclonal Antibody Directed Against the IGF-1 Receptor, in Normal Healthy Volunteers (NHVs) and Subjects With Thyroid Eye Disease (TED)",Thyroid Eye Disease,2021-12-15,2023-06-30,2023-12-31,Interventional,Recruiting,Phase 1/Phase 2,"Viridian Therapeutics, Inc.","Viridian Therapeutics, Inc.","Sarasota Retina Institute|TKL Research, Inc.|Neuro-Eye Clinical Trials",Drug|Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT05176639
NCT05182931,thyroid cancer,"A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (I-FIRST Study)",Thyroid Cancer,2021-11-23,2024-12-30,2025-12-30,Interventional,Not yet recruiting,Phase 2,Olivia Newton-John Cancer Research Institute,"Austin Health|Eastern Health|Monash Health|Olivia Newton-John Cancer Research Institute|Peter MacCallum Cancer Centre, Australia|Royal Brisbane and Women's Hospital|Royal North Shore Hospital|Sir Charles Gairdner Hospital|The Alfred",Royal North Shore Hospital|Royal Brisbane and Women's Hospital|Eastern Health|Monash Health|Austin Health|Alfred Hospital|Sir Charles Gairdner Hospital|Peter MacCallum Cancer Centre,Drug|Drug,Australia,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05182931
NCT05216718,thyroid nodule,Prospective Randomized Controlled Study on Mini-flap Bilateral Axillo-breast Approach Robotic Thyroidectomy : Effect on Postoperative Pain and Sensation,Thyroid Nodule,2021-12-30,2022-12-31,2023-12-01,Interventional,Not yet recruiting,Not Applicable,Inje University,Inje University,Dong sik Bae,Procedure|Procedure,"Korea, Republic of",19.0,69.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT05216718
NCT05218395,thyroid cancer,Association Between Persistent Organic Pollutants and Type 2 Diabetes /Thyroid Cancer,Organic Pollutant|Thyroid Cancer|Type 2 Diabetes,2022-01-20,2024-12-29,2025-12-30,Observational,Recruiting,,Qianfoshan Hospital,Chinese Academy of Sciences|Qianfoshan Hospital,Xiaoling Guan,,China,18.0,75.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05218395
NCT05221008,secondary hyperparathyroidism,"Study on Tolerability, Pharmacokinetics and Pharmacodynamics of SHR6508 in Chinese Patients With Secondary Hyperparathyroidism of Chronic Kidney Disease Treated by Maintenance Hemodialysis",Secondary Hyperparathyroidism,2022-01-07,2022-09-01,2022-09-30,Interventional,Not yet recruiting,Phase 1,"Shanghai Hengrui Pharmaceutical Co., Ltd.","Shanghai Hengrui Pharmaceutical Co., Ltd.",,Drug|Drug|Drug|Drug,,18.0,70.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT05221008
NCT05228184,congenital hypothyroidism,A Randomized Comparative Study Between Liquid (Tirosint®-SOL) and Tablet Formulations of Levothyroxine in Neonates and Infants With Congenital Hypothyroidism,Congenital Hypothyroidism,2021-12-21,2023-06-15,2023-06-15,Interventional,Recruiting,Phase 4,IBSA Institut Biochimique SA,Cromsource|IBSA Institut Biochimique SA,CHOC Children's Hospital|Ann & Robert H. Lurie Children's Hospital of Chicago|Children's Mercy Hospital and Clinics|Icahn School of Medicine at Mount Sinai|Cook Children's Health Care Systems,Drug|Drug,United States,0.0,9.0,[0-17],Hypothyroidism,Congenital hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT05228184
NCT05229341,thyroid gland carcinoma,Evaluation of DNA Methylation Signatures in Diagnosis and Management of Thyroid Nodules,Thyroid Gland Carcinoma,2022-02-04,2026-10-22,2026-10-22,Interventional,Recruiting,Not Applicable,City of Hope Medical Center,City of Hope Medical Center|National Cancer Institute (NCI),City of Hope Medical Center,Procedure|Other|Procedure,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05229341
NCT05240911,thyroid neoplasms,Compare a New Method to the Traditional One to Estimate Levothyroxine Dose for Patients Needing Replacement Therapy After Total or Completion Thyroidectomy,Hypothyroidism|Surgery|Thyroid Neoplasms,2022-02-06,2023-02-10,2023-06-10,Interventional,Recruiting,Not Applicable,"Second Affiliated Hospital, School of Medicine, Zhejiang University","Second Affiliated Hospital, School of Medicine, Zhejiang University",Second Affiliated Hospital Zhejiang University School of Medicine,Drug,China,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05240911
NCT05240911,hypothyroidism,Compare a New Method to the Traditional One to Estimate Levothyroxine Dose for Patients Needing Replacement Therapy After Total or Completion Thyroidectomy,Hypothyroidism|Surgery|Thyroid Neoplasms,2022-02-06,2023-02-10,2023-06-10,Interventional,Recruiting,Not Applicable,"Second Affiliated Hospital, School of Medicine, Zhejiang University","Second Affiliated Hospital, School of Medicine, Zhejiang University",Second Affiliated Hospital Zhejiang University School of Medicine,Drug,China,18.0,120.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT05240911
NCT05241834,thyroid neoplasms,"A Phase 1 Study of Oral LOXO-260 in Patients With RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation Refractory to Selective RET Inhibitors","Carcinoma, Non-Small-Cell Lung|Thyroid Neoplasms",2022-02-08,2026-04-30,2026-04-30,Interventional,Not yet recruiting,Phase 1,Eli Lilly and Company,"Eli Lilly and Company|Loxo Oncology, Inc.",Sarah Cannon Cancer Center,Drug,United States,12.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05241834
NCT05243979,parathyroid diseases,"The Relation Between Thyroid , Parathyroid Hormones and Estimated Glomerular Filtration Rate in Chronic Kidney Disease Patients in Assiut",CKD|Parathyroid Diseases|Thyroid,2022-02-08,2023-03-01,2023-04-01,Observational,Not yet recruiting,,Assiut University,Assiut University,,Radiation,,18.0,80.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT05243979
NCT05247476,"thyroid cancer, papillary",Type 2 Deiodinase Gene Polymorphism and the Treatment of Hypothyroidism Caused,"Hypothyroidism|Thyroid Cancer, Papillary",2022-02-09,2022-03-31,2022-09-30,Interventional,Recruiting,Phase 4,Zhongshan Hospital Xiamen University,Zhongshan Hospital Xiamen University,Yan Ling,Drug|Drug,China,18.0,70.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT05247476
NCT05247476,hypothyroidism,Type 2 Deiodinase Gene Polymorphism and the Treatment of Hypothyroidism Caused,"Hypothyroidism|Thyroid Cancer, Papillary",2022-02-09,2022-03-31,2022-09-30,Interventional,Recruiting,Phase 4,Zhongshan Hospital Xiamen University,Zhongshan Hospital Xiamen University,Yan Ling,Drug|Drug,China,18.0,70.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT05247476
NCT05252884,hyperthyroidism,Comparison of Routine Prophylactic Calcium + Calcitriol and Selective Use Based on PTH for the Prevention of Postoperative Hypocalcemia in Patients With Total Thyroidectomy. Randomized Clinical Trial,Goiter|Hyperthyroidism|Thyroid Cancer|Thyroiditis,2022-02-13,2023-08-31,2023-12-31,Interventional,Not yet recruiting,Not Applicable,Centro de Excelencia en Enfermedades de Cabeza y Cuello,Centro de Excelencia en Enfermedades de Cabeza y Cuello|IPS universitaria,IPS Universitaria,Diagnostic Test|Drug,Colombia,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT05252884
NCT05252884,thyroiditis,Comparison of Routine Prophylactic Calcium + Calcitriol and Selective Use Based on PTH for the Prevention of Postoperative Hypocalcemia in Patients With Total Thyroidectomy. Randomized Clinical Trial,Goiter|Hyperthyroidism|Thyroid Cancer|Thyroiditis,2022-02-13,2023-08-31,2023-12-31,Interventional,Not yet recruiting,Not Applicable,Centro de Excelencia en Enfermedades de Cabeza y Cuello,Centro de Excelencia en Enfermedades de Cabeza y Cuello|IPS universitaria,IPS Universitaria,Diagnostic Test|Drug,Colombia,18.0,120.0,[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT05252884
NCT05252884,thyroid cancer,Comparison of Routine Prophylactic Calcium + Calcitriol and Selective Use Based on PTH for the Prevention of Postoperative Hypocalcemia in Patients With Total Thyroidectomy. Randomized Clinical Trial,Goiter|Hyperthyroidism|Thyroid Cancer|Thyroiditis,2022-02-13,2023-08-31,2023-12-31,Interventional,Not yet recruiting,Not Applicable,Centro de Excelencia en Enfermedades de Cabeza y Cuello,Centro de Excelencia en Enfermedades de Cabeza y Cuello|IPS universitaria,IPS Universitaria,Diagnostic Test|Drug,Colombia,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05252884
NCT05252884,goiter,Comparison of Routine Prophylactic Calcium + Calcitriol and Selective Use Based on PTH for the Prevention of Postoperative Hypocalcemia in Patients With Total Thyroidectomy. Randomized Clinical Trial,Goiter|Hyperthyroidism|Thyroid Cancer|Thyroiditis,2022-02-13,2023-08-31,2023-12-31,Interventional,Not yet recruiting,Not Applicable,Centro de Excelencia en Enfermedades de Cabeza y Cuello,Centro de Excelencia en Enfermedades de Cabeza y Cuello|IPS universitaria,IPS Universitaria,Diagnostic Test|Drug,Colombia,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT05252884
NCT05260255,hyperparathyroidism,The Effect of Vitamin D Supplementation on Disease Activity of Systemic Lupus Erythematosus Patients: A Randomized Clinical Trial in Rajavithi Hospital,Hyperparathyroidism|Hypocalcemia|Systemic Lupus Erythematosus (Disorder)|Vitamin D Deficiency,2021-05-12,2022-05-01,2022-12-01,Interventional,Recruiting,Not Applicable,Rajavithi Hospital,Rajavithi Hospital,Rajavithi Hospital,Drug|Drug,Thailand,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT05260255
NCT05263141,papillary thyroid carcinoma,"Single-center, Prospective, Non-Randomized Control Clinical Trial of Retro-Auricular Single-Site Endoscopic Versus Open Surgery in Patients With Early Stage Papillary Thyroid Carcinoma",Papillary Thyroid Carcinoma,2022-02-20,2023-06-30,2023-06-30,Interventional,Recruiting,Not Applicable,Sun Yat-sen University,Sun Yat-sen University,Sun Yat-Sen University Cancer Center,Procedure|Procedure,China,18.0,70.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT05263141
NCT05264857,thyroid nodule,Decision Aid for Management of Thyroid Nodules and Early Thyroid Cancer,Thyroid Nodule,2022-02-17,2026-09-30,2026-09-30,Interventional,Recruiting,Not Applicable,Stony Brook University,Stony Brook University,Stony Brook University Cancer Center,Behavioral,United States,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT05264857
NCT05265819,thyroid cancer,Effect of Exergaming Exercises and Mediterranean Diet on Thyroid Cancer Patients Following Total Thyroidectomy,Thyroid Cancer,2022-02-23,2022-12-05,2022-12-05,Interventional,Not yet recruiting,Not Applicable,Cairo University,Nabil Mahmoud Ismail Abdel-Aal,,Device|Dietary Supplement|Drug,,18.0,45.0,[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05265819
NCT05270798,euthyroid sick syndromes,Triiodothyronine Hormone Replacement Therapy in Patients With Septic Shock With Euthyroid Sick Syndrome,Euthyroid Sick Syndromes|Septic Shock,2022-02-26,2023-03-15,2023-03-15,Interventional,Not yet recruiting,Phase 2,Cantonal Hospital Zenica,Cantonal Hospital Zenica,,Drug,,18.0,120.0,[18-65]|[65 and more],Euthyroid Sick Syndromes,Euthyroid Sick Syndromes,https://clinicaltrials.gov/ct2/show/NCT05270798
NCT05275374,thyroid cancer,A Dose-escalation and Expansion Phase I/IIa Study of XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation (ENHANCE),BRAF V600 Mutation|Cancer|Colorectal Cancer|Melanoma|Nonsmall Cell Lung Cancer|Thyroid Cancer,2022-02-20,2024-12-31,2026-12-31,Interventional,Not yet recruiting,Phase 1/Phase 2,"Xynomic Pharmaceuticals, Inc.","Xynomic Pharmaceuticals, Inc.",,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05275374
NCT05275946,thyroid cancer,"Phase I Investigator-initiated Clinical Trial in Patients With Differentiated Thyroid Cancer (Papillary Cancer, Follicular Cancer) by the Targeted Alpha Therapy Drug TAH-1005 ([211At] NaAt) (Alpha-T1 Study)",Thyroid Cancer,2022-01-22,2023-09-30,2024-03-31,Interventional,Recruiting,Phase 1,Osaka University,Osaka University,Osaka University Hospital,Drug,Japan,0.0,18.0,[0-17]|[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05275946
NCT05276063,thyroid eye disease,"A Phase 2b, Randomized, Double-Mask, Placebo-Controlled, Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)",Endocrine System Diseases|Exophthalmos|Eye Diseases|Graves Ophthalmopathy|Graves Orbitopathy|Hashimoto|IGF1R|Orbital Diseases|Proptosis|Thyroid Associated Ophthalmopathy|Thyroid Diseases|Thyroid Eye Disease,2022-03-02,2023-05-15,2025-06-13,Interventional,Not yet recruiting,Phase 2/Phase 3,"VasaraGen, Inc.","VasaraGen, Inc.",,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT05276063
NCT05276063,hashimoto,"A Phase 2b, Randomized, Double-Mask, Placebo-Controlled, Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)",Endocrine System Diseases|Exophthalmos|Eye Diseases|Graves Ophthalmopathy|Graves Orbitopathy|Hashimoto|IGF1R|Orbital Diseases|Proptosis|Thyroid Associated Ophthalmopathy|Thyroid Diseases|Thyroid Eye Disease,2022-03-02,2023-05-15,2025-06-13,Interventional,Not yet recruiting,Phase 2/Phase 3,"VasaraGen, Inc.","VasaraGen, Inc.",,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT05276063
NCT05276063,thyroid diseases,"A Phase 2b, Randomized, Double-Mask, Placebo-Controlled, Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)",Endocrine System Diseases|Exophthalmos|Eye Diseases|Graves Ophthalmopathy|Graves Orbitopathy|Hashimoto|IGF1R|Orbital Diseases|Proptosis|Thyroid Associated Ophthalmopathy|Thyroid Diseases|Thyroid Eye Disease,2022-03-02,2023-05-15,2025-06-13,Interventional,Not yet recruiting,Phase 2/Phase 3,"VasaraGen, Inc.","VasaraGen, Inc.",,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT05276063
NCT05278364,medullary thyroid cancer,"A Phase I, Open-Label, Single-arm , Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antineoplastic Activity of SY-5007 in Patients With RET-altered Advanced Solid Tumor.",Medullary Thyroid Cancer|Non-Small Cell Lung Cancer|Solid Tumor,2022-03-08,2023-03-01,2023-06-01,Interventional,Recruiting,Phase 1,Shouyao Holdings (Beijing) Co. LTD,Shouyao Holdings (Beijing) Co. LTD,Shanghai Pulmonary Hospital|Tianjin People's Hospital,Drug,China,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, medullary",https://clinicaltrials.gov/ct2/show/NCT05278364
NCT05299632,hyperparathyroidism,Pre-operative Localization of Parathyroid Adenomas Using F-18 PSMA PET/CT: A Pilot Study,Hyperparathyroidism,2022-03-09,2023-03-31,2023-12-31,Observational,Recruiting,,Emory University,Emory University,Emory Saint Joseph's Hospital|Emory University Hospital (EUH)|Emory Johns Creek Hospital,Diagnostic Test|Diagnostic Test,United States,18.0,99.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT05299632
NCT02868476,thyroid diseases,Long Period Observation of Biochemical Survey and Ultrasonography in Thyroid Diseases and Subclinical Thyroid Diseases,Thyroid Diseases,2016-08-05,2017-05-26,2024-07-30,Observational [Patient Registry],"Active, not recruiting",,National Taiwan University Hospital,National Taiwan University Hospital,,,,20.0,80.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT02868476
NCT03191188,thyroid disease,A Pilot Feasibility Trial of Thyroid Hormone Replacement in Dialysis Patients,"Kidney Diseases, Chronic|Thyroid Disease",2017-06-13,2021-07-31,2021-07-31,Interventional,Recruiting,Not Applicable,"University of California, Irvine","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|University of California, Irvine",University Dialysis Center of Orange,Drug|Drug,United States,18.0,75.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT03191188
NCT03369405,thyroid diseases,Thyroid Insufficiency as a Modifying Factor for Chronic Periodontitis,Chronic Periodontitis|Thyroid Diseases,2017-11-28,2022-08-01,2022-08-01,Observational,"Active, not recruiting",,University at Buffalo,University at Buffalo,"School of Dental Medicine, University at Buffalo",Other,United States,35.0,120.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT03369405
NCT03414021,thyroid diseases,Quantification in Nuclear Medicine: Interest of the in SPECT-CT Scan SUVspect in Thea New Generation of Gamma-cameras With Semiconductor. Data Collection for the Constitution of an Observatory of Scintigraphies,Bone Diseases|Brain Diseases|Heart Diseases|Kidney Diseases|Thyroid Diseases,2018-01-23,2023-01-30,2023-01-30,Observational,Recruiting,,Lille Catholic University,Lille Catholic University,Humanitep|Hopital Privé Le Bois,Diagnostic Test,France,18.0,120.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT03414021
NCT04167423,thyroid diseases,Thyroid Disease in Pregnancy and Its Impact on the Quality of Life,Pregnancy Related|Quality of Life|Thyroid Diseases,2019-11-11,2022-05-31,2022-05-31,Observational,Recruiting,,Value Outcomes Ltd.,"Charles University, Czech Republic|Institute of Health Information and Statistics of the Czech Republic|Value Outcomes Ltd.","MUDr. Milan Kučera. s.r.o.|MUDr. Eva Novotná - FEMCARE s.r.o.|Mediva s.r.o.|MUDr.Tereza Šmrhová-Kovács|Nemocnice Havlíčkův Brod|Všeobecná Fakultní Nemocnice|Oblastní nemocnice Příbram, a.s.",,Czechia,0.0,120.0,[0-17]|[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT04167423
NCT04279184,thyroid diseases,Urinary Incontinence and Endocrine Factors.,Diabetes|Thyroid Diseases|Urinary Incontinence,2020-01-16,2020-02-29,2021-02-28,Observational,Recruiting,,Nykøbing Falster County Hospital,Nykøbing Falster County Hospital|Region Zealand|University of Southern Denmark|Zealand University Hospital,Randi Jepsen,,Denmark,18.0,120.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT04279184
NCT04351945,thyroid diseases,A Study of Endocrine Changes and Their Correction in Heart and Lung Transplant Recipients and Donors,Cortisol Deficiency|Diabetes Insipidus|Endocrine System Diseases|End-stage Heart Failure|End Stage Lung Disease|Thyroid Diseases,2020-04-15,2022-05-15,2022-07-01,Observational,"Active, not recruiting",,Semmelweis University Heart and Vascular Center,Semmelweis University|Semmelweis University Heart and Vascular Center,Heart and Vascular Center,Procedure,Hungary,18.0,120.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT04351945
NCT04427904,thyroid diseases,Bupivacaine Versus Lidocaine Infiltration for Postoperative Pain in Thyroid Surgery: A Randomized Controlled Trial,"Anesthesia, Local|Postoperative Pain|Thyroid Diseases",2020-05-26,2023-12-31,2024-12-31,Interventional,Not yet recruiting,Phase 2,St. Joseph's Healthcare Hamilton,St. Joseph's Healthcare Hamilton,St. Joeseph's Healthcare Hamilton,Drug|Drug,Canada,18.0,100.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT04427904
NCT04471597,thyroid diseases,Topical Bupivacaine Effect On The Response To Awake Extubation During Emergence From General Anesthesia In Patients Undergoing Elective Thyroidectomy. A Randomized Controlled Study,Thyroid Diseases,2020-07-12,2022-04-01,2022-05-01,Interventional,Recruiting,Not Applicable,Zagazig University,Zagazig University,"Faculty of medicine, zagazig university",Drug|Drug,Egypt,21.0,60.0,[18-65],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT04471597
NCT04542278,thyroid diseases,Randomized Controlled Trial of Preoperative Steroids in Autoimmune Thyroid Disease,Thyroid Diseases,2020-09-01,2022-04-30,2022-04-30,Interventional,Recruiting,Phase 4,"University of Wisconsin, Madison","University of Wisconsin, Madison",University of Wisconsin Hospital and Clinics,Drug,United States,18.0,120.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT04542278
NCT04794257,thyroid diseases,Clinical Validation of NerveTrend vs. Conventional i-IONM Mode of NIM Vital in Prevention of Recurrent Laryngeal Nerve Events During Bilateral Thyroid Surgery.,Recurrent Laryngeal Nerve Injuries|Surgery|Thyroid Diseases,2021-03-07,2022-12-31,2023-03-31,Interventional,Recruiting,Not Applicable,Jagiellonian University,Marcin Barczynski,"Department of Endocrine Surgery, Jagiellonian University College of Medicine",Device,Poland,18.0,65.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT04794257
NCT04842942,thyroid diseases,The Safety and Feasibility of Transoral Endoscopic Thyroidectomy Vestibular Approach,Surgery|Thyroid Diseases,2021-02-19,2021-12-31,2022-07-31,Interventional,Recruiting,Phase 1,"University Health Network, Toronto","University Health Network, Toronto",Univeristy Health Network,Procedure,Canada,18.0,80.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT04842942
NCT04943146,thyroid diseases,An Assessment of Aspirin Plus Prednisone Treatment for Euthyroid Women With Thyroid Autoimmunity Undergoing In Vitro Fertilization,Thyroid Diseases,2021-06-21,2021-06-30,2022-03-31,Observational,Recruiting,,"Second Affiliated Hospital, School of Medicine, Zhejiang University","Ningbo Women and Children's Hospital|People's Hospital of Jinhua|Second Affiliated Hospital, School of Medicine, Zhejiang University",People's Hospital of Jinhua|Ningbo Women and Children's Hospital,Drug,China,18.0,40.0,[18-65],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT04943146
NCT05036525,thyroid diseases,"Evaluation of the Efficacy and Safety of a High Molecular Weight Native Hyaluronic Acid Gel (HANBIO BarriGel) in Adhesion Prevention After Open Thyroidectomy: a Prospective, Randomized Controlled, Single Blind Study.",Adhesion|Thyroid Diseases,2021-09-02,2023-06-30,2023-06-30,Interventional,Not yet recruiting,Not Applicable,HAN Biomedical Inc,HAN Biomedical Inc,,Device,,20.0,70.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT05036525
